Compounds > rolipram
Page last updated: 2024-09-20

rolipram

Description

(-)-rolipram : The (R)-enantiomer of rolipram. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID448055
CHEMBL ID430893
CHEBI ID40133
SCHEMBL ID576805
MeSH IDM0067312
PubMed CID5092
CHEMBL ID63
CHEBI ID104872
SCHEMBL ID27930
MeSH IDM0067312

Synonyms (238)

Synonym
bdbm50042058
HMS3267P19
BRD-K75516118-001-01-7
NCGC00016899-01
cas-61413-54-5
NCGC00024862-01
tocris-0905
tocris-1350
tocris-1349
NCGC00015898-01
lopac-r-6520
NCGC00024862-02
NCGC00024862-03
r-rolipram
(r)-4-(3-cyclopentyloxy-4-methoxy-phenyl)-pyrrolidin-2-one
(-)-rolipram
1Q9M
(r)-(-)-rolipram
DB04149
1RO6
(4r)-4-[3-(cyclopentyloxy)-4-methoxyphenyl]pyrrolidin-2-one
(r)-rolipram
2-pyrrolidinone, 4-(3-(cyclopentyloxy)-4-methoxyphenyl)-, (r)-
c16h21no3
NCGC00015898-02
(4r)-4-(3-cyclopentyloxy-4-methoxyphenyl)pyrrolidin-2-one
chebi:40133 ,
CHEMBL430893 ,
85416-75-7
dpx51kup08 ,
unii-dpx51kup08
rolipram, (-)-
NCGC00016899-02
NCGC00016899-05
NCGC00016899-04
NCGC00016899-03
NCGC00015898-10
(r)-4-(3-(cyclopentyloxy)-4-methoxyphenyl)pyrrolidin-2-one
1XMY
AKOS015891287
rolipram, (r)-
2-pyrrolidinone, 4-(3-(cyclopentyloxy)-4-methoxyphenyl)-, (4r)-
(4r)-4-(3-(cyclopentyloxy)-4-methoxyphenyl)-2-pyrrolidinone
SCHEMBL576805
CCG-208064
HY-16900A
CS-3246
3G4K
AC-22384
SR-01000597573-1
sr-01000597573
2-pyrrolidinone, 4-[3-(cyclopentyloxy)-4-methoxyphenyl]-, (4r)-
mfcd03093860
(4r)-[3-(cyclopentyloxy)-4-methoxyphenyl]-2-pyrrolidinone
4r)-4-[3-(cyclopentyloxy)-4-methoxyphenyl]pyrrolidin-2-one
HB2898
HMS3676I06
Q27094987
R0182
(r)-(-)-4-[3-(cyclopentyloxy)-4-methoxyphenyl]pyrrolidin-2-one
AS-31755
BCP14111
HMS3412I06
AE-641/11320426
A863588
DTXSID101318033
(r)-rolipram;(-)-rolipram
4-(3-cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone
rolipram [usan:inn]
einecs 262-771-1
2-pyrrolidinone, 4-(3-(cyclopentyloxy)-4-methoxyphenyl)-
brn 1588548
MLS001146912
HMS3267A05
HMS3393N15
BRD-A34255068-001-04-8
rolipramum [latin]
smr000058510
zk-62711
me-3167
adeo
EU-0101072
rolipram, solid, >=98% (hplc)
BPBIO1_000912
BSPBIO_000828
BIO2_000556
BIO2_000076
rolipram ,
4-[4-methoxy-3-(cyclopentyloxy)phenyl]-2-pyrrolidinone
zk 62711
61413-54-5
4-[3-(cyclopentoxy)-4-methoxy-phenyl]pyrrolidin-2-one
PRESTWICK2_000924
PRESTWICK3_000924
IDI1_033826
2-pyrrolidinone, 4-[3-(cyclopentyloxy)-4-methoxyphenyl]- (9ci)
sb 95952
4-[3-(cyclopentyloxy)-4-methoxyphenyl]-2-pyrrolidinone
(+/-)-rolipram
UPCMLD-DP110:001
AB00513966
MLS000759531
MLS000758273
UPCMLD-DP110
4-(3-(cyclopentyloxy)-4-methoxyphenyl)-2-pyrrolidinone
DB01954
D01783
rolipram (jan/usan/inn)
LOPAC0_001072
UPCMLD-DP110:002
NCGC00089796-07
NCGC00089796-04
NCGC00089796-06
MLS000069691 ,
KBIO2_002644
KBIO3_000152
KBIO2_000076
KBIO2_005212
KBIOGR_000076
KBIO3_000151
KBIOSS_000076
PRESTWICK1_000924
SPBIO_003007
PRESTWICK0_000924
(4r)-4-[3-(cyclopentyloxy)-4 methoxyphenyl)pyrrolidin-2-one
BSPBIO_001356
NCGC00089796-05
NCGC00089796-08
NCGC00089796-02
[3h]-rolipram
4-(3-cyclopentyloxy-4-methoxyphenyl)pyrrolidin-2-one
[3h]rolipram
gtpl5313
4-(3-cyclopentyloxy-4-methoxy-phenyl)pyrrolidin-2-one
chembl63 ,
(r,s)-rolipram
bdbm14361
4-[3-(cyclopentyloxy)-4-methoxyphenyl]pyrrolidin-2-one
NCGC00015898-04
rolipramum
CHEBI:104872 ,
HMS1989D18
R 6520
HMS2051N15
HMS2090J16
NCGC00015898-12
sb-95952
zk 62 711
nsc-760125
zk-62771
HMS1361D18
HMS1791D18
HMS1570J10
HMS2097J10
HMS3263G06
nsc760125
MLS001424084
pharmakon1600-01505683
tox21_110672
dtxcid1024124
dtxsid3044124 ,
CCG-205149
AKOS015959793
HMS2232F06
CCG-100965
NCGC00015898-08
NCGC00015898-03
NCGC00015898-09
NCGC00015898-06
NCGC00015898-07
NCGC00015898-05
NCGC00015898-11
nsc 760125
k676nl63n7 ,
unii-k676nl63n7
LP01072
BRD-A34255068-001-26-1
4-(3-(cyclopentyloxy)-4-methoxyphenyl)-2-pyrrolidinon
S1430
rolipram [who-dd]
rolipram [mart.]
rolipram [jan]
4-(3-cyclopentyloxy-4-methoxyphenyl)pyrrolidone
85416-74-6
rolipram [mi]
rolipram [inn]
rolipram [usan]
gtpl5260
HMS3369J08
(plusmn)-rolipram
CS-1754
HY-16900
MLS006010272
NC00215
SCHEMBL27930
NCGC00015898-15
tox21_110672_1
KS-1400
AB00384360-17
NCGC00261757-01
tox21_501072
4-(3-cyclopentyloxy-4-methoxy-phenyl)-pyrrolidin-2-one
4-[3-cyclopentyloxy-4-methoxyphenyl]-2-pyrrolidinone
4-[3-(cyclopentyloxy)-4-methoxyphenyl]pyrrolidinone
4-(3-cyclopentyloxy-4-methoxyphenyl)-pyrrolidin-2-one
4-(3-(cyclopentyloxy)-4-methoxyphenyl)pyrrolidin-2-one
AC-32927
HMS3402D18
R0110
OPERA_ID_1749
AB00384360_19
2-pyrrolidinone, 4-[3-(cyclopentyloxy)-4-methoxyphenyl]-
HMS3655J21
HMS3654P06
SR-01000000162-5
SR-01000000162-4
SR-01000000162-12
SR-01000000162-9
SR-01000000162-3
sr-01000000162
SBI-0051042.P002
HMS3714J10
SW196583-4
FT-0738515
BCP21910
Q410285
HB2896
rolipram - cas 61413-54-5
HMS3675F08
BCP23388
(+)-rolipram; (s)-rolipram
HMS3411F08
SB12922
SDCCGSBI-0051042.P003
NCGC00015898-31
(r,s)-rolipram;sb 95952;zk 62711
r-(-)-rolipram
A847969

Research Excerpts

Overview

ExcerptReference
"Rolipram is a selective phosphodiesterase-4 (PDE4) inhibitor. "( Huang, Y; Qi, C; Wang, Q; Zheng, Y, 2023)
"Rolipram is a selective phosphodiesterase 4 (PDE4) inhibitor that exerts a variety of effects, including anti-inflammatory, immunosuppressive, and anti-tumor effects. "( Liang, Y; Liu, Q; Wang, Z; Zhang, L; Zhang, N, 2018)
"Rolipram is a multifaceted antiinflammatory and antithrombotic compound that protects from ischemic neurodegeneration in clinically meaningful settings."( Brede, M; Göb, E; Heydenreich, N; Kleinschnitz, C; Kraft, P; Meuth, SG; Schwarz, T, 2013)
"Rolipram is a selective phosphodiesterase 4 inhibitor, which increases intracellular cyclic AMP in nerve and immune cells."( Abdi, S; Kim, HK; Kwon, JY; Yoo, C, 2015)
"Rolipram is a selective inhibitor of phosphodiesterase-4 (PDE4), and positron emission tomography (PET) using [(11)C]rolipram can monitor the in vivo activity of this enzyme that is part of the cAMP second messenger cascade. "( Abe, K; Fujita, M; Hong, J; Innis, RB; Inoue, O; Itoh, T; Pike, VW, 2010)
"Rolipram is a specific type IV phosphodiesterase inhibitor that suppresses the activity of immune cells and the production of pro-inflammatory cytokines. "( Hatakeyama, N; Horikawa, Y; Jin, M; Komatsu, K; Konishi, N; Matsuhashi, T; Odashima, M; Ohba, R; Otaka, M; Oyake, J; Sato, T; Wada, I; Watanabe, S, 2005)
"Rolipram is a selective PDE4 inhibitor which exists in two enantiomeric forms, R(-) and S(+)."( Bender, D; Brown, J; Cunningham, VJ; Dommett, D; Gee, AD; Gunn, RN; Jakobsen, S; Knibb, ST; Martarello, L; Matthews, JC; Parker, CA, 2005)
"Rolipram is a potent inhibitor HIV-1 replication and therefore deserves further investigation as a potential therapeutic agent in the treatment of HIV-1-infected patients."( Angel, JB; Dinarello, CA; Endres, S; Greten, TF; Saget, BM; Skolnik, PR; Walsh, SP, 1995)
"Rolipram is a selective inhibitor of Type IV phosphodiesterase isozymes (PDE IV) which is often used as a baseline comparator for compounds in this class. "( Geiger, LE; Larson, JL; Pino, MV; Simeone, CR, 1996)
"Rolipram is a type IV phosphodiesterase inhibitor that suppresses inflammation and TNF-alpha production. "( Feldmann, M; Maini, RN; Malfait, AM; Marinova-Mutafchieva, L; Mason, LJ; Mauri, C; Ross, SE; Williams, RO, 1997)
"Rolipram is a clinically effective antidepressant with cyclic AMP-selective phosphodiesterase (cyclic-AMP PDE) inhibiting action. "( Araki, T; Chen, T; Itoyama, Y; Kato, H; Kogure, K, 1998)
"Rolipram is a type IV phosphodiesterase inhibitor endowed with powerful immunomodulatory properties. "( Beltrami, B; Di Marco, R; Di Mauro, M; Magro, G; Meroni, PL; Nicoletti, F; Xiang, M; Zaccone, P, 1999)
"Rolipram is a specific cAMP phosphodiesterase type 4 (PDE4) inhibitor in the brain, which induces an increase in the intracellular levels of cAMP. "( Fernández, AG; Palacios, JM; Silvestre, JS, 1999)
"Rolipram is a selective inhibitor of phosphodiesterases (PDE) IV, especially of the subtype PDE IVB. "( Mix, E; Winblad, B; Zhu, J, 2001)
"Rolipram is a racemic drug that increases brain cAMP availability by inhibiting phosphodiesterase. "( Smith, DF, 1990)
"Rolipram is a clinically effective antidepressant with selective cAMP phosphodiesterase (PDE) inhibiting properties. "( Baumgarten, HG; Brüning, G; Kaulen, P; Sarter, M; Schneider, HH, 1989)
"Rolipram is an antidepressant with a novel mechanism of action: enhanced noradrenaline (first messenger) synthesis and release, and inhibition of cAMP (second messenger) breakdown. "( Meya, U; Murray, GH; Ross, CE; Rowland, M; Toon, S, 1988)
"Rolipram is a potent phosphodiesterase inhibitor, active in classical pharmacological tests used in the screening of antidepressants (AD). "( Dresse, A; Giesbers, I; Scuvée-Moreau, J, 1987)

Effects

ExcerptReference
"Rolipram has a good anti-fibrosis effect after inhibiting the activity of PDE4."( Chen, Y; Fan, J; Guo, Q; Meng, D; Song, G; Wu, L; Xu, G; Xu, L; Xu, P, 2021)
"Rolipram has a pharmacologic profile similar to that of the atypical antipsychotics and has low extrapyramidal symptom liability. "( Chapin, DS; Martin, AN; McCarthy, SA; Siuciak, JA, 2007)
"Rolipram has a phenyl-pyrrolidinone structure, unrelated to the methylxanthines, and acts as a specific inhibitor of the type IV phosphodiesterase."( Endres, S; Semmler, J; Wachtel, H, 1993)
"Rolipram has a good anti-fibrosis effect after inhibiting the activity of PDE4."( Chen, Y; Fan, J; Guo, Q; Meng, D; Song, G; Wu, L; Xu, G; Xu, L; Xu, P, 2021)
"Rolipram has been shown to play a neuroprotective role in some central nervous system (CNS) diseases."( Dong, XL; Wang, YH; Xu, J; Zhang, N, 2021)
"Rolipram has been shown to relief inflammation and BBB damage in a variety of neurological disorders."( Brede, M; Göb, E; Heydenreich, N; Kleinschnitz, C; Kraft, P; Meuth, SG; Schwarz, T, 2013)
"Rolipram has antipsychotic properties."( Manahan-Vaughan, D; Wiescholleck, V, 2012)
"Rolipram has a pharmacologic profile similar to that of the atypical antipsychotics and has low extrapyramidal symptom liability. "( Chapin, DS; Martin, AN; McCarthy, SA; Siuciak, JA, 2007)
"Rolipram has high (PDE4(H)) and low (PDE4(L)) affinities for phosphodiesterase (PDE)-4, respectively. "( Chan, AL; Chen, CM; Chien, HC; Huang, HL; Ko, WC; Lin, CN, 2008)
"Rolipram has extensively been studied in humans for the treatment of depression, but has not yet been marketed."( Fontana, A; Lichtenfels, R; Löschmann, PA; Meyermann, R; Northoff, GH; Riethmüller, A; Sommer, N; Steinbach, JP; Steinbrecher, A; Weller, M, 1995)
"Rolipram has a phenyl-pyrrolidinone structure, unrelated to the methylxanthines, and acts as a specific inhibitor of the type IV phosphodiesterase."( Endres, S; Semmler, J; Wachtel, H, 1993)

Actions

ExcerptReference
"Rolipram caused an increase in the frequency of Ca(2+) sparks and the spontaneous transient BK currents (TBKCs), hyperpolarized the cell membrane potential (MP), and decreased the intracellular Ca(2+) levels."( Cheng, Q; Li, N; Petkov, GV; Xin, W, 2014)
"Rolipram could suppress the inflammatory signals and could be a potential therapeutic strategy against LPS-induced inflammation to protect the salivary gland cells."( Hong, JH; Lee, DU; Shin, DM, 2016)
"Rolipram induces an increase in pERK expression in these interneurons."( Anzilotti, S; Bernardi, G; Colucci D'Amato, L; Dato, C; Fusco, FR; Giampà, C; Laurenti, D; Leuti, A; Melone, MA; Perrone, L, 2012)
"Rolipram promotes the maturation of OPCs, facilitates remyelination, and increases ERK phosphorylation. "( Liu, B; Liu, Y; Sun, X; Xiao, Z; Zhang, L, 2012)
"Rolipram reduced the increase of F-actin content of polymorphonuclear leukocytes and the increase of transit time of 100 micro L of blood sample through a microchannel. "( Hiramatsu, Y; Homma, S; Onizuka, M; Sakakibara, Y; Sato, S; Sato, Y, 2003)
"Rolipram reduced the increase in CD11b expression and the decrease in L-selectin expression of monocytes in response to simulated extracorporeal circulation."( Endo, S; Hiramatsu, Y; Homma, S; Sato, M; Sato, S; Sato, Y; Sohara, Y, 2005)
"Rolipram did not inhibit 5-lipoxygenase activity but did inhibit human monocyte production of leukotriene B4 (LTB4, IC50 3.5 microM)."( Breton, J; Griswold, DE; Marshall, PJ; Torphy, TJ; Webb, EF; White, JR, 1993)
"Rolipram failed to increase perfusate cAMP alone but dramatically increased perfusate cAMP above ISO alone."( Barnard, JW; Prasad, VR; Seibert, AF; Smart, DA; Strada, SJ; Taylor, AE; Thompson, WJ, 1994)
"Rolipram appears to inhibit the expansion and effector function of uveitogenic T cells, raising the possibility that it may be useful for treatment of established disease. "( Caspi, RR; Chan, CC; Rizzo, LV; Silver, PB; Strassmann, G; Wiggert, B; Xu, H, 1999)
"Rolipram may increase intra-cellular levels of cAMP by selectively inhibiting Type IV phosphodiesterases, enzymes that catalyze cAMP breakdown."( Ciraulo, DA; Foye, M; Knapp, CM; Kornetsky, C; Lee, K, 2001)
"Rolipram reduced the increase of F-actin and CD11b but did not change the decrease of L-selectin."( Ishikawa, S; Onizuka, M; Sakakibara, Y; Sato, S; Sato, Y; Yamamoto, T, 2002)

Treatment

ExcerptReference
"Rolipram pretreatments in vivo prevented cocaine-induced reductions in GABAergic inhibition but did not further increase cocaine-induced potentiation of excitation, leading to the restoration of a balance between excitation and inhibition and normalization of the E/I ratio."( Li, Y; Liu, QS; Liu, X; Vickstrom, C; Zhong, P, 2017)
"Rolipram treatment remarkably promoted the expression of Sirtuin 1 (SIRT1) while inhibited NF-κB activation."( Chen, G; Chen, T; Fan, L; He, P; Jin, J; Li, J; Peng, Y; Ruan, W; Xu, H, 2018)
"Rolipram-treated MSCs (Roli-MSCs) had significantly increased expression of the neuroprogenitor proteins Nestin, Musashi, GFAP, and Sox-2."( Cho, GW; Joe, IS, 2016)
"Rolipram treatment significantly attenuated STZ induced and age related memory deficits, biochemical and histopathological alterations."( Kumar, A; Singh, N, 2017)
"Rolipram treatment significantly increased the number of motoneurons that regenerated axons across the repair site at 1 and 2 weeks, and increased the number of sensory neurons that regenerated axons across the repair site at 2 weeks."( Brushart, T; Furey, M; Gordon, T; Ladak, A; Tyreman, N; Udina, E, 2010)
"Rolipram-treated A172 or U87MG cell survival was lower in the presence of forskolin, adenylate cyclase activator, than that in its absence."( Kim, HM; Lee, GH; Lee, JW; Lee, MS; Moon, EY, 2012)
"Rolipram/forskolin treatment also induced Bad to accumulate in CLL heavy-membrane fractions, consistent with Bad translocation to mitochondria."( Lerner, A; Moon, EY, 2003)
"Rolipram treatment did not affect KC expression and the recruitment of neutrophils in the lung tissue."( Barsante, MM; Nicoli, JR; Pinho, V; Soares, AC; Souza, DG; Teixeira, M; Vieira, AT, 2003)
"Rolipram pretreatment shifted the thapsigargin-induced fluid leak site from extra-alveolar to alveolar vessels in the intact pulmonary circulation."( Alvarez, D; Chen, H; Cioffi, DL; Cioffi, EA; Creighton, JR; Goodman, SR; King, J; Sayner, SL; Stevens, T; Townsley, M; Wu, S, 2005)
"Rolipram and tofisopam treatments induced higher BV/TV than placebo (+23.8% and +18.3% respectively)."( Beaupied, H; Benhamou, CL; Bernard, P; Bizot, JC; Bonnet, N; Courteix, D; Trovero, F, 2007)
"Rolipram treatment increases levels of transcripts derived from the 1A3 promoter to a greater extent than the 1B promoter."( Chaves, J; Lerner, A; Makkinje, A; Meyers, JA; Taverna, J, 2007)
"Rolipram treatment restored cAMP to sham levels and significantly reduced cortical contusion volume and improved neuronal cell survival in the parietal cortex and CA3 region of the hippocampus."( Alonso, OF; Atkins, CM; Bramlett, HM; Dietrich, WD; Oliva, AA; Pearse, DD, 2007)
"Rolipram-treated and control animals equally developed circulating antibodies to myelin basic protein."( Davis, RL; Faulds, D; Genain, CP; Hauser, SL; Hedgpeth, J; Li, Y; Nguyen, MH; Roberts, T; Uccelli, A, 1995)
"Rolipram pretreatment was protective against LPS-induced mortality and also resulted in reduced plasma TNF alpha concentrations."( Esser, KM; Turner, CR; Wheeldon, EB, 1993)
"Rolipram treatment of animals with manifest arthritis inhibited further arthritis development and also tended to diminish its severity at a phase of disease where non-treated control animals showed a rapidly progressing disease development."( Klareskog, L; Larsson, E; Lorentzen, J; Müssener, A; Nyman, U, 1997)
"Rolipram treatment significantly elevated intracellular cyclic AMP (adenosine 3',5'-cyclic monophosphate) in clonal T cells (P < .01 for Th1 or Th2 clones); these elevations were consistently greater in the Th2 clones (P < .05)."( Essayan, DM; Huang, SK; Kagey-Sobotka, A; Lichtenstein, LM, 1997)
"Rolipram treatment from days -1 to 7 after immunization (afferent phase) was not protective, but severity of EAU was reduced to 50% by treatment from days 8 to 16 after immunization or when EAU was induced by adoptive transfer (efferent phase). "( Caspi, RR; Chan, CC; Rizzo, LV; Silver, PB; Strassmann, G; Wiggert, B; Xu, H, 1999)
"In rolipram-treated animals, the epithelium was completely disturbed until Day 14. "( Funk, RH; Kasper, M; Ploetze, K; Roth-Eichhorn, S; Schade, I; Schueler, S; Wunderlich, J, 2001)
"Rolipram pretreatment, markedly inhibited these parameters by 100, 95 and 95% respectively."( Alvarez, A; Cerdá, M; Cortijo, J; Issekutz, AC; Lobb, RR; Morcillo, EJ; Piqueras, L; Sanz, MJ, 2002)
"Pretreatment with rolipram (0.1 or 0.2 mg/kg) significantly increased entries and time spent in the open arms of the elevated plus maze test in rats with repeated ethanol abstinence. "( Fei, N; Gong, MF; Liang, JH; Pan, JC; Wen, RT; Xu, JP; Xu, Y; Zhang, HT; Zhou, YM, 2017)
"Treatment with rolipram increased the AMPK phosphorylation and SIRT6 levels in the liver and kidney while reducing NF-κB acetylation."( Liang, Y; Liu, Q; Wang, Z; Zhang, L; Zhang, N, 2018)
"Pre-treatment with rolipram enhanced Akt phosphorylation and associated cytoprotection in CSE-treated cells, which could be reversed by the PI3K inhibitor LY294002 partly."( Jeong, SH; Kyung, SY; Lee, SP; Park, JW; Ryter, SW, 2013)
"Treatment with rolipram increased expression of CREB and pCREB, reduced the inflammatory reaction (decreased TNF-α levels and increased IL-10 levels), and prevented cognitive impairment in these diabetic animals."( He, T; Li, W; Miao, Y; Wang, B; Zhong, Y; Zhu, Y, 2015)
"Treatment with rolipram blocked LPS-induced Ca(2+) increase and ROS production."( Hong, JH; Lee, DU; Shin, DM, 2016)
"Pretreatment with rolipram significantly reduced the increase in bladder wet weight and MPO activity, and ameliorated histological inflammatory changes caused by CYP."( Kawakami, S; Kihara, K; Masuda, H; Matsuoka, Y; Sakura, M; Yokoyama, M, 2009)
"Pre-treatment with rolipram, motapizone or PGE2 only reached about 20% of inhibition but was not affected by oxidative stress."( Almudéver, P; Cortijo, J; Lluch, J; Milara, J; Morcillo, EJ; Navarro, A, 2011)
"Co-treatment with rolipram and forskolin also enhanced CREB phosphorylation on serine 133 that was inhibited by H-89, PKA inhibitor and cAMP-responsive guanine nucleotide exchange factor 1(Epac1), a Rap GDP exchange factor-mediated Rap1 activity in A172 cells."( Kim, HM; Lee, GH; Lee, JW; Lee, MS; Moon, EY, 2012)
"Pretreatment with rolipram decreased the duration of ventricular tachycardia without any change in the incidences of dysrhythmias or the mortality rate. "( Aleixandre, F; Carceles, MD; Fuente, T; Laorden, ML; López-Vidal, J, 2003)
"Treatment with rolipram (3-30 mg kg-1) was associated with earlier lethality and significant inhibition of the TNF-alpha production."( Barsante, MM; Nicoli, JR; Pinho, V; Soares, AC; Souza, DG; Teixeira, M; Vieira, AT, 2003)
"Pretreatment with rolipram significantly attenuated the intramuscular distribution of 14C-DG, producing a relatively homogeneous distribution of radioactivity."( Gee, A; Hosoi, R; Inoue, O; Nishimura, T; Shukuri, M; Terai, M, 2005)
"Pretreatment with rolipram significantly reduced LR, eosinophils infiltration, and histamine release into the bronchoalveolar space during the early asthmatic reaction."( Chazan, R; Glapiński, J; Grubek-Jaworska, H; Hoser, G; Nejman-Gryz, P, 2006)
"Treatment with rolipram was followed by inhibition of the early phase of AIA associated with downregulation of both OVA-specific splenocyte proliferation and decreases of IFN-gamma released from the spleen cells but no decreases of the amount of IL-10, or levels of anti-OVA IgG, IgG2a, and IgG1."( Alam, AH; Hossain, MA; Li, X; Takano, H; Taneda, S; Yamaki, K; Yanagisawa, R; Yoshino, S, 2007)
"Mice treated with Rolipram (10 mg/kg after training showed elevated cyclic AMP but not cyclic GMP in frontal cortex, thalamus, and hypothalamus."( Bonnet, KA; Judge, ME; Quartermain, D; Randt, CT, 1982)
"Pretreatment with rolipram (30 mumol/kg) and Org 20421 (30 mumol/kg) abolished the eosinophilia and neutrophilia evoked by ovalbumin."( Barnes, PJ; Chung, KF; Elwood, W; Giembycz, MA; Sun, J, 1995)
"Pretreatment with rolipram (10 mg kg-1, i.p.) prevented airway hyperreactivity to histamine which develops 24 h after exposure of conscious guinea-pigs to aerosol PAF (500 micrograms ml-1) or antigen (5 mg ml-1)."( Cortijo, J; Martí-Cabrera, M; Morcillo, EJ; Ortiz, JL; Vallés, JM, 1996)
"Treatment with rolipram, but not theophylline, prevented the increase in responsiveness to inhaled histamine 24 h after antigen challenge."( Blake, SM; Gozzard, N; Herd, CM; Higgs, GA; Holbrook, M; Hughes, B; Page, CP, 1996)
"Pretreatment with rolipram also attenuated increases in serum tumor necrosis factor alpha (TNFalpha) levels induced by LPS and zymosan treatment, measured after 2.5 h."( Hellewell, PG; Miotla, JM; Teixeira, MM, 1998)
"Treatment with rolipram (10 microM) and forskolin (5 microM) for 25 min decreased Lp to 37% of control."( Adamson, RH; Curry, FE; Fry, GN; Liu, B; Rubin, LL, 1998)
"Treatment with rolipram, and to a lesser extent pentoxifylline, significantly reduced the severity of the colonic histopathology and MPO levels."( Diaz-Granados, N; Howe, K; Lu, J; McKay, DM, 2000)
"Pretreatment with rolipram abrogated oedema formation and significantly inhibited hyperalgesia."( Cunha, FQ; Francischi, JN; Poole, S; Tafuri, WL; Teixeira, MM; Yokoro, CM, 2000)
"Pre-treatment with rolipram prevented the decline in cardiac index in animals that received LPS."( Dutta, P; Ryan, DE; Tabrizchi, R, 2001)
"Treatment with rolipram when started at 6 h after QA injection resulted in neuronal damage amounting to 60%; the result after starting at 24 h was not different from solvent (91%)."( Block, F; Nolden-Koch, M; Schmidt, W; Schwarz, M, 2001)
"6. Treatment with rolipram and RP 73401 dose-dependently inhibited eosinophil adhesion and migration in vitro."( Alves, AC; Barreto, EO; Cordeiro, RS; Jose, PJ; Lagente, V; Martins, MA; Pires, AL; Serra, MF; Silva, JP; Silva, PM; Teixeira, MM, 2001)
"Treatment with rolipram reduced the escape latency."( Nagakura, A; Niimura, M; Takeo, S, 2002)

Roles (2)

RoleDescription
antidepressantAntidepressants are mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions.
EC 3.1.4.* (phosphoric diester hydrolase) inhibitorAn EC 3.1.* (ester hydrolase) inhibitor that interferes with the action of a phosphoric diester hydrolase (EC 3.1.4.*).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
rolipramA member of the lclass of pyrrolidin-2-ones that is pyrrolidin-2-one bearing a 3-(cyclopentyloxy)-4-methoxyphenyl substituent at the 4-position. It is a type IV-specific phosphodiesterase (PDE4) inhibitor.
pyrrolidin-2-onesA pyrrolidinone in which the oxo group is at position 2 of the pyrrolidine ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

rolipram is involved in 1 pathway(s), involving a total of 0 unique proteins and 13 unique compounds

PathwayProteinsCompounds
Phosphodiesterases in neuronal function013

Protein Targets (102)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
15-lipoxygenase, partialHomo sapiens (human)Potency14.21910.012610.691788.5700AID887
TDP1 proteinHomo sapiens (human)Potency16.78890.000811.382244.6684AID686978; AID686979
Microtubule-associated protein tauHomo sapiens (human)Potency3.54810.180013.557439.8107AID1468
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency39.81070.011212.4002100.0000AID1030
EWS/FLI fusion proteinHomo sapiens (human)Potency3.59920.001310.157742.8575AID1259252; AID1259253; AID1259255; AID1259256
heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa)Homo sapiens (human)Potency63.09570.016525.307841.3999AID602332
cytochrome P450 2C9 precursorHomo sapiens (human)Potency39.81070.00636.904339.8107AID883
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency7.75430.005612.367736.1254AID624032
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency22.74960.031610.279239.8107AID884; AID885
lethal factor (plasmid)Bacillus anthracis str. A2012Potency12.58930.020010.786931.6228AID912
lamin isoform A-delta10Homo sapiens (human)Potency0.00200.891312.067628.1838AID1487
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency22.74961.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency22.74961.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency22.74961.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency22.74961.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency22.74961.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency22.74961.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency22.74961.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency22.74961.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency22.74961.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency22.74961.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency22.74961.000012.224831.6228AID885
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency39.81070.00638.235039.8107AID883
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency22.74961.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency22.74961.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency22.74961.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency22.74961.000012.224831.6228AID885
CREB-binding proteinHomo sapiens (human)Potency0.03910.02822.360012.5893AID907; AID916
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency22.74961.000012.224831.6228AID885
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency2.41080.003245.467312,589.2998AID2517
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency39.81070.177814.390939.8107AID2147
Chain A, CruzipainTrypanosoma cruziPotency21.45090.002014.677939.8107AID1476; AID1478
glp-1 receptor, partialHomo sapiens (human)Potency0.20040.01846.806014.1254AID624148; AID624417
thioredoxin reductaseRattus norvegicus (Norway rat)Potency4.25960.100020.879379.4328AID488772; AID588453
USP1 protein, partialHomo sapiens (human)Potency70.79460.031637.5844354.8130AID743255
GLI family zinc finger 3Homo sapiens (human)Potency0.06010.000714.592883.7951AID1259369; AID1259392
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency27.54040.01237.983543.2770AID1645841
estrogen nuclear receptor alphaHomo sapiens (human)Potency6.44180.000229.305416,493.5996AID743069
arylsulfatase AHomo sapiens (human)Potency0.02391.069113.955137.9330AID720538
IDH1Homo sapiens (human)Potency29.09290.005210.865235.4813AID686970
Bloom syndrome protein isoform 1Homo sapiens (human)Potency1.00000.540617.639296.1227AID2364; AID2528
chromobox protein homolog 1Homo sapiens (human)Potency100.00000.006026.168889.1251AID540317
mitogen-activated protein kinase 1Homo sapiens (human)Potency3.98110.039816.784239.8107AID1454
flap endonuclease 1Homo sapiens (human)Potency8.43680.133725.412989.1251AID588795
histone-lysine N-methyltransferase 2A isoform 2 precursorHomo sapiens (human)Potency35.48130.010323.856763.0957AID2662
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency11.22020.050127.073689.1251AID588590
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency19.95260.031610.279239.8107AID884; AID885
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, cAMP-specific phosphodiesterase PDE4D2Homo sapiens (human)IC50 (µMol)0.33000.33000.44000.5500AID977608
Chain A, cAMP-specific phosphodiesterase PDE4D2Homo sapiens (human)IC50 (µMol)0.33000.33000.44000.5500AID977608
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)IC50 (µMol)0.28800.00090.07390.2880AID977608
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)IC50 (µMol)0.28800.00090.07390.2880AID977608
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)IC50 (µMol)0.28800.00090.07390.2880AID977608
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)IC50 (µMol)0.28800.00090.07390.2880AID977608
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)IC50 (µMol)0.28800.00090.07390.2880AID977608
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)IC50 (µMol)0.28800.00090.07390.2880AID977608
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)IC50 (µMol)0.28800.00090.07390.2880AID977608
cAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)IC50 (µMol)0.93030.00001.068010.0000AID157302; AID157779; AID158447; AID158466; AID159936; AID275702; AID695680
cAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)IC50 (µMol)0.36660.00001.104010.0000AID1060996; AID157302; AID158447; AID158466; AID159936; AID1625374; AID1625375; AID275701; AID448555; AID647425; AID735056
cAMP-specific 3',5'-cyclic phosphodiesterase 4CHomo sapiens (human)IC50 (µMol)1.09800.00001.465110.0000AID157302; AID158447; AID158466; AID159936; AID275703
cAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)IC50 (µMol)0.44220.00001.146310.0000AID157302; AID158447; AID158466; AID159936; AID1625379; AID275704
cGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)IC50 (µMol)3.16230.00002.072410.0000AID157297
cGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)IC50 (µMol)3.16230.00031.990110.0000AID157297
Beta-2 adrenergic receptorCavia porcellus (domestic guinea pig)IC50 (µMol)0.50000.00040.16800.9772AID1060996
cGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)IC50 (µMol)116.85440.00001.77679.2000AID159057; AID159067; AID1797296; AID1799753; AID241176; AID260821
cGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)Ki200.00001.00001.90002.8000AID159075
High affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8AHomo sapiens (human)IC50 (µMol)127.66690.00001.85239.2000AID1797296; AID1799753; AID260828
Retina-specific copper amine oxidaseHomo sapiens (human)IC50 (µMol)0.00030.00030.00520.0100AID159969
cGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)IC50 (µMol)115.02170.00001.18439.6140AID157937; AID157952; AID158099; AID158112; AID158584; AID1797296; AID1799753; AID260827
cGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)Ki200.00000.00071.07978.5000AID158118
High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9AHomo sapiens (human)IC50 (µMol)16.00000.00801.16175.6000AID260830
3',5'-cyclic-AMP phosphodiesterase Sus scrofa (pig)IC50 (µMol)3.63000.00103.40026.4000AID158405
ReninHomo sapiens (human)IC50 (µMol)3.50000.00000.77968.2000AID160134
Tumor necrosis factorHomo sapiens (human)IC50 (µMol)4.23330.20000.67911.3000AID1372328; AID1372331; AID215076
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A Bos taurus (cattle)IC50 (µMol)1,355.00000.40002.23759.9000AID158756; AID46326
cAMP-specific 3',5'-cyclic phosphodiesterase 4D Rattus norvegicus (Norway rat)IC50 (µMol)0.72870.00032.723210.0000AID158402; AID158405; AID159952; AID159964; AID159969; AID160103; AID160105; AID195536; AID219415; AID45804; AID45806
cAMP-specific 3',5'-cyclic phosphodiesterase 4D Rattus norvegicus (Norway rat)Ki0.01100.01101.01233.0000AID160121
cAMP-specific 3',5'-cyclic phosphodiesterase 4CRattus norvegicus (Norway rat)IC50 (µMol)0.72870.00032.723210.0000AID158402; AID158405; AID159952; AID159964; AID159969; AID160103; AID160105; AID195536; AID219415; AID45804; AID45806
cAMP-specific 3',5'-cyclic phosphodiesterase 4CRattus norvegicus (Norway rat)Ki0.01100.01101.01233.0000AID160121
cAMP-specific 3',5'-cyclic phosphodiesterase 4BRattus norvegicus (Norway rat)IC50 (µMol)0.84470.00032.663810.0000AID157915; AID158402; AID158405; AID159952; AID159964; AID159969; AID160103; AID160105; AID195536; AID219415; AID45804; AID45806
cAMP-specific 3',5'-cyclic phosphodiesterase 4BRattus norvegicus (Norway rat)Ki0.01100.01101.01233.0000AID160121
Prostaglandin G/H synthase 1Homo sapiens (human)IC50 (µMol)10.00000.00021.557410.0000AID241176
Sodium-dependent noradrenaline transporter Homo sapiens (human)Ki0.05890.00031.465610.0000AID1799063
Adenosine receptor A1Rattus norvegicus (Norway rat)IC50 (µMol)100.00000.00020.552110.0000AID31403
cAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)IC50 (µMol)1.19420.00001.068010.0000AID1254336; AID1335402; AID1404140; AID155682; AID157744; AID157775; AID158402; AID158457; AID158463; AID158465; AID158469; AID159517; AID159628; AID159632; AID159634; AID159635; AID159636; AID159640; AID159645; AID159654; AID159656; AID159777; AID159778; AID159783; AID159787; AID159793; AID159796; AID159935; AID160128; AID160129; AID160134; AID160135; AID1703915; AID219165; AID225258; AID260823; AID314437; AID349551; AID349562; AID363083; AID363084; AID363085; AID363086; AID363087; AID363094; AID440693; AID517457; AID662984; AID695680; AID704168; AID759595
cAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)Ki1.79150.00041.43528.7600AID157304; AID157758; AID157760; AID159650; AID159663; AID159806; AID159810; AID1797212; AID1799063; AID225259; AID238295; AID239332
Adenosine receptor A2bRattus norvegicus (Norway rat)IC50 (µMol)100.00000.00240.68169.0000AID33406
Adenosine receptor A2aRattus norvegicus (Norway rat)IC50 (µMol)100.00000.00120.48289.0000AID33406
Sodium-dependent serotonin transporterRattus norvegicus (Norway rat)IC50 (µMol)0.09500.00030.81978.4900AID759595
Delta-type opioid receptorMus musculus (house mouse)IC50 (µMol)1.50000.00010.729810.0000AID1311212
Delta-type opioid receptorRattus norvegicus (Norway rat)IC50 (µMol)1.50000.00030.38877.0000AID1311212
Bifunctional epoxide hydrolase 2Homo sapiens (human)IC50 (µMol)100.00000.00000.54509.1000AID1480235
cAMP-specific 3',5'-cyclic phosphodiesterase 4ARattus norvegicus (Norway rat)IC50 (µMol)0.72870.00032.723210.0000AID158402; AID158405; AID159952; AID159964; AID159969; AID160103; AID160105; AID195536; AID219415; AID45804; AID45806
cAMP-specific 3',5'-cyclic phosphodiesterase 4ARattus norvegicus (Norway rat)Ki0.01100.01101.01233.0000AID160121
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1AHomo sapiens (human)IC50 (µMol)112.50000.23002.510510.0000AID158884; AID158890; AID158909; AID314434
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1AHomo sapiens (human)Ki200.00009.50009.750010.0000AID158913
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BBos taurus (cattle)IC50 (µMol)1,355.00000.40002.23759.9000AID158756; AID46326
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BHomo sapiens (human)IC50 (µMol)149.35920.00002.14179.2000AID158884; AID158890; AID158909; AID1797296
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BHomo sapiens (human)Ki200.00009.50009.750010.0000AID158913
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BRattus norvegicus (Norway rat)IC50 (µMol)100.00000.10000.20000.3000AID179556
cAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)IC50 (µMol)17.00120.00001.104010.0000AID1160998; AID1166735; AID1247790; AID1254336; AID1254337; AID1311212; AID1335403; AID1374977; AID1381681; AID1404136; AID1404141; AID1420132; AID1420139; AID1421678; AID1427214; AID1464265; AID1512227; AID1512233; AID155682; AID157744; AID157785; AID158457; AID158463; AID158465; AID1593011; AID159517; AID1596202; AID159628; AID159632; AID159634; AID159635; AID159636; AID159640; AID159645; AID159654; AID159656; AID159777; AID159778; AID159783; AID159787; AID159793; AID159796; AID159935; AID160128; AID160129; AID160134; AID160135; AID1625373; AID1625374; AID1667995; AID1703916; AID1707985; AID1724978; AID1727166; AID1743663; AID1743666; AID1783024; AID1797296; AID1884344; AID219165; AID225256; AID225258; AID260824; AID314438; AID318118; AID318127; AID349551; AID349562; AID363083; AID363084; AID363085; AID363086; AID363087; AID363088; AID363089; AID363090; AID363091; AID363092; AID363093; AID363094; AID425684; AID425685; AID440693; AID517456; AID662984; AID704167; AID731227; AID733565; AID736493
cAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)Ki1.25770.00041.16418.7600AID157304; AID157758; AID157760; AID159650; AID159663; AID159806; AID159810; AID159939; AID159940; AID1797212; AID1799063; AID225259; AID238295; AID239333
cAMP-specific 3',5'-cyclic phosphodiesterase 4CHomo sapiens (human)IC50 (µMol)2.78120.00001.465110.0000AID1254336; AID1335404; AID1404142; AID155682; AID157744; AID157917; AID157918; AID158457; AID158463; AID158465; AID159517; AID159628; AID159632; AID159634; AID159635; AID159636; AID159640; AID159645; AID159654; AID159656; AID159777; AID159778; AID159783; AID159787; AID159793; AID159796; AID159935; AID160128; AID160129; AID160134; AID160135; AID1703917; AID1773140; AID1773141; AID219165; AID225258; AID260825; AID349551; AID349562; AID363083; AID363084; AID363085; AID363086; AID363087; AID363094; AID440693; AID662984; AID704166
cAMP-specific 3',5'-cyclic phosphodiesterase 4CHomo sapiens (human)Ki0.22640.00040.12471.0000AID157304; AID157758; AID157760; AID159650; AID159663; AID159806; AID159810; AID225259; AID238295
cAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)IC50 (µMol)15.88510.00001.146310.0000AID1129294; AID1160999; AID1166733; AID1177596; AID1177597; AID1187760; AID1254336; AID1254338; AID1261704; AID1335405; AID1351564; AID1374976; AID1404143; AID1420133; AID1420140; AID1427215; AID1464266; AID1512234; AID1543153; AID1543154; AID155682; AID157744; AID157921; AID157922; AID158457; AID158463; AID158465; AID1591866; AID159517; AID1596204; AID159628; AID159632; AID159634; AID159635; AID159636; AID159640; AID159645; AID159654; AID159656; AID159777; AID159778; AID159783; AID159787; AID159793; AID159796; AID1598959; AID159935; AID160128; AID160129; AID160134; AID160135; AID1605515; AID1623076; AID1625378; AID1625379; AID1703918; AID1724979; AID1727184; AID1743664; AID1773990; AID1797296; AID1799753; AID1884574; AID219165; AID225258; AID260822; AID260824; AID260826; AID260838; AID260839; AID260840; AID260841; AID314439; AID349551; AID349562; AID363083; AID363084; AID363085; AID363086; AID363087; AID363094; AID363095; AID363096; AID363097; AID363098; AID363099; AID363100; AID363101; AID363102; AID389793; AID425687; AID440693; AID440695; AID440702; AID440708; AID440709; AID440710; AID462320; AID517458; AID662984; AID704164
cAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)Ki1.44180.00041.52938.7600AID157304; AID157758; AID157760; AID159650; AID159663; AID159806; AID159810; AID1797212; AID1799063; AID225259; AID238295; AID239334; AID239335; AID239336; AID395330; AID440708; AID440709; AID440710
cGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)IC50 (µMol)145.18350.00002.072410.0000AID155664; AID155672; AID159213; AID159214; AID159219; AID159222; AID159227; AID159342; AID1797296; AID241177; AID260822
cGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)Ki200.00000.00500.33811.4000AID159490
High affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7AHomo sapiens (human)IC50 (µMol)200.00000.09001.63104.6900AID1381682; AID1421679
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1CHomo sapiens (human)IC50 (µMol)133.33330.23001.98149.0000AID158884; AID158890; AID158909
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1CHomo sapiens (human)Ki200.00009.50009.750010.0000AID158913
cGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)IC50 (µMol)122.00000.00031.990110.0000AID155664; AID155672; AID159213; AID159214; AID159219; AID159222; AID159227; AID159342; AID1799753; AID241177; AID260822
cGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)Ki200.00000.00500.32091.4000AID159490
cGMP-specific 3',5'-cyclic phosphodiesteraseBos taurus (cattle)IC50 (µMol)88.66670.00331.624010.0000AID157930; AID219317; AID662985
Endothelin-1 receptorSus scrofa (pig)Ki0.00450.00450.00450.0045AID159650
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1CRattus norvegicus (Norway rat)IC50 (µMol)100.00000.10000.20000.3000AID179556
Protein cereblonHomo sapiens (human)IC50 (µMol)202.00000.28601.70663.0000AID1685005
Protein cereblonHomo sapiens (human)Ki102.00001.49006.580010.0000AID1685005
Phosphodiesterase Rattus norvegicus (Norway rat)IC50 (µMol)100.00000.10000.20000.3000AID179556
Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11AHomo sapiens (human)IC50 (µMol)141.60640.00001.97009.2000AID1797296; AID260832
cAMP-specific 3',5'-cyclic phosphodiesterase 7BHomo sapiens (human)IC50 (µMol)154.16700.00002.05139.2000AID1797296
Phosphodiesterase Sus scrofa (pig)IC50 (µMol)100.00000.62000.73150.8430AID155675
cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10AHomo sapiens (human)IC50 (µMol)141.60640.00001.49049.2000AID1797296; AID260831
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
cAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)EC50 (µMol)0.48000.01701.21593.4000AID695683
cAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)EC50 (µMol)0.50000.01701.21593.4000AID695683
cAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)EC50 (µMol)0.66000.22000.66001.1000AID260834; AID650863
cAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)EC50 (µMol)1.10001.10001.10001.1000AID260834
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
cAMP-specific 3',5'-cyclic phosphodiesterase 4BRattus norvegicus (Norway rat)Log IC500.00570.00570.00570.0057AID157916
cAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)Log IC500.00590.00590.00590.0059AID157781
cAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)Log IC500.00640.00640.00640.0064AID157924
cGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)Log IC500.00400.00400.00400.0040AID159498
cGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)Log IC500.00400.00400.00400.0040AID159498
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (330)

Processvia Protein(s)Taxonomy
cAMP catabolic processcAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
signal transductioncAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
G protein-coupled receptor signaling pathwaycAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
sensory perception of smellcAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
regulation of protein kinase A signalingcAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
cellular response to xenobiotic stimuluscAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathwaycAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
cAMP-mediated signalingcAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
neutrophil homeostasiscAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
cAMP catabolic processcAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
neutrophil chemotaxiscAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
positive regulation of type II interferon productioncAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
positive regulation of interleukin-2 productioncAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
T cell receptor signaling pathwaycAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
leukocyte migrationcAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
cellular response to lipopolysaccharidecAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
cellular response to xenobiotic stimuluscAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
cellular response to epinephrine stimuluscAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
negative regulation of adenylate cyclase-activating adrenergic receptor signaling pathwaycAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
regulation of cardiac muscle cell contractioncAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
negative regulation of relaxation of cardiac musclecAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
regulation of calcium ion transmembrane transport via high voltage-gated calcium channelcAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
cAMP-mediated signalingcAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
cAMP catabolic processcAMP-specific 3',5'-cyclic phosphodiesterase 4CHomo sapiens (human)
cAMP-mediated signalingcAMP-specific 3',5'-cyclic phosphodiesterase 4CHomo sapiens (human)
regulation of heart ratecAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
cAMP catabolic processcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
positive regulation of heart ratecAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
regulation of release of sequestered calcium ion into cytosol by sarcoplasmic reticulumcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
positive regulation of type II interferon productioncAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
positive regulation of interleukin-2 productioncAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
positive regulation of interleukin-5 productioncAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
negative regulation of peptidyl-serine phosphorylationcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
negative regulation of heart contractioncAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
T cell receptor signaling pathwaycAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
establishment of endothelial barriercAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
adrenergic receptor signaling pathwaycAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
regulation of cardiac muscle cell contractioncAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
negative regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathwaycAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
regulation of cell communication by electrical coupling involved in cardiac conductioncAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
negative regulation of relaxation of cardiac musclecAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
regulation of calcium ion transmembrane transport via high voltage-gated calcium channelcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
cAMP-mediated signalingcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
angiogenesiscGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
negative regulation of cell adhesioncGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
G protein-coupled receptor signaling pathwaycGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
negative regulation of angiogenesiscGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
cellular response to insulin stimuluscGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
negative regulation of cell adhesion mediated by integrincGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
negative regulation of lipid catabolic processcGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
negative regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathwaycGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
cAMP-mediated signalingcGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
oocyte maturationcGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
lipid metabolic processcGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
G protein-coupled receptor signaling pathwaycGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
response to xenobiotic stimuluscGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
cAMP-mediated signalingcGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
cGMP-mediated signalingcGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
regulation of meiotic nuclear divisioncGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
negative regulation of apoptotic processcGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
negative regulation of vascular permeabilitycGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
positive regulation of vascular permeabilitycGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
steroid hormone mediated signaling pathwaycGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
negative regulation of cAMP-mediated signalingcGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
positive regulation of oocyte developmentcGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
regulation of ribonuclease activitycGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
cellular response to cGMPcGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
cellular response to transforming growth factor beta stimuluscGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
apoptotic signaling pathwaycGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
negative regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathwaycGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
negative regulation of transcription by RNA polymerase IICREB-binding proteinHomo sapiens (human)
response to hypoxiaCREB-binding proteinHomo sapiens (human)
stimulatory C-type lectin receptor signaling pathwayCREB-binding proteinHomo sapiens (human)
chromatin remodelingCREB-binding proteinHomo sapiens (human)
regulation of DNA-templated transcriptionCREB-binding proteinHomo sapiens (human)
protein acetylationCREB-binding proteinHomo sapiens (human)
signal transductionCREB-binding proteinHomo sapiens (human)
canonical NF-kappaB signal transductionCREB-binding proteinHomo sapiens (human)
regulation of smoothened signaling pathwayCREB-binding proteinHomo sapiens (human)
negative regulation of transcription by RNA polymerase ICREB-binding proteinHomo sapiens (human)
N-terminal peptidyl-lysine acetylationCREB-binding proteinHomo sapiens (human)
positive regulation of transforming growth factor beta receptor signaling pathwayCREB-binding proteinHomo sapiens (human)
protein destabilizationCREB-binding proteinHomo sapiens (human)
cellular response to nutrient levelsCREB-binding proteinHomo sapiens (human)
cellular response to UVCREB-binding proteinHomo sapiens (human)
homeostatic processCREB-binding proteinHomo sapiens (human)
embryonic digit morphogenesisCREB-binding proteinHomo sapiens (human)
positive regulation of DNA-templated transcriptionCREB-binding proteinHomo sapiens (human)
positive regulation of transcription by RNA polymerase IICREB-binding proteinHomo sapiens (human)
rhythmic processCREB-binding proteinHomo sapiens (human)
protein-containing complex assemblyCREB-binding proteinHomo sapiens (human)
regulation of cellular response to heatCREB-binding proteinHomo sapiens (human)
positive regulation of protein localization to nucleusCREB-binding proteinHomo sapiens (human)
positive regulation of double-strand break repair via homologous recombinationCREB-binding proteinHomo sapiens (human)
heart valve developmentcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
ventricular septum developmentcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
aorta developmentcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwaycGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
regulation of cGMP-mediated signalingcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cAMP-mediated signalingcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cGMP-mediated signalingcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cellular response to macrophage colony-stimulating factor stimuluscGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
negative regulation of vascular permeabilitycGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
positive regulation of vascular permeabilitycGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
regulation of cAMP-mediated signalingcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cGMP catabolic processcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
positive regulation of inflammatory responsecGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
establishment of endothelial barriercGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cellular response to mechanical stimuluscGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cellular response to cAMPcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cellular response to cGMPcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cellular response to transforming growth factor beta stimuluscGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
negative regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathwaycGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cellular response to 2,3,7,8-tetrachlorodibenzodioxinecGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
positive regulation of gene expressioncGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
negative regulation of cGMP-mediated signalingcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
negative regulation of cAMP-mediated signalingcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
regulation of mitochondrion organizationcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cAMP catabolic processHigh affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8AHomo sapiens (human)
regulation of DNA-templated transcriptionHigh affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8AHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeHigh affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8AHomo sapiens (human)
cellular response to epidermal growth factor stimulusHigh affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8AHomo sapiens (human)
cAMP-mediated signalingHigh affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8AHomo sapiens (human)
catecholamine metabolic processRetina-specific copper amine oxidaseHomo sapiens (human)
xenobiotic metabolic processRetina-specific copper amine oxidaseHomo sapiens (human)
visual perceptionRetina-specific copper amine oxidaseHomo sapiens (human)
amine metabolic processRetina-specific copper amine oxidaseHomo sapiens (human)
positive regulation of cardiac muscle hypertrophycGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
regulation of nitric oxide mediated signal transductioncGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
T cell proliferationcGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
negative regulation of T cell proliferationcGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cGMP catabolic processcGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
oocyte developmentcGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
negative regulation of cardiac muscle contractioncGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
relaxation of cardiac musclecGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
positive regulation of oocyte developmentcGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cAMP-mediated signalingcGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
signal transductionHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9AHomo sapiens (human)
positive regulation of cardiac muscle hypertrophyHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9AHomo sapiens (human)
cGMP metabolic processHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9AHomo sapiens (human)
cGMP catabolic processHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9AHomo sapiens (human)
positive regulation of long-term synaptic potentiationHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9AHomo sapiens (human)
negative regulation of neural precursor cell proliferationHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9AHomo sapiens (human)
cAMP-mediated signalingHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9AHomo sapiens (human)
behavioral fear responseHigh affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8BHomo sapiens (human)
cAMP catabolic processHigh affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8BHomo sapiens (human)
visual learningHigh affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8BHomo sapiens (human)
operant conditioningHigh affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8BHomo sapiens (human)
neuromuscular process controlling balanceHigh affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8BHomo sapiens (human)
negative regulation of insulin secretion involved in cellular response to glucose stimulusHigh affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8BHomo sapiens (human)
negative regulation of steroid hormone biosynthetic processHigh affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8BHomo sapiens (human)
cAMP-mediated signalingHigh affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8BHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeHigh affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8BHomo sapiens (human)
kidney developmentReninHomo sapiens (human)
mesonephros developmentReninHomo sapiens (human)
angiotensin maturationReninHomo sapiens (human)
renin-angiotensin regulation of aldosterone productionReninHomo sapiens (human)
proteolysisReninHomo sapiens (human)
regulation of blood pressureReninHomo sapiens (human)
male gonad developmentReninHomo sapiens (human)
hormone-mediated signaling pathwayReninHomo sapiens (human)
response to lipopolysaccharideReninHomo sapiens (human)
response to immobilization stressReninHomo sapiens (human)
drinking behaviorReninHomo sapiens (human)
regulation of MAPK cascadeReninHomo sapiens (human)
cell maturationReninHomo sapiens (human)
amyloid-beta metabolic processReninHomo sapiens (human)
response to cAMPReninHomo sapiens (human)
response to cGMPReninHomo sapiens (human)
cellular response to xenobiotic stimulusReninHomo sapiens (human)
juxtaglomerular apparatus developmentReninHomo sapiens (human)
positive regulation of gene expressionTumor necrosis factorHomo sapiens (human)
negative regulation of gene expressionTumor necrosis factorHomo sapiens (human)
positive regulation of MAP kinase activityTumor necrosis factorHomo sapiens (human)
positive regulation of MAPK cascadeTumor necrosis factorHomo sapiens (human)
positive regulation of interleukin-33 productionTumor necrosis factorHomo sapiens (human)
positive regulation of cytokine production involved in inflammatory responseTumor necrosis factorHomo sapiens (human)
negative regulation of miRNA transcriptionTumor necrosis factorHomo sapiens (human)
positive regulation of miRNA transcriptionTumor necrosis factorHomo sapiens (human)
negative regulation of signaling receptor activityTumor necrosis factorHomo sapiens (human)
negative regulation of transcription by RNA polymerase IITumor necrosis factorHomo sapiens (human)
positive regulation of gene expressionTumor necrosis factorHomo sapiens (human)
negative regulation of gene expressionTumor necrosis factorHomo sapiens (human)
positive regulation of interleukin-8 productionTumor necrosis factorHomo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic processTumor necrosis factorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IITumor necrosis factorHomo sapiens (human)
positive regulation of NF-kappaB transcription factor activityTumor necrosis factorHomo sapiens (human)
positive regulation of calcineurin-NFAT signaling cascadeTumor necrosis factorHomo sapiens (human)
positive regulation of cytokine production involved in inflammatory responseTumor necrosis factorHomo sapiens (human)
positive regulation of non-canonical NF-kappaB signal transductionTumor necrosis factorHomo sapiens (human)
positive regulation of synoviocyte proliferationTumor necrosis factorHomo sapiens (human)
positive regulation of I-kappaB phosphorylationTumor necrosis factorHomo sapiens (human)
negative regulation of apoptotic signaling pathwayTumor necrosis factorHomo sapiens (human)
negative regulation of transcription by RNA polymerase IITumor necrosis factorHomo sapiens (human)
response to hypoxiaTumor necrosis factorHomo sapiens (human)
microglial cell activationTumor necrosis factorHomo sapiens (human)
positive regulation of cytokine productionTumor necrosis factorHomo sapiens (human)
positive regulation of protein phosphorylationTumor necrosis factorHomo sapiens (human)
negative regulation of endothelial cell proliferationTumor necrosis factorHomo sapiens (human)
negative regulation of L-glutamate import across plasma membraneTumor necrosis factorHomo sapiens (human)
macrophage activation involved in immune responseTumor necrosis factorHomo sapiens (human)
chronic inflammatory response to antigenic stimulusTumor necrosis factorHomo sapiens (human)
leukocyte migration involved in inflammatory responseTumor necrosis factorHomo sapiens (human)
regulation of immunoglobulin productionTumor necrosis factorHomo sapiens (human)
negative regulation of cytokine production involved in immune responseTumor necrosis factorHomo sapiens (human)
positive regulation of chronic inflammatory response to antigenic stimulusTumor necrosis factorHomo sapiens (human)
positive regulation of humoral immune response mediated by circulating immunoglobulinTumor necrosis factorHomo sapiens (human)
skeletal muscle contractionTumor necrosis factorHomo sapiens (human)
negative regulation of systemic arterial blood pressureTumor necrosis factorHomo sapiens (human)
glucose metabolic processTumor necrosis factorHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processTumor necrosis factorHomo sapiens (human)
inflammatory responseTumor necrosis factorHomo sapiens (human)
humoral immune responseTumor necrosis factorHomo sapiens (human)
JNK cascadeTumor necrosis factorHomo sapiens (human)
circadian rhythmTumor necrosis factorHomo sapiens (human)
extrinsic apoptotic signaling pathway via death domain receptorsTumor necrosis factorHomo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damageTumor necrosis factorHomo sapiens (human)
response to xenobiotic stimulusTumor necrosis factorHomo sapiens (human)
response to virusTumor necrosis factorHomo sapiens (human)
response to salt stressTumor necrosis factorHomo sapiens (human)
response to fructoseTumor necrosis factorHomo sapiens (human)
negative regulation of heart rateTumor necrosis factorHomo sapiens (human)
vascular endothelial growth factor productionTumor necrosis factorHomo sapiens (human)
positive regulation of gene expressionTumor necrosis factorHomo sapiens (human)
negative regulation of gene expressionTumor necrosis factorHomo sapiens (human)
negative regulation of lipid storageTumor necrosis factorHomo sapiens (human)
response to activityTumor necrosis factorHomo sapiens (human)
regulation of metabolic processTumor necrosis factorHomo sapiens (human)
calcium-mediated signalingTumor necrosis factorHomo sapiens (human)
extracellular matrix organizationTumor necrosis factorHomo sapiens (human)
osteoclast differentiationTumor necrosis factorHomo sapiens (human)
sequestering of triglycerideTumor necrosis factorHomo sapiens (human)
cortical actin cytoskeleton organizationTumor necrosis factorHomo sapiens (human)
positive regulation of protein-containing complex assemblyTumor necrosis factorHomo sapiens (human)
positive regulation of fever generationTumor necrosis factorHomo sapiens (human)
negative regulation of myelinationTumor necrosis factorHomo sapiens (human)
response to nutrient levelsTumor necrosis factorHomo sapiens (human)
negative regulation of interleukin-6 productionTumor necrosis factorHomo sapiens (human)
positive regulation of chemokine productionTumor necrosis factorHomo sapiens (human)
positive regulation of fractalkine productionTumor necrosis factorHomo sapiens (human)
positive regulation of type II interferon productionTumor necrosis factorHomo sapiens (human)
positive regulation of interleukin-1 beta productionTumor necrosis factorHomo sapiens (human)
positive regulation of interleukin-18 productionTumor necrosis factorHomo sapiens (human)
positive regulation of interleukin-6 productionTumor necrosis factorHomo sapiens (human)
positive regulation of interleukin-8 productionTumor necrosis factorHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationTumor necrosis factorHomo sapiens (human)
tumor necrosis factor-mediated signaling pathwayTumor necrosis factorHomo sapiens (human)
positive regulation of heterotypic cell-cell adhesionTumor necrosis factorHomo sapiens (human)
toll-like receptor 3 signaling pathwayTumor necrosis factorHomo sapiens (human)
negative regulation of myosin-light-chain-phosphatase activityTumor necrosis factorHomo sapiens (human)
response to isolation stressTumor necrosis factorHomo sapiens (human)
response to macrophage colony-stimulating factorTumor necrosis factorHomo sapiens (human)
vasodilationTumor necrosis factorHomo sapiens (human)
positive regulation of tyrosine phosphorylation of STAT proteinTumor necrosis factorHomo sapiens (human)
positive regulation of apoptotic processTumor necrosis factorHomo sapiens (human)
positive regulation of programmed cell deathTumor necrosis factorHomo sapiens (human)
regulation of canonical NF-kappaB signal transductionTumor necrosis factorHomo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionTumor necrosis factorHomo sapiens (human)
negative regulation of protein-containing complex disassemblyTumor necrosis factorHomo sapiens (human)
positive regulation of protein-containing complex disassemblyTumor necrosis factorHomo sapiens (human)
positive regulation of cysteine-type endopeptidase activity involved in apoptotic processTumor necrosis factorHomo sapiens (human)
positive regulation of MAP kinase activityTumor necrosis factorHomo sapiens (human)
positive regulation of MAPK cascadeTumor necrosis factorHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transductionTumor necrosis factorHomo sapiens (human)
positive regulation of JUN kinase activityTumor necrosis factorHomo sapiens (human)
positive regulation of neuron apoptotic processTumor necrosis factorHomo sapiens (human)
negative regulation of blood vessel endothelial cell migrationTumor necrosis factorHomo sapiens (human)
negative regulation of viral genome replicationTumor necrosis factorHomo sapiens (human)
positive regulation of nitric oxide biosynthetic processTumor necrosis factorHomo sapiens (human)
response to ethanolTumor necrosis factorHomo sapiens (human)
regulation of fat cell differentiationTumor necrosis factorHomo sapiens (human)
negative regulation of fat cell differentiationTumor necrosis factorHomo sapiens (human)
negative regulation of myoblast differentiationTumor necrosis factorHomo sapiens (human)
negative regulation of osteoblast differentiationTumor necrosis factorHomo sapiens (human)
positive regulation of osteoclast differentiationTumor necrosis factorHomo sapiens (human)
positive regulation of protein catabolic processTumor necrosis factorHomo sapiens (human)
positive regulation of action potentialTumor necrosis factorHomo sapiens (human)
positive regulation of cell adhesionTumor necrosis factorHomo sapiens (human)
positive regulation of mitotic nuclear divisionTumor necrosis factorHomo sapiens (human)
negative regulation of DNA-templated transcriptionTumor necrosis factorHomo sapiens (human)
positive regulation of DNA-templated transcriptionTumor necrosis factorHomo sapiens (human)
negative regulation of mitotic cell cycleTumor necrosis factorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IITumor necrosis factorHomo sapiens (human)
positive regulation of translational initiation by ironTumor necrosis factorHomo sapiens (human)
negative regulation of glucose importTumor necrosis factorHomo sapiens (human)
positive regulation of JNK cascadeTumor necrosis factorHomo sapiens (human)
positive regulation of receptor signaling pathway via JAK-STATTumor necrosis factorHomo sapiens (human)
astrocyte activationTumor necrosis factorHomo sapiens (human)
embryonic digestive tract developmentTumor necrosis factorHomo sapiens (human)
positive regulation of smooth muscle cell proliferationTumor necrosis factorHomo sapiens (human)
positive regulation of inflammatory responseTumor necrosis factorHomo sapiens (human)
negative regulation of neurogenesisTumor necrosis factorHomo sapiens (human)
regulation of insulin secretionTumor necrosis factorHomo sapiens (human)
positive regulation of synaptic transmissionTumor necrosis factorHomo sapiens (human)
regulation of synapse organizationTumor necrosis factorHomo sapiens (human)
defense response to Gram-positive bacteriumTumor necrosis factorHomo sapiens (human)
cognitionTumor necrosis factorHomo sapiens (human)
leukocyte tethering or rollingTumor necrosis factorHomo sapiens (human)
detection of mechanical stimulus involved in sensory perception of painTumor necrosis factorHomo sapiens (human)
negative regulation of lipid catabolic processTumor necrosis factorHomo sapiens (human)
positive regulation of membrane protein ectodomain proteolysisTumor necrosis factorHomo sapiens (human)
positive regulation of DNA-binding transcription factor activityTumor necrosis factorHomo sapiens (human)
positive regulation of NF-kappaB transcription factor activityTumor necrosis factorHomo sapiens (human)
positive regulation of protein transportTumor necrosis factorHomo sapiens (human)
response to glucocorticoidTumor necrosis factorHomo sapiens (human)
positive regulation of hair follicle developmentTumor necrosis factorHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionTumor necrosis factorHomo sapiens (human)
regulation of synaptic transmission, glutamatergicTumor necrosis factorHomo sapiens (human)
positive regulation of glial cell proliferationTumor necrosis factorHomo sapiens (human)
positive regulation of vitamin D biosynthetic processTumor necrosis factorHomo sapiens (human)
positive regulation of calcidiol 1-monooxygenase activityTumor necrosis factorHomo sapiens (human)
epithelial cell proliferation involved in salivary gland morphogenesisTumor necrosis factorHomo sapiens (human)
regulation of branching involved in salivary gland morphogenesisTumor necrosis factorHomo sapiens (human)
negative regulation of vascular wound healingTumor necrosis factorHomo sapiens (human)
negative regulation of branching involved in lung morphogenesisTumor necrosis factorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeTumor necrosis factorHomo sapiens (human)
cellular response to lipopolysaccharideTumor necrosis factorHomo sapiens (human)
cellular response to amino acid stimulusTumor necrosis factorHomo sapiens (human)
cellular response to retinoic acidTumor necrosis factorHomo sapiens (human)
cellular response to nicotineTumor necrosis factorHomo sapiens (human)
cellular response to type II interferonTumor necrosis factorHomo sapiens (human)
cellular response to ionizing radiationTumor necrosis factorHomo sapiens (human)
positive regulation of mononuclear cell migrationTumor necrosis factorHomo sapiens (human)
positive regulation of podosome assemblyTumor necrosis factorHomo sapiens (human)
endothelial cell apoptotic processTumor necrosis factorHomo sapiens (human)
protein localization to plasma membraneTumor necrosis factorHomo sapiens (human)
negative regulation of oxidative phosphorylationTumor necrosis factorHomo sapiens (human)
inflammatory response to woundingTumor necrosis factorHomo sapiens (human)
extrinsic apoptotic signaling pathwayTumor necrosis factorHomo sapiens (human)
cellular response to toxic substanceTumor necrosis factorHomo sapiens (human)
liver regenerationTumor necrosis factorHomo sapiens (human)
necroptotic signaling pathwayTumor necrosis factorHomo sapiens (human)
negative regulation of bile acid secretionTumor necrosis factorHomo sapiens (human)
antiviral innate immune responseTumor necrosis factorHomo sapiens (human)
response to Gram-negative bacteriumTumor necrosis factorHomo sapiens (human)
positive regulation of neuroinflammatory responseTumor necrosis factorHomo sapiens (human)
negative regulation of amyloid-beta clearanceTumor necrosis factorHomo sapiens (human)
positive regulation of non-canonical NF-kappaB signal transductionTumor necrosis factorHomo sapiens (human)
positive regulation of amyloid-beta formationTumor necrosis factorHomo sapiens (human)
response to L-glutamateTumor necrosis factorHomo sapiens (human)
positive regulation of neutrophil activationTumor necrosis factorHomo sapiens (human)
positive regulation of protein localization to plasma membraneTumor necrosis factorHomo sapiens (human)
regulation of establishment of endothelial barrierTumor necrosis factorHomo sapiens (human)
negative regulation of bicellular tight junction assemblyTumor necrosis factorHomo sapiens (human)
cellular response to amyloid-betaTumor necrosis factorHomo sapiens (human)
positive regulation of vascular associated smooth muscle cell proliferationTumor necrosis factorHomo sapiens (human)
positive regulation of leukocyte adhesion to vascular endothelial cellTumor necrosis factorHomo sapiens (human)
positive regulation of leukocyte adhesion to arterial endothelial cellTumor necrosis factorHomo sapiens (human)
regulation of membrane lipid metabolic processTumor necrosis factorHomo sapiens (human)
response to 3,3',5-triiodo-L-thyronineTumor necrosis factorHomo sapiens (human)
response to gold nanoparticleTumor necrosis factorHomo sapiens (human)
positive regulation of protein localization to cell surfaceTumor necrosis factorHomo sapiens (human)
positive regulation of blood microparticle formationTumor necrosis factorHomo sapiens (human)
positive regulation of chemokine (C-X-C motif) ligand 2 productionTumor necrosis factorHomo sapiens (human)
positive regulation of hepatocyte proliferationTumor necrosis factorHomo sapiens (human)
regulation of endothelial cell apoptotic processTumor necrosis factorHomo sapiens (human)
regulation of reactive oxygen species metabolic processTumor necrosis factorHomo sapiens (human)
positive regulation of DNA biosynthetic processTumor necrosis factorHomo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathway in absence of ligandTumor necrosis factorHomo sapiens (human)
positive regulation of extrinsic apoptotic signaling pathwayTumor necrosis factorHomo sapiens (human)
prostaglandin biosynthetic processProstaglandin G/H synthase 1Homo sapiens (human)
response to oxidative stressProstaglandin G/H synthase 1Homo sapiens (human)
regulation of blood pressureProstaglandin G/H synthase 1Homo sapiens (human)
cyclooxygenase pathwayProstaglandin G/H synthase 1Homo sapiens (human)
regulation of cell population proliferationProstaglandin G/H synthase 1Homo sapiens (human)
cellular oxidant detoxificationProstaglandin G/H synthase 1Homo sapiens (human)
monoamine transportSodium-dependent noradrenaline transporter Homo sapiens (human)
neurotransmitter transportSodium-dependent noradrenaline transporter Homo sapiens (human)
chemical synaptic transmissionSodium-dependent noradrenaline transporter Homo sapiens (human)
response to xenobiotic stimulusSodium-dependent noradrenaline transporter Homo sapiens (human)
response to painSodium-dependent noradrenaline transporter Homo sapiens (human)
norepinephrine uptakeSodium-dependent noradrenaline transporter Homo sapiens (human)
neuron cellular homeostasisSodium-dependent noradrenaline transporter Homo sapiens (human)
amino acid transportSodium-dependent noradrenaline transporter Homo sapiens (human)
norepinephrine transportSodium-dependent noradrenaline transporter Homo sapiens (human)
dopamine uptake involved in synaptic transmissionSodium-dependent noradrenaline transporter Homo sapiens (human)
sodium ion transmembrane transportSodium-dependent noradrenaline transporter Homo sapiens (human)
cAMP catabolic processcAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
signal transductioncAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
G protein-coupled receptor signaling pathwaycAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
sensory perception of smellcAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
regulation of protein kinase A signalingcAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
cellular response to xenobiotic stimuluscAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathwaycAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
cAMP-mediated signalingcAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
response to toxic substanceBifunctional epoxide hydrolase 2Homo sapiens (human)
positive regulation of gene expressionBifunctional epoxide hydrolase 2Homo sapiens (human)
dephosphorylationBifunctional epoxide hydrolase 2Homo sapiens (human)
cholesterol homeostasisBifunctional epoxide hydrolase 2Homo sapiens (human)
stilbene catabolic processBifunctional epoxide hydrolase 2Homo sapiens (human)
phospholipid dephosphorylationBifunctional epoxide hydrolase 2Homo sapiens (human)
regulation of cholesterol metabolic processBifunctional epoxide hydrolase 2Homo sapiens (human)
epoxide metabolic processBifunctional epoxide hydrolase 2Homo sapiens (human)
regulation of smooth muscle cell apoptotic processCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1AHomo sapiens (human)
cGMP catabolic processCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1AHomo sapiens (human)
regulation of smooth muscle cell proliferationCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1AHomo sapiens (human)
cAMP-mediated signalingCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1AHomo sapiens (human)
response to amphetamineCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BHomo sapiens (human)
locomotory behaviorCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BHomo sapiens (human)
visual learningCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BHomo sapiens (human)
monocyte differentiationCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BHomo sapiens (human)
cellular response to macrophage colony-stimulating factor stimulusCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BHomo sapiens (human)
dopamine catabolic processCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BHomo sapiens (human)
serotonin metabolic processCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BHomo sapiens (human)
cellular response to granulocyte macrophage colony-stimulating factor stimulusCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BHomo sapiens (human)
cAMP-mediated signalingCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BHomo sapiens (human)
neutrophil homeostasiscAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
cAMP catabolic processcAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
neutrophil chemotaxiscAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
positive regulation of type II interferon productioncAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
positive regulation of interleukin-2 productioncAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
T cell receptor signaling pathwaycAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
leukocyte migrationcAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
cellular response to lipopolysaccharidecAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
cellular response to xenobiotic stimuluscAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
cellular response to epinephrine stimuluscAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
negative regulation of adenylate cyclase-activating adrenergic receptor signaling pathwaycAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
regulation of cardiac muscle cell contractioncAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
negative regulation of relaxation of cardiac musclecAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
regulation of calcium ion transmembrane transport via high voltage-gated calcium channelcAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
cAMP-mediated signalingcAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
cAMP catabolic processcAMP-specific 3',5'-cyclic phosphodiesterase 4CHomo sapiens (human)
cAMP-mediated signalingcAMP-specific 3',5'-cyclic phosphodiesterase 4CHomo sapiens (human)
regulation of heart ratecAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
cAMP catabolic processcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
positive regulation of heart ratecAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
regulation of release of sequestered calcium ion into cytosol by sarcoplasmic reticulumcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
positive regulation of type II interferon productioncAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
positive regulation of interleukin-2 productioncAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
positive regulation of interleukin-5 productioncAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
negative regulation of peptidyl-serine phosphorylationcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
negative regulation of heart contractioncAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
T cell receptor signaling pathwaycAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
establishment of endothelial barriercAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
adrenergic receptor signaling pathwaycAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
regulation of cardiac muscle cell contractioncAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
negative regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathwaycAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
regulation of cell communication by electrical coupling involved in cardiac conductioncAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
negative regulation of relaxation of cardiac musclecAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
regulation of calcium ion transmembrane transport via high voltage-gated calcium channelcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
cAMP-mediated signalingcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
angiogenesiscGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
negative regulation of cell adhesioncGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
G protein-coupled receptor signaling pathwaycGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
negative regulation of angiogenesiscGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
cellular response to insulin stimuluscGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
negative regulation of cell adhesion mediated by integrincGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
negative regulation of lipid catabolic processcGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
negative regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathwaycGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
cAMP-mediated signalingcGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
cAMP catabolic processHigh affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7AHomo sapiens (human)
cAMP-mediated signalingHigh affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7AHomo sapiens (human)
cAMP-mediated signalingCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1CHomo sapiens (human)
oocyte maturationcGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
lipid metabolic processcGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
G protein-coupled receptor signaling pathwaycGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
response to xenobiotic stimuluscGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
cAMP-mediated signalingcGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
cGMP-mediated signalingcGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
regulation of meiotic nuclear divisioncGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
negative regulation of apoptotic processcGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
negative regulation of vascular permeabilitycGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
positive regulation of vascular permeabilitycGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
steroid hormone mediated signaling pathwaycGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
negative regulation of cAMP-mediated signalingcGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
positive regulation of oocyte developmentcGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
regulation of ribonuclease activitycGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
cellular response to cGMPcGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
cellular response to transforming growth factor beta stimuluscGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
apoptotic signaling pathwaycGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
negative regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathwaycGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
cGMP catabolic processcGMP-specific 3',5'-cyclic phosphodiesteraseBos taurus (cattle)
protein ubiquitinationProtein cereblonHomo sapiens (human)
positive regulation of Wnt signaling pathwayProtein cereblonHomo sapiens (human)
negative regulation of protein-containing complex assemblyProtein cereblonHomo sapiens (human)
positive regulation of protein-containing complex assemblyProtein cereblonHomo sapiens (human)
negative regulation of monoatomic ion transmembrane transportProtein cereblonHomo sapiens (human)
locomotory exploration behaviorProtein cereblonHomo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processProtein cereblonHomo sapiens (human)
signal transductionDual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11AHomo sapiens (human)
negative regulation of cGMP-mediated signalingDual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11AHomo sapiens (human)
negative regulation of cAMP-mediated signalingDual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11AHomo sapiens (human)
cAMP-mediated signalingDual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11AHomo sapiens (human)
cAMP catabolic processcAMP-specific 3',5'-cyclic phosphodiesterase 7BHomo sapiens (human)
signal transductioncAMP-specific 3',5'-cyclic phosphodiesterase 7BHomo sapiens (human)
chemical synaptic transmissioncAMP-specific 3',5'-cyclic phosphodiesterase 7BHomo sapiens (human)
cAMP-mediated signalingcAMP-specific 3',5'-cyclic phosphodiesterase 7BHomo sapiens (human)
cAMP catabolic processcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10AHomo sapiens (human)
cGMP catabolic processcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10AHomo sapiens (human)
negative regulation of cGMP-mediated signalingcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10AHomo sapiens (human)
cAMP-mediated signalingcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10AHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (83)

Processvia Protein(s)Taxonomy
3',5'-cyclic-AMP phosphodiesterase activitycAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
protein bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
cAMP bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
metal ion bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
3',5'-cyclic-GMP phosphodiesterase activitycAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
3',5'-cyclic-AMP phosphodiesterase activitycAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
calcium channel regulator activitycAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
protein bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
cAMP bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
gamma-tubulin bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
transmembrane transporter bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
metal ion bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
3',5'-cyclic-GMP phosphodiesterase activitycAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
3',5'-cyclic-AMP phosphodiesterase activitycAMP-specific 3',5'-cyclic phosphodiesterase 4CHomo sapiens (human)
metal ion bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4CHomo sapiens (human)
3',5'-cyclic-GMP phosphodiesterase activitycAMP-specific 3',5'-cyclic phosphodiesterase 4CHomo sapiens (human)
3',5'-cyclic-nucleotide phosphodiesterase activitycAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
3',5'-cyclic-AMP phosphodiesterase activitycAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
calcium channel regulator activitycAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
protein bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
enzyme bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
signaling receptor regulator activitycAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
cAMP bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
beta-2 adrenergic receptor bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
transmembrane transporter bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
metal ion bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
ATPase bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
scaffold protein bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
heterocyclic compound bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
3',5'-cyclic-GMP phosphodiesterase activitycAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
3',5'-cyclic-nucleotide phosphodiesterase activitycGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
3',5'-cyclic-AMP phosphodiesterase activitycGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
cGMP-inhibited cyclic-nucleotide phosphodiesterase activitycGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
protein bindingcGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
protein kinase B bindingcGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
metal ion bindingcGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
3',5'-cyclic-GMP phosphodiesterase activitycGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
3',5'-cyclic-nucleotide phosphodiesterase activitycGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
3',5'-cyclic-AMP phosphodiesterase activitycGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
cGMP-inhibited cyclic-nucleotide phosphodiesterase activitycGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
protein bindingcGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
nuclear estrogen receptor activitycGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
metal ion bindingcGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
3',5'-cyclic-GMP phosphodiesterase activitycGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
estrogen bindingcGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
transcription coactivator bindingCREB-binding proteinHomo sapiens (human)
p53 bindingCREB-binding proteinHomo sapiens (human)
chromatin bindingCREB-binding proteinHomo sapiens (human)
damaged DNA bindingCREB-binding proteinHomo sapiens (human)
transcription coactivator activityCREB-binding proteinHomo sapiens (human)
transcription corepressor activityCREB-binding proteinHomo sapiens (human)
histone acetyltransferase activityCREB-binding proteinHomo sapiens (human)
protein bindingCREB-binding proteinHomo sapiens (human)
zinc ion bindingCREB-binding proteinHomo sapiens (human)
acetyltransferase activityCREB-binding proteinHomo sapiens (human)
peptide N-acetyltransferase activityCREB-binding proteinHomo sapiens (human)
MRF bindingCREB-binding proteinHomo sapiens (human)
histone H3K18 acetyltransferase activityCREB-binding proteinHomo sapiens (human)
histone H3K27 acetyltransferase activityCREB-binding proteinHomo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCREB-binding proteinHomo sapiens (human)
peptide-lysine-N-acetyltransferase activityCREB-binding proteinHomo sapiens (human)
peptide lactyltransferase activityCREB-binding proteinHomo sapiens (human)
DNA-binding transcription factor bindingCREB-binding proteinHomo sapiens (human)
chromatin DNA bindingCREB-binding proteinHomo sapiens (human)
magnesium ion bindingcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
3',5'-cyclic-AMP phosphodiesterase activitycGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cGMP-stimulated cyclic-nucleotide phosphodiesterase activitycGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
protein bindingcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
zinc ion bindingcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cAMP bindingcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cGMP bindingcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
TPR domain bindingcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
phosphate ion bindingcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
protein homodimerization activitycGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
3',5'-cyclic-GMP phosphodiesterase activitycGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
3',5'-cyclic-AMP phosphodiesterase activityHigh affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8AHomo sapiens (human)
kinase bindingHigh affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8AHomo sapiens (human)
protein kinase activator activityHigh affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8AHomo sapiens (human)
metal ion bindingHigh affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8AHomo sapiens (human)
3',5'-cyclic-GMP phosphodiesterase activityHigh affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8AHomo sapiens (human)
protein bindingRetina-specific copper amine oxidaseHomo sapiens (human)
primary amine oxidase activityRetina-specific copper amine oxidaseHomo sapiens (human)
electron transfer activityRetina-specific copper amine oxidaseHomo sapiens (human)
quinone bindingRetina-specific copper amine oxidaseHomo sapiens (human)
aliphatic amine oxidase activityRetina-specific copper amine oxidaseHomo sapiens (human)
copper ion bindingRetina-specific copper amine oxidaseHomo sapiens (human)
3',5'-cyclic-nucleotide phosphodiesterase activitycGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
protein bindingcGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cGMP bindingcGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
metal ion bindingcGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
3',5'-cyclic-GMP phosphodiesterase activitycGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
3',5'-cyclic-AMP phosphodiesterase activitycGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
3',5'-cyclic-nucleotide phosphodiesterase activityHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9AHomo sapiens (human)
protein bindingHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9AHomo sapiens (human)
metal ion bindingHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9AHomo sapiens (human)
3',5'-cyclic-GMP phosphodiesterase activityHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9AHomo sapiens (human)
3',5'-cyclic-AMP phosphodiesterase activityHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9AHomo sapiens (human)
3',5'-cyclic-AMP phosphodiesterase activityHigh affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8BHomo sapiens (human)
metal ion bindingHigh affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8BHomo sapiens (human)
3',5'-cyclic-GMP phosphodiesterase activityHigh affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8BHomo sapiens (human)
aspartic-type endopeptidase activityReninHomo sapiens (human)
signaling receptor bindingReninHomo sapiens (human)
insulin-like growth factor receptor bindingReninHomo sapiens (human)
protein bindingReninHomo sapiens (human)
peptidase activityReninHomo sapiens (human)
transcription cis-regulatory region bindingTumor necrosis factorHomo sapiens (human)
protease bindingTumor necrosis factorHomo sapiens (human)
cytokine activityTumor necrosis factorHomo sapiens (human)
tumor necrosis factor receptor bindingTumor necrosis factorHomo sapiens (human)
protein bindingTumor necrosis factorHomo sapiens (human)
death receptor agonist activityTumor necrosis factorHomo sapiens (human)
identical protein bindingTumor necrosis factorHomo sapiens (human)
calmodulin-activated dual specificity 3',5'-cyclic-GMP, 3',5'-cyclic-AMP phosphodiesterase activityCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A Bos taurus (cattle)
protein bindingCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A Bos taurus (cattle)
calmodulin bindingCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A Bos taurus (cattle)
metal ion bindingCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A Bos taurus (cattle)
3',5'-cyclic-GMP phosphodiesterase activityCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A Bos taurus (cattle)
calmodulin-activated 3',5'-cyclic-GMP phosphodiesterase activityCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A Bos taurus (cattle)
peroxidase activityProstaglandin G/H synthase 1Homo sapiens (human)
prostaglandin-endoperoxide synthase activityProstaglandin G/H synthase 1Homo sapiens (human)
protein bindingProstaglandin G/H synthase 1Homo sapiens (human)
heme bindingProstaglandin G/H synthase 1Homo sapiens (human)
metal ion bindingProstaglandin G/H synthase 1Homo sapiens (human)
oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygenProstaglandin G/H synthase 1Homo sapiens (human)
actin bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
neurotransmitter transmembrane transporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
neurotransmitter:sodium symporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
dopamine:sodium symporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
norepinephrine:sodium symporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
protein bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
monoamine transmembrane transporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
alpha-tubulin bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
metal ion bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
beta-tubulin bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
3',5'-cyclic-AMP phosphodiesterase activitycAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
protein bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
cAMP bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
metal ion bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
3',5'-cyclic-GMP phosphodiesterase activitycAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
G protein-coupled adenosine receptor activityAdenosine receptor A2aRattus norvegicus (Norway rat)
magnesium ion bindingBifunctional epoxide hydrolase 2Homo sapiens (human)
epoxide hydrolase activityBifunctional epoxide hydrolase 2Homo sapiens (human)
toxic substance bindingBifunctional epoxide hydrolase 2Homo sapiens (human)
phosphatase activityBifunctional epoxide hydrolase 2Homo sapiens (human)
10-hydroxy-9-(phosphonooxy)octadecanoate phosphatase activityBifunctional epoxide hydrolase 2Homo sapiens (human)
lipid phosphatase activityBifunctional epoxide hydrolase 2Homo sapiens (human)
protein homodimerization activityBifunctional epoxide hydrolase 2Homo sapiens (human)
lysophosphatidic acid phosphatase activityBifunctional epoxide hydrolase 2Homo sapiens (human)
calmodulin-activated dual specificity 3',5'-cyclic-GMP, 3',5'-cyclic-AMP phosphodiesterase activityCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1AHomo sapiens (human)
calmodulin bindingCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1AHomo sapiens (human)
metal ion bindingCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1AHomo sapiens (human)
calmodulin-activated 3',5'-cyclic-GMP phosphodiesterase activityCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1AHomo sapiens (human)
3',5'-cyclic-AMP phosphodiesterase activityCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BBos taurus (cattle)
calmodulin-activated dual specificity 3',5'-cyclic-GMP, 3',5'-cyclic-AMP phosphodiesterase activityCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BBos taurus (cattle)
calmodulin bindingCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BBos taurus (cattle)
metal ion bindingCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BBos taurus (cattle)
3',5'-cyclic-GMP phosphodiesterase activityCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BBos taurus (cattle)
calmodulin-activated 3',5'-cyclic-GMP phosphodiesterase activityCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BBos taurus (cattle)
3',5'-cyclic-AMP phosphodiesterase activityCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BHomo sapiens (human)
calmodulin-activated dual specificity 3',5'-cyclic-GMP, 3',5'-cyclic-AMP phosphodiesterase activityCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BHomo sapiens (human)
protein bindingCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BHomo sapiens (human)
calmodulin bindingCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BHomo sapiens (human)
metal ion bindingCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BHomo sapiens (human)
3',5'-cyclic-GMP phosphodiesterase activityCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BHomo sapiens (human)
calmodulin-activated 3',5'-cyclic-GMP phosphodiesterase activityCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BHomo sapiens (human)
3',5'-cyclic-AMP phosphodiesterase activitycAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
calcium channel regulator activitycAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
protein bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
cAMP bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
gamma-tubulin bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
transmembrane transporter bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
metal ion bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
3',5'-cyclic-GMP phosphodiesterase activitycAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
3',5'-cyclic-AMP phosphodiesterase activitycAMP-specific 3',5'-cyclic phosphodiesterase 4CHomo sapiens (human)
metal ion bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4CHomo sapiens (human)
3',5'-cyclic-GMP phosphodiesterase activitycAMP-specific 3',5'-cyclic phosphodiesterase 4CHomo sapiens (human)
3',5'-cyclic-nucleotide phosphodiesterase activitycAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
3',5'-cyclic-AMP phosphodiesterase activitycAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
calcium channel regulator activitycAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
protein bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
enzyme bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
signaling receptor regulator activitycAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
cAMP bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
beta-2 adrenergic receptor bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
transmembrane transporter bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
metal ion bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
ATPase bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
scaffold protein bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
heterocyclic compound bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
3',5'-cyclic-GMP phosphodiesterase activitycAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
3',5'-cyclic-nucleotide phosphodiesterase activitycGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
3',5'-cyclic-AMP phosphodiesterase activitycGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
cGMP-inhibited cyclic-nucleotide phosphodiesterase activitycGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
protein bindingcGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
protein kinase B bindingcGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
metal ion bindingcGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
3',5'-cyclic-GMP phosphodiesterase activitycGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
3',5'-cyclic-AMP phosphodiesterase activityHigh affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7AHomo sapiens (human)
metal ion bindingHigh affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7AHomo sapiens (human)
3',5'-cyclic-GMP phosphodiesterase activityHigh affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7AHomo sapiens (human)
3',5'-cyclic-AMP phosphodiesterase activityCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1CHomo sapiens (human)
calmodulin-activated dual specificity 3',5'-cyclic-GMP, 3',5'-cyclic-AMP phosphodiesterase activityCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1CHomo sapiens (human)
calmodulin bindingCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1CHomo sapiens (human)
metal ion bindingCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1CHomo sapiens (human)
3',5'-cyclic-GMP phosphodiesterase activityCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1CHomo sapiens (human)
calmodulin-activated 3',5'-cyclic-GMP phosphodiesterase activityCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1CHomo sapiens (human)
3',5'-cyclic-nucleotide phosphodiesterase activitycGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
3',5'-cyclic-AMP phosphodiesterase activitycGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
cGMP-inhibited cyclic-nucleotide phosphodiesterase activitycGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
protein bindingcGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
nuclear estrogen receptor activitycGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
metal ion bindingcGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
3',5'-cyclic-GMP phosphodiesterase activitycGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
estrogen bindingcGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
cyclic-nucleotide phosphodiesterase activitycGMP-specific 3',5'-cyclic phosphodiesteraseBos taurus (cattle)
cGMP bindingcGMP-specific 3',5'-cyclic phosphodiesteraseBos taurus (cattle)
metal ion bindingcGMP-specific 3',5'-cyclic phosphodiesteraseBos taurus (cattle)
3',5'-cyclic-GMP phosphodiesterase activitycGMP-specific 3',5'-cyclic phosphodiesteraseBos taurus (cattle)
protein bindingProtein cereblonHomo sapiens (human)
transmembrane transporter bindingProtein cereblonHomo sapiens (human)
metal ion bindingProtein cereblonHomo sapiens (human)
cyclic-nucleotide phosphodiesterase activityDual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11AHomo sapiens (human)
3',5'-cyclic-nucleotide phosphodiesterase activityDual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11AHomo sapiens (human)
cGMP-stimulated cyclic-nucleotide phosphodiesterase activityDual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11AHomo sapiens (human)
cGMP bindingDual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11AHomo sapiens (human)
metal ion bindingDual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11AHomo sapiens (human)
3',5'-cyclic-GMP phosphodiesterase activityDual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11AHomo sapiens (human)
3',5'-cyclic-AMP phosphodiesterase activityDual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11AHomo sapiens (human)
3',5'-cyclic-AMP phosphodiesterase activitycAMP-specific 3',5'-cyclic phosphodiesterase 7BHomo sapiens (human)
metal ion bindingcAMP-specific 3',5'-cyclic phosphodiesterase 7BHomo sapiens (human)
3',5'-cyclic-GMP phosphodiesterase activitycAMP-specific 3',5'-cyclic phosphodiesterase 7BHomo sapiens (human)
3',5'-cyclic-nucleotide phosphodiesterase activitycAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10AHomo sapiens (human)
cGMP-stimulated cyclic-nucleotide phosphodiesterase activitycAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10AHomo sapiens (human)
cAMP bindingcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10AHomo sapiens (human)
cGMP bindingcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10AHomo sapiens (human)
metal ion bindingcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10AHomo sapiens (human)
3',5'-cyclic-AMP phosphodiesterase activitycAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10AHomo sapiens (human)
3',5'-cyclic-GMP phosphodiesterase activitycAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10AHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (56)

Processvia Protein(s)Taxonomy
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
nucleoplasmcAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
cytosolcAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
plasma membranecAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
membranecAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
ruffle membranecAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
perinuclear region of cytoplasmcAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
perinuclear region of cytoplasmcAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
cytosolcAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
nucleuscAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
centrosomecAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
cytosolcAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
synaptic vesiclecAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
postsynaptic densitycAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
Z disccAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
dendritic spinecAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
excitatory synapsecAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
gamma-tubulin complexcAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
voltage-gated calcium channel complexcAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
nucleuscAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
perinuclear region of cytoplasmcAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
cytosolcAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
extracellular spacecAMP-specific 3',5'-cyclic phosphodiesterase 4CHomo sapiens (human)
cytosolcAMP-specific 3',5'-cyclic phosphodiesterase 4CHomo sapiens (human)
ciliumcAMP-specific 3',5'-cyclic phosphodiesterase 4CHomo sapiens (human)
cytosolcAMP-specific 3',5'-cyclic phosphodiesterase 4CHomo sapiens (human)
nucleuscAMP-specific 3',5'-cyclic phosphodiesterase 4CHomo sapiens (human)
perinuclear region of cytoplasmcAMP-specific 3',5'-cyclic phosphodiesterase 4CHomo sapiens (human)
centrosomecAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
cytosolcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
plasma membranecAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
apical plasma membranecAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
voltage-gated calcium channel complexcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
calcium channel complexcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
cytosolcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
nucleuscAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
perinuclear region of cytoplasmcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
endoplasmic reticulumcGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
Golgi apparatuscGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
cytosolcGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
membranecGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
guanyl-nucleotide exchange factor complexcGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
cytosolcGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
membranecGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
cytosolcGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
cytoplasmCREB-binding proteinHomo sapiens (human)
nucleusCREB-binding proteinHomo sapiens (human)
nucleoplasmCREB-binding proteinHomo sapiens (human)
cytoplasmCREB-binding proteinHomo sapiens (human)
cytosolCREB-binding proteinHomo sapiens (human)
nuclear bodyCREB-binding proteinHomo sapiens (human)
chromatinCREB-binding proteinHomo sapiens (human)
histone acetyltransferase complexCREB-binding proteinHomo sapiens (human)
transcription regulator complexCREB-binding proteinHomo sapiens (human)
plasma membranecGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
nucleuscGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cytoplasmcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
mitochondrial outer membranecGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
mitochondrial inner membranecGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
endoplasmic reticulumcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
Golgi apparatuscGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cytosolcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
plasma membranecGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
presynaptic membranecGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
perinuclear region of cytoplasmcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
nucleuscGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
mitochondrial inner membranecGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
perinuclear region of cytoplasmcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
mitochondrial outer membranecGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
synaptic membranecGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cytosolcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
mitochondrial matrixcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cytosolHigh affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8AHomo sapiens (human)
extracellular exosomeHigh affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8AHomo sapiens (human)
perinuclear region of cytoplasmHigh affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8AHomo sapiens (human)
cytosolHigh affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8AHomo sapiens (human)
nucleusHigh affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8AHomo sapiens (human)
cytoplasmRetina-specific copper amine oxidaseHomo sapiens (human)
plasma membraneRetina-specific copper amine oxidaseHomo sapiens (human)
plasma membraneRetina-specific copper amine oxidaseHomo sapiens (human)
cellular_componentcGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cytosolcGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
nucleoplasmHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9AHomo sapiens (human)
endoplasmic reticulumHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9AHomo sapiens (human)
Golgi apparatusHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9AHomo sapiens (human)
cytosolHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9AHomo sapiens (human)
plasma membraneHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9AHomo sapiens (human)
ruffle membraneHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9AHomo sapiens (human)
sarcolemmaHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9AHomo sapiens (human)
perikaryonHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9AHomo sapiens (human)
perinuclear region of cytoplasmHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9AHomo sapiens (human)
cellular_componentHigh affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8BHomo sapiens (human)
cytosolHigh affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8BHomo sapiens (human)
perinuclear region of cytoplasmHigh affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8BHomo sapiens (human)
nucleusHigh affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8BHomo sapiens (human)
cytosolHigh affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8BHomo sapiens (human)
extracellular regionReninHomo sapiens (human)
extracellular spaceReninHomo sapiens (human)
plasma membraneReninHomo sapiens (human)
apical part of cellReninHomo sapiens (human)
extracellular spaceReninHomo sapiens (human)
extracellular spaceTumor necrosis factorHomo sapiens (human)
phagocytic cupTumor necrosis factorHomo sapiens (human)
extracellular regionTumor necrosis factorHomo sapiens (human)
extracellular spaceTumor necrosis factorHomo sapiens (human)
plasma membraneTumor necrosis factorHomo sapiens (human)
external side of plasma membraneTumor necrosis factorHomo sapiens (human)
cell surfaceTumor necrosis factorHomo sapiens (human)
neuronal cell bodyTumor necrosis factorHomo sapiens (human)
membrane raftTumor necrosis factorHomo sapiens (human)
recycling endosomeTumor necrosis factorHomo sapiens (human)
cell surfaceTumor necrosis factorHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
photoreceptor outer segmentProstaglandin G/H synthase 1Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 1Homo sapiens (human)
endoplasmic reticulum membraneProstaglandin G/H synthase 1Homo sapiens (human)
Golgi apparatusProstaglandin G/H synthase 1Homo sapiens (human)
intracellular membrane-bounded organelleProstaglandin G/H synthase 1Homo sapiens (human)
extracellular exosomeProstaglandin G/H synthase 1Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 1Homo sapiens (human)
neuron projectionProstaglandin G/H synthase 1Homo sapiens (human)
plasma membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
cell surfaceSodium-dependent noradrenaline transporter Homo sapiens (human)
membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
neuronal cell body membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
presynaptic membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
plasma membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
axonSodium-dependent noradrenaline transporter Homo sapiens (human)
nucleoplasmcAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
cytosolcAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
plasma membranecAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
membranecAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
ruffle membranecAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
perinuclear region of cytoplasmcAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
perinuclear region of cytoplasmcAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
cytosolcAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
nucleuscAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
Golgi membraneAdenosine receptor A2aRattus norvegicus (Norway rat)
peroxisomeBifunctional epoxide hydrolase 2Homo sapiens (human)
peroxisomal matrixBifunctional epoxide hydrolase 2Homo sapiens (human)
cytosolBifunctional epoxide hydrolase 2Homo sapiens (human)
extracellular exosomeBifunctional epoxide hydrolase 2Homo sapiens (human)
peroxisomeBifunctional epoxide hydrolase 2Homo sapiens (human)
cytosolCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1AHomo sapiens (human)
neuronal cell bodyCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1AHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
cytosolCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BBos taurus (cattle)
cytosolCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BHomo sapiens (human)
neuronal cell bodyCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BHomo sapiens (human)
centrosomecAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
cytosolcAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
synaptic vesiclecAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
postsynaptic densitycAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
Z disccAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
dendritic spinecAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
excitatory synapsecAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
gamma-tubulin complexcAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
voltage-gated calcium channel complexcAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
nucleuscAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
perinuclear region of cytoplasmcAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
cytosolcAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
extracellular spacecAMP-specific 3',5'-cyclic phosphodiesterase 4CHomo sapiens (human)
cytosolcAMP-specific 3',5'-cyclic phosphodiesterase 4CHomo sapiens (human)
ciliumcAMP-specific 3',5'-cyclic phosphodiesterase 4CHomo sapiens (human)
cytosolcAMP-specific 3',5'-cyclic phosphodiesterase 4CHomo sapiens (human)
nucleuscAMP-specific 3',5'-cyclic phosphodiesterase 4CHomo sapiens (human)
perinuclear region of cytoplasmcAMP-specific 3',5'-cyclic phosphodiesterase 4CHomo sapiens (human)
centrosomecAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
cytosolcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
plasma membranecAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
apical plasma membranecAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
voltage-gated calcium channel complexcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
calcium channel complexcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
cytosolcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
nucleuscAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
perinuclear region of cytoplasmcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
endoplasmic reticulumcGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
Golgi apparatuscGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
cytosolcGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
membranecGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
guanyl-nucleotide exchange factor complexcGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
cytosolHigh affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7AHomo sapiens (human)
perinuclear region of cytoplasmHigh affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7AHomo sapiens (human)
nucleusHigh affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7AHomo sapiens (human)
cytosolHigh affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7AHomo sapiens (human)
lysosomeCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1CHomo sapiens (human)
cytosolCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1CHomo sapiens (human)
neuronal cell bodyCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1CHomo sapiens (human)
cytosolcGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
membranecGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
cytosolcGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
nucleusProtein cereblonHomo sapiens (human)
cytoplasmProtein cereblonHomo sapiens (human)
cytosolProtein cereblonHomo sapiens (human)
membraneProtein cereblonHomo sapiens (human)
perinuclear region of cytoplasmProtein cereblonHomo sapiens (human)
Cul4A-RING E3 ubiquitin ligase complexProtein cereblonHomo sapiens (human)
cellular_componentDual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11AHomo sapiens (human)
cytosolDual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11AHomo sapiens (human)
cytosolcAMP-specific 3',5'-cyclic phosphodiesterase 7BHomo sapiens (human)
synapsecAMP-specific 3',5'-cyclic phosphodiesterase 7BHomo sapiens (human)
cytosolcAMP-specific 3',5'-cyclic phosphodiesterase 7BHomo sapiens (human)
perinuclear region of cytoplasmcAMP-specific 3',5'-cyclic phosphodiesterase 7BHomo sapiens (human)
nucleuscAMP-specific 3',5'-cyclic phosphodiesterase 7BHomo sapiens (human)
cytosolcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10AHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (809)

Assay IDTitleYearJournalArticle
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID977608Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB2001Journal of medicinal chemistry, Aug-02, Volume: 44, Issue:16
Novel selective PDE4 inhibitors. 2. Synthesis and structure-activity relationships of 4-aryl-substituted cis-tetra- and cis-hexahydrophthalazinones.
AID157779PDE4A activity assessed using human recombinant purified GST-PDE4A2481999Bioorganic & medicinal chemistry letters, Feb-08, Volume: 9, Issue:3
Substituted furans as inhibitors of the PDE4 enzyme.
AID448555Inhibition of human recombinant PDE4B by scintillation proximity assay2009Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17
Quinolines as a novel structural class of potent and selective PDE4 inhibitors. Optimisation for inhaled administration.
AID1598194Selectivity ratio of IC50 for recombinant human His6-tagged PDE4B1 UCR1 S133D mutant expressed in baculovirus infected Sf9 insect cells to IC50 for recombinant human His6-tagged PDE4D7 UCR1 S129D mutant expressed in baculovirus infected Sf9 insect cells2019Journal of medicinal chemistry, 05-23, Volume: 62, Issue:10
Design and Synthesis of Selective Phosphodiesterase 4D (PDE4D) Allosteric Inhibitors for the Treatment of Fragile X Syndrome and Other Brain Disorders.
AID1060996Inhibition of human recombinant PDE4B2 assessed as inhibition of cAMP hydrolysis by colorimetric assay2014Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1
Design, synthesis and evaluation of dual pharmacology β2-adrenoceptor agonists and PDE4 inhibitors.
AID76664Antigen-induced bronchoconstriction in guinea pigs after peroral administration 1 hour pre-treatment1998Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6
1,4-Cyclohexanecarboxylates: potent and selective inhibitors of phosophodiesterase 4 for the treatment of asthma.
AID695680Inhibition of full-length PDE4A4 using cAMP as substrate by two-step radiochemical assay2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Elucidation of a structural basis for the inhibitor-driven, p62 (SQSTM1)-dependent intracellular redistribution of cAMP phosphodiesterase-4A4 (PDE4A4).
AID210151Inhibition of LPS-stimulated tumor necrosis factor-alpha release by human whole blood2002Journal of medicinal chemistry, Jun-06, Volume: 45, Issue:12
Novel selective PDE4 inhibitors. 3. In vivo antiinflammatory activity of a new series of N-substituted cis-tetra- and cis-hexahydrophthalazinones.
AID158447Inhibition of partially-purified PDE 4 from human monocytes1993Journal of medicinal chemistry, Oct-29, Volume: 36, Issue:22
The crystal structure, absolute configuration, and phosphodiesterase inhibitory activity of (+)-1-(4-bromobenzyl)-4-(3-(cyclopentyloxy)- 4-methoxyphenyl)-pyrrolidin-2-one.
AID1370513Antiviral activity against Zika virus infected in human A549 cells preincubated for 5 hrs followed by compound wash measured after 48 hrs by viral plague-forming assay2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Identification of novel small-molecule inhibitors of Zika virus infection.
AID158468Competition of [3H]rolipram binding sites in the central nervous system (HPDE4) in rat brain cytosol1998Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6
1,4-Cyclohexanecarboxylates: potent and selective inhibitors of phosophodiesterase 4 for the treatment of asthma.
AID267646Cytotoxicity against HEK293T cells2006Bioorganic & medicinal chemistry letters, Jul-01, Volume: 16, Issue:13
Synthesis and evaluation of N-aryl pyrrolidinones as novel anti-HIV-1 agents. Part 1.
AID1370515Cytotoxicity against human A549 cells assessed as cell viability at 1 uM by MTT assay relative to control2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Identification of novel small-molecule inhibitors of Zika virus infection.
AID1625379Inhibition of human PDE4D2 catalytic domain (79 to 438 residues) Escherichia coli BL21-CodonPlus(DE3) cells2016Journal of medicinal chemistry, Aug-11, Volume: 59, Issue:15
PDEStrIAn: A Phosphodiesterase Structure and Ligand Interaction Annotated Database As a Tool for Structure-Based Drug Design.
AID130614Inhibition of lipopolysaccharide (LPS)-induced TNF alpha generation in mouse1998Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6
1,4-Cyclohexanecarboxylates: potent and selective inhibitors of phosophodiesterase 4 for the treatment of asthma.
AID167443Stimulation of acid secretion from rabbit parietal glands1998Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6
1,4-Cyclohexanecarboxylates: potent and selective inhibitors of phosophodiesterase 4 for the treatment of asthma.
AID1598192Selectivity ratio of IC50 for recombinant human wild-type His6-tagged PDE4D7 UCR1 domain (S129 residues) expressed in baculovirus infected Sf9 insect cells to IC50 for recombinant human His6-tagged PDE4D7 UCR1 S129D mutant expressed in baculovirus infecte2019Journal of medicinal chemistry, 05-23, Volume: 62, Issue:10
Design and Synthesis of Selective Phosphodiesterase 4D (PDE4D) Allosteric Inhibitors for the Treatment of Fragile X Syndrome and Other Brain Disorders.
AID275702Inhibition of human recombinant PDE4A2007Journal of medicinal chemistry, Jan-25, Volume: 50, Issue:2
SAR of a series of 5,6-dihydro-(9H)-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-alpha]pyridines as potent inhibitors of human eosinophil phosphodiesterase.
AID695683Induction of SQSTM1-dependent intracellular redistribution of GFP-tagged PDE4A4 assessed as maximal accretion of enzyme into foci2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Elucidation of a structural basis for the inhibitor-driven, p62 (SQSTM1)-dependent intracellular redistribution of cAMP phosphodiesterase-4A4 (PDE4A4).
AID157297Inhibitory activity of the against phosphodiesterase 3 (PDE3); No significant inhibitory activity at pIC502001Journal of medicinal chemistry, Aug-02, Volume: 44, Issue:16
Novel selective PDE4 inhibitors. 2. Synthesis and structure-activity relationships of 4-aryl-substituted cis-tetra- and cis-hexahydrophthalazinones.
AID159936Inhibitory concentration against phosphodiesterase 4 (PDE4) in cytosol of human neutrophils2002Journal of medicinal chemistry, Jun-06, Volume: 45, Issue:12
Novel selective PDE4 inhibitors. 3. In vivo antiinflammatory activity of a new series of N-substituted cis-tetra- and cis-hexahydrophthalazinones.
AID156050Inhibition of N-formyl-methionyl-leucyl-phenylalanine (fMLP)-stimulated production of reactive oxygen species (ROS) in human PMNL by 35% of control2002Journal of medicinal chemistry, Jun-06, Volume: 45, Issue:12
Novel selective PDE4 inhibitors. 3. In vivo antiinflammatory activity of a new series of N-substituted cis-tetra- and cis-hexahydrophthalazinones.
AID275704Inhibition of human recombinant PDE4D2007Journal of medicinal chemistry, Jan-25, Volume: 50, Issue:2
SAR of a series of 5,6-dihydro-(9H)-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-alpha]pyridines as potent inhibitors of human eosinophil phosphodiesterase.
AID1370516Cytotoxicity against human A549 cells assessed as cell viability at 10 uM by MTT assay relative to control2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Identification of novel small-molecule inhibitors of Zika virus infection.
AID90823Inhibition of lipopolysaccharide (LPS)-induced TNF alpha release by human monocytes1998Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6
1,4-Cyclohexanecarboxylates: potent and selective inhibitors of phosophodiesterase 4 for the treatment of asthma.
AID267645Antiviral activity against wild type HIV1 virus2006Bioorganic & medicinal chemistry letters, Jul-01, Volume: 16, Issue:13
Synthesis and evaluation of N-aryl pyrrolidinones as novel anti-HIV-1 agents. Part 1.
AID1370514Cytotoxicity against human A549 cells assessed as cell viability at 0.1 uM by MTT assay relative to control2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Identification of novel small-molecule inhibitors of Zika virus infection.
AID210611The value for hypothermia against antigen provocation (po)1998Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6
1,4-Cyclohexanecarboxylates: potent and selective inhibitors of phosophodiesterase 4 for the treatment of asthma.
AID647425Inhibition of human recombinant PDE4B2-mediated cAMP hydrolysis for 30 mins by colorimetric assay2012Bioorganic & medicinal chemistry letters, Feb-15, Volume: 22, Issue:4
Dual β2-adrenoceptor agonists-PDE4 inhibitors for the treatment of asthma and COPD.
AID131562Reversal of reserpine-induced hypothermia in the mouse on peroral administration1998Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6
1,4-Cyclohexanecarboxylates: potent and selective inhibitors of phosophodiesterase 4 for the treatment of asthma.
AID76663Antigen-induced bronchoconstriction in guinea pigs after iv administration 10 min pre-treatment1998Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6
1,4-Cyclohexanecarboxylates: potent and selective inhibitors of phosophodiesterase 4 for the treatment of asthma.
AID233957Ratio of ROS IC35/PDE4 IC50 was determined2002Journal of medicinal chemistry, Jun-06, Volume: 45, Issue:12
Novel selective PDE4 inhibitors. 3. In vivo antiinflammatory activity of a new series of N-substituted cis-tetra- and cis-hexahydrophthalazinones.
AID219081Emetic effect in ferret model, threshold value1999Bioorganic & medicinal chemistry letters, Feb-08, Volume: 9, Issue:3
Substituted furans as inhibitors of the PDE4 enzyme.
AID1625374Inhibition of human His-tagged PDE4B catalytic domain expressed in Escherichia coli BL21-CodonPlus(DE3) cells using [3H]cAMP or [3H]cGMP as substrate incubated for 30 mins by scintillation counting method2016Journal of medicinal chemistry, Aug-11, Volume: 59, Issue:15
PDEStrIAn: A Phosphodiesterase Structure and Ligand Interaction Annotated Database As a Tool for Structure-Based Drug Design.
AID59636Emetic effect in dogs1998Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6
1,4-Cyclohexanecarboxylates: potent and selective inhibitors of phosophodiesterase 4 for the treatment of asthma.
AID1625375Inhibition of human N-terminal His6-tagged C-terminal FLAG-tagged PDE4B2 expressed in baculovirus infected sf9 cells using cAMP as substrate by microplate reader analysis2016Journal of medicinal chemistry, Aug-11, Volume: 59, Issue:15
PDEStrIAn: A Phosphodiesterase Structure and Ligand Interaction Annotated Database As a Tool for Structure-Based Drug Design.
AID157302Inhibition of phosphodiesterase 4 (PDE4) in human neutrophils2001Journal of medicinal chemistry, Aug-02, Volume: 44, Issue:16
Novel selective PDE4 inhibitors. 2. Synthesis and structure-activity relationships of 4-aryl-substituted cis-tetra- and cis-hexahydrophthalazinones.
AID735056Inhibition of human recombinant PDE4B2 assessed as decrease in cAMP hydrolysis preincubated with substrate prior to enzyme addition measured after 30 mins by colorimetric assay method2013Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5
Hybrids consisting of the pharmacophores of salmeterol and roflumilast or phthalazinone: dual β₂-adrenoceptor agonists-PDE4 inhibitors for the treatment of COPD.
AID275701Inhibition of human recombinant PDE4B2007Journal of medicinal chemistry, Jan-25, Volume: 50, Issue:2
SAR of a series of 5,6-dihydro-(9H)-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-alpha]pyridines as potent inhibitors of human eosinophil phosphodiesterase.
AID1370517Cytotoxicity against human A549 cells assessed as cell viability at 100 uM by MTT assay relative to control2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Identification of novel small-molecule inhibitors of Zika virus infection.
AID158466Inhibition activity against human monocyte derived PDE4 catalytic activity (LPDE4)1998Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6
1,4-Cyclohexanecarboxylates: potent and selective inhibitors of phosophodiesterase 4 for the treatment of asthma.
AID133069Percent inhibition of arachidonic acid induced mouse ear edema after 1 hr pretreatment with 30 uM/kg peroral dose2002Journal of medicinal chemistry, Jun-06, Volume: 45, Issue:12
Novel selective PDE4 inhibitors. 3. In vivo antiinflammatory activity of a new series of N-substituted cis-tetra- and cis-hexahydrophthalazinones.
AID275703Inhibition of human recombinant PDE4C2007Journal of medicinal chemistry, Jan-25, Volume: 50, Issue:2
SAR of a series of 5,6-dihydro-(9H)-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-alpha]pyridines as potent inhibitors of human eosinophil phosphodiesterase.
AID235540Value is the ratio between HPDE4 and LPDE41998Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6
1,4-Cyclohexanecarboxylates: potent and selective inhibitors of phosophodiesterase 4 for the treatment of asthma.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID977608Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB2010Nature biotechnology, Jan, Volume: 28, Issue:1
Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety.
AID1811Experimentally measured binding affinity data derived from PDB2003Structure (London, England : 1993), Jul, Volume: 11, Issue:7
Three-dimensional structures of PDE4D in complex with roliprams and implication on inhibitor selectivity.
AID977608Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB2003Structure (London, England : 1993), Jul, Volume: 11, Issue:7
Three-dimensional structures of PDE4D in complex with roliprams and implication on inhibitor selectivity.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID159966Inhibition of rolipram binding to rat brain2002Bioorganic & medicinal chemistry letters, Feb-11, Volume: 12, Issue:3
7-Methoxyfuro[2,3-c]pyridine-4-carboxamides as PDE4 inhibitors: a potential treatment for asthma.
AID159072Inhibitory concentration against phosphodiesterase 2 from rat kidney2004Bioorganic & medicinal chemistry letters, Jun-07, Volume: 14, Issue:11
Identification of purine inhibitors of phosphodiesterase 7 (PDE7).
AID1464267Inhibition of LPS-induced TNFalpha production in human PBMC pre-incubated for 30 mins before LPS stimulation for 18 hrs by TR-FRET assay2017Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20
Rational design of conformationally constrained oxazolidinone-fused 1,2,3,4-tetrahydroisoquinoline derivatives as potential PDE4 inhibitors.
AID159806Inhibition of rolipram binding to Phosphodiesterase 42002Bioorganic & medicinal chemistry letters, Jan-07, Volume: 12, Issue:1
Phthalazine PDE4 inhibitors. Part 3: the synthesis and in vitro evaluation of derivatives with a hydrogen bond acceptor.
AID260839Inhibition of C5a mediated human eosinophil chemotaxis2006Bioorganic & medicinal chemistry letters, Feb, Volume: 16, Issue:3
A new chemical tool for exploring the role of the PDE4D isozyme in leukocyte function.
AID1598203Induction of emesis in ICR mouse assessed as reduction in ketamine/xylazine-induced duration of anesthesia at 0.1 mg/kg, ip pretreated for 15 mins followed by ketamine/xylazine addition2019Journal of medicinal chemistry, 05-23, Volume: 62, Issue:10
Design and Synthesis of Selective Phosphodiesterase 4D (PDE4D) Allosteric Inhibitors for the Treatment of Fragile X Syndrome and Other Brain Disorders.
AID1480237Solubility in sodium phosphate buffer at pH 7.42018Journal of medicinal chemistry, 04-26, Volume: 61, Issue:8
Orally Available Soluble Epoxide Hydrolase/Phosphodiesterase 4 Dual Inhibitor Treats Inflammatory Pain.
AID1725049Inhibition of Pam3Cys-induced TNFalpha production in C57BL/6 mouse bone marrow derived Macrophage at 1 to 10 uM preincubated for 30 mins followed by LPS stimulation and measured after 24 hrs by ELISA2020ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10
Synthesis and SAR Studies of 1
AID260825Inhibition of PDE4C2006Bioorganic & medicinal chemistry letters, Feb, Volume: 16, Issue:3
A new chemical tool for exploring the role of the PDE4D isozyme in leukocyte function.
AID160109Inhibition of phosphodiesterase 4 from rat liver at 0.1 uM2001Bioorganic & medicinal chemistry letters, Mar-12, Volume: 11, Issue:5
Syntheses and evaluation of pyrido[2,3-dlpyrimidine-2,4-diones as PDE 4 inhibitors.
AID160128Inhibition of Rolipram binding to PDE4 at 1 uM1998Bioorganic & medicinal chemistry letters, Oct-06, Volume: 8, Issue:19
Synthesis and evaluation of a novel series of phosphodiesterase IV inhibitors. A potential treatment for asthma.
AID612628Antiinflammatory activity in mouse neutrophils assessed as inhibition of LPS-stimulated TNFalpha cytokine expression at 100 ug/ml after 3 hrs by flow cytometeric analysis2011Bioorganic & medicinal chemistry letters, Aug-15, Volume: 21, Issue:16
Psilostachyin, acetylated pseudoguaianolides and their analogues: preparation and evaluation of their anti-inflammatory potential.
AID632290Inhibition of His-tagged catalytic domain Trypanosoma brucei brucei PDEB1 expressed in baculovirus infected insect Sf21 cells2011Journal of medicinal chemistry, Dec-08, Volume: 54, Issue:23
Pharmacological validation of Trypanosoma brucei phosphodiesterases B1 and B2 as druggable targets for African sleeping sickness.
AID159656Inhibition of human Phosphodiesterase 42001Bioorganic & medicinal chemistry letters, Jan-08, Volume: 11, Issue:1
Phthalazine PDE4 inhibitors. Part 2: the synthesis and biological evaluation of 6-methoxy-1,4-disubstituted derivatives.
AID1311212Inhibition of PDE4B derived from human monocytes using [3H]-cAMP as substrate after 30 mins2016Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15
Synthesis and bioactivity of pyrazole and triazole derivatives as potential PDE4 inhibitors.
AID1480239Inhibition of PDE4 (unknown origin) expressed in HEK293 cells co-expressing PM-AKAR3 assessed as increase in cAMP levels by FRET assay2018Journal of medicinal chemistry, 04-26, Volume: 61, Issue:8
Orally Available Soluble Epoxide Hydrolase/Phosphodiesterase 4 Dual Inhibitor Treats Inflammatory Pain.
AID77063Reduced histamine-induced bronchoconstriction in anesthetized guinea pig at 1 mg/kg intravenous dose1996Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14
Novel selective PDE IV inhibitors as antiasthmatic agents. Synthesis and biological activities of a series of 1-aryl-2,3-bis(hydroxymethyl)naphthalene lignans.
AID363088Inhibition of human PDE4B1 in cytosolic fraction of lung2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Recent advances on phosphodiesterase 4 inhibitors for the treatment of asthma and chronic obstructive pulmonary disease.
AID160134Inhibition of phosphodiesterase 41998Bioorganic & medicinal chemistry letters, Oct-06, Volume: 8, Issue:19
Synthesis and evaluation of a novel series of phosphodiesterase IV inhibitors. A potential treatment for asthma.
AID1365249Anti-inflammatory activity in human U937 cells assessed as inhibition of LPS-induced IL6 production at 10 uM pre-incubated for 1 hr before LPS stimulation for 24 hrs by ELISA method2017Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20
Synthesis, pharmacological activities and molecular docking studies of pyrazolyltriazoles as anti-bacterial and anti-inflammatory agents.
AID759595Inhibition of human full length PDE4A4 expressed in baculovirus infected sf21 cells2013Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15
Discovery of triazines as potent, selective and orally active PDE4 inhibitors.
AID159645Inhibitory potency against guinea pig ventricular phosphodiesterase 42000Bioorganic & medicinal chemistry letters, Dec-04, Volume: 10, Issue:23
Synthesis and biological evaluation of 2,5-dihydropyrazol.
AID425689Inhibition of PDE7A2009Bioorganic & medicinal chemistry letters, Jul-01, Volume: 19, Issue:13
Exploration and optimization of substituted triazolothiadiazines and triazolopyridazines as PDE4 inhibitors.
AID1370517Cytotoxicity against human A549 cells assessed as cell viability at 100 uM by MTT assay relative to control2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Identification of novel small-molecule inhibitors of Zika virus infection.
AID425687Inhibition of PDE4D22009Bioorganic & medicinal chemistry letters, Jul-01, Volume: 19, Issue:13
Exploration and optimization of substituted triazolothiadiazines and triazolopyridazines as PDE4 inhibitors.
AID314436Inhibition of PDE3A2008Bioorganic & medicinal chemistry letters, Feb-15, Volume: 18, Issue:4
Identification of a potent new chemotype for the selective inhibition of PDE4.
AID1591866Inhibition of recombinant human PDE4D2 catalytic domain (86 to 413 residues) expressed in Escherichia coli BL21 codonplus cells using [3H]cAMP as substrate preincubated for 15 mins followed by substrate addition by liquid scintillation counting method2019Bioorganic & medicinal chemistry letters, 08-15, Volume: 29, Issue:16
Dual functional cholinesterase and PDE4D inhibitors for the treatment of Alzheimer's disease: Design, synthesis and evaluation of tacrine-pyrazolo[3,4-b]pyridine hybrids.
AID1543153Inhibition of human PDE4D2 catalytic domain (86 to 413 residues) expressed in Escherichia coli strain BL21 using [3H]cAMP as substrate after 15 mins by liquid scintillation counter analysis
AID222150Inhibition of fMLP-induced oxidative burst in human eosinophils2000Journal of medicinal chemistry, Feb-24, Volume: 43, Issue:4
Palladium-catalyzed cross-coupling reactions for the synthesis of 6, 8-disubstituted 1,7-naphthyridines: a novel class of potent and selective phosphodiesterase type 4D inhibitors.
AID1372328Inhibition of LPS-induced TNF-alpha production in human PBMC preincubated for 30 mins followed by LPS addition measured after 5 hrs by ELISA2018Bioorganic & medicinal chemistry letters, 01-01, Volume: 28, Issue:1
Synthesis and in vitro evaluations of 6-(hetero)-aryl-imidazo[1,2-b]pyridazine-3-sulfonamide's as an inhibitor of TNF-α production.
AID239334Inhibition of [3H]cAMP binding to recombinant human Phosphodiesterase 4DE (PDE4DE) in baculovirus expression system2005Journal of medicinal chemistry, Feb-24, Volume: 48, Issue:4
8-Substituted analogues of 3-(3-cyclopentyloxy-4-methoxy-benzyl)-8-isopropyl-adenine: highly potent and selective PDE4 inhibitors.
AID1512230Antiinflammatory activity against LPS-induced sepsis Swiss albino mouse model assessed as downregulation of IL6 production in serum at 10 mg/kg, po administered once at 1.5 hrs before LPS challenge and measured after 90 mins2019Bioorganic & medicinal chemistry letters, 11-15, Volume: 29, Issue:22
Discovery of novel inhibitors of phosphodiesterase 4 with 1-phenyl-3,4-dihydroisoquinoline scaffold: Structure-based drug design and fragment identification.
AID440693Inhibition of PDE4 from human U937 cells2009Journal of medicinal chemistry, Nov-12, Volume: 52, Issue:21
New selective phosphodiesterase 4D inhibitors differently acting on long, short, and supershort isoforms.
AID314439Inhibition of PDE4D2008Bioorganic & medicinal chemistry letters, Feb-15, Volume: 18, Issue:4
Identification of a potent new chemotype for the selective inhibition of PDE4.
AID1598959Inhibition of PDE4D (unknown origin) using cAMP as substrate2019Journal of medicinal chemistry, 06-13, Volume: 62, Issue:11
Structure-Aided Identification and Optimization of Tetrahydro-isoquinolines as Novel PDE4 Inhibitors Leading to Discovery of an Effective Antipsoriasis Agent.
AID395508Antidepressant activity in ICR mouse assessed as decrease in immobility duration at 0.5 mg/kg, ip once a day for 8 days by forced swimming test2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
Dual inhibitors of phosphodiesterase-4 and serotonin reuptake.
AID157760Inhibition of Phosphodiesterase 41997Journal of medicinal chemistry, Jun-06, Volume: 40, Issue:12
9-Benzyladenines: potent and selective cAMP phosphodiesterase inhibitors.
AID1153963Inhibition of LPS-induced TNF-alpha production in human PBMC2014Bioorganic & medicinal chemistry letters, Jul-01, Volume: 24, Issue:13
Synthesis and structure-activity relationship of cyclopentenone oximes as novel inhibitors of the production of tumor necrosis factor-α.
AID1512233Inhibition of PDE4B in human U937 cells using [3H] cAMP as substrate incubated for 30 mins2019Bioorganic & medicinal chemistry letters, 11-15, Volume: 29, Issue:22
Discovery of novel inhibitors of phosphodiesterase 4 with 1-phenyl-3,4-dihydroisoquinoline scaffold: Structure-based drug design and fragment identification.
AID1374975Inhibition of PDE4 in human PBMC assessed as reduction in LPS-stimulated TNFalpha release preincubated for 30 mins followed by LPS stimulation for 18 hrs by TR-FRET assay2018Bioorganic & medicinal chemistry letters, 04-15, Volume: 28, Issue:7
Structure-based design and structure-activity relationships of 1,2,3,4-tetrahydroisoquinoline derivatives as potential PDE4 inhibitors.
AID215247Inhibition of tumor necrosis factor alpha (TNF-alpha) release in murine endotoxemia model after peroral administration1998Journal of medicinal chemistry, Oct-22, Volume: 41, Issue:22
Novel cyclic compounds as potent phosphodiesterase 4 inhibitors.
AID349562Inhibition of human recombinant PDE4 catalytic domain expressed in baculovirus-infected insect Sf9 cells by modified two-step method2009Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8
Discovery and structure-activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis.
AID43768In vivo inhibition of antigen induced eosinophil recruitment in Brown-Norvway Rats at 10 mg/kg peroral dose2000Journal of medicinal chemistry, Dec-14, Volume: 43, Issue:25
Synthesis, structure-activity relationships, and pharmacological profile of 9-amino-4-oxo-1-phenyl-3,4,6,7-tetrahydro[1,4]diazepino[6, 7,1-hi]indoles: discovery of potent, selective phosphodiesterase type 4 inhibitors.
AID318123Antiviral activity against HIV2 ROD in MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay2008Bioorganic & medicinal chemistry letters, Feb-15, Volume: 18, Issue:4
Investigation of the alkenyldiarylmethane non-nucleoside reverse transcriptase inhibitors as potential cAMP phosphodiesterase-4B2 inhibitors.
AID159506Inhibition of bovine arterial Phosphodiesterase 41996Journal of medicinal chemistry, Jan-05, Volume: 39, Issue:1
Studies of cardiotonic agents. 8. Synthesis and biological activities of optically active 6-(4-(benzylamino)-7-quinazolinyl)-4,5-dihydro-5-methyl-3(2H)- pyridazinone (KF15232).
AID159342Inhibitory concentration against phosphodiesterase 3 from human platelet2004Bioorganic & medicinal chemistry letters, Jun-07, Volume: 14, Issue:11
Identification of purine inhibitors of phosphodiesterase 7 (PDE7).
AID1667995Inhibition of recombinant human PDE4B expressed in baculovirus infected Sf9 cells using [3H] cAMP as substrate after 30 min by scintillation proximity assay2020Bioorganic & medicinal chemistry letters, 05-15, Volume: 30, Issue:10
Ultrasound assisted rapid synthesis of mefenamic acid based indole derivatives under ligand free Cu-catalysis: Their pharmacological evaluation.
AID1703918Inhibition of PDE4D (unknown origin)2020European journal of medicinal chemistry, Oct-15, Volume: 204Discovery of sulfonyl hydrazone derivative as a new selective PDE4A and PDE4D inhibitor by lead-optimization approach on the prototype LASSBio-448: In vitro and in vivo preclinical studies.
AID219415Inhibition of [3H]rolipram binding to Wistar rat brain membranes2000Journal of medicinal chemistry, Dec-14, Volume: 43, Issue:25
Synthesis, structure-activity relationships, and pharmacological profile of 9-amino-4-oxo-1-phenyl-3,4,6,7-tetrahydro[1,4]diazepino[6, 7,1-hi]indoles: discovery of potent, selective phosphodiesterase type 4 inhibitors.
AID225258Inhibition of phosphodiesterase type IV (PDE4) activity1998Bioorganic & medicinal chemistry letters, Nov-03, Volume: 8, Issue:21
Orally active indole N-oxide PDE4 inhibitors.
AID1335399Inhibition of human PDE2A using FAM-3',5'-cAMP as substrate after 1 hr by fluorescence polarization assay2016European journal of medicinal chemistry, Nov-29, Volume: 124Development of highly potent phosphodiesterase 4 inhibitors with anti-neuroinflammation potential: Design, synthesis, and structure-activity relationship study of catecholamides bearing aromatic rings.
AID77059Reduced histamine-induced bronchoconstriction in anesthetized guinea pig at 0.1 mg/kg intravenous dose1996Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14
Novel selective PDE IV inhibitors as antiasthmatic agents. Synthesis and biological activities of a series of 1-aryl-2,3-bis(hydroxymethyl)naphthalene lignans.
AID159213Inhibitory activity against cGMP inhibited Phosphodiesterase 3, isolated from guinea pig ventricular tissue1998Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21
Design, synthesis, and biological activities of new thieno[3,2-d] pyrimidines as selective type 4 phosphodiesterase inhibitors.
AID133091Inhibition of reserpine-induced hypothermia in mice by peroral dose1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Structure-activity relationship of quinazolinedione inhibitors of calcium-independent phosphodiesterase.
AID1177597Inhibition of human PDE4D22014Journal of natural products, Aug-22, Volume: 77, Issue:8
Prostaglandin Derivatives: Nonaromatic Phosphodiesterase-4 Inhibitors from the Soft Coral Sarcophyton ehrenbergi.
AID1157542Toxicity in Marshall ferret assessed as vomiting at 1 mg/kg, po after 2 hrs2014Bioorganic & medicinal chemistry letters, Jun-15, Volume: 24, Issue:12
Identification of 2,3-disubstituted pyridines as potent, non-emetic PDE4 inhibitors.
AID260831Inhibition of PDE102006Bioorganic & medicinal chemistry letters, Feb, Volume: 16, Issue:3
A new chemical tool for exploring the role of the PDE4D isozyme in leukocyte function.
AID1187756Inhibition of PDE4D3 (unknown origin) at 10 uM2014Journal of medicinal chemistry, Aug-28, Volume: 57, Issue:16
Synthesis, biological evaluation, and molecular modeling of new 3-(cyclopentyloxy)-4-methoxybenzaldehyde O-(2-(2,6-dimethylmorpholino)-2-oxoethyl) Oxime (GEBR-7b) related phosphodiesterase 4D (PDE4D) inhibitors.
AID159932Relative inhibition of rolipram binding and Phosphodiesterase 4 activity2002Bioorganic & medicinal chemistry letters, Jan-07, Volume: 12, Issue:1
Phthalazine PDE4 inhibitors. Part 3: the synthesis and in vitro evaluation of derivatives with a hydrogen bond acceptor.
AID158402Inhibition of recombinant human PDE4A expressed in Sf9 cells2000Journal of medicinal chemistry, Oct-19, Volume: 43, Issue:21
Hunting the emesis and efficacy targets of PDE4 inhibitors: identification of the photoaffinity probe 8-(3-azidophenyl)-6- [(4-iodo-1H-1-imidazolyl)methyl]quinoline (APIIMQ).
AID1593011Inhibition of human full length N-terminal GST-tagged PDE4B1 expressed in baculovirus infected Sf9 cells using cAMP as substrate incubated for 1 hr by fluorescence polarization assay2019European journal of medicinal chemistry, Apr-15, Volume: 168Discovery of arylbenzylamines as PDE4 inhibitors with potential neuroprotective effect.
AID1420141Selectivity index, ratio of IC50 for human U937 cells-derived PDE4D to IC50 for human U937 cells-derived PDE4B2018Bioorganic & medicinal chemistry letters, 10-15, Volume: 28, Issue:19
Tetrahydroquinoline and tetrahydroisoquinoline derivatives as potential selective PDE4B inhibitors.
AID1254339Selectivity ratio of IC50 for human full-length PDE4B1 to IC50 for human full-length PDE4D72015Bioorganic & medicinal chemistry, Nov-15, Volume: 23, Issue:22
Catecholic amides as potential selective phosphodiesterase 4D inhibitors: Design, synthesis, pharmacological evaluation and structure-activity relationships.
AID1707985Inhibition of recombinant human PDE4B using 5'-cGMP as substrate measured after 90 mins by colorimetric assay2021European journal of medicinal chemistry, Feb-15, Volume: 212Novel cyanothiouracil and cyanothiocytosine derivatives as concentration-dependent selective inhibitors of U87MG glioblastomas: Adenosine receptor binding and potent PDE4 inhibition.
AID1884344Inhibition of PDE4B (unknown origin) using [3H]cAMP as substrate incubated for 1 hr by PDElight HTS cAMP phosphodiesterase assay2022European journal of medicinal chemistry, Aug-05, Volume: 238Novel quinoline-based derivatives: A new class of PDE4B inhibitors for adjuvant-induced arthritis.
AID389793Inhibition of full length human PDE4D2 expressed in Escherichia coli BL21 by liquid scintillation counting2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Design, synthesis, and structure-activity relationship, molecular modeling, and NMR studies of a series of phenyl alkyl ketones as highly potent and selective phosphodiesterase-4 inhibitors.
AID1872570Inhibition of PDE4 (unknown origin)2022European journal of medicinal chemistry, Mar-15, Volume: 232Therapeutic potential of phosphodiesterase inhibitors for cognitive amelioration in Alzheimer's disease.
AID157781Inhibition of phosphodiesterase (PDE) 4A1998Bioorganic & medicinal chemistry letters, Nov-17, Volume: 8, Issue:22
N-arylrolipram derivatives as potent and selective PDE4 inhibitors.
AID158909Inhibition of phosphodiesterase 1 at 20 uM1998Bioorganic & medicinal chemistry letters, Oct-06, Volume: 8, Issue:19
Aryl sulfonamides as selective PDE4 inhibitors.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID1166735Inhibition of human recombinant PDE4B2 assessed after 60 mins by IMAP fluorescence polarization assay2014Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20
Modulation of cAMP-specific PDE without emetogenic activity: new sulfide-like PDE7 inhibitors.
AID1512234Inhibition of PDE4D in human U937 cells using [3H]cAMP as substrate incubated for 30 mins2019Bioorganic & medicinal chemistry letters, 11-15, Volume: 29, Issue:22
Discovery of novel inhibitors of phosphodiesterase 4 with 1-phenyl-3,4-dihydroisoquinoline scaffold: Structure-based drug design and fragment identification.
AID159635Inhibition of guinea pig PDE IV1994Journal of medicinal chemistry, May-27, Volume: 37, Issue:11
Selective type IV phosphodiesterase inhibitors as antiasthmatic agents. The syntheses and biological activities of 3-(cyclopentyloxy)-4-methoxybenzamides and analogues.
AID1160999Inhibition of human recombinant PDE4D2 activity assessed as residual cAMP concentration by HTRF assay2014Bioorganic & medicinal chemistry letters, Sep-15, Volume: 24, Issue:18
Novel Roflumilast analogs as soft PDE4 inhibitors.
AID71925In vitro inotropic effect, 20% increase in the force of contraction of isolated ferret papillary muscle strips (Not reached at 100 uM)1993Journal of medicinal chemistry, Apr-16, Volume: 36, Issue:8
(Imidazolylphenyl)pyrrol-2-one inhibitors of cardiac cAMP phosphodiesterase.
AID159783Inhibition of human Phosphodiesterase 42002Bioorganic & medicinal chemistry letters, Jan-07, Volume: 12, Issue:1
Phthalazine PDE4 inhibitors. Part 3: the synthesis and in vitro evaluation of derivatives with a hydrogen bond acceptor.
AID1625378Inhibition of human His-tagged PDE4D catalytic domain expressed in Escherichia coli BL21-CodonPlus(DE3) cells using [3H]cAMP or [3H]cGMP as substrate incubated for 30 mins by scintillation counting method2016Journal of medicinal chemistry, Aug-11, Volume: 59, Issue:15
PDEStrIAn: A Phosphodiesterase Structure and Ligand Interaction Annotated Database As a Tool for Structure-Based Drug Design.
AID241177Inhibition of Phosphodiesterase 32005Bioorganic & medicinal chemistry letters, Apr-01, Volume: 15, Issue:7
Fused pyrimidine based inhibitors of phosphodiesterase 7 (PDE7): synthesis and initial structure-activity relationships.
AID241180Inhibition of Phosphodiesterase 72005Bioorganic & medicinal chemistry letters, Apr-01, Volume: 15, Issue:7
Fused pyrimidine based inhibitors of phosphodiesterase 7 (PDE7): synthesis and initial structure-activity relationships.
AID1773135Antiproliferative activity against human A549 cells after 48 hrs by MTT assay2021European journal of medicinal chemistry, Nov-15, Volume: 224Discovery of novel trimethoxyphenylbenzo[d]oxazoles as dual tubulin/PDE4 inhibitors capable of inducing apoptosis at G2/M phase arrest in glioma and lung cancer cells.
AID349559Antiinflammatory activity in human PBMC assessed as inhibition of phytohemagglutininin-induced IL10 release after 48 hrs by FACS Array analysis2009Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8
Discovery and structure-activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis.
AID440712Selectivity ratio of Ki for human PDE4D2 to Ki for human PDE4D32009Journal of medicinal chemistry, Nov-12, Volume: 52, Issue:21
New selective phosphodiesterase 4D inhibitors differently acting on long, short, and supershort isoforms.
AID1727186Hepatoprotective activity in ConA-induced BALB/c hepatitis mouse model assessed as decrease in serum alanine aminotransferase level at 50 mg/kg, ip administration and measured after 8 hrs relative to control2021European journal of medicinal chemistry, Jan-01, Volume: 209New imidazopyridines with phosphodiesterase 4 and 7 inhibitory activity and their efficacy in animal models of inflammatory and autoimmune diseases.
AID131172In vivo inhibition of LPS induced tumor necrosis factor (TNF-alpha) in mice1998Bioorganic & medicinal chemistry letters, Nov-03, Volume: 8, Issue:21
Orally active indole N-oxide PDE4 inhibitors.
AID215591Inhibition of LPS stimulated Tumor Necrosis Factor-alpha (TNF-alpha) release by human PBMC1998Bioorganic & medicinal chemistry letters, Oct-06, Volume: 8, Issue:19
Thalidomide analogs and PDE4 inhibition.
AID260833Selectivity for PDE4D2006Bioorganic & medicinal chemistry letters, Feb, Volume: 16, Issue:3
A new chemical tool for exploring the role of the PDE4D isozyme in leukocyte function.
AID241178Inhibition of Phosphodiesterase 42005Bioorganic & medicinal chemistry letters, Apr-01, Volume: 15, Issue:7
Fused pyrimidine based inhibitors of phosphodiesterase 7 (PDE7): synthesis and initial structure-activity relationships.
AID219317Inhibitory activity against phosphodiesterase was determined in vitro using bovine aorta, at 1 uM cGMP for cGMP-PDE.1989Journal of medicinal chemistry, Jul, Volume: 32, Issue:7
Inhibition of cyclic adenosine-3',5'-monophosphate phosphodiesterase from vascular smooth muscle by rolipram analogues.
AID425690Inhibition of PDE7B2009Bioorganic & medicinal chemistry letters, Jul-01, Volume: 19, Issue:13
Exploration and optimization of substituted triazolothiadiazines and triazolopyridazines as PDE4 inhibitors.
AID318118Inhibition of PDE4B2008Bioorganic & medicinal chemistry letters, Mar-15, Volume: 18, Issue:6
Rhodanine derivatives as novel inhibitors of PDE4.
AID1157532Inhibition of Hartley guinea pig PDE4 assessed as hydrolization of cAMP by measuring [3H]cAMP at 100 nM by radioisotope method2014Bioorganic & medicinal chemistry letters, Jun-15, Volume: 24, Issue:12
Identification of 2,3-disubstituted pyridines as potent, non-emetic PDE4 inhibitors.
AID1353616Anti-inflammatory activity in human PBMC assessed as inhibition of LPS-induced IL-1beta production at 10 uM after 24 hrs by ELISA relative to control2018European journal of medicinal chemistry, Mar-10, Volume: 147Phenylpyridine-2-ylguanidines and rigid mimetics as novel inhibitors of TNFα overproduction: Beneficial action in models of neuropathic pain and of acute lung inflammation.
AID1703891Vasorelaxant activity in OVA-sensitized guinea pig-derived trachea assessed as decrease in CCh-induced tracheal tonic contraction in absence of functional epithelium treated with compound after contraction stabilised2020European journal of medicinal chemistry, Oct-15, Volume: 204Discovery of sulfonyl hydrazone derivative as a new selective PDE4A and PDE4D inhibitor by lead-optimization approach on the prototype LASSBio-448: In vitro and in vivo preclinical studies.
AID1773165Induction of apoptosis in human A549 cells assessed as increase in late apoptotic cells at 500 nM measured after 24 hrs by PI/FITC analysis (Rvb = 0.955%)2021European journal of medicinal chemistry, Nov-15, Volume: 224Discovery of novel trimethoxyphenylbenzo[d]oxazoles as dual tubulin/PDE4 inhibitors capable of inducing apoptosis at G2/M phase arrest in glioma and lung cancer cells.
AID759554Toxicity in iv dosed ferret assessed as first emetic dose by measuring occurrence of vomiting episode after 6 hrs2013Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15
Discovery of triazines as potent, selective and orally active PDE4 inhibitors.
AID632939Inhibition of PDE in rat UMR106 cells co-expressing CRE-luc assessed as PTH-induced cAMP accumulation by luciferase reporter gene assay2011Bioorganic & medicinal chemistry letters, Dec-01, Volume: 21, Issue:23
Thiophene inhibitors of PDE4: crystal structures show a second binding mode at the catalytic domain of PDE4D2.
AID157917Evaluated in vitro for its inhibitory activity on unpurified recombinant Phosphodiesterase 4C1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
Striking effect of hydroxamic acid substitution on the phosphodiesterase type 4 (PDE4) and TNF alpha inhibitory activity of two series of rolipram analogues: implications for a new active site model of PDE4.
AID230413Ratio of PDEIV IC50 to IC50 [3H]rolipram high affinity binding.1998Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21
Design, synthesis, and biological activities of new thieno[3,2-d] pyrimidines as selective type 4 phosphodiesterase inhibitors.
AID1335403Inhibition of full length human PDE4B1 using FAM-3',5'-cAMP as substrate after 1 hr by fluorescence polarization assay2016European journal of medicinal chemistry, Nov-29, Volume: 124Development of highly potent phosphodiesterase 4 inhibitors with anti-neuroinflammation potential: Design, synthesis, and structure-activity relationship study of catecholamides bearing aromatic rings.
AID425677Inhibition of PDE1A2009Bioorganic & medicinal chemistry letters, Jul-01, Volume: 19, Issue:13
Exploration and optimization of substituted triazolothiadiazines and triazolopyridazines as PDE4 inhibitors.
AID1311213Anti-inflammatory activity in human PBMC assessed as suppression of LPS-induced TNF-alpha release preincubated for 30 mins followed by LPS stimulation for 18 hrs by TR-FRET assay2016Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15
Synthesis and bioactivity of pyrazole and triazole derivatives as potential PDE4 inhibitors.
AID159632Inhibition of guinea pig macrophage Phosphodiesterase 41998Bioorganic & medicinal chemistry letters, Jan-20, Volume: 8, Issue:2
Quaternary substituted PDE4 inhibitors I: the synthesis and in vitro evaluation of a novel series of oxindoles.
AID1743666Inhibition of PDE4B in human PBMC assessed as reduction in LPS-induced TNFalpha release preincubated for 30 mins followed by LPS stimulation and measured after 18 hrs by TR-FRET assay2020European journal of medicinal chemistry, Dec-01, Volume: 207Synthesis and bioactivity of phenyl substituted furan and oxazole carboxylic acid derivatives as potential PDE4 inhibitors.
AID1872571Displacement of [3H]-Rolipram from full-length recombinant human PDE4 expressed in yeast membrane by liquid scintillation counting method2022European journal of medicinal chemistry, Mar-15, Volume: 232Therapeutic potential of phosphodiesterase inhibitors for cognitive amelioration in Alzheimer's disease.
AID239336Inhibition of [3H]cAMP binding to recombinant human Phosphodiesterase 4D5 (PDE4D5) in baculovirus expression system2005Journal of medicinal chemistry, Feb-24, Volume: 48, Issue:4
8-Substituted analogues of 3-(3-cyclopentyloxy-4-methoxy-benzyl)-8-isopropyl-adenine: highly potent and selective PDE4 inhibitors.
AID363086Inhibition of human PDE4A10 in cytosolic fraction of inflammatory cells2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Recent advances on phosphodiesterase 4 inhibitors for the treatment of asthma and chronic obstructive pulmonary disease.
AID1464280Inhibition of LPS-induced TNFalpha production in Swiss Albino mouse model of sepsis at 10 mg/kg, po pre-treated 30 mins before LPS challenge and measured 90 mins post LPS injection by ELISA method relative to untreated control2017Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20
Rational design of conformationally constrained oxazolidinone-fused 1,2,3,4-tetrahydroisoquinoline derivatives as potential PDE4 inhibitors.
AID1157545Toxicity in po dosed Marshall ferret assessed as vomiting2014Bioorganic & medicinal chemistry letters, Jun-15, Volume: 24, Issue:12
Identification of 2,3-disubstituted pyridines as potent, non-emetic PDE4 inhibitors.
AID1231629Inhibition of human recombinant PDE4A4 expressed in baculoviral system using cAMP as substrate at 10 uM by fluorescence polarization assay relative to control2015Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13
Synthesis, biological activities and pharmacokinetic properties of new fluorinated derivatives of selective PDE4D inhibitors.
AID1773177Induction of apoptosis in human U-251 cells assessed as increase in late apoptotic cells at 200 nM measured after 24 hrs by PI/FITC analysis (Rvb = 0.311%)2021European journal of medicinal chemistry, Nov-15, Volume: 224Discovery of novel trimethoxyphenylbenzo[d]oxazoles as dual tubulin/PDE4 inhibitors capable of inducing apoptosis at G2/M phase arrest in glioma and lung cancer cells.
AID157763Relative inhibition of phosphodiesterase 4 activity and rolipram binding to PDE42002Bioorganic & medicinal chemistry letters, Jun-17, Volume: 12, Issue:12
8-Methoxyquinoline-5-carboxamides as PDE4 inhibitors: a potential treatment for asthma.
AID612629Antiinflammatory activity in mouse neutrophils assessed as inhibition of LPS-stimulated IL1-beta expression after 4-5 hrs by ELISA relative to control2011Bioorganic & medicinal chemistry letters, Aug-15, Volume: 21, Issue:16
Psilostachyin, acetylated pseudoguaianolides and their analogues: preparation and evaluation of their anti-inflammatory potential.
AID1623117Neuroprotection in amyloid beta (25 to 35 residues) induced C57BL/6J mouse model of Alzheimer's disease assessed as reduction in ratio of apoptotic neuron in CA3 hippocampus region at 4 mg/kg/day, ig administered for 26 consecutive days by hematoxylin and2019European journal of medicinal chemistry, Feb-01, Volume: 163Synthesis and evaluation of clioquinol-rolipram/roflumilast hybrids as multitarget-directed ligands for the treatment of Alzheimer's disease.
AID704139Antiinflammatory activity in A/J mouse assessed as inhibition of mononuclear cell accumulation in bronchoalveolar space at 45 umol/kg, po administered 1 hr prior to LPS-challenge measured after 18 hrs relative to vehicle-treated control2012Journal of medicinal chemistry, Sep-13, Volume: 55, Issue:17
Design, synthesis, and pharmacological evaluation of N-acylhydrazones and novel conformationally constrained compounds as selective and potent orally active phosphodiesterase-4 inhibitors.
AID260834cAMP elevation in U937 cells2006Bioorganic & medicinal chemistry letters, Feb, Volume: 16, Issue:3
A new chemical tool for exploring the role of the PDE4D isozyme in leukocyte function.
AID314444Inhibition of PDE10A2008Bioorganic & medicinal chemistry letters, Feb-15, Volume: 18, Issue:4
Identification of a potent new chemotype for the selective inhibition of PDE4.
AID232484Selectivity ratio indicated as IC50 value in inhibiting PDE4B or PDE4A compared to PDE4D2000Journal of medicinal chemistry, Feb-24, Volume: 43, Issue:4
Palladium-catalyzed cross-coupling reactions for the synthesis of 6, 8-disubstituted 1,7-naphthyridines: a novel class of potent and selective phosphodiesterase type 4D inhibitors.
AID1261704Inhibition of human PDE4D using 3H-cAMP as substrate after 15 mins by liquid scintillation counting analysis2015Journal of medicinal chemistry, Nov-12, Volume: 58, Issue:21
Design, Synthesis, and Evaluation of Orally Available Clioquinol-Moracin M Hybrids as Multitarget-Directed Ligands for Cognitive Improvement in a Rat Model of Neurodegeneration in Alzheimer's Disease.
AID704166Inhibition of human recombinant PDE4C2012Journal of medicinal chemistry, Sep-13, Volume: 55, Issue:17
Design, synthesis, and pharmacological evaluation of N-acylhydrazones and novel conformationally constrained compounds as selective and potent orally active phosphodiesterase-4 inhibitors.
AID158459Binding affinity against PDE4 was determined using [3H]- rolipram in guinea pig brain membrane binding assay1998Bioorganic & medicinal chemistry letters, Jul-21, Volume: 8, Issue:14
The synthesis and biological evaluation of a novel series of indole PDE4 inhibitors I.
AID704168Inhibition of human recombinant PDE4A2012Journal of medicinal chemistry, Sep-13, Volume: 55, Issue:17
Design, synthesis, and pharmacological evaluation of N-acylhydrazones and novel conformationally constrained compounds as selective and potent orally active phosphodiesterase-4 inhibitors.
AID1365250Anti-inflammatory activity in human U937 cells assessed as inhibition of LPS-induced IL6 production pre-incubated for 1 hr before LPS stimulation for 24 hrs by ELISA method2017Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20
Synthesis, pharmacological activities and molecular docking studies of pyrazolyltriazoles as anti-bacterial and anti-inflammatory agents.
AID473491Antiinflammatory activity in mouse assessed as inhibition of phorbol ester-induced ear edema at 1 mg/ear2010Bioorganic & medicinal chemistry letters, Apr-01, Volume: 20, Issue:7
Design and synthesis of boron-containing PDE4 inhibitors using soft-drug strategy for potential dermatologic anti-inflammatory application.
AID157770Inhibition of phosphodiesterase (PDE) 4C1998Bioorganic & medicinal chemistry letters, Nov-17, Volume: 8, Issue:22
N-arylrolipram derivatives as potent and selective PDE4 inhibitors.
AID612630Antiinflammatory activity in mouse neutrophils assessed as inhibition of LPS-stimulated IL-6 expression at 100 ug/ml after 4-5 hrs by ELISA relative to control2011Bioorganic & medicinal chemistry letters, Aug-15, Volume: 21, Issue:16
Psilostachyin, acetylated pseudoguaianolides and their analogues: preparation and evaluation of their anti-inflammatory potential.
AID440709Inhibition of human recombinant PDE4D2 expressed in baculovirus system by radiometric assay2009Journal of medicinal chemistry, Nov-12, Volume: 52, Issue:21
New selective phosphodiesterase 4D inhibitors differently acting on long, short, and supershort isoforms.
AID155672Inhibition of Phosphodiesterase 3 from human platelets2000Journal of medicinal chemistry, Feb-24, Volume: 43, Issue:4
Palladium-catalyzed cross-coupling reactions for the synthesis of 6, 8-disubstituted 1,7-naphthyridines: a novel class of potent and selective phosphodiesterase type 4D inhibitors.
AID1685005Binding affinity to human CRBN-thalidomide binding domain expressed in Escherichia coli by measuring baseline corrected normalized fluorescence by MST based assay2021ACS medicinal chemistry letters, Jan-14, Volume: 12, Issue:1
Sweet and Blind Spots in E3 Ligase Ligand Space Revealed by a Thermophoresis-Based Assay.
AID425697Inhibition of beta2 adrenergic receptor expressed in HEK293 cells co-transfected with PKA fragments Reg-F[1] and cat-F[2]-fused renilla luciferase assessed as effect on receptor regulated PKA activation at 100 uM after 30 mins by protein-fragment compleme2009Bioorganic & medicinal chemistry letters, Jul-01, Volume: 19, Issue:13
Exploration and optimization of substituted triazolothiadiazines and triazolopyridazines as PDE4 inhibitors.
AID318124Cytotoxicity against human CEM-SS cells2008Bioorganic & medicinal chemistry letters, Feb-15, Volume: 18, Issue:4
Investigation of the alkenyldiarylmethane non-nucleoside reverse transcriptase inhibitors as potential cAMP phosphodiesterase-4B2 inhibitors.
AID92723Evaluated in vitro for its inhibitory activity on LPS-induced TNF-Alpha release in human whole blood.1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
Striking effect of hydroxamic acid substitution on the phosphodiesterase type 4 (PDE4) and TNF alpha inhibitory activity of two series of rolipram analogues: implications for a new active site model of PDE4.
AID1231631Inhibition of human recombinant PDE4C2 expressed in baculoviral system using cAMP as substrate at 10 uM by fluorescence polarization assay relative to control2015Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13
Synthesis, biological activities and pharmacokinetic properties of new fluorinated derivatives of selective PDE4D inhibitors.
AID704146Antiinflammatory activity in A/J mouse lung assessed as inhibition of LPS-induced IL6 production at 45 umol/kg, po administered 1 hr prior to LPS-challenge measured after 18 hrs relative to vehicle-treated control2012Journal of medicinal chemistry, Sep-13, Volume: 55, Issue:17
Design, synthesis, and pharmacological evaluation of N-acylhydrazones and novel conformationally constrained compounds as selective and potent orally active phosphodiesterase-4 inhibitors.
AID1773143Cell cycle arrest in human A549 cells assessed as G2/M phase at 500 nM measured after 24 hrs by propidium iodide staining based flow cytometry analysis (Rvb = 6.08%)2021European journal of medicinal chemistry, Nov-15, Volume: 224Discovery of novel trimethoxyphenylbenzo[d]oxazoles as dual tubulin/PDE4 inhibitors capable of inducing apoptosis at G2/M phase arrest in glioma and lung cancer cells.
AID1335406Inhibition of human PDE5A using FAM-3',5'-cAMP as substrate after 1 hr by fluorescence polarization assay2016European journal of medicinal chemistry, Nov-29, Volume: 124Development of highly potent phosphodiesterase 4 inhibitors with anti-neuroinflammation potential: Design, synthesis, and structure-activity relationship study of catecholamides bearing aromatic rings.
AID314435Inhibition of PDE1B2008Bioorganic & medicinal chemistry letters, Feb-15, Volume: 18, Issue:4
Identification of a potent new chemotype for the selective inhibition of PDE4.
AID1404137Inhibition of recombinant full length human N-terminal GST-tagged PDE4A1 expressed in baculovirus infected Sf9 cells using cAMP as substrate after 1 hr by LANCE TR-FRET assay2018European journal of medicinal chemistry, Feb-10, Volume: 145Design, synthesis, and biological evaluation of novel catecholopyrimidine based PDE4 inhibitor for the treatment of atopic dermatitis.
AID210148In vitro inhibition of TNF-alpha-release from human whole blood2000Journal of medicinal chemistry, Dec-14, Volume: 43, Issue:25
Synthesis, structure-activity relationships, and pharmacological profile of 9-amino-4-oxo-1-phenyl-3,4,6,7-tetrahydro[1,4]diazepino[6, 7,1-hi]indoles: discovery of potent, selective phosphodiesterase type 4 inhibitors.
AID314441Inhibition of PDE7A2008Bioorganic & medicinal chemistry letters, Feb-15, Volume: 18, Issue:4
Identification of a potent new chemotype for the selective inhibition of PDE4.
AID115571Percentage inhibition of serum TNF-alpha in lipopolysaccharide injected mice at 3 mg/kg peroral dose1995Journal of medicinal chemistry, Apr-28, Volume: 38, Issue:9
Phosphodiesterase type IV inhibition. Structure-activity relationships of 1,3-disubstituted pyrrolidines.
AID195716Displacement of [3H]rolipram from rat brain membranes1997Journal of medicinal chemistry, May-09, Volume: 40, Issue:10
Novel heterocyclic-fused pyridazinones as potent and selective phosphodiesterase IV inhibitors.
AID158884Inhibition of Phosphodiesterase 1 from guinea pig cardiac ventricle1996Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14
Novel selective PDE IV inhibitors as antiasthmatic agents. Synthesis and biological activities of a series of 1-aryl-2,3-bis(hydroxymethyl)naphthalene lignans.
AID1773134Antiproliferative activity against human U-251 cells after 48 hrs by MTT assay2021European journal of medicinal chemistry, Nov-15, Volume: 224Discovery of novel trimethoxyphenylbenzo[d]oxazoles as dual tubulin/PDE4 inhibitors capable of inducing apoptosis at G2/M phase arrest in glioma and lung cancer cells.
AID363083Inhibition of human PDE4A12008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Recent advances on phosphodiesterase 4 inhibitors for the treatment of asthma and chronic obstructive pulmonary disease.
AID766608Bronchodilatory activity in ovalbumin-treated guinea pig at 10 mg/kg, po administered 1 hr prior to ovalbumin challenge relative to vehicle-treated control2013Bioorganic & medicinal chemistry, Sep-15, Volume: 21, Issue:18
Identification of 2,3-disubstituted pyridines as potent, orally active PDE4 inhibitors.
AID704138Antiinflammatory activity in A/J mouse assessed as inhibition of eosinophils accumulation in bronchoalveolar space at 45 umol/kg, po administered 1 hr prior to LPS-challenge measured after 18 hrs relative to vehicle-treated control2012Journal of medicinal chemistry, Sep-13, Volume: 55, Issue:17
Design, synthesis, and pharmacological evaluation of N-acylhydrazones and novel conformationally constrained compounds as selective and potent orally active phosphodiesterase-4 inhibitors.
AID74179Inhibition of antigen-induced bronchoconstriction in anesthetized guinea pig at 0.1 mg/kg intravenous dose1996Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14
Novel selective PDE IV inhibitors as antiasthmatic agents. Synthesis and biological activities of a series of 1-aryl-2,3-bis(hydroxymethyl)naphthalene lignans.
AID1404138Inhibition of recombinant human N-terminal GST-tagged PDE3B (592-end residues) expressed in baculovirus infected Sf9 cells using cAMP as substrate after 1 hr by LANCE TR-FRET assay2018European journal of medicinal chemistry, Feb-10, Volume: 145Design, synthesis, and biological evaluation of novel catecholopyrimidine based PDE4 inhibitor for the treatment of atopic dermatitis.
AID662984Inhibition of human neutrophil PDE42012Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
Identification of chalcones as potent and selective PDE5A1 inhibitors.
AID1365248Anti-inflammatory activity in human U937 cells assessed as inhibition of LPS-induced TNFalpha production pre-incubated for 1 hr before LPS stimulation for 24 hrs by ELISA method2017Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20
Synthesis, pharmacological activities and molecular docking studies of pyrazolyltriazoles as anti-bacterial and anti-inflammatory agents.
AID126634Percent cytokine TNF inhibition in monkeys at 10 mg/kg oral dose1998Journal of medicinal chemistry, Jun-18, Volume: 41, Issue:13
7-Oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridines as novel inhibitors of human eosinophil phosphodiesterase.
AID158756Inhibitory concentration against phosphodiesterase 1 from bovine, calmodulin2004Bioorganic & medicinal chemistry letters, Jun-07, Volume: 14, Issue:11
Identification of purine inhibitors of phosphodiesterase 7 (PDE7).
AID1157535Toxicity in Marshall ferret assessed as vomiting at 30 mg/kg, po after 2 hrs2014Bioorganic & medicinal chemistry letters, Jun-15, Volume: 24, Issue:12
Identification of 2,3-disubstituted pyridines as potent, non-emetic PDE4 inhibitors.
AID260830Inhibition of PDE92006Bioorganic & medicinal chemistry letters, Feb, Volume: 16, Issue:3
A new chemical tool for exploring the role of the PDE4D isozyme in leukocyte function.
AID1731331Displacement of [3H]SR141716A from human CB1R receptor expressed in rat Chem-1 cells at 10 uM incubated for 60 mins by scintillation counting method relative to control2021European journal of medicinal chemistry, Mar-15, Volume: 214Discovery of novel positive allosteric modulators of the α7 nicotinic acetylcholine receptor: Scaffold hopping approach.
AID1353614Anti-inflammatory activity in human PBMC assessed as inhibition of LPS-induced TNFalpha production at 10 uM after 24 hrs by ELISA relative to control2018European journal of medicinal chemistry, Mar-10, Volume: 147Phenylpyridine-2-ylguanidines and rigid mimetics as novel inhibitors of TNFα overproduction: Beneficial action in models of neuropathic pain and of acute lung inflammation.
AID159075Inhibition of Phosphodiesterase 21997Journal of medicinal chemistry, Jun-06, Volume: 40, Issue:12
9-Benzyladenines: potent and selective cAMP phosphodiesterase inhibitors.
AID159227Inhibition of Phosphodiesterase 3 from guinea pig cardiac ventricle1996Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14
Novel selective PDE IV inhibitors as antiasthmatic agents. Synthesis and biological activities of a series of 1-aryl-2,3-bis(hydroxymethyl)naphthalene lignans.
AID1773178Induction of apoptosis in human U-251 cells assessed as increase in necrotic cells at 200 nM measured after 24 hrs by PI/FITC analysis (Rvb = 0.301%)2021European journal of medicinal chemistry, Nov-15, Volume: 224Discovery of novel trimethoxyphenylbenzo[d]oxazoles as dual tubulin/PDE4 inhibitors capable of inducing apoptosis at G2/M phase arrest in glioma and lung cancer cells.
AID158899Inhibition of phosphodiesterase 1 (PDE1) from porcine adrenal tissue2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
4-(3-Chloro-4-methoxybenzyl)aminophthalazines: synthesis and inhibitory activity toward phosphodiesterase 5.
AID158309Inhibition of low Km cyclic AMP phosphodiesterase PDE III of rabbit renal cortex1985Journal of medicinal chemistry, May, Volume: 28, Issue:5
A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity.
AID157744Inhibition of phosphodiesterase 42003Bioorganic & medicinal chemistry letters, Jul-21, Volume: 13, Issue:14
Synthesis and biological activities of 1-pyridylisoquinoline and 1-pyridyldihydroisoquinoline derivatives as PDE4 inhibitors.
AID1727189Hepatoprotective activity in ConA-induced BALB/c hepatitis mouse model assessed as decrease in serum aspartate aminotransferase level at 10 mg/kg, ip administration and measured after 8 hrs relative to control2021European journal of medicinal chemistry, Jan-01, Volume: 209New imidazopyridines with phosphodiesterase 4 and 7 inhibitory activity and their efficacy in animal models of inflammatory and autoimmune diseases.
AID222460Inhibition of TNF alpha synthesis in human monocytes2000Bioorganic & medicinal chemistry letters, Oct-02, Volume: 10, Issue:19
The synthesis and biological evaluation of a novel series of phthalazine PDE4 inhibitors I.
AID1129294Inhibition of human PDE4D2 catalytic domain (86 to 413aa) expressed in Escherichia coli strain BL21 after 15 mins by liquid scintillation counting in presence of [3H]-cAMP2014Journal of natural products, Apr-25, Volume: 77, Issue:4
Prenylated coumarins: natural phosphodiesterase-4 inhibitors from Toddalia asiatica.
AID1254332Selectivity ratio of IC50 for PDE4B (unknown origin) to IC50 for PDE4D (unknown origin)2015Bioorganic & medicinal chemistry, Nov-15, Volume: 23, Issue:22
Catecholic amides as potential selective phosphodiesterase 4D inhibitors: Design, synthesis, pharmacological evaluation and structure-activity relationships.
AID736493Inhibition of recombinant His-tagged PDE4B (unknown origin) expressed in Sf9 cells using cAMP as substrate incubated for 15 mins prior to substrate addition measured after 1 hr by luminescence-based assay2013European journal of medicinal chemistry, Apr, Volume: 62Montmorillonite K-10 catalyzed green synthesis of 2,6-unsubstituted dihydropyridines as potential inhibitors of PDE4.
AID260838Inhibition of LTB4 mediated human eosinophil chemotaxis2006Bioorganic & medicinal chemistry letters, Feb, Volume: 16, Issue:3
A new chemical tool for exploring the role of the PDE4D isozyme in leukocyte function.
AID74184Inhibition of antigen-induced bronchoconstriction in anesthetized guinea pig at 0.1 mg/kg intravenous dose1996Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14
Novel selective PDE IV inhibitors as antiasthmatic agents. Synthesis and biological activities of a series of 1-aryl-2,3-bis(hydroxymethyl)naphthalene lignans.
AID1353618Cytotoxicity against human PBMC assessed as cell viability at 10 um after 24 hrs by WST-1 assay relative to control2018European journal of medicinal chemistry, Mar-10, Volume: 147Phenylpyridine-2-ylguanidines and rigid mimetics as novel inhibitors of TNFα overproduction: Beneficial action in models of neuropathic pain and of acute lung inflammation.
AID517457Inhibition of PDE4A4 expressed in yeast2010Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19
Synthesis and biological activity of pyrido[3',2':4,5]thieno[3,2-d]pyrimidines as phosphodiesterase type 4 inhibitors.
AID1335401Inhibition of human PDE4 catalytic domain using FAM-3',5'-cAMP as substrate after 1 hr by fluorescence polarization assay2016European journal of medicinal chemistry, Nov-29, Volume: 124Development of highly potent phosphodiesterase 4 inhibitors with anti-neuroinflammation potential: Design, synthesis, and structure-activity relationship study of catecholamides bearing aromatic rings.
AID222461Inhibition of TNF-alpha synthesis in human monocytes2001Bioorganic & medicinal chemistry letters, Jan-08, Volume: 11, Issue:1
Phthalazine PDE4 inhibitors. Part 2: the synthesis and biological evaluation of 6-methoxy-1,4-disubstituted derivatives.
AID363085Inhibition of human PDE4A4B in particular fraction of inflammatory cells2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Recent advances on phosphodiesterase 4 inhibitors for the treatment of asthma and chronic obstructive pulmonary disease.
AID159952Affinity for the high affinity rolipram binding site of phosphodiesterase (PDE IV) by [3H]rolipram displacement.1998Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21
Design, synthesis, and biological activities of new thieno[3,2-d] pyrimidines as selective type 4 phosphodiesterase inhibitors.
AID159796Inhibitory activity on human eosinophil phosphodiesterase 4.1998Journal of medicinal chemistry, Jun-18, Volume: 41, Issue:13
7-Oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridines as novel inhibitors of human eosinophil phosphodiesterase.
AID1773990Inhibition of PDE4D2 (86-413) (unknown origin) expressed in Escherichia coli BL21 assessed as using [3H]-cAMP as substrate measured for 15 mins by liquid scintillation counting analysis
AID1335412Inhibition of human PDE11A using FAM-3',5'-cAMP as substrate after 1 hr by fluorescence polarization assay2016European journal of medicinal chemistry, Nov-29, Volume: 124Development of highly potent phosphodiesterase 4 inhibitors with anti-neuroinflammation potential: Design, synthesis, and structure-activity relationship study of catecholamides bearing aromatic rings.
AID226828Ratio of inhibitory activity against PDE4 to that of binding affinity towards rolipram binding site on PDE4 was determined2003Bioorganic & medicinal chemistry letters, Jul-21, Volume: 13, Issue:14
Synthesis and biological activities of 1-pyridylisoquinoline and 1-pyridyldihydroisoquinoline derivatives as PDE4 inhibitors.
AID159350Inhibition of Phosphodiesterase 3 at 50 uM1995Journal of medicinal chemistry, Apr-28, Volume: 38, Issue:9
Phosphodiesterase type IV inhibition. Structure-activity relationships of 1,3-disubstituted pyrrolidines.
AID1166733Inhibition of human recombinant PDE4D3 assessed after 60 mins by IMAP fluorescence polarization assay2014Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20
Modulation of cAMP-specific PDE without emetogenic activity: new sulfide-like PDE7 inhibitors.
AID209003Emetic effect in shrews at 10 mg/kg peroral dose, 3 of 3 animals affected1997Journal of medicinal chemistry, Sep-26, Volume: 40, Issue:20
Selective inhibitors of cyclic AMP-specific phosphodiesterase: heterocycle-condensed purines.
AID1598202Memory enhancement effect in ICR mouse assessed as improvement in novel object discrimination at 0.1 mg/kg, ip administered via gavage measured for 5 mins by open field test2019Journal of medicinal chemistry, 05-23, Volume: 62, Issue:10
Design and Synthesis of Selective Phosphodiesterase 4D (PDE4D) Allosteric Inhibitors for the Treatment of Fragile X Syndrome and Other Brain Disorders.
AID314438Inhibition of PDE4B2008Bioorganic & medicinal chemistry letters, Feb-15, Volume: 18, Issue:4
Identification of a potent new chemotype for the selective inhibition of PDE4.
AID214056Arbitary maximal response for cAMP elevation from baseline level was evaluated in Human U-937 cells1998Journal of medicinal chemistry, Jun-18, Volume: 41, Issue:13
7-Oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridines as novel inhibitors of human eosinophil phosphodiesterase.
AID1773163Induction of apoptosis in human A549 cells assessed as increase in viable cells at 500 nM measured after 24 hrs by PI/FITC analysis (Rvb = 98.4%)2021European journal of medicinal chemistry, Nov-15, Volume: 224Discovery of novel trimethoxyphenylbenzo[d]oxazoles as dual tubulin/PDE4 inhibitors capable of inducing apoptosis at G2/M phase arrest in glioma and lung cancer cells.
AID1420144Anti-inflammatory activity in Sprague-Dawley rat model of LPS-induced asthma/COPD assessed as inhibition of neutrophilia in BALF at 10 mg/kg, po administered 30 mins prior to LPS challenge for 40 mins and measured after 6 hrs relative to control2018Bioorganic & medicinal chemistry letters, 10-15, Volume: 28, Issue:19
Tetrahydroquinoline and tetrahydroisoquinoline derivatives as potential selective PDE4B inhibitors.
AID15809950% inhibitory concentration against phosphodiesterase 5 (PDE5) from porcine platelets2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
4-(3-Chloro-4-methoxybenzyl)aminophthalazines: synthesis and inhibitory activity toward phosphodiesterase 5.
AID704169Inhibition of bovine PDE4 using [3H]cAMP as substrate2012Journal of medicinal chemistry, Sep-13, Volume: 55, Issue:17
Design, synthesis, and pharmacological evaluation of N-acylhydrazones and novel conformationally constrained compounds as selective and potent orally active phosphodiesterase-4 inhibitors.
AID179558Evaluated for Ca++ independent phosphodiesterase activity. 1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
4-Amino[1,2,4]triazolo[4,3-a]quinoxalines. A novel class of potent adenosine receptor antagonists and potential rapid-onset antidepressants.
AID159778Inhibition of Phosphodiesterase 4 (PDE-4) from human U937 cells2002Bioorganic & medicinal chemistry letters, Jun-17, Volume: 12, Issue:12
8-Methoxyquinoline-5-carboxamides as PDE4 inhibitors: a potential treatment for asthma.
AID157915Inhibitory activity against Phosphodiesterase 4B (PDE4B) from rat source expressed in Saccharomyces cerevisiae2000Journal of medicinal chemistry, Feb-24, Volume: 43, Issue:4
Palladium-catalyzed cross-coupling reactions for the synthesis of 6, 8-disubstituted 1,7-naphthyridines: a novel class of potent and selective phosphodiesterase type 4D inhibitors.
AID363089Inhibition of human PDE4B1 in particular fraction of lung2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Recent advances on phosphodiesterase 4 inhibitors for the treatment of asthma and chronic obstructive pulmonary disease.
AID1703893Vasorelaxant activity in OVA-sensitized guinea pig-derived trachea assessed as decrease in CCh-induced tracheal tonic contraction in presence of functional epithelium treated with compound after contraction stabilised2020European journal of medicinal chemistry, Oct-15, Volume: 204Discovery of sulfonyl hydrazone derivative as a new selective PDE4A and PDE4D inhibitor by lead-optimization approach on the prototype LASSBio-448: In vitro and in vivo preclinical studies.
AID1335404Inhibition of full length human PDE4C1 using FAM-3',5'-cAMP as substrate after 1 hr by fluorescence polarization assay2016European journal of medicinal chemistry, Nov-29, Volume: 124Development of highly potent phosphodiesterase 4 inhibitors with anti-neuroinflammation potential: Design, synthesis, and structure-activity relationship study of catecholamides bearing aromatic rings.
AID363092Inhibition of human PDE4B3 in cytosolic fraction of lung2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Recent advances on phosphodiesterase 4 inhibitors for the treatment of asthma and chronic obstructive pulmonary disease.
AID363094Inhibition of human PDE4B4 in cytosolic fraction of liver and brain2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Recent advances on phosphodiesterase 4 inhibitors for the treatment of asthma and chronic obstructive pulmonary disease.
AID158469Evaluated in vitro for its inhibitory activity on unpurified recombinant Phosphodiesterase type 4A (PDE4A).1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
Striking effect of hydroxamic acid substitution on the phosphodiesterase type 4 (PDE4) and TNF alpha inhibitory activity of two series of rolipram analogues: implications for a new active site model of PDE4.
AID155675Inhibition of phosphodiesterase 3 (PDE3) from porcine platelets2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
4-(3-Chloro-4-methoxybenzyl)aminophthalazines: synthesis and inhibitory activity toward phosphodiesterase 5.
AID232680Selectivity as ratio of IC50 against PDE III to IC50 against PDE IV from guinea pig1996Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14
Novel selective PDE IV inhibitors as antiasthmatic agents. Synthesis and biological activities of a series of 1-aryl-2,3-bis(hydroxymethyl)naphthalene lignans.
AID1625373Inhibition of human PDE4B catalytic domain (152 to 528 residues)2016Journal of medicinal chemistry, Aug-11, Volume: 59, Issue:15
PDEStrIAn: A Phosphodiesterase Structure and Ligand Interaction Annotated Database As a Tool for Structure-Based Drug Design.
AID363078Binding affinity to PDE4 catalytic domain2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Recent advances on phosphodiesterase 4 inhibitors for the treatment of asthma and chronic obstructive pulmonary disease.
AID159939Inhibition of human Phosphodiesterase 4B1995Journal of medicinal chemistry, Nov-24, Volume: 38, Issue:24
Design and synthesis of conformationally constrained analogues of 4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one (Ro 20-1724) as potent inhibitors of cAMP-specific phosphodiesterase.
AID517456Inhibition of PDE4B1 expressed in yeast2010Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19
Synthesis and biological activity of pyrido[3',2':4,5]thieno[3,2-d]pyrimidines as phosphodiesterase type 4 inhibitors.
AID1404139Inhibition of PDE11A (unknown origin) using cAMP as substrate after 1 hr by LANCE TR-FRET assay2018European journal of medicinal chemistry, Feb-10, Volume: 145Design, synthesis, and biological evaluation of novel catecholopyrimidine based PDE4 inhibitor for the treatment of atopic dermatitis.
AID1272079Anti-inflammatory activity in BALB/c mouse assessed as inhibition of LPS-induced TNFalpha expression at 10 mg/kg, po pre-treated for 1 hr followed by LPS administration measured 2.5 hrs after LPS challenge by ELISA2016Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2
Analogues of boswellic acids as inhibitors of pro-inflammatory cytokines TNF-α and IL-6.
AID363102Inhibition of human PDE4D5 in particular fraction of lung2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Recent advances on phosphodiesterase 4 inhibitors for the treatment of asthma and chronic obstructive pulmonary disease.
AID1335400Inhibition of human PDE3B using FAM-3',5'-cAMP as substrate after 1 hr by fluorescence polarization assay2016European journal of medicinal chemistry, Nov-29, Volume: 124Development of highly potent phosphodiesterase 4 inhibitors with anti-neuroinflammation potential: Design, synthesis, and structure-activity relationship study of catecholamides bearing aromatic rings.
AID233754Evaluated for the ratio of binding affinity to rolipram binding site to that of PDE-4 inhibitory activity2001Bioorganic & medicinal chemistry letters, Mar-12, Volume: 11, Issue:5
Syntheses and evaluation of pyrido[2,3-dlpyrimidine-2,4-diones as PDE 4 inhibitors.
AID1370518Antiviral activity against Zika virus infected in human A549 cells assessed as virus titer preincubated for 5 hrs followed by compound wash measured after 48 hrs by viral plague-forming assay2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Identification of novel small-molecule inhibitors of Zika virus infection.
AID260826Inhibition of PDE4D2006Bioorganic & medicinal chemistry letters, Feb, Volume: 16, Issue:3
A new chemical tool for exploring the role of the PDE4D isozyme in leukocyte function.
AID1157536Induction of bronchodilation in ovalbumin-sensitized guinea pig at 10 mg/kg, po administered 4 hrs prior to ovalbumin challenge measured for 20 mins relative to vehicle-treated control2014Bioorganic & medicinal chemistry letters, Jun-15, Volume: 24, Issue:12
Identification of 2,3-disubstituted pyridines as potent, non-emetic PDE4 inhibitors.
AID425688Inhibition of PDE5A12009Bioorganic & medicinal chemistry letters, Jul-01, Volume: 19, Issue:13
Exploration and optimization of substituted triazolothiadiazines and triazolopyridazines as PDE4 inhibitors.
AID1783024Inhibition of PDE4B (unknown origin) using [3H]cAMP as substrate incubated for 30 mins by scintillation proximity assay2021European journal of medicinal chemistry, Oct-05, Volume: 221PdCl
AID462320Inhibition of human PDE4D2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
In silico search for multi-target anti-inflammatories in Chinese herbs and formulas.
AID1727187Hepatoprotective activity in ConA-induced BALB/c hepatitis mouse model assessed as decrease in serum aspartate aminotransferase level at 50 mg/kg, ip administration and measured after 8 hrs relative to control2021European journal of medicinal chemistry, Jan-01, Volume: 209New imidazopyridines with phosphodiesterase 4 and 7 inhibitory activity and their efficacy in animal models of inflammatory and autoimmune diseases.
AID1187754Inhibition of PDE4D1 (unknown origin) at 10 uM2014Journal of medicinal chemistry, Aug-28, Volume: 57, Issue:16
Synthesis, biological evaluation, and molecular modeling of new 3-(cyclopentyloxy)-4-methoxybenzaldehyde O-(2-(2,6-dimethylmorpholino)-2-oxoethyl) Oxime (GEBR-7b) related phosphodiesterase 4D (PDE4D) inhibitors.
AID1545635Inhibition of human recombinant full length N-terminal GST-tagged PDE4B1 expressed in baculovirus infected Sf9 cells at 10'-5.5 M using cAMP as substrate incubated for 20 mins followed by substrate addition by luciferase assay relative to control2019Bioorganic & medicinal chemistry, 09-15, Volume: 27, Issue:18
Novel multitarget 5-arylidenehydantoins with arylpiperazinealkyl fragment: Pharmacological evaluation and investigation of cytotoxicity and metabolic stability.
AID1605538Toxicity in Beagle dog assessed as animals exhibiting emesis at 1 mg/kg, po observed for 180 mins2020Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6
Discovery and Optimization of α-Mangostin Derivatives as Novel PDE4 Inhibitors for the Treatment of Vascular Dementia.
AID33406Evaluated for the binding affinity towards the Adenosine A2 receptor in corpora striata of rats using [3H]NECA as radioligand.1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
4-Amino[1,2,4]triazolo[4,3-a]quinoxalines. A novel class of potent adenosine receptor antagonists and potential rapid-onset antidepressants.
AID241179Inhibition of Phosphodiesterase 52005Bioorganic & medicinal chemistry letters, Apr-01, Volume: 15, Issue:7
Fused pyrimidine based inhibitors of phosphodiesterase 7 (PDE7): synthesis and initial structure-activity relationships.
AID158919Inhibition of phosphodiesterase 1/5 isozyme (PDE1/5) mixture isolated from the guinea pig trachea.2000Journal of medicinal chemistry, Dec-14, Volume: 43, Issue:25
Synthesis, structure-activity relationships, and pharmacological profile of 9-amino-4-oxo-1-phenyl-3,4,6,7-tetrahydro[1,4]diazepino[6, 7,1-hi]indoles: discovery of potent, selective phosphodiesterase type 4 inhibitors.
AID260827Inhibition of PDE52006Bioorganic & medicinal chemistry letters, Feb, Volume: 16, Issue:3
A new chemical tool for exploring the role of the PDE4D isozyme in leukocyte function.
AID1157543Toxicity in Marshall ferret assessed as vomiting at 10 mg/kg, po after 2 hrs2014Bioorganic & medicinal chemistry letters, Jun-15, Volume: 24, Issue:12
Identification of 2,3-disubstituted pyridines as potent, non-emetic PDE4 inhibitors.
AID160111In vitro inhibitory activity against phosphodiesterase 4 from rat liver at concentration of 0.3 uM2001Bioorganic & medicinal chemistry letters, Mar-12, Volume: 11, Issue:5
Syntheses and evaluation of pyrido[2,3-dlpyrimidine-2,4-diones as PDE 4 inhibitors.
AID155792Inhibition of LPS induced TNF-alpha release by human peripheral blood mononuclear cells.1998Bioorganic & medicinal chemistry letters, Nov-17, Volume: 8, Issue:22
N-arylrolipram derivatives as potent and selective PDE4 inhibitors.
AID349551Inhibition of PDE4 in human U937 cells assessed as accumulation of [3H]adenosine by scintillation counting2009Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8
Discovery and structure-activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis.
AID159940Inhibition of cAMP hydrolysis by the human phosphodiesterase 4B enzyme1995Journal of medicinal chemistry, Apr-28, Volume: 38, Issue:9
Phosphodiesterase type IV inhibition. Structure-activity relationships of 1,3-disubstituted pyrrolidines.
AID1703916Inhibition of PDE4B (unknown origin)2020European journal of medicinal chemistry, Oct-15, Volume: 204Discovery of sulfonyl hydrazone derivative as a new selective PDE4A and PDE4D inhibitor by lead-optimization approach on the prototype LASSBio-448: In vitro and in vivo preclinical studies.
AID89020Inhibition of LPS-induced TNF-alpha secretion from purified human peripheral blood monocytes1995Journal of medicinal chemistry, Nov-24, Volume: 38, Issue:24
Design and synthesis of conformationally constrained analogues of 4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one (Ro 20-1724) as potent inhibitors of cAMP-specific phosphodiesterase.
AID1335409Inhibition of human PDE8A1 using FAM-3',5'-cAMP as substrate after 1 hr by fluorescence polarization assay2016European journal of medicinal chemistry, Nov-29, Volume: 124Development of highly potent phosphodiesterase 4 inhibitors with anti-neuroinflammation potential: Design, synthesis, and structure-activity relationship study of catecholamides bearing aromatic rings.
AID157922Inhibitory activity against Phosphodiesterase 4D (PDE4D) from human source expressed in Saccharomyces cerevisiae2000Journal of medicinal chemistry, Feb-24, Volume: 43, Issue:4
Palladium-catalyzed cross-coupling reactions for the synthesis of 6, 8-disubstituted 1,7-naphthyridines: a novel class of potent and selective phosphodiesterase type 4D inhibitors.
AID1623111Cognition enhancement activity in amyloid beta (25 to 35 residues) induced C57BL/6J mouse model of Alzheimer's disease assessed as swimming path length in virtual platform at 4 mg/kg/day, ig administered for 26 consecutive days by Morris water maze test (2019European journal of medicinal chemistry, Feb-01, Volume: 163Synthesis and evaluation of clioquinol-rolipram/roflumilast hybrids as multitarget-directed ligands for the treatment of Alzheimer's disease.
AID1623116Neuroprotection in amyloid beta (25 to 35 residues) induced C57BL/6J mouse model of Alzheimer's disease assessed as reduction in ratio of apoptotic neuron in CA1 hippocampus region at 4 mg/kg/day, ig administered for 26 consecutive days by hematoxylin and2019European journal of medicinal chemistry, Feb-01, Volume: 163Synthesis and evaluation of clioquinol-rolipram/roflumilast hybrids as multitarget-directed ligands for the treatment of Alzheimer's disease.
AID126633Percent cytokine IL-8 inhibition in monkeys at 10 mg/kg oral dose1998Journal of medicinal chemistry, Jun-18, Volume: 41, Issue:13
7-Oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridines as novel inhibitors of human eosinophil phosphodiesterase.
AID1153962Inhibition of LPS-induced TNF-alpha production in rat PBMC2014Bioorganic & medicinal chemistry letters, Jul-01, Volume: 24, Issue:13
Synthesis and structure-activity relationship of cyclopentenone oximes as novel inhibitors of the production of tumor necrosis factor-α.
AID260821Inhibition of PDE22006Bioorganic & medicinal chemistry letters, Feb, Volume: 16, Issue:3
A new chemical tool for exploring the role of the PDE4D isozyme in leukocyte function.
AID1254337Inhibition of human full-length PDE4B1 using AM-Cyclic-3',5'-AMP after 60 mins by fluorescence polarization assay2015Bioorganic & medicinal chemistry, Nov-15, Volume: 23, Issue:22
Catecholic amides as potential selective phosphodiesterase 4D inhibitors: Design, synthesis, pharmacological evaluation and structure-activity relationships.
AID425679Inhibition of PDE1C2009Bioorganic & medicinal chemistry letters, Jul-01, Volume: 19, Issue:13
Exploration and optimization of substituted triazolothiadiazines and triazolopyridazines as PDE4 inhibitors.
AID159351Inhibition of human platelet Phosphodiesterase 3 at 20 uM2002Bioorganic & medicinal chemistry letters, Feb-11, Volume: 12, Issue:3
7-Methoxyfuro[2,3-c]pyridine-4-carboxamides as PDE4 inhibitors: a potential treatment for asthma.
AID1272077Anti-inflammatory activity in human PBMC assessed as inhibition of LPS-induced IL-6 expression at 10 uM after 5 hrs2016Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2
Analogues of boswellic acids as inhibitors of pro-inflammatory cytokines TNF-α and IL-6.
AID425694Inhibition of PDE4 expressed in HEK293 cells coexpressing G-protein coupled receptor and cyclic nucleotide gated ion channel by fluorescence assay2009Bioorganic & medicinal chemistry letters, Jul-01, Volume: 19, Issue:13
Exploration and optimization of substituted triazolothiadiazines and triazolopyridazines as PDE4 inhibitors.
AID695680Inhibition of full-length PDE4A4 using cAMP as substrate by two-step radiochemical assay2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Elucidation of a structural basis for the inhibitor-driven, p62 (SQSTM1)-dependent intracellular redistribution of cAMP phosphodiesterase-4A4 (PDE4A4).
AID704163Proemetic activity in A/J mouse assessed as reversal of xylazine/katamine-induced anesthesia at 1 to 50 umol/kg, sc administered 30 mins prior xylazine/ketamine-administration2012Journal of medicinal chemistry, Sep-13, Volume: 55, Issue:17
Design, synthesis, and pharmacological evaluation of N-acylhydrazones and novel conformationally constrained compounds as selective and potent orally active phosphodiesterase-4 inhibitors.
AID159489Inhibition of phosphodiesterase 3 at 200 uM1998Bioorganic & medicinal chemistry letters, Oct-06, Volume: 8, Issue:19
Aryl sulfonamides as selective PDE4 inhibitors.
AID1623078Effective permeability of the compound at 100 ug/ml after 10 hrs by BBB-PAMPA method2019European journal of medicinal chemistry, Feb-01, Volume: 163Synthesis and evaluation of clioquinol-rolipram/roflumilast hybrids as multitarget-directed ligands for the treatment of Alzheimer's disease.
AID1464266Inhibition of PDE4D isolated from human U937 cells using [3H]-cAMP incubated for 30 mins2017Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20
Rational design of conformationally constrained oxazolidinone-fused 1,2,3,4-tetrahydroisoquinoline derivatives as potential PDE4 inhibitors.
AID159219Inhibition of guinea pig ventricular Phosphodiesterase 31997Journal of medicinal chemistry, May-09, Volume: 40, Issue:10
Novel heterocyclic-fused pyridazinones as potent and selective phosphodiesterase IV inhibitors.
AID1335411Inhibition of human PDE10A2 using FAM-3',5'-cAMP as substrate after 1 hr by fluorescence polarization assay2016European journal of medicinal chemistry, Nov-29, Volume: 124Development of highly potent phosphodiesterase 4 inhibitors with anti-neuroinflammation potential: Design, synthesis, and structure-activity relationship study of catecholamides bearing aromatic rings.
AID1427214Inhibition of human U937 cells-derived PDE4B using [3H]cAMP as substrate after 30 mins
AID1420133Inhibition of human U937 cells-derived PDE4D using [3H]-cAMP as substrate measured after 30 mins2018Bioorganic & medicinal chemistry letters, 10-15, Volume: 28, Issue:19
Synthesis and bioactivity of 3,5-dimethylpyrazole derivatives as potential PDE4 inhibitors.
AID1724979Inhibition of recombinant human N-terminal GST-tagged PDE4D3 expressed in baculovirus infected Sf9 cells by radioligand binding assay2020ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10
Synthesis and SAR Studies of 1
AID440700Inhibition of human recombinant PDE4D2 expressed in baculovirus system at 10 uM by IMAP assay2009Journal of medicinal chemistry, Nov-12, Volume: 52, Issue:21
New selective phosphodiesterase 4D inhibitors differently acting on long, short, and supershort isoforms.
AID78186Inhibition of eosinophil recruitment in guinea pig lung asthma model at 10 mg/kg1998Bioorganic & medicinal chemistry letters, Oct-20, Volume: 8, Issue:20
PDE4 inhibitors: new xanthine analogues.
AID76563Inhibition of bronchoconstriction in passively-sensitized guinea pig at 1 mg/kg iv dose 10 min prior to challenge2003Bioorganic & medicinal chemistry letters, Jul-21, Volume: 13, Issue:14
Improvement of therapeutic index of phosphodiesterase type IV inhibitors as anti-Asthmatics.
AID363095Inhibition of human PDE4D1 in cytosolic fraction of lung2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Recent advances on phosphodiesterase 4 inhibitors for the treatment of asthma and chronic obstructive pulmonary disease.
AID1335407Inhibition of human PDE6C using FAM-3',5'-cAMP as substrate after 1 hr by fluorescence polarization assay2016European journal of medicinal chemistry, Nov-29, Volume: 124Development of highly potent phosphodiesterase 4 inhibitors with anti-neuroinflammation potential: Design, synthesis, and structure-activity relationship study of catecholamides bearing aromatic rings.
AID160105Inhibition of Phosphodiesterase 4 from rat liver2002Bioorganic & medicinal chemistry letters, Sep-02, Volume: 12, Issue:17
A prenylated flavonol, sophoflavescenol: a potent and selective inhibitor of cGMP phosphodiesterase 5.
AID229961Relative inhibition of PDE 4 activity and rolipram binding1997Journal of medicinal chemistry, May-09, Volume: 40, Issue:10
Novel heterocyclic-fused pyridazinones as potent and selective phosphodiesterase IV inhibitors.
AID1247790Inhibition of PDE4B isolated from human U937 cells using [3H]-cAMP as substrate after 30 mins2015Bioorganic & medicinal chemistry letters, Oct-15, Volume: 25, Issue:20
Design, synthesis and biological evaluation of novel tetrahydroisoquinoline derivatives as potential PDE4 inhibitors.
AID1743667Antiinflammatory activity in LPS induced Swiss albino mouse model of sepsis assessed as inhibition of TNFalpha production at 10 mg/kg, po preincubated for 30 mins followed by LPS stimulation and measured after 90 mins by ELISA relative to control2020European journal of medicinal chemistry, Dec-01, Volume: 207Synthesis and bioactivity of phenyl substituted furan and oxazole carboxylic acid derivatives as potential PDE4 inhibitors.
AID157775Inhibitory activity against Phosphodiesterase 4A (PDE4A) from human source expressed in Saccharomyces cerevisiae2000Journal of medicinal chemistry, Feb-24, Volume: 43, Issue:4
Palladium-catalyzed cross-coupling reactions for the synthesis of 6, 8-disubstituted 1,7-naphthyridines: a novel class of potent and selective phosphodiesterase type 4D inhibitors.
AID229338Relative inhibition of rolipram binding and PDE4 activity2002Bioorganic & medicinal chemistry letters, Feb-11, Volume: 12, Issue:3
7-Methoxyfuro[2,3-c]pyridine-4-carboxamides as PDE4 inhibitors: a potential treatment for asthma.
AID318120Inhibition of HIV1 reverse transcriptase2008Bioorganic & medicinal chemistry letters, Feb-15, Volume: 18, Issue:4
Investigation of the alkenyldiarylmethane non-nucleoside reverse transcriptase inhibitors as potential cAMP phosphodiesterase-4B2 inhibitors.
AID1773152Cell cycle arrest in human U-251 cells assessed as G2/M phase at 200 nM measured after 24 hrs by propidium iodide staining based flow cytometry analysis (Rvb = 14.43%)2021European journal of medicinal chemistry, Nov-15, Volume: 224Discovery of novel trimethoxyphenylbenzo[d]oxazoles as dual tubulin/PDE4 inhibitors capable of inducing apoptosis at G2/M phase arrest in glioma and lung cancer cells.
AID158584Inhibitory activity against cGMP-phosphodiesterase from porcine aorta1994Journal of medicinal chemistry, Jun-24, Volume: 37, Issue:13
Cyclic GMP phosphodiesterase inhibitors. 2. Requirement of 6-substitution of quinazoline derivatives for potent and selective inhibitory activity.
AID226824Ratio inhibition of phosphodiesterase 4 to Rolipram binding site activity was reported.1998Bioorganic & medicinal chemistry letters, Oct-06, Volume: 8, Issue:19
Aryl sulfonamides as selective PDE4 inhibitors.
AID45804Inhibition of cAMP-specific calcium-independent phosphodiesterase (IPDE)1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Calcium-independent phosphodiesterase inhibitors as putative antidepressants: [3-(bicycloalkyloxy)-4-methoxyphenyl]-2-imidazolidinones.
AID1187753Inhibition of recombinant human PDE4D3 expressed in baculoviral system at 10 uM2014Journal of medicinal chemistry, Aug-28, Volume: 57, Issue:16
Synthesis, biological evaluation, and molecular modeling of new 3-(cyclopentyloxy)-4-methoxybenzaldehyde O-(2-(2,6-dimethylmorpholino)-2-oxoethyl) Oxime (GEBR-7b) related phosphodiesterase 4D (PDE4D) inhibitors.
AID77843Change in heart rate in guinea pigs after 0.1 mg/kg intravenous dose1996Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14
Novel selective PDE IV inhibitors as antiasthmatic agents. Synthesis and biological activities of a series of 1-aryl-2,3-bis(hydroxymethyl)naphthalene lignans.
AID349557Antiinflammatory activity in human PBMC assessed as inhibition of phytohemagglutininin-induced IL5 release after 48 hrs by FACS Array analysis2009Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8
Discovery and structure-activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis.
AID78274Schultz-Dale (SD) reaction in tracheal strip isolated from passively sensitized guinea pigs1992Journal of medicinal chemistry, Dec-25, Volume: 35, Issue:26
New bronchodilators. 3. Imidazo[4,5-c][1,8]naphthyridin-4(5H)-ones.
AID318122Antiviral activity against HIV1 3B in MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay2008Bioorganic & medicinal chemistry letters, Feb-15, Volume: 18, Issue:4
Investigation of the alkenyldiarylmethane non-nucleoside reverse transcriptase inhibitors as potential cAMP phosphodiesterase-4B2 inhibitors.
AID637704Inhibition of recombinant His-tagged PDE4B using cAMP as substrate at 30 uM preincubated for 15 mins before substrate addition measured after 1 hr by luminescence assay2012European journal of medicinal chemistry, Feb, Volume: 48Montmorillonite K-10 mediated green synthesis of cyano pyridines: Their evaluation as potential inhibitors of PDE4.
AID1335398Inhibition of human PDE1A using FAM-3',5'-cAMP as substrate after 1 hr by fluorescence polarization assay2016European journal of medicinal chemistry, Nov-29, Volume: 124Development of highly potent phosphodiesterase 4 inhibitors with anti-neuroinflammation potential: Design, synthesis, and structure-activity relationship study of catecholamides bearing aromatic rings.
AID1370513Antiviral activity against Zika virus infected in human A549 cells preincubated for 5 hrs followed by compound wash measured after 48 hrs by viral plague-forming assay2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Identification of novel small-molecule inhibitors of Zika virus infection.
AID1381681Inhibition of human GST-tagged PDE4B expressed in baculovirus infected Sf9 insect cells using cAMP as substrate after 10 mins by PDE-Glo Phosphodiesterase Assay2018European journal of medicinal chemistry, Feb-25, Volume: 146Novel butanehydrazide derivatives of purine-2,6-dione as dual PDE4/7 inhibitors with potential anti-inflammatory activity: Design, synthesis and biological evaluation.
AID239333Inhibition of [3H]cAMP binding to recombinant human Phosphodiesterase 4BL (PDE4BL) in baculovirus expression system2005Journal of medicinal chemistry, Feb-24, Volume: 48, Issue:4
8-Substituted analogues of 3-(3-cyclopentyloxy-4-methoxy-benzyl)-8-isopropyl-adenine: highly potent and selective PDE4 inhibitors.
AID225256Inhibitory activity against recombinant phosphodiesterase 4B (PDE4B) of human mononuclear lymphocytes2002Bioorganic & medicinal chemistry letters, Feb-25, Volume: 12, Issue:4
Synthesis and biological evaluation of imidazol-2-one and 2-cyanoiminoimidazole derivatives: novel series of PDE4 inhibitors.
AID241176Inhibition of Phosphodiesterase 22005Bioorganic & medicinal chemistry letters, Apr-01, Volume: 15, Issue:7
Fused pyrimidine based inhibitors of phosphodiesterase 7 (PDE7): synthesis and initial structure-activity relationships.
AID260823Inhibition of PDE4A2006Bioorganic & medicinal chemistry letters, Feb, Volume: 16, Issue:3
A new chemical tool for exploring the role of the PDE4D isozyme in leukocyte function.
AID1374973Anti-inflammatory activity in Sprague-Dawley rat model of LPS-induced asthma/COPD assessed as inhibition of neutrophilia in BALF at 10 mg/kg, po administered 30 mins prior to LPS challenge for 40 mins relative to control2018Bioorganic & medicinal chemistry letters, 04-15, Volume: 28, Issue:7
Structure-based design and structure-activity relationships of 1,2,3,4-tetrahydroisoquinoline derivatives as potential PDE4 inhibitors.
AID72088Emetic effect in ferrets at 0.03 mg/kg peroral dose, 2 of 10 animals affected1996Journal of medicinal chemistry, Jan-05, Volume: 39, Issue:1
Biarylcarboxylic acids and -amides: inhibition of phosphodiesterase type IV versus [3H]rolipram binding activity and their relationship to emetic behavior in the ferret.
AID363098Inhibition of human PDE4D3 in particular fraction of lung2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Recent advances on phosphodiesterase 4 inhibitors for the treatment of asthma and chronic obstructive pulmonary disease.
AID1187761Inhibition of PDE4B2 (unknown origin)2014Journal of medicinal chemistry, Aug-28, Volume: 57, Issue:16
Synthesis, biological evaluation, and molecular modeling of new 3-(cyclopentyloxy)-4-methoxybenzaldehyde O-(2-(2,6-dimethylmorpholino)-2-oxoethyl) Oxime (GEBR-7b) related phosphodiesterase 4D (PDE4D) inhibitors.
AID260832Inhibition of PDE112006Bioorganic & medicinal chemistry letters, Feb, Volume: 16, Issue:3
A new chemical tool for exploring the role of the PDE4D isozyme in leukocyte function.
AID766607Antiinflammatory activity in mouse assessed as inhibition ovalbumin-induced eosinophil infiltration into lung at 10 mg/kg, po administered 30 mins prior to ovalbumin challenge followed by once per day compound administration measured after 2 days relative2013Bioorganic & medicinal chemistry, Sep-15, Volume: 21, Issue:18
Identification of 2,3-disubstituted pyridines as potent, orally active PDE4 inhibitors.
AID1460297Inhibition of recombinant His-tagged PDE4B1 (unknown origin) expressed in baculovirus infected sf9 cells at 10 uM using cAMP as substrate preincubated for 15 mins followed by cAMP addition measured after 1 hr by PDE light HTS assay relative to control2017Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3
1,2,3-Triazole-nimesulide hybrid: Their design, synthesis and evaluation as potential anticancer agents.
AID1261705Inhibition of recombinant human Amyloid beta (1 to 42) self-induced aggregation at 5 uM after 48 hrs by thioflavin T-based fluorescence assay2015Journal of medicinal chemistry, Nov-12, Volume: 58, Issue:21
Design, Synthesis, and Evaluation of Orally Available Clioquinol-Moracin M Hybrids as Multitarget-Directed Ligands for Cognitive Improvement in a Rat Model of Neurodegeneration in Alzheimer's Disease.
AID1884589Neuroprotective activity against rat PC-12 cells assessed as inhibition of Abeta(25-35)-induced cytotoxicity by measuring increase in cell viability at 10 uM incubated for 24 hrs by MTT assay2022European journal of medicinal chemistry, Aug-05, Volume: 238Discovery of novel 2,3-dihydro-1H-inden-1-ones as dual PDE4/AChE inhibitors with more potency against neuroinflammation for the treatment of Alzheimer's disease.
AID751649Displacement of [3H]Rolipram from rolipram binding site in Wistar rat brain after 60 mins2013Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
Cinnamides as selective small-molecule inhibitors of a cellular model of breast cancer stem cells.
AID1773151Cell cycle arrest in human U-251 cells assessed as G0/G1 phase at 200 nM measured after 24 hrs by propidium iodide staining based flow cytometry analysis (Rvb = 67.34%)2021European journal of medicinal chemistry, Nov-15, Volume: 224Discovery of novel trimethoxyphenylbenzo[d]oxazoles as dual tubulin/PDE4 inhibitors capable of inducing apoptosis at G2/M phase arrest in glioma and lung cancer cells.
AID1380118Inhibition of PDE4 (unknown origin)2018Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13
Novel Phosphodiesterase Inhibitors for Cognitive Improvement in Alzheimer's Disease.
AID219165Inhibitory activity against phosphodiesterase was determined in vitro using bovine aorta, at 1 uM cAMP for cAMP-PDE.1989Journal of medicinal chemistry, Jul, Volume: 32, Issue:7
Inhibition of cyclic adenosine-3',5'-monophosphate phosphodiesterase from vascular smooth muscle by rolipram analogues.
AID751715Displacement of [3H]Rolipram from rolipram binding site in Wistar rat brain at 10 uM after 60 mins relative to control2013Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
Cinnamides as selective small-molecule inhibitors of a cellular model of breast cancer stem cells.
AID157937Inhibition of Phosphodiesterase 5 of guinea pig lung1999Journal of medicinal chemistry, Mar-25, Volume: 42, Issue:6
Novel, potent, and selective phosphodiesterase-4 inhibitors as antiasthmatic agents: synthesis and biological activities of a series of 1-pyridylnaphthalene derivatives.
AID1480256Increase in thermal withdrawal latency in naive Sprague-Dawley rat at 3 mg/kg administered via oral gavage measured over 4 hrs2018Journal of medicinal chemistry, 04-26, Volume: 61, Issue:8
Orally Available Soluble Epoxide Hydrolase/Phosphodiesterase 4 Dual Inhibitor Treats Inflammatory Pain.
AID1773164Induction of apoptosis in human A549 cells assessed as increase in early apoptotic cells at 500 nM measured after 24 hrs by PI/FITC analysis (Rvb = 0.955%)2021European journal of medicinal chemistry, Nov-15, Volume: 224Discovery of novel trimethoxyphenylbenzo[d]oxazoles as dual tubulin/PDE4 inhibitors capable of inducing apoptosis at G2/M phase arrest in glioma and lung cancer cells.
AID1703915Inhibition of PDE4A (unknown origin)2020European journal of medicinal chemistry, Oct-15, Volume: 204Discovery of sulfonyl hydrazone derivative as a new selective PDE4A and PDE4D inhibitor by lead-optimization approach on the prototype LASSBio-448: In vitro and in vivo preclinical studies.
AID155682Inhibition of phosphodiesterase type 4 isozyme (PDE4) from the U937 human cell line.2000Journal of medicinal chemistry, Dec-14, Volume: 43, Issue:25
Synthesis, structure-activity relationships, and pharmacological profile of 9-amino-4-oxo-1-phenyl-3,4,6,7-tetrahydro[1,4]diazepino[6, 7,1-hi]indoles: discovery of potent, selective phosphodiesterase type 4 inhibitors.
AID1335402Inhibition of full length human PDE4A4 using FAM-3',5'-cAMP as substrate after 1 hr by fluorescence polarization assay2016European journal of medicinal chemistry, Nov-29, Volume: 124Development of highly potent phosphodiesterase 4 inhibitors with anti-neuroinflammation potential: Design, synthesis, and structure-activity relationship study of catecholamides bearing aromatic rings.
AID1427217Anti-inflammatory activity in LPS-induced Swiss albino mouse sepsis model assessed as inhibition of TNF-alpha release in serum at 10 mg/kg, po administered 30 mins prior to LPS challenge measured after 90 mins by ELISA relative to control
AID157304Inhibition of rolipram binding to PDE4 from human neutrophils2000Bioorganic & medicinal chemistry letters, Oct-02, Volume: 10, Issue:19
The synthesis and biological evaluation of a novel series of phthalazine PDE4 inhibitors I.
AID234199Relative inhibition of PDE4 activity and [3H]rolipram binding to guinea pig brain1999Journal of medicinal chemistry, Mar-25, Volume: 42, Issue:6
Novel, potent, and selective phosphodiesterase-4 inhibitors as antiasthmatic agents: synthesis and biological activities of a series of 1-pyridylnaphthalene derivatives.
AID349564Antiinflammatory activity in mouse ear edema model assessed as inhibition of PMA-induced ear edema at 1 mg/ear administered 2 times 30 mins before and 15 mins after PMA challenge measured after 6 hrs of PMA application relative to control2009Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8
Discovery and structure-activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis.
AID666554Antiinflammatory activity in rat astrocytes assessed as inhibition of LPS-induced nitrite production at 30 uM incubated for 1 hr prior to LPS-challenge measured after 24 hrs by Griess method2012Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7
Effect of phosphodiesterase 7 (PDE7) inhibitors in experimental autoimmune encephalomyelitis mice. Discovery of a new chemically diverse family of compounds.
AID159517Inhibition of Canine Tracheal Smooth Muscle PDE 41992Journal of medicinal chemistry, Dec-25, Volume: 35, Issue:26
New bronchodilators. 3. Imidazo[4,5-c][1,8]naphthyridin-4(5H)-ones.
AID1231630Inhibition of human recombinant PDE4B2 expressed in baculoviral system using cAMP as substrate at 10 uM by fluorescence polarization assay relative to control2015Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13
Synthesis, biological activities and pharmacokinetic properties of new fluorinated derivatives of selective PDE4D inhibitors.
AID704149Antiinflammatory activity in human PBMC assessed as inhibition of LPS-induced TNFalpha production after 24 hrs by ELISA2012Journal of medicinal chemistry, Sep-13, Volume: 55, Issue:17
Design, synthesis, and pharmacological evaluation of N-acylhydrazones and novel conformationally constrained compounds as selective and potent orally active phosphodiesterase-4 inhibitors.
AID1596207Inhibition of PDE4C (unknown origin) at 10 uM using cAMP as substrate preincubated with enzyme for 15 mins followed by substrate addition and incubated for 1 hr by PDELight HTS cAMP phosphodiesterase Kit based luminometry relative to control2019European journal of medicinal chemistry, Jul-15, Volume: 174InCl
AID1596202Inhibition of recombinant His-tagged human PDE4B expressed in Sf9 cells using cAMP as substrate preincubated with enzyme for 15 mins followed by substrate addition and incubated for 1 hr by PDELight HTS cAMP phosphodiesterase Kit based luminometry2019European journal of medicinal chemistry, Jul-15, Volume: 174InCl
AID1187759Inhibition of PDE4C2 (unknown origin) at 10 uM2014Journal of medicinal chemistry, Aug-28, Volume: 57, Issue:16
Synthesis, biological evaluation, and molecular modeling of new 3-(cyclopentyloxy)-4-methoxybenzaldehyde O-(2-(2,6-dimethylmorpholino)-2-oxoethyl) Oxime (GEBR-7b) related phosphodiesterase 4D (PDE4D) inhibitors.
AID159941Displacement of [3H]rolipram from mouse brain homogenates1996Journal of medicinal chemistry, Jan-05, Volume: 39, Issue:1
Biarylcarboxylic acids and -amides: inhibition of phosphodiesterase type IV versus [3H]rolipram binding activity and their relationship to emetic behavior in the ferret.
AID159222Inhibitory potency against guinea pig ventricular phosphodiesterase 32000Bioorganic & medicinal chemistry letters, Dec-04, Volume: 10, Issue:23
Synthesis and biological evaluation of 2,5-dihydropyrazol.
AID1703917Inhibition of PDE4C (unknown origin)2020European journal of medicinal chemistry, Oct-15, Volume: 204Discovery of sulfonyl hydrazone derivative as a new selective PDE4A and PDE4D inhibitor by lead-optimization approach on the prototype LASSBio-448: In vitro and in vivo preclinical studies.
AID133090Inhibition of immobility in mouse forced swim test by peroral dose1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Structure-activity relationship of quinazolinedione inhibitors of calcium-independent phosphodiesterase.
AID1161988Inhibition of recombinant His-tagged PDE4B1 (unknown origin) expressed in Sf9 cells at 30 uM pre-incubated for 15 mins before cAMP substrate addition by luminescence assay2014European journal of medicinal chemistry, Oct-30, Volume: 86Ligand-free Pd-catalyzed C-N cross-coupling/cyclization strategy: an unprecedented access to 1-thienyl pyrroloquinoxalines for the new approach towards apoptosis.
AID205269Inhibition of binding of Batrachotoxinin [3H]BTX-B to high-affinity sites on voltage-dependent sodium channels in a vesicular preparation from guinea pig cerebral cortex at 100 uM1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
[3H]Batrachotoxinin A 20 alpha-benzoate binding to voltage-sensitive sodium channels: a rapid and quantitative assay for local anesthetic activity in a variety of drugs.
AID158278Inhibition of Phosphodiesterase 72004Bioorganic & medicinal chemistry letters, Jun-07, Volume: 14, Issue:11
Identification of purine inhibitors of phosphodiesterase 7 (PDE7).
AID363087Inhibition of human PDE4A10 in particular fraction of brain and lung2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Recent advances on phosphodiesterase 4 inhibitors for the treatment of asthma and chronic obstructive pulmonary disease.
AID1353617Anti-inflammatory activity in human PBMC assessed as inhibition of LPS-induced IL-1beta production after 24 hrs by ELISA2018European journal of medicinal chemistry, Mar-10, Volume: 147Phenylpyridine-2-ylguanidines and rigid mimetics as novel inhibitors of TNFα overproduction: Beneficial action in models of neuropathic pain and of acute lung inflammation.
AID130856Percent inhibition of arachidonic acid induced mouse ear edema after 30 uM/kg peroral pretreatment2002Journal of medicinal chemistry, Jun-06, Volume: 45, Issue:12
Novel selective phosphodiesterase (PDE4) inhibitors. 4. Resolution, absolute configuration, and PDE4 inhibitory activity of cis-tetra- and cis-hexahydrophthalazinones.
AID517458Inhibition of PDE4D3 expressed in yeast2010Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19
Synthesis and biological activity of pyrido[3',2':4,5]thieno[3,2-d]pyrimidines as phosphodiesterase type 4 inhibitors.
AID1374977Inhibition of human U937 cells-derived PDE4B using [3H]-cAMP as substrate after 30 mins2018Bioorganic & medicinal chemistry letters, 04-15, Volume: 28, Issue:7
Structure-based design and structure-activity relationships of 1,2,3,4-tetrahydroisoquinoline derivatives as potential PDE4 inhibitors.
AID59504Emetic effect in dogs on intravenous dose (2/2)1998Bioorganic & medicinal chemistry letters, Nov-03, Volume: 8, Issue:21
Orally active indole N-oxide PDE4 inhibitors.
AID1166731Inhibition of human recombinant PDE3A assessed as inhibition of hydrolysis of [3H]cAMP at 10 uM after 20 mins by scintillation proximity assay2014Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20
Modulation of cAMP-specific PDE without emetogenic activity: new sulfide-like PDE7 inhibitors.
AID1231638Toxicity in mouse assessed as sedative effect by measuring prolongation of immobility time at 10 mg/kg, po measured over 60 mins by open-field test2015Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13
Synthesis, biological activities and pharmacokinetic properties of new fluorinated derivatives of selective PDE4D inhibitors.
AID704167Inhibition of human recombinant PDE4B2012Journal of medicinal chemistry, Sep-13, Volume: 55, Issue:17
Design, synthesis, and pharmacological evaluation of N-acylhydrazones and novel conformationally constrained compounds as selective and potent orally active phosphodiesterase-4 inhibitors.
AID1058566Inhibition of recombinant His-tagged PDE4B1 (unknown origin) expressed in insect Sf9 cells using cAMP as substrate at 30 uM preincubated for 15 mins followed by substrate addition measured after 1 hr by luminescence assay relative to control2013Bioorganic & medicinal chemistry letters, Dec-15, Volume: 23, Issue:24
Synthesis and biological evaluation of nimesulide based new class of triazole derivatives as potential PDE4B inhibitors against cancer cells.
AID704142Antiinflammatory activity in A/J mouse assessed as inhibition of neutrophil accumulation in bronchoalveolar space at 45 umol/kg, po administered 1 hr prior to LPS-challenge measured after 18 hrs relative to vehicle-treated control2012Journal of medicinal chemistry, Sep-13, Volume: 55, Issue:17
Design, synthesis, and pharmacological evaluation of N-acylhydrazones and novel conformationally constrained compounds as selective and potent orally active phosphodiesterase-4 inhibitors.
AID158118Inhibition of Phosphodiesterase 51997Journal of medicinal chemistry, Jun-06, Volume: 40, Issue:12
9-Benzyladenines: potent and selective cAMP phosphodiesterase inhibitors.
AID363100Inhibition of human PDE4D4 in particular fraction of lung2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Recent advances on phosphodiesterase 4 inhibitors for the treatment of asthma and chronic obstructive pulmonary disease.
AID1743668Antiinflammatory activity in LPS induced Sprague-Dawley rat model of asthma and COPD assessed as inhibition of neutrophilia at 10 mg/kg, po preincubated for 30 mins followed by LPS stimulation and measured after 6 hrs relative to control2020European journal of medicinal chemistry, Dec-01, Volume: 207Synthesis and bioactivity of phenyl substituted furan and oxazole carboxylic acid derivatives as potential PDE4 inhibitors.
AID440696Inhibition of human recombinant PDE4A4 expressed in baculovirus system at 10 uM by IMAP assay2009Journal of medicinal chemistry, Nov-12, Volume: 52, Issue:21
New selective phosphodiesterase 4D inhibitors differently acting on long, short, and supershort isoforms.
AID1335408Inhibition of human PDE7A using FAM-3',5'-cAMP as substrate after 1 hr by fluorescence polarization assay2016European journal of medicinal chemistry, Nov-29, Volume: 124Development of highly potent phosphodiesterase 4 inhibitors with anti-neuroinflammation potential: Design, synthesis, and structure-activity relationship study of catecholamides bearing aromatic rings.
AID363123Displacement of [3H]rolipram from PDE4 at 100 uM by RBA2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Recent advances on phosphodiesterase 4 inhibitors for the treatment of asthma and chronic obstructive pulmonary disease.
AID1420140Inhibition of human U937 cells-derived PDE4D using [3H]-cAMP as substrate after 30 mins2018Bioorganic & medicinal chemistry letters, 10-15, Volume: 28, Issue:19
Tetrahydroquinoline and tetrahydroisoquinoline derivatives as potential selective PDE4B inhibitors.
AID363101Inhibition of human PDE4D5 in cytosolic fraction of lung2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Recent advances on phosphodiesterase 4 inhibitors for the treatment of asthma and chronic obstructive pulmonary disease.
AID1166749Emetogenic potential in surrogate emesis CD1 mouse model assessed as effect on xyclacine/ketamine-induced loss of righting reflex at 5 mg/kg, sc2014Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20
Modulation of cAMP-specific PDE without emetogenic activity: new sulfide-like PDE7 inhibitors.
AID1420134Inhibition of PDE4 in human PBMC assessed as reduction in LPS-stimulated TNFalpha release preincubated for 30 mins followed by LPS stimulation for 18 hrs by TR-FRET assay2018Bioorganic & medicinal chemistry letters, 10-15, Volume: 28, Issue:19
Synthesis and bioactivity of 3,5-dimethylpyrazole derivatives as potential PDE4 inhibitors.
AID126631Percent Eosinophil inhibition in monkeys at 10 mg/kg oral dose1998Journal of medicinal chemistry, Jun-18, Volume: 41, Issue:13
7-Oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridines as novel inhibitors of human eosinophil phosphodiesterase.
AID503307Antiproliferative activity against human PC3 cells at 25 uM after 120 hrs by MTT assay relative to DMSO2006Nature chemical biology, Jun, Volume: 2, Issue:6
Identifying off-target effects and hidden phenotypes of drugs in human cells.
AID260837Inhibition of release of TNF alpha in human whole blood2006Bioorganic & medicinal chemistry letters, Feb, Volume: 16, Issue:3
A new chemical tool for exploring the role of the PDE4D isozyme in leukocyte function.
AID159969Inhibitory activity against purified rat liver phosphodiesterase 42003Bioorganic & medicinal chemistry letters, Jul-21, Volume: 13, Issue:14
Improvement of therapeutic index of phosphodiesterase type IV inhibitors as anti-Asthmatics.
AID77072In vivo bronchodilator effect on histamine-induced bronchospasm in anaesthetized guinea pigs at 50 ug intravenous dose1994Journal of medicinal chemistry, May-27, Volume: 37, Issue:11
Selective type IV phosphodiesterase inhibitors as antiasthmatic agents. The syntheses and biological activities of 3-(cyclopentyloxy)-4-methoxybenzamides and analogues.
AID1261708Permeability of the compound at 100 ug/ml after 10 hrs by PAMPA assay2015Journal of medicinal chemistry, Nov-12, Volume: 58, Issue:21
Design, Synthesis, and Evaluation of Orally Available Clioquinol-Moracin M Hybrids as Multitarget-Directed Ligands for Cognitive Improvement in a Rat Model of Neurodegeneration in Alzheimer's Disease.
AID1404136Inhibition of recombinant full length human N-terminal GST-tagged PDE4B1 expressed in baculovirus infected Sf9 cells using cAMP as substrate after 1 hr by LANCE TR-FRET assay2018European journal of medicinal chemistry, Feb-10, Volume: 145Design, synthesis, and biological evaluation of novel catecholopyrimidine based PDE4 inhibitor for the treatment of atopic dermatitis.
AID1605515Inhibition of human PDE4D2 (86 to 413 residues) expressed in Escherichia coli BL21 codon-plus cells using [3H]cAMP as substrate incubated for 15 mins by liquid scintillation counting method2020Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6
Discovery and Optimization of α-Mangostin Derivatives as Novel PDE4 Inhibitors for the Treatment of Vascular Dementia.
AID314445Inhibition of PDE11A2008Bioorganic & medicinal chemistry letters, Feb-15, Volume: 18, Issue:4
Identification of a potent new chemotype for the selective inhibition of PDE4.
AID1395052Inhibition of PDE4 (unknown origin)2018European journal of medicinal chemistry, Apr-25, Volume: 150Inhibitors of phosphodiesterase as cancer therapeutics.
AID1166727Inhibition of human recombinant PDE7A1 assessed as inhibition of hydrolysis of [3H]cAMP at 10 uM after 20 mins by scintillation proximity assay2014Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20
Modulation of cAMP-specific PDE without emetogenic activity: new sulfide-like PDE7 inhibitors.
AID159935Inhibitory activity against phosphodiesterase 4 carried out in the cytosol of human neutrophils2002Journal of medicinal chemistry, Jun-06, Volume: 45, Issue:12
Novel selective phosphodiesterase (PDE4) inhibitors. 4. Resolution, absolute configuration, and PDE4 inhibitory activity of cis-tetra- and cis-hexahydrophthalazinones.
AID318125Cytotoxicity against human MT4 cells2008Bioorganic & medicinal chemistry letters, Feb-15, Volume: 18, Issue:4
Investigation of the alkenyldiarylmethane non-nucleoside reverse transcriptase inhibitors as potential cAMP phosphodiesterase-4B2 inhibitors.
AID1404141Inhibition of recombinant human full length N-terminal GST-tagged PDE4B1 expressed in baculovirus infected Sf9 cells using cAMP as substrate after 1 hr by LANCE TR-FRET assay2018European journal of medicinal chemistry, Feb-10, Volume: 145Design, synthesis, and biological evaluation of novel catecholopyrimidine based PDE4 inhibitor for the treatment of atopic dermatitis.
AID425682Inhibition of PDE3B2009Bioorganic & medicinal chemistry letters, Jul-01, Volume: 19, Issue:13
Exploration and optimization of substituted triazolothiadiazines and triazolopyridazines as PDE4 inhibitors.
AID1404142Inhibition of recombinant human full length N-terminal GST-tagged PDE4C1 expressed in baculovirus infected Sf9 cells using cAMP as substrate after 1 hr by LANCE TR-FRET assay2018European journal of medicinal chemistry, Feb-10, Volume: 145Design, synthesis, and biological evaluation of novel catecholopyrimidine based PDE4 inhibitor for the treatment of atopic dermatitis.
AID314440Inhibition of PDE5A2008Bioorganic & medicinal chemistry letters, Feb-15, Volume: 18, Issue:4
Identification of a potent new chemotype for the selective inhibition of PDE4.
AID440699Inhibition of human recombinant PDE4D1 expressed in baculovirus system at 10 uM by IMAP assay2009Journal of medicinal chemistry, Nov-12, Volume: 52, Issue:21
New selective phosphodiesterase 4D inhibitors differently acting on long, short, and supershort isoforms.
AID440710Inhibition of human recombinant PDE4D3 expressed in baculovirus system by radiometric assay2009Journal of medicinal chemistry, Nov-12, Volume: 52, Issue:21
New selective phosphodiesterase 4D inhibitors differently acting on long, short, and supershort isoforms.
AID58399Emetic effect in dogs at 0.2 mg/kg intravenous dose, 2 of 2 animals affected1998Journal of medicinal chemistry, Oct-22, Volume: 41, Issue:22
Novel cyclic compounds as potent phosphodiesterase 4 inhibitors.
AID1596204Inhibition of PDE4D2 (unknown origin) using cAMP as substrate preincubated with enzyme for 15 mins followed by substrate addition and incubated for 1 hr by PDELight HTS cAMP phosphodiesterase Kit based luminometry2019European journal of medicinal chemistry, Jul-15, Volume: 174InCl
AID318127Inhibition of PDE4B2 expressed in COS7 cells assessed as cAMP hydrolysis2008Bioorganic & medicinal chemistry letters, Feb-15, Volume: 18, Issue:4
Investigation of the alkenyldiarylmethane non-nucleoside reverse transcriptase inhibitors as potential cAMP phosphodiesterase-4B2 inhibitors.
AID76100Inhibition of Eosinophilia after peroral administration at 10 mg/Kg compound in guinea pig2000Bioorganic & medicinal chemistry letters, Dec-04, Volume: 10, Issue:23
Synthesis and biological evaluation of 2,5-dihydropyrazol.
AID159498Inhibition of phosphodiesterase (PDE) 31998Bioorganic & medicinal chemistry letters, Nov-17, Volume: 8, Issue:22
N-arylrolipram derivatives as potent and selective PDE4 inhibitors.
AID1774030Toxicity in dog assessed as emesis at 1 mg/kg, po
AID543624Antiinflammatory activity against human neutrophils assessed as inhibition of LPS-stimulated TNFalpha production at 100 ug/ml after 3 hrs by FACS analysis2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Evaluation of the antimicrobial, antioxidant, and anti-inflammatory activities of hydroxychavicol for its potential use as an oral care agent.
AID58625Minimum emetic dose in dogs after intravenous administration2000Bioorganic & medicinal chemistry letters, Dec-04, Volume: 10, Issue:23
Synthesis and biological evaluation of 2,5-dihydropyrazol.
AID1773175Induction of apoptosis in human U-251 cells assessed as increase in viable cells at 200 nM measured after 24 hrs by PI/FITC analysis (Rvb = 98.3%)2021European journal of medicinal chemistry, Nov-15, Volume: 224Discovery of novel trimethoxyphenylbenzo[d]oxazoles as dual tubulin/PDE4 inhibitors capable of inducing apoptosis at G2/M phase arrest in glioma and lung cancer cells.
AID59481Emetic effect in dogs after intravenous dose2000Bioorganic & medicinal chemistry letters, Oct-02, Volume: 10, Issue:19
The synthesis and biological evaluation of a novel series of phthalazine PDE4 inhibitors I.
AID1727166Inhibition of human recombinant PDE4B using cAMP as substrate incubated for 20 mins measured by Kinase Glo reagent based microplate reader assay2021European journal of medicinal chemistry, Jan-01, Volume: 209New imidazopyridines with phosphodiesterase 4 and 7 inhibitory activity and their efficacy in animal models of inflammatory and autoimmune diseases.
AID1365234Anti-inflammatory activity in human U937 cells assessed as inhibition of LPS-induced TNFalpha production at 10 uM pre-incubated for 1 hr before LPS stimulation for 24 hrs by ELISA method2017Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20
Synthesis, pharmacological activities and molecular docking studies of pyrazolyltriazoles as anti-bacterial and anti-inflammatory agents.
AID159628Inhibitory activity against phosphodiesterase 4 isolated from guinea pig ventricular tissue1998Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21
Design, synthesis, and biological activities of new thieno[3,2-d] pyrimidines as selective type 4 phosphodiesterase inhibitors.
AID159640Inhibition of guinea pig ventricular Phosphodiesterase 41997Journal of medicinal chemistry, May-09, Volume: 40, Issue:10
Novel heterocyclic-fused pyridazinones as potent and selective phosphodiesterase IV inhibitors.
AID314434Inhibition of PDE1A2008Bioorganic & medicinal chemistry letters, Feb-15, Volume: 18, Issue:4
Identification of a potent new chemotype for the selective inhibition of PDE4.
AID159074Inhibition of phosphodiesterase 2 at 200 uM1998Bioorganic & medicinal chemistry letters, Oct-06, Volume: 8, Issue:19
Aryl sulfonamides as selective PDE4 inhibitors.
AID159777Inhibition of Phosphodiesterase 4 from human U937 cells2000Bioorganic & medicinal chemistry letters, Sep-18, Volume: 10, Issue:18
7-Methoxybenzofuran-4-carboxamides as PDE 4 inhibitors: a potential treatment for asthma.
AID234774Selectivity as ratio of IC50 against PDE3 to IC50 against PDE41999Journal of medicinal chemistry, Mar-25, Volume: 42, Issue:6
Novel, potent, and selective phosphodiesterase-4 inhibitors as antiasthmatic agents: synthesis and biological activities of a series of 1-pyridylnaphthalene derivatives.
AID160121Inhibition of [3H]rolipram binding to Phosphodiesterase 4 of rat forebrain membrane2002Bioorganic & medicinal chemistry letters, Feb-25, Volume: 12, Issue:4
Synthesis and biological evaluation of imidazol-2-one and 2-cyanoiminoimidazole derivatives: novel series of PDE4 inhibitors.
AID239332Inhibition of [3H]cAMP binding to recombinant human Phosphodiesterase 4AL (PDE4AL) in baculovirus expression system2005Journal of medicinal chemistry, Feb-24, Volume: 48, Issue:4
8-Substituted analogues of 3-(3-cyclopentyloxy-4-methoxy-benzyl)-8-isopropyl-adenine: highly potent and selective PDE4 inhibitors.
AID363084Inhibition of human PDE4A4B in cytosolic fraction of inflammatory cells2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Recent advances on phosphodiesterase 4 inhibitors for the treatment of asthma and chronic obstructive pulmonary disease.
AID159634In vitro inhibition of Phosphodiesterase 4 from guinea pig lung1999Journal of medicinal chemistry, Mar-25, Volume: 42, Issue:6
Novel, potent, and selective phosphodiesterase-4 inhibitors as antiasthmatic agents: synthesis and biological activities of a series of 1-pyridylnaphthalene derivatives.
AID91106Inhibition of fMLP induced oxidative burst in human eosinophils.1998Bioorganic & medicinal chemistry letters, Nov-17, Volume: 8, Issue:22
N-arylrolipram derivatives as potent and selective PDE4 inhibitors.
AID159057Inhibition of guinea pig cardiac ventricle Phosphodiesterase 21999Journal of medicinal chemistry, Mar-25, Volume: 42, Issue:6
Novel, potent, and selective phosphodiesterase-4 inhibitors as antiasthmatic agents: synthesis and biological activities of a series of 1-pyridylnaphthalene derivatives.
AID58398Emetic effect in dogs at 0.03 mg/kg intravenous dose, 2 of 2 animals affected1998Journal of medicinal chemistry, Oct-22, Volume: 41, Issue:22
Novel cyclic compounds as potent phosphodiesterase 4 inhibitors.
AID132956Reversal of reserpine-induced hypothermia in mice by intraperitoneal dose1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Calcium-independent phosphodiesterase inhibitors as putative antidepressants: [3-(bicycloalkyloxy)-4-methoxyphenyl]-2-imidazolidinones.
AID158405Inhibition of phosphodiesterase 4 (PDE4) from porcine liver2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
4-(3-Chloro-4-methoxybenzyl)aminophthalazines: synthesis and inhibitory activity toward phosphodiesterase 5.
AID157921In vitro inhibitory activity on unpurified recombinant Phosphodiesterase 4D1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
Striking effect of hydroxamic acid substitution on the phosphodiesterase type 4 (PDE4) and TNF alpha inhibitory activity of two series of rolipram analogues: implications for a new active site model of PDE4.
AID159653Inhibition of Phosphodiesterase 4 from guinea pig lung1996Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14
Novel selective PDE IV inhibitors as antiasthmatic agents. Synthesis and biological activities of a series of 1-aryl-2,3-bis(hydroxymethyl)naphthalene lignans.
AID158894Inhibition of human Phosphodiesterase 1 at 10 uM1995Journal of medicinal chemistry, Apr-28, Volume: 38, Issue:9
Phosphodiesterase type IV inhibition. Structure-activity relationships of 1,3-disubstituted pyrrolidines.
AID159358Inhibition of Phosphodiesterase 3 from human platelets2000Bioorganic & medicinal chemistry letters, Sep-18, Volume: 10, Issue:18
7-Methoxybenzofuran-4-carboxamides as PDE 4 inhibitors: a potential treatment for asthma.
AID160114In vitro inhibitory activity against phosphodiesterase 4 from rat liver at concentration of 10 uM2001Bioorganic & medicinal chemistry letters, Mar-12, Volume: 11, Issue:5
Syntheses and evaluation of pyrido[2,3-dlpyrimidine-2,4-diones as PDE 4 inhibitors.
AID57331Emetic effect in dogs administered at 0.03 mg/kg intravenously (No effect)2000Bioorganic & medicinal chemistry letters, Jan-03, Volume: 10, Issue:1
Synthesis and structure-activity relationships of 4-oxo-1-phenyl-3,4,6,7-tetrahydro-[1,4]diazepino[6,7,1-hi]indoles: novel PDE4 inhibitors.
AID314442Inhibition of PDE7B2008Bioorganic & medicinal chemistry letters, Feb-15, Volume: 18, Issue:4
Identification of a potent new chemotype for the selective inhibition of PDE4.
AID275700Inhibition of human eosinophil phosphodiesterase2007Journal of medicinal chemistry, Jan-25, Volume: 50, Issue:2
SAR of a series of 5,6-dihydro-(9H)-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-alpha]pyridines as potent inhibitors of human eosinophil phosphodiesterase.
AID132958Minimum effective peroral dose (MED) in mouse forced-swim test1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Calcium-independent phosphodiesterase inhibitors as putative antidepressants: [3-(bicycloalkyloxy)-4-methoxyphenyl]-2-imidazolidinones.
AID192815Percentage inhibition of carrageenan-induced rat foot edema at a dose of 32 mg/kg when administered perorally (po).1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Structure-activity relationship of quinazolinedione inhibitors of calcium-independent phosphodiesterase.
AID158112Inhibition of phosphodiesterase 5 at 20 uM1998Bioorganic & medicinal chemistry letters, Oct-06, Volume: 8, Issue:19
Aryl sulfonamides as selective PDE4 inhibitors.
AID1512231Antiinflammatory activity against LPS-induced sepsis Swiss albino mouse model assessed as downregulation of TNFalpha production in serum at 10 mg/kg, po administered once at 1.5 hrs before LPS challenge and measured after 90 mins by ELISA2019Bioorganic & medicinal chemistry letters, 11-15, Volume: 29, Issue:22
Discovery of novel inhibitors of phosphodiesterase 4 with 1-phenyl-3,4-dihydroisoquinoline scaffold: Structure-based drug design and fragment identification.
AID1743665Selectivity ratio of IC50 for inhibition of human U937 cells derived PDE4D to inhibition of human U937 cells derived PDE4B2020European journal of medicinal chemistry, Dec-01, Volume: 207Synthesis and bioactivity of phenyl substituted furan and oxazole carboxylic acid derivatives as potential PDE4 inhibitors.
AID1331250Inhibition of PDE4 (unknown origin)2017Bioorganic & medicinal chemistry letters, 01-01, Volume: 27, Issue:1
Design and synthesis of 4,5,6,7-tetrahydro-1H-1,2-diazepin-7-one derivatives as a new series of Phosphodiesterase 4 (PDE4) inhibitors.
AID46326Inhibitory activity against phosphodiesterase was determined in vitro using bovine aorta, at 1 uM cGMP in the presence of calcium (10 uM) and calmodulin (15 nM)1989Journal of medicinal chemistry, Jul, Volume: 32, Issue:7
Inhibition of cyclic adenosine-3',5'-monophosphate phosphodiesterase from vascular smooth muscle by rolipram analogues.
AID155664Inhibition of phosphodiesterase 3 (PDE3) isolated from the dog aorta2000Journal of medicinal chemistry, Dec-14, Volume: 43, Issue:25
Synthesis, structure-activity relationships, and pharmacological profile of 9-amino-4-oxo-1-phenyl-3,4,6,7-tetrahydro[1,4]diazepino[6, 7,1-hi]indoles: discovery of potent, selective phosphodiesterase type 4 inhibitors.
AID156987Inhibition of cAMP PDE in canine cardiac tissue1993Journal of medicinal chemistry, Apr-16, Volume: 36, Issue:8
(Imidazolylphenyl)pyrrol-2-one inhibitors of cardiac cAMP phosphodiesterase.
AID1884574Inhibition of PDE4D7 (unknown origin)2022European journal of medicinal chemistry, Aug-05, Volume: 238Discovery of novel 2,3-dihydro-1H-inden-1-ones as dual PDE4/AChE inhibitors with more potency against neuroinflammation for the treatment of Alzheimer's disease.
AID1724982Inhibition of LPS-induced TNFalpha production in C57BL/6 mouse bone marrow derived Macrophage at 1 to 10 uM preincubated for 30 mins followed by LPS stimulation and measured after 24 hrs by ELISA2020ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10
Synthesis and SAR Studies of 1
AID1187758Inhibition of PDE4B2 (unknown origin) at 10 uM2014Journal of medicinal chemistry, Aug-28, Volume: 57, Issue:16
Synthesis, biological evaluation, and molecular modeling of new 3-(cyclopentyloxy)-4-methoxybenzaldehyde O-(2-(2,6-dimethylmorpholino)-2-oxoethyl) Oxime (GEBR-7b) related phosphodiesterase 4D (PDE4D) inhibitors.
AID440695Inhibition of human recombinant PDE4D expressed in Sf9 cells2009Journal of medicinal chemistry, Nov-12, Volume: 52, Issue:21
New selective phosphodiesterase 4D inhibitors differently acting on long, short, and supershort isoforms.
AID90830Inhibition of TNF-alpha release from LPS-stimulated human mononuclear cells1998Journal of medicinal chemistry, Oct-22, Volume: 41, Issue:22
Novel cyclic compounds as potent phosphodiesterase 4 inhibitors.
AID155789Inhibition of anti-CD3 induced IFN-gamma-release in human peripheral blood mononuclear cells.1998Bioorganic & medicinal chemistry letters, Nov-17, Volume: 8, Issue:22
N-arylrolipram derivatives as potent and selective PDE4 inhibitors.
AID157941Inhibition of Phosphodiesterase 5 from guinea pig lung1996Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14
Novel selective PDE IV inhibitors as antiasthmatic agents. Synthesis and biological activities of a series of 1-aryl-2,3-bis(hydroxymethyl)naphthalene lignans.
AID1420139Inhibition of human U937 cells-derived PDE4B using [3H]-cAMP as substrate after 30 mins2018Bioorganic & medicinal chemistry letters, 10-15, Volume: 28, Issue:19
Tetrahydroquinoline and tetrahydroisoquinoline derivatives as potential selective PDE4B inhibitors.
AID238295Inhibition of human phosphodiesterase 42005Journal of medicinal chemistry, May-19, Volume: 48, Issue:10
The next generation of phosphodiesterase inhibitors: structural clues to ligand and substrate selectivity of phosphodiesterases.
AID232652Relative activity against human Phosphodiesterase type 4 (PDE4) and rat rolipram binding protein (RBA)2000Bioorganic & medicinal chemistry letters, Sep-18, Volume: 10, Issue:18
7-Methoxybenzofuran-4-carboxamides as PDE 4 inhibitors: a potential treatment for asthma.
AID395330Inhibition of human recombinant PDE4D32009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
Dual inhibitors of phosphodiesterase-4 and serotonin reuptake.
AID159663Inhibition of rolipram binding to PDE42001Bioorganic & medicinal chemistry letters, Jan-08, Volume: 11, Issue:1
Phthalazine PDE4 inhibitors. Part 2: the synthesis and biological evaluation of 6-methoxy-1,4-disubstituted derivatives.
AID425685Inhibition of PDE4B22009Bioorganic & medicinal chemistry letters, Jul-01, Volume: 19, Issue:13
Exploration and optimization of substituted triazolothiadiazines and triazolopyridazines as PDE4 inhibitors.
AID1492733Inhibition of PDE4 (unknown origin) using FAM-Cyclic-3',5'-AMP as substrate after 1 hr by fluorescence polarization assay2017European journal of medicinal chemistry, Dec-01, Volume: 141Design, synthesis and biological evaluation of substituted aminopyridazin-3(2H)-ones as G0/G1-phase arresting agents with apoptosis-inducing activities.
AID181692Increased acid secretion in isolated whole rat stomach2000Bioorganic & medicinal chemistry letters, Oct-02, Volume: 10, Issue:19
The synthesis and biological evaluation of a novel series of phthalazine PDE4 inhibitors I.
AID157952Inhibitory concentration against phosphodiesterase 5 (PDE5) from human platelet2004Bioorganic & medicinal chemistry letters, Jun-07, Volume: 14, Issue:11
Identification of purine inhibitors of phosphodiesterase 7 (PDE7).
AID160124Ratio of inhibition of [3H]rolipram binding to that of inhibitory activity against Phosphodiesterase 4 was determined2003Bioorganic & medicinal chemistry letters, Jul-21, Volume: 13, Issue:14
Improvement of therapeutic index of phosphodiesterase type IV inhibitors as anti-Asthmatics.
AID159951Displacement of [3H]rolipram binding to Phosphodiesterase 4 in rat brain1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Structure-activity relationship of quinazolinedione inhibitors of calcium-independent phosphodiesterase.
AID666553Antiinflammatory activity in rat microglia cells assessed as inhibition of LPS-induced nitrite production at 30 uM incubated for 1 hr prior to LPS-challenge measured after 24 hrs by Griess method2012Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7
Effect of phosphodiesterase 7 (PDE7) inhibitors in experimental autoimmune encephalomyelitis mice. Discovery of a new chemically diverse family of compounds.
AID72066Emetic effect in ferrets after peroral administration at 0.03 mg/kg (2/5)2003Bioorganic & medicinal chemistry letters, Jul-21, Volume: 13, Issue:14
Improvement of therapeutic index of phosphodiesterase type IV inhibitors as anti-Asthmatics.
AID1372329Cytotoxicity against human PBMC by MTS assay2018Bioorganic & medicinal chemistry letters, 01-01, Volume: 28, Issue:1
Synthesis and in vitro evaluations of 6-(hetero)-aryl-imidazo[1,2-b]pyridazine-3-sulfonamide's as an inhibitor of TNF-α production.
AID1773153Cell cycle arrest in human U-251 cells assessed as S phase at 200 nM measured after 24 hrs by propidium iodide staining based flow cytometry analysis (Rvb = 18.23%)2021European journal of medicinal chemistry, Nov-15, Volume: 224Discovery of novel trimethoxyphenylbenzo[d]oxazoles as dual tubulin/PDE4 inhibitors capable of inducing apoptosis at G2/M phase arrest in glioma and lung cancer cells.
AID440701Inhibition of human recombinant PDE4D3 expressed in baculovirus system at 10 uM by IMAP assay2009Journal of medicinal chemistry, Nov-12, Volume: 52, Issue:21
New selective phosphodiesterase 4D inhibitors differently acting on long, short, and supershort isoforms.
AID219078Emetic effect in ferrets, plasma concentration2000Journal of medicinal chemistry, Oct-19, Volume: 43, Issue:21
Hunting the emesis and efficacy targets of PDE4 inhibitors: identification of the photoaffinity probe 8-(3-azidophenyl)-6- [(4-iodo-1H-1-imidazolyl)methyl]quinoline (APIIMQ).
AID363093Inhibition of human PDE4B3 in particular fraction of lung2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Recent advances on phosphodiesterase 4 inhibitors for the treatment of asthma and chronic obstructive pulmonary disease.
AID1272080Anti-inflammatory activity in BALB/c mouse assessed as inhibition of LPS-induced IL-6 expression at 10 mg/kg, po pre-treated for 1 hr followed by LPS administration measured 2.5 hrs after LPS challenge by ELISA2016Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2
Analogues of boswellic acids as inhibitors of pro-inflammatory cytokines TNF-α and IL-6.
AID1335405Inhibition of full length human PDE4D7 using FAM-3',5'-cAMP as substrate after 1 hr by fluorescence polarization assay2016European journal of medicinal chemistry, Nov-29, Volume: 124Development of highly potent phosphodiesterase 4 inhibitors with anti-neuroinflammation potential: Design, synthesis, and structure-activity relationship study of catecholamides bearing aromatic rings.
AID702885Antitrypanosomal activity against trypomastigotes of Trypanosoma brucei brucei Squib-427 after 72 hrs by fluorescence assay2012Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20
Catechol pyrazolinones as trypanocidals: fragment-based design, synthesis, and pharmacological evaluation of nanomolar inhibitors of trypanosomal phosphodiesterase B1.
AID363090Inhibition of human PDE4B2 in cytosolic fraction of lung2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Recent advances on phosphodiesterase 4 inhibitors for the treatment of asthma and chronic obstructive pulmonary disease.
AID1404140Inhibition of recombinant human N-terminal GST-tagged PDE4A4 (2 to 886 residues) expressed in baculovirus infected Sf9 cells using cAMP as substrate after 1 hr by LANCE TR-FRET assay2018European journal of medicinal chemistry, Feb-10, Volume: 145Design, synthesis, and biological evaluation of novel catecholopyrimidine based PDE4 inhibitor for the treatment of atopic dermatitis.
AID1625374Inhibition of human His-tagged PDE4B catalytic domain expressed in Escherichia coli BL21-CodonPlus(DE3) cells using [3H]cAMP or [3H]cGMP as substrate incubated for 30 mins by scintillation counting method2016Journal of medicinal chemistry, Aug-11, Volume: 59, Issue:15
PDEStrIAn: A Phosphodiesterase Structure and Ligand Interaction Annotated Database As a Tool for Structure-Based Drug Design.
AID152782Inhibitory concentration against growth of LPS stimulated human peripheral blood mononuclear cells2001Bioorganic & medicinal chemistry letters, Feb-26, Volume: 11, Issue:4
Structure-activity relationships of quinazoline derivatives: dual-acting compounds with inhibitory activities toward both TNF-alpha production and T cell proliferation.
AID318126Inhibition of PDE4B2 expressed in COS7 cells assessed as cAMP hydrolysis at 100 uM2008Bioorganic & medicinal chemistry letters, Feb-15, Volume: 18, Issue:4
Investigation of the alkenyldiarylmethane non-nucleoside reverse transcriptase inhibitors as potential cAMP phosphodiesterase-4B2 inhibitors.
AID1727199Antiinflammatory activity in LPS-induced Wistar rat endotoxemia model assessed as decrease in plasma TNFalpha level at 5 mg/kg, ip measured after 2 hr2021European journal of medicinal chemistry, Jan-01, Volume: 209New imidazopyridines with phosphodiesterase 4 and 7 inhibitory activity and their efficacy in animal models of inflammatory and autoimmune diseases.
AID695683Induction of SQSTM1-dependent intracellular redistribution of GFP-tagged PDE4A4 assessed as maximal accretion of enzyme into foci2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Elucidation of a structural basis for the inhibitor-driven, p62 (SQSTM1)-dependent intracellular redistribution of cAMP phosphodiesterase-4A4 (PDE4A4).
AID1420143Anti-inflammatory activity in Swiss albino mouse model of sepsis assessed as inhibition of LPS-induced TNFalpha release at 10 mg/kg, po administered 30 mins prior to LPS challenge for 90 mins by ELISA relative to control2018Bioorganic & medicinal chemistry letters, 10-15, Volume: 28, Issue:19
Tetrahydroquinoline and tetrahydroisoquinoline derivatives as potential selective PDE4B inhibitors.
AID159347Inhibition of Phosphodiesterase 3 (PDE3) from human platelet at 20 uM2002Bioorganic & medicinal chemistry letters, Jun-17, Volume: 12, Issue:12
8-Methoxyquinoline-5-carboxamides as PDE4 inhibitors: a potential treatment for asthma.
AID340315Inhibition of human phosphodiesterase 42008Journal of medicinal chemistry, Jul-24, Volume: 51, Issue:14
Identification of a potent, selective, and orally active leukotriene a4 hydrolase inhibitor with anti-inflammatory activity.
AID1254336Inhibition of core catalytic domains of human PDE4 using AM-Cyclic-3',5'-AMP after 60 mins by fluorescence polarization assay2015Bioorganic & medicinal chemistry, Nov-15, Volume: 23, Issue:22
Catecholic amides as potential selective phosphodiesterase 4D inhibitors: Design, synthesis, pharmacological evaluation and structure-activity relationships.
AID179556Evaluated for Ca++ dependent phosphodiesterase activity. 1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
4-Amino[1,2,4]triazolo[4,3-a]quinoxalines. A novel class of potent adenosine receptor antagonists and potential rapid-onset antidepressants.
AID155676PDE4-related emetic activity in ferrets after intravenous administration at 0.6 mg/kg2000Journal of medicinal chemistry, Dec-14, Volume: 43, Issue:25
Synthesis, structure-activity relationships, and pharmacological profile of 9-amino-4-oxo-1-phenyl-3,4,6,7-tetrahydro[1,4]diazepino[6, 7,1-hi]indoles: discovery of potent, selective phosphodiesterase type 4 inhibitors.
AID1464265Inhibition of PDE4B isolated from human U937 cells using [3H]-cAMP incubated for 30 mins2017Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20
Rational design of conformationally constrained oxazolidinone-fused 1,2,3,4-tetrahydroisoquinoline derivatives as potential PDE4 inhibitors.
AID76954Effective dose (mg/kg) in Aerosolized Antigen Induced airway Obstruction assay in guinea pig1996Journal of medicinal chemistry, Jan-05, Volume: 39, Issue:1
Biarylcarboxylic acids and -amides: inhibition of phosphodiesterase type IV versus [3H]rolipram binding activity and their relationship to emetic behavior in the ferret.
AID425693Inhibition of PDE11A42009Bioorganic & medicinal chemistry letters, Jul-01, Volume: 19, Issue:13
Exploration and optimization of substituted triazolothiadiazines and triazolopyridazines as PDE4 inhibitors.
AID181540Binding affinity against high affinity rolipram binding site (HARBS) was determined by displacing radioactive [3H]rolipram from brain membrane suspensions of Wistar rats2000Bioorganic & medicinal chemistry letters, Jan-03, Volume: 10, Issue:1
Synthesis and structure-activity relationships of 4-oxo-1-phenyl-3,4,6,7-tetrahydro-[1,4]diazepino[6,7,1-hi]indoles: novel PDE4 inhibitors.
AID225259Affinity for rolipram binding site of phosphodiesterase type IV (PDE4)1998Bioorganic & medicinal chemistry letters, Nov-03, Volume: 8, Issue:21
Orally active indole N-oxide PDE4 inhibitors.
AID733565Inhibition of human PDE4B22013Journal of natural products, Mar-22, Volume: 76, Issue:3
Benzoquinones and terphenyl compounds as phosphodiesterase-4B inhibitors from a fungus of the order Chaetothyriales (MSX 47445).
AID1420136Anti-inflammatory activity in Sprague-Dawley rat model of LPS-induced asthma/COPD assessed as inhibition of neutrophilia in BALF at 10 mg/kg, po2018Bioorganic & medicinal chemistry letters, 10-15, Volume: 28, Issue:19
Synthesis and bioactivity of 3,5-dimethylpyrazole derivatives as potential PDE4 inhibitors.
AID731227Inhibition of PDE4B1 (unknown origin) expressed in sf9 cells using cAMP as substrate preincubated for 15 mins before substrate addition measured after 1 hr by luminescence assay2013Bioorganic & medicinal chemistry, Apr-01, Volume: 21, Issue:7
Novel imidazophenoxazine-4-sulfonamides: their synthesis and evaluation as potential inhibitors of PDE4.
AID45806Inhibition of phosphodiesterase 4 from rat brain cortex1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Structure-activity relationship of quinazolinedione inhibitors of calcium-independent phosphodiesterase.
AID157916Inhibition of phosphodiesterase (PDE) 4B1998Bioorganic & medicinal chemistry letters, Nov-17, Volume: 8, Issue:22
N-arylrolipram derivatives as potent and selective PDE4 inhibitors.
AID160117Inhibition of phosphodiesterase 4 from rat liver at 3 uM (not determined)2001Bioorganic & medicinal chemistry letters, Mar-12, Volume: 11, Issue:5
Syntheses and evaluation of pyrido[2,3-dlpyrimidine-2,4-diones as PDE 4 inhibitors.
AID209811Inhibitory concentration against T cell proliferation using concanavalin A stimulated mice spleen cells2001Bioorganic & medicinal chemistry letters, Feb-26, Volume: 11, Issue:4
Structure-activity relationships of quinazoline derivatives: dual-acting compounds with inhibitory activities toward both TNF-alpha production and T cell proliferation.
AID195536Binding affinity to rolipram binding site in isolated rat brain by rolipram binding assay2001Bioorganic & medicinal chemistry letters, Mar-12, Volume: 11, Issue:5
Syntheses and evaluation of pyrido[2,3-dlpyrimidine-2,4-diones as PDE 4 inhibitors.
AID159957Inhibition of rolipram binding in rat brain2002Bioorganic & medicinal chemistry letters, Jun-17, Volume: 12, Issue:12
8-Methoxyquinoline-5-carboxamides as PDE4 inhibitors: a potential treatment for asthma.
AID1187760Inhibition of recombinant human PDE4D3 expressed in baculoviral system2014Journal of medicinal chemistry, Aug-28, Volume: 57, Issue:16
Synthesis, biological evaluation, and molecular modeling of new 3-(cyclopentyloxy)-4-methoxybenzaldehyde O-(2-(2,6-dimethylmorpholino)-2-oxoethyl) Oxime (GEBR-7b) related phosphodiesterase 4D (PDE4D) inhibitors.
AID1335410Inhibition of human PDE9A2 using FAM-3',5'-cAMP as substrate after 1 hr by fluorescence polarization assay2016European journal of medicinal chemistry, Nov-29, Volume: 124Development of highly potent phosphodiesterase 4 inhibitors with anti-neuroinflammation potential: Design, synthesis, and structure-activity relationship study of catecholamides bearing aromatic rings.
AID184448Tested in vivo for lowest active dose that induced inhibitory effect on gastric emptying in rats2002Bioorganic & medicinal chemistry letters, Feb-25, Volume: 12, Issue:4
Synthesis and biological evaluation of imidazol-2-one and 2-cyanoiminoimidazole derivatives: novel series of PDE4 inhibitors.
AID1727193Hepatoprotective activity in ConA-induced BALB/c hepatitis mouse model assessed as decrease in serum IFNgamma level at 10 mg/kg, ip administration and measured after 8 hrs relative to control2021European journal of medicinal chemistry, Jan-01, Volume: 209New imidazopyridines with phosphodiesterase 4 and 7 inhibitory activity and their efficacy in animal models of inflammatory and autoimmune diseases.
AID704164Inhibition of human recombinant PDE4D2012Journal of medicinal chemistry, Sep-13, Volume: 55, Issue:17
Design, synthesis, and pharmacological evaluation of N-acylhydrazones and novel conformationally constrained compounds as selective and potent orally active phosphodiesterase-4 inhibitors.
AID158890Inhibition of Phosphodiesterase 1 of guinea pig cardiac ventricle1999Journal of medicinal chemistry, Mar-25, Volume: 42, Issue:6
Novel, potent, and selective phosphodiesterase-4 inhibitors as antiasthmatic agents: synthesis and biological activities of a series of 1-pyridylnaphthalene derivatives.
AID159636Inhibition of solubilized eosinophil PDE IV1994Journal of medicinal chemistry, May-27, Volume: 37, Issue:11
Selective type IV phosphodiesterase inhibitors as antiasthmatic agents. The syntheses and biological activities of 3-(cyclopentyloxy)-4-methoxybenzamides and analogues.
AID159654Inhibition of Phosphodiesterase 4 from human neutrophils2000Bioorganic & medicinal chemistry letters, Oct-02, Volume: 10, Issue:19
The synthesis and biological evaluation of a novel series of phthalazine PDE4 inhibitors I.
AID1727184Inhibition of human recombinant PDE4D using cAMP as substrate incubated for 20 mins measured by Kinase Glo reagent based microplate reader assay2021European journal of medicinal chemistry, Jan-01, Volume: 209New imidazopyridines with phosphodiesterase 4 and 7 inhibitory activity and their efficacy in animal models of inflammatory and autoimmune diseases.
AID363010Inhibition of human PDE4 at 2 uM after 20 mins2008European journal of medicinal chemistry, May, Volume: 43, Issue:5
Synthesis, anti-bacterial, anti-asthmatic and anti-diabetic activities of novel N-substituted-2-(4-phenylethynyl-phenyl)-1H-benzimidazoles and N-substituted 2[4-(4,4-dimethyl-thiochroman-6-yl-ethynyl)-phenyl)-1H-benzimidazoles.
AID349552Antiinflammatory activity in human PBMC assessed as inhibition of LPS-induced TNFalpha release in after 24 hrs by FACS Array analysis2009Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8
Discovery and structure-activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis.
AID1370516Cytotoxicity against human A549 cells assessed as cell viability at 10 uM by MTT assay relative to control2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Identification of novel small-molecule inhibitors of Zika virus infection.
AID517459Antiinflammatory activity against LPS-induced TNFalpha production in human whole blood by ELISA2010Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19
Synthesis and biological activity of pyrido[3',2':4,5]thieno[3,2-d]pyrimidines as phosphodiesterase type 4 inhibitors.
AID318119Inhibition of PDE3A2008Bioorganic & medicinal chemistry letters, Mar-15, Volume: 18, Issue:6
Rhodanine derivatives as novel inhibitors of PDE4.
AID90658Evaluated in vitro for its inhibitory activity on LPS-induced TNF-Alpha release in human monocyte.1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
Striking effect of hydroxamic acid substitution on the phosphodiesterase type 4 (PDE4) and TNF alpha inhibitory activity of two series of rolipram analogues: implications for a new active site model of PDE4.
AID1625377Inhibition of recombinant human PDE4D7 catalytic domain expressed in baculovirus infected sf9 cells using cAMP as substrate2016Journal of medicinal chemistry, Aug-11, Volume: 59, Issue:15
PDEStrIAn: A Phosphodiesterase Structure and Ligand Interaction Annotated Database As a Tool for Structure-Based Drug Design.
AID1727191Hepatoprotective activity in ConA-induced BALB/c hepatitis mouse model assessed as decrease in serum IFNgamma level at 50 mg/kg, ip administration and measured after 8 hrs relative to control2021European journal of medicinal chemistry, Jan-01, Volume: 209New imidazopyridines with phosphodiesterase 4 and 7 inhibitory activity and their efficacy in animal models of inflammatory and autoimmune diseases.
AID58397Emetic effect in dogs at 0.01 mg/kg intravenous dose, 1 of 2 animals affected1998Journal of medicinal chemistry, Oct-22, Volume: 41, Issue:22
Novel cyclic compounds as potent phosphodiesterase 4 inhibitors.
AID440698Inhibition of human recombinant PDE4C2 expressed in baculovirus system at 10 uM by IMAP assay2009Journal of medicinal chemistry, Nov-12, Volume: 52, Issue:21
New selective phosphodiesterase 4D inhibitors differently acting on long, short, and supershort isoforms.
AID1512227Inhibition of PDE4B in human PBMC assessed as inhibition in LPS-induced TNFalpha production preincubated for 30 mins followed by LPS stimulation for 18 hrs by TR-FRET analysis2019Bioorganic & medicinal chemistry letters, 11-15, Volume: 29, Issue:22
Discovery of novel inhibitors of phosphodiesterase 4 with 1-phenyl-3,4-dihydroisoquinoline scaffold: Structure-based drug design and fragment identification.
AID1623118Neuroprotection in amyloid beta (25 to 35 residues) induced C57BL/6J mouse model of Alzheimer's disease assessed as reduction in ratio of apoptotic neuron in DG hippocampus region at 4 mg/kg/day, ig administered for 26 consecutive days by hematoxylin and 2019European journal of medicinal chemistry, Feb-01, Volume: 163Synthesis and evaluation of clioquinol-rolipram/roflumilast hybrids as multitarget-directed ligands for the treatment of Alzheimer's disease.
AID1069505Inhibition of PDE4B (unknown origin) expressed in HEK293 cells assessed as increase in forskolin-stimulated cAMP level at 30 uM preincubated for 30 mins followed by forskolin-stimulation measured after 4 hrs by luciferase reporter gene assay relative to c2014Bioorganic & medicinal chemistry letters, Feb-15, Volume: 24, Issue:4
Synthesis of 2H-1,3-benzoxazin-4(3H)-one derivatives containing indole moiety: their in vitro evaluation against PDE4B.
AID76949Effect on Aerosolized Antigen Induced Airway Obstruction (AAIAO) in guinea pig after oral dose1998Journal of medicinal chemistry, Jun-18, Volume: 41, Issue:13
7-Oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridines as novel inhibitors of human eosinophil phosphodiesterase.
AID363091Inhibition of human PDE4B2 in particular fraction of lung2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Recent advances on phosphodiesterase 4 inhibitors for the treatment of asthma and chronic obstructive pulmonary disease.
AID1374976Inhibition of human U937 cells-derived PDE4D using [3H]-cAMP as substrate after 30 mins2018Bioorganic & medicinal chemistry letters, 04-15, Volume: 28, Issue:7
Structure-based design and structure-activity relationships of 1,2,3,4-tetrahydroisoquinoline derivatives as potential PDE4 inhibitors.
AID1420135Anti-inflammatory activity in Swiss albino mouse model of sepsis assessed as inhibition of LPS-induced TNFalpha release at 10 mg/kg, po2018Bioorganic & medicinal chemistry letters, 10-15, Volume: 28, Issue:19
Synthesis and bioactivity of 3,5-dimethylpyrazole derivatives as potential PDE4 inhibitors.
AID1783023Inhibition of PDE4B (unknown origin) using [3H]cAMP as substrate at 10 uM incubated for 30 mins by scintillation proximity assay relative to control2021European journal of medicinal chemistry, Oct-05, Volume: 221PdCl
AID425683Inhibition of PDE4A1A2009Bioorganic & medicinal chemistry letters, Jul-01, Volume: 19, Issue:13
Exploration and optimization of substituted triazolothiadiazines and triazolopyridazines as PDE4 inhibitors.
AID1743663Inhibition of human U-937 cells derived PDE4B using [3H] cAMP as substrate measured after 30 mins2020European journal of medicinal chemistry, Dec-01, Volume: 207Synthesis and bioactivity of phenyl substituted furan and oxazole carboxylic acid derivatives as potential PDE4 inhibitors.
AID440697Inhibition of human recombinant PDE4B2 expressed in baculovirus system at 10 uM by IMAP assay2009Journal of medicinal chemistry, Nov-12, Volume: 52, Issue:21
New selective phosphodiesterase 4D inhibitors differently acting on long, short, and supershort isoforms.
AID117194Evaluated for antiinflammatory activity in the TPA induced ear inflammation model at a dose 2 mg/kg (50 ug)2002Bioorganic & medicinal chemistry letters, Feb-25, Volume: 12, Issue:4
Synthesis and biological evaluation of imidazol-2-one and 2-cyanoiminoimidazole derivatives: novel series of PDE4 inhibitors.
AID260835Inhibition of release of Eosinophil derived neurotoxin in human whole blood2006Bioorganic & medicinal chemistry letters, Feb, Volume: 16, Issue:3
A new chemical tool for exploring the role of the PDE4D isozyme in leukocyte function.
AID1374974Anti-inflammatory activity in Swiss albino mouse model of sepsis assessed as inhibition of LPS-induced TNFalpha release at 10 mg/kg, po administered 30 mins prior to LPS challenge for 90 mins by ELISA relative to control2018Bioorganic & medicinal chemistry letters, 04-15, Volume: 28, Issue:7
Structure-based design and structure-activity relationships of 1,2,3,4-tetrahydroisoquinoline derivatives as potential PDE4 inhibitors.
AID77070In vivo bronchodilator effect on histamine-induced bronchospasm in anaesthetized guinea pigs at 20 ug intravenous dose1994Journal of medicinal chemistry, May-27, Volume: 37, Issue:11
Selective type IV phosphodiesterase inhibitors as antiasthmatic agents. The syntheses and biological activities of 3-(cyclopentyloxy)-4-methoxybenzamides and analogues.
AID159650Inhibition of rolipram binding to Phosphodiesterase 41998Bioorganic & medicinal chemistry letters, Jan-20, Volume: 8, Issue:2
Quaternary substituted PDE4 inhibitors I: the synthesis and in vitro evaluation of a novel series of oxindoles.
AID75781In vivo bronchodilator effect on histamine-induced bronchospasm in anaesthetized guinea pigs at 20 ug intravenous dose1994Journal of medicinal chemistry, May-27, Volume: 37, Issue:11
Selective type IV phosphodiesterase inhibitors as antiasthmatic agents. The syntheses and biological activities of 3-(cyclopentyloxy)-4-methoxybenzamides and analogues.
AID1404143Inhibition of recombinant human N-terminal GST-tagged PDE4D7 (2 to 748 residues) expressed in baculovirus infected Sf9 cells using cAMP as substrate after 1 hr by LANCE TR-FRET assay2018European journal of medicinal chemistry, Feb-10, Volume: 145Design, synthesis, and biological evaluation of novel catecholopyrimidine based PDE4 inhibitor for the treatment of atopic dermatitis.
AID314443Inhibition of PDE9A2008Bioorganic & medicinal chemistry letters, Feb-15, Volume: 18, Issue:4
Identification of a potent new chemotype for the selective inhibition of PDE4.
AID425675Inhibition of PDE10A12009Bioorganic & medicinal chemistry letters, Jul-01, Volume: 19, Issue:13
Exploration and optimization of substituted triazolothiadiazines and triazolopyridazines as PDE4 inhibitors.
AID1773176Induction of apoptosis in human U-251 cells assessed as increase in early apoptotic cells at 200 nM measured after 24 hrs by PI/FITC analysis (Rvb = 1.12%)2021European journal of medicinal chemistry, Nov-15, Volume: 224Discovery of novel trimethoxyphenylbenzo[d]oxazoles as dual tubulin/PDE4 inhibitors capable of inducing apoptosis at G2/M phase arrest in glioma and lung cancer cells.
AID1773136Antiproliferative activity against human NCI-H460 cells after 48 hrs by MTT assay2021European journal of medicinal chemistry, Nov-15, Volume: 224Discovery of novel trimethoxyphenylbenzo[d]oxazoles as dual tubulin/PDE4 inhibitors capable of inducing apoptosis at G2/M phase arrest in glioma and lung cancer cells.
AID260828Inhibition of PDE8A2006Bioorganic & medicinal chemistry letters, Feb, Volume: 16, Issue:3
A new chemical tool for exploring the role of the PDE4D isozyme in leukocyte function.
AID1254338Inhibition of human full-length PDE4D7 using AM-Cyclic-3',5'-AMP after 60 mins by fluorescence polarization assay2015Bioorganic & medicinal chemistry, Nov-15, Volume: 23, Issue:22
Catecholic amides as potential selective phosphodiesterase 4D inhibitors: Design, synthesis, pharmacological evaluation and structure-activity relationships.
AID160113In vitro inhibitory activity against phosphodiesterase 4 from rat liver at concentration of 1 uM2001Bioorganic & medicinal chemistry letters, Mar-12, Volume: 11, Issue:5
Syntheses and evaluation of pyrido[2,3-dlpyrimidine-2,4-diones as PDE 4 inhibitors.
AID210152In vivo inhibition of LPS-stimulated TNF-alpha release in Wistar rats at 10 mg/kg oral dose2000Journal of medicinal chemistry, Dec-14, Volume: 43, Issue:25
Synthesis, structure-activity relationships, and pharmacological profile of 9-amino-4-oxo-1-phenyl-3,4,6,7-tetrahydro[1,4]diazepino[6, 7,1-hi]indoles: discovery of potent, selective phosphodiesterase type 4 inhibitors.
AID314437Inhibition of PDE4A2008Bioorganic & medicinal chemistry letters, Feb-15, Volume: 18, Issue:4
Identification of a potent new chemotype for the selective inhibition of PDE4.
AID76038In vivo bronchodilator effect on histamine-induced bronchospasm in anaesthetized guinea pigs at 10 ug intravenous dose1994Journal of medicinal chemistry, May-27, Volume: 37, Issue:11
Selective type IV phosphodiesterase inhibitors as antiasthmatic agents. The syntheses and biological activities of 3-(cyclopentyloxy)-4-methoxybenzamides and analogues.
AID1464281Inhibition of LPS-induced neutropenia in Sprague-Dawley rat model of asthma assessed as reduction in neutrophils in BAL fluid at 10 mg/kg, po pre-treated 30 mins before LPS challenge and measured 6 hrs after LPS injection relative to untreated control2017Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20
Rational design of conformationally constrained oxazolidinone-fused 1,2,3,4-tetrahydroisoquinoline derivatives as potential PDE4 inhibitors.
AID363096Inhibition of human PDE4D2 in cytosolic fraction of lung2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Recent advances on phosphodiesterase 4 inhibitors for the treatment of asthma and chronic obstructive pulmonary disease.
AID219079Emetic effect in ferrets, peroral mg/kg dose2000Journal of medicinal chemistry, Oct-19, Volume: 43, Issue:21
Hunting the emesis and efficacy targets of PDE4 inhibitors: identification of the photoaffinity probe 8-(3-azidophenyl)-6- [(4-iodo-1H-1-imidazolyl)methyl]quinoline (APIIMQ).
AID31403Binding affinity towards the adenosine A1 receptor in cerebral cortices of Sprague-Dawley male rats using [3H]CHA as radioligand.1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
4-Amino[1,2,4]triazolo[4,3-a]quinoxalines. A novel class of potent adenosine receptor antagonists and potential rapid-onset antidepressants.
AID159787Inhibition of human phosphodiesterase 4 from U937 cells2002Bioorganic & medicinal chemistry letters, Feb-11, Volume: 12, Issue:3
7-Methoxyfuro[2,3-c]pyridine-4-carboxamides as PDE4 inhibitors: a potential treatment for asthma.
AID759553Binding affinity to human serum albumin2013Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15
Discovery of triazines as potent, selective and orally active PDE4 inhibitors.
AID1512255Antiinflammatory activity against LPS-induced asthma/COPD Sprague-Dawley rat model assessed as inhibition of LPS-induced neutrophilia treated 30 mins prior to LPS challenge measured after 6 hrs2019Bioorganic & medicinal chemistry letters, 11-15, Volume: 29, Issue:22
Discovery of novel inhibitors of phosphodiesterase 4 with 1-phenyl-3,4-dihydroisoquinoline scaffold: Structure-based drug design and fragment identification.
AID77242Inhibition of histamine induced bronchoconstriction in guinea pig after intravenous administration2000Bioorganic & medicinal chemistry letters, Dec-04, Volume: 10, Issue:23
Synthesis and biological evaluation of 2,5-dihydropyrazol.
AID241175Inhibition of Phosphodiesterase 12005Bioorganic & medicinal chemistry letters, Apr-01, Volume: 15, Issue:7
Fused pyrimidine based inhibitors of phosphodiesterase 7 (PDE7): synthesis and initial structure-activity relationships.
AID195719Displacement of [3H]rolipram from high affinity binding site (HARBS) in rat brain membrane.2000Bioorganic & medicinal chemistry letters, Dec-04, Volume: 10, Issue:23
Synthesis and biological evaluation of 2,5-dihydropyrazol.
AID159964Concentration for inhibitory activity against phosphodiesterase 4 from rat liver2001Bioorganic & medicinal chemistry letters, Mar-12, Volume: 11, Issue:5
Syntheses and evaluation of pyrido[2,3-dlpyrimidine-2,4-diones as PDE 4 inhibitors.
AID1773140Inhibition of PDE4 CAT (unknown origin) at 1 uM relative to control2021European journal of medicinal chemistry, Nov-15, Volume: 224Discovery of novel trimethoxyphenylbenzo[d]oxazoles as dual tubulin/PDE4 inhibitors capable of inducing apoptosis at G2/M phase arrest in glioma and lung cancer cells.
AID205268Inhibition of binding of Batrachotoxinin [3H]BTX-B to high affinity sites on voltage dependent sodium channels in a vesicular preparation from guinea pig cerebral cortex at 10 uM1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
[3H]Batrachotoxinin A 20 alpha-benzoate binding to voltage-sensitive sodium channels: a rapid and quantitative assay for local anesthetic activity in a variety of drugs.
AID425698Inhibition of beta2 adrenergic receptor expressed in HEK293 cells co-transfected with PKA fragments Reg-F[1] and cat-F[2]-fused renilla luciferase assessed as effect on receptor regulated PKA activation at 100 uM after 30 mins by protein-fragment compleme2009Bioorganic & medicinal chemistry letters, Jul-01, Volume: 19, Issue:13
Exploration and optimization of substituted triazolothiadiazines and triazolopyridazines as PDE4 inhibitors.
AID1623105Cognition enhancement activity in amyloid beta (25 to 35 residues) induced C57BL/6J mouse model of Alzheimer's disease assessed as swimming speed at 30 mg/kg/day, ig administered for 26 consecutive days by Morris water maze test (Rvb = 15.6 +/- 2.4 cm/sec2019European journal of medicinal chemistry, Feb-01, Volume: 163Synthesis and evaluation of clioquinol-rolipram/roflumilast hybrids as multitarget-directed ligands for the treatment of Alzheimer's disease.
AID158913Inhibition of calcium-calmodulin dependent Phosphodiesterase 11997Journal of medicinal chemistry, Jun-06, Volume: 40, Issue:12
9-Benzyladenines: potent and selective cAMP phosphodiesterase inhibitors.
AID1703895Vasorelaxant activity in non-sensitized guinea pig-derived trachea assessed as decrease in CCh-induced tracheal tonic contraction in presence of functional epithelium2020European journal of medicinal chemistry, Oct-15, Volume: 204Discovery of sulfonyl hydrazone derivative as a new selective PDE4A and PDE4D inhibitor by lead-optimization approach on the prototype LASSBio-448: In vitro and in vivo preclinical studies.
AID158463Inhibition of phosphodiesterase 4 from U937 cells1998Bioorganic & medicinal chemistry letters, Oct-06, Volume: 8, Issue:19
Thalidomide analogs and PDE4 inhibition.
AID160129Relative inhibition of phosphodiesterase 4 activity and Rolipram binding to PDE41998Bioorganic & medicinal chemistry letters, Oct-06, Volume: 8, Issue:19
Aryl sulfonamides as selective PDE4 inhibitors.
AID157930Inhibition of bovine arterial Phosphodiesterase 51996Journal of medicinal chemistry, Jan-05, Volume: 39, Issue:1
Studies of cardiotonic agents. 8. Synthesis and biological activities of optically active 6-(4-(benzylamino)-7-quinazolinyl)-4,5-dihydro-5-methyl-3(2H)- pyridazinone (KF15232).
AID1773141Inhibition of PDE4 CAT (unknown origin)2021European journal of medicinal chemistry, Nov-15, Volume: 224Discovery of novel trimethoxyphenylbenzo[d]oxazoles as dual tubulin/PDE4 inhibitors capable of inducing apoptosis at G2/M phase arrest in glioma and lung cancer cells.
AID1427216Anti-inflammatory activity in human PBMC assessed as inhibition of LPS-induced TNFalpha secretion preincubated for 30 mins followed by LPS stimulation for 18 hrs by TR-FRET assay
AID349565Antiinflammatory activity in mouse ear edema model assessed as inhibition of PMA-induced ear edema at 3 mg/ear administered 2 times 30 mins before and 15 mins after PMA challenge measured after 6 hrs of PMA application relative to control2009Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8
Discovery and structure-activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis.
AID21669Compound tested for plasma levels in monkeys dosed at 10 mg/kg, po1998Journal of medicinal chemistry, Jun-18, Volume: 41, Issue:13
7-Oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridines as novel inhibitors of human eosinophil phosphodiesterase.
AID1727192Hepatoprotective activity in ConA-induced BALB/c hepatitis mouse model assessed as decrease in serum IL-6 level at 10 mg/kg, ip administration and measured after 8 hrs relative to control2021European journal of medicinal chemistry, Jan-01, Volume: 209New imidazopyridines with phosphodiesterase 4 and 7 inhibitory activity and their efficacy in animal models of inflammatory and autoimmune diseases.
AID1166748Emetogenic potential in surrogate emesis CD1 mouse model assessed as effect on xyclacine/ketamine-induced loss of righting reflex at 1 mg/kg, sc2014Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20
Modulation of cAMP-specific PDE without emetogenic activity: new sulfide-like PDE7 inhibitors.
AID1724978Inhibition of recombinant human C-terminal His-tagged N-terminal GST-tagged PDE4B2 expressed in baculovirus infected Sf9 cells by radioligand binding assay2020ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10
Synthesis and SAR Studies of 1
AID239335Inhibition of [3H]cAMP binding to recombinant human Phosphodiesterase 4D3 (PDE4D3) in baculovirus expression system2005Journal of medicinal chemistry, Feb-24, Volume: 48, Issue:4
8-Substituted analogues of 3-(3-cyclopentyloxy-4-methoxy-benzyl)-8-isopropyl-adenine: highly potent and selective PDE4 inhibitors.
AID1427218Anti-inflammatory activity in Sprague-Dawley rat model of LPS-induced asthma/COPD assessed as inhibition of neutrophilia in lungs at 10 mg/kg, po administered 30 mins prior to LPS challenge for 40 mins measured after 6 hrs relative to control
AID425692Inhibition of PDE9A22009Bioorganic & medicinal chemistry letters, Jul-01, Volume: 19, Issue:13
Exploration and optimization of substituted triazolothiadiazines and triazolopyridazines as PDE4 inhibitors.
AID759589Aqueous solubility of the compound at pH 7.42013Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15
Discovery of triazines as potent, selective and orally active PDE4 inhibitors.
AID90807Inhibition of TNF-alpha release by lipopolysaccharide stimulated human monocytes1995Journal of medicinal chemistry, Apr-28, Volume: 38, Issue:9
Phosphodiesterase type IV inhibition. Structure-activity relationships of 1,3-disubstituted pyrrolidines.
AID158904Inhibition of [Ca(2+)]/calmodulin dependent phosphodiesterase PDE 1 of rabbit renal cortex1985Journal of medicinal chemistry, May, Volume: 28, Issue:5
A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity.
AID395521Antidepressant activity in ICR mouse assessed as decrease in immobility duration at 0.5 mg/kg, ip by forced swimming test2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
Dual inhibitors of phosphodiesterase-4 and serotonin reuptake.
AID260822Inhibition of PDE32006Bioorganic & medicinal chemistry letters, Feb, Volume: 16, Issue:3
A new chemical tool for exploring the role of the PDE4D isozyme in leukocyte function.
AID1625379Inhibition of human PDE4D2 catalytic domain (79 to 438 residues) Escherichia coli BL21-CodonPlus(DE3) cells2016Journal of medicinal chemistry, Aug-11, Volume: 59, Issue:15
PDEStrIAn: A Phosphodiesterase Structure and Ligand Interaction Annotated Database As a Tool for Structure-Based Drug Design.
AID1157533Induction of bronchodilation in ovalbumin-sensitized guinea pig at 10 mg/kg, po administered 1 hr prior to ovalbumin challenge measured for 20 mins relative to vehicle-treated control2014Bioorganic & medicinal chemistry letters, Jun-15, Volume: 24, Issue:12
Identification of 2,3-disubstituted pyridines as potent, non-emetic PDE4 inhibitors.
AID704137Antiinflammatory activity in A/J mouse assessed as inhibition of LPS-induced airway resistance provoked by methacholine at 45 umol/kg, po administered 1 hr prior to LPS-challenge measured after 18 hrs relative to vehicle-treated control2012Journal of medicinal chemistry, Sep-13, Volume: 55, Issue:17
Design, synthesis, and pharmacological evaluation of N-acylhydrazones and novel conformationally constrained compounds as selective and potent orally active phosphodiesterase-4 inhibitors.
AID1420142Inhibition of PDE4 in human PBMC assessed as reduction in LPS-stimulated TNFalpha release preincubated for 30 mins followed by LPS stimulation for 18 hrs by TR-FRET assay2018Bioorganic & medicinal chemistry letters, 10-15, Volume: 28, Issue:19
Tetrahydroquinoline and tetrahydroisoquinoline derivatives as potential selective PDE4B inhibitors.
AID1187757Inhibition of PDE4A4 (unknown origin) at 10 uM2014Journal of medicinal chemistry, Aug-28, Volume: 57, Issue:16
Synthesis, biological evaluation, and molecular modeling of new 3-(cyclopentyloxy)-4-methoxybenzaldehyde O-(2-(2,6-dimethylmorpholino)-2-oxoethyl) Oxime (GEBR-7b) related phosphodiesterase 4D (PDE4D) inhibitors.
AID440702Inhibition of human recombinant PDE4D3 expressed in baculovirus system by IMAP assay2009Journal of medicinal chemistry, Nov-12, Volume: 52, Issue:21
New selective phosphodiesterase 4D inhibitors differently acting on long, short, and supershort isoforms.
AID702886Cytotoxicity against human MRC5 cells after 72 hrs by resazurin assay2012Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20
Catechol pyrazolinones as trypanocidals: fragment-based design, synthesis, and pharmacological evaluation of nanomolar inhibitors of trypanosomal phosphodiesterase B1.
AID318121Antiviral activity against HIV1 RF in CEM-SS cells assessed as inhibition of virus-induced cytopathic effect by XTT assay2008Bioorganic & medicinal chemistry letters, Feb-15, Volume: 18, Issue:4
Investigation of the alkenyldiarylmethane non-nucleoside reverse transcriptase inhibitors as potential cAMP phosphodiesterase-4B2 inhibitors.
AID184683Minimal effective dose in an rat anti-immobility effect using behavioral despair test1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
4-Amino[1,2,4]triazolo[4,3-a]quinoxalines. A novel class of potent adenosine receptor antagonists and potential rapid-onset antidepressants.
AID1157544Toxicity in Marshall ferret assessed as vomiting at 300 mg/kg, po after 2 hrs2014Bioorganic & medicinal chemistry letters, Jun-15, Volume: 24, Issue:12
Identification of 2,3-disubstituted pyridines as potent, non-emetic PDE4 inhibitors.
AID157924Inhibition of phosphodiesterase (PDE) 4D1998Bioorganic & medicinal chemistry letters, Nov-17, Volume: 8, Issue:22
N-arylrolipram derivatives as potent and selective PDE4 inhibitors.
AID1727188Hepatoprotective activity in ConA-induced BALB/c hepatitis mouse model assessed as decrease in serum alanine aminotransferase level at 10 mg/kg, ip administration and measured after 8 hrs relative to control2021European journal of medicinal chemistry, Jan-01, Volume: 209New imidazopyridines with phosphodiesterase 4 and 7 inhibitory activity and their efficacy in animal models of inflammatory and autoimmune diseases.
AID1272076Anti-inflammatory activity in human PBMC assessed as inhibition of LPS-induced TNFalpha expression at 10 uM after 5 hrs2016Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2
Analogues of boswellic acids as inhibitors of pro-inflammatory cytokines TNF-α and IL-6.
AID1773144Cell cycle arrest in human A549 cells assessed as S phase at 500 nM measured after 24 hrs by propidium iodide staining based flow cytometry analysis (Rvb = 14.78%)2021European journal of medicinal chemistry, Nov-15, Volume: 224Discovery of novel trimethoxyphenylbenzo[d]oxazoles as dual tubulin/PDE4 inhibitors capable of inducing apoptosis at G2/M phase arrest in glioma and lung cancer cells.
AID157918Inhibitory activity against Phosphodiesterase 4C (PDE4C) from human source expressed in Saccharomyces cerevisiae2000Journal of medicinal chemistry, Feb-24, Volume: 43, Issue:4
Palladium-catalyzed cross-coupling reactions for the synthesis of 6, 8-disubstituted 1,7-naphthyridines: a novel class of potent and selective phosphodiesterase type 4D inhibitors.
AID1372331Inhibition of LPS-induced TNF-alpha production in human MNC suspension after 20 hrs by radioimmunoassay2018Bioorganic & medicinal chemistry letters, 01-01, Volume: 28, Issue:1
Synthesis and in vitro evaluations of 6-(hetero)-aryl-imidazo[1,2-b]pyridazine-3-sulfonamide's as an inhibitor of TNF-α production.
AID77068In vivo bronchodilator effect on histamine-induced bronchospasm in anaesthetized guinea pigs at 10 ug intravenous dose1994Journal of medicinal chemistry, May-27, Volume: 37, Issue:11
Selective type IV phosphodiesterase inhibitors as antiasthmatic agents. The syntheses and biological activities of 3-(cyclopentyloxy)-4-methoxybenzamides and analogues.
AID1198119Inhibition of PDE4B (unknown origin) transfected into Sf9 cells at 10 uM by PDElight HTS cAMP phosphodiesterase assay2015Bioorganic & medicinal chemistry letters, Mar-01, Volume: 25, Issue:5
Design of new hybrid template by linking quinoline, triazole and dihydroquinoline pharmacophoric groups: A greener approach to novel polyazaheterocycles as cytotoxic agents.
AID1727197Antiinflammatory activity in LPS-induced Wistar rat endotoxemia model assessed as decrease in plasma TNFalpha level at 5 mg/kg, ip measured after 1 hr2021European journal of medicinal chemistry, Jan-01, Volume: 209New imidazopyridines with phosphodiesterase 4 and 7 inhibitory activity and their efficacy in animal models of inflammatory and autoimmune diseases.
AID160119Binding affinity towards rolipram binding site on phosphodiesterase 4 using [3H]rolipram as radioligand in crude rat brain homogenate2003Bioorganic & medicinal chemistry letters, Jul-21, Volume: 13, Issue:14
Improvement of therapeutic index of phosphodiesterase type IV inhibitors as anti-Asthmatics.
AID158457Inhibitory activity against Phosphodiesterase type IV (PDE4) obtained from guinea-pig macrophage was evaluated1998Bioorganic & medicinal chemistry letters, Jul-21, Volume: 8, Issue:14
The synthesis and biological evaluation of a novel series of indole PDE4 inhibitors I.
AID115570Percentage inhibition of serum TNF-alpha in lipopolysaccharide injected mice at 10 mg/kg peroral dose1995Journal of medicinal chemistry, Apr-28, Volume: 38, Issue:9
Phosphodiesterase type IV inhibition. Structure-activity relationships of 1,3-disubstituted pyrrolidines.
AID198611Inhibition of rolipram binding to rat brain tissue at 20 uM2000Bioorganic & medicinal chemistry letters, Sep-18, Volume: 10, Issue:18
7-Methoxybenzofuran-4-carboxamides as PDE 4 inhibitors: a potential treatment for asthma.
AID425874Inhibition of PDE4C1 at 10 uM2009Bioorganic & medicinal chemistry letters, Jul-01, Volume: 19, Issue:13
Exploration and optimization of substituted triazolothiadiazines and triazolopyridazines as PDE4 inhibitors.
AID1623101Cognition enhancement activity in amyloid beta (25 to 35 residues) induced C57BL/6J mouse model of Alzheimer's disease assessed as decrease in escape latancy at 4 mg/kg/day, ig administered for 26 consecutive days by Morris water maze test2019European journal of medicinal chemistry, Feb-01, Volume: 163Synthesis and evaluation of clioquinol-rolipram/roflumilast hybrids as multitarget-directed ligands for the treatment of Alzheimer's disease.
AID157785Inhibition of recombinant human Phosphodiesterase 4B1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
Striking effect of hydroxamic acid substitution on the phosphodiesterase type 4 (PDE4) and TNF alpha inhibitory activity of two series of rolipram analogues: implications for a new active site model of PDE4.
AID1353615Anti-inflammatory activity in human PBMC assessed as inhibition of LPS-induced TNFalpha production after 24 hrs by ELISA2018European journal of medicinal chemistry, Mar-10, Volume: 147Phenylpyridine-2-ylguanidines and rigid mimetics as novel inhibitors of TNFα overproduction: Beneficial action in models of neuropathic pain and of acute lung inflammation.
AID418770Antiinflammatory activity in human neutrophils assessed as inhibition of LPS-induced intracellular TNFalpha expression at 10 ug/mL after 3 hrs by flow cytometry2009Bioorganic & medicinal chemistry letters, Apr-01, Volume: 19, Issue:7
Semi-synthetic analogs of pinitol as potential inhibitors of TNF-alpha cytokine expression in human neutrophils.
AID425691Inhibition of PDE8A12009Bioorganic & medicinal chemistry letters, Jul-01, Volume: 19, Issue:13
Exploration and optimization of substituted triazolothiadiazines and triazolopyridazines as PDE4 inhibitors.
AID159793Inhibition of Phosphodiesterase 41996Journal of medicinal chemistry, Jan-05, Volume: 39, Issue:1
Biarylcarboxylic acids and -amides: inhibition of phosphodiesterase type IV versus [3H]rolipram binding activity and their relationship to emetic behavior in the ferret.
AID159961Inhibition of [3H]- rolipram binding to phosphodiesterase 4 of rat cerebral cortex membranes.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Calcium-independent phosphodiesterase inhibitors as putative antidepressants: [3-(bicycloalkyloxy)-4-methoxyphenyl]-2-imidazolidinones.
AID425680Inhibition of PDE2A2009Bioorganic & medicinal chemistry letters, Jul-01, Volume: 19, Issue:13
Exploration and optimization of substituted triazolothiadiazines and triazolopyridazines as PDE4 inhibitors.
AID349555Antiinflammatory activity in human PBMC assessed as inhibition of phytohemagglutininin-induced IFN-gamma release after 24 hrs by FACSArray analysis2009Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8
Discovery and structure-activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis.
AID440708Inhibition of human recombinant PDE4D1 expressed in baculovirus system by radiometric assay2009Journal of medicinal chemistry, Nov-12, Volume: 52, Issue:21
New selective phosphodiesterase 4D inhibitors differently acting on long, short, and supershort isoforms.
AID160103Inhibitory concentration against phosphodiesterase 4 (PDE4) from rat kidney2004Bioorganic & medicinal chemistry letters, Jun-07, Volume: 14, Issue:11
Identification of purine inhibitors of phosphodiesterase 7 (PDE7).
AID1480235Inhibition of recombinant human sEH using MNPC as substrate by fluorescence-based assay2018Journal of medicinal chemistry, 04-26, Volume: 61, Issue:8
Orally Available Soluble Epoxide Hydrolase/Phosphodiesterase 4 Dual Inhibitor Treats Inflammatory Pain.
AID260841Inhibition of Eotaxin mediated by human eosinophil chemotaxis2006Bioorganic & medicinal chemistry letters, Feb, Volume: 16, Issue:3
A new chemical tool for exploring the role of the PDE4D isozyme in leukocyte function.
AID160135Inhibition of phosphodiesterase 41998Bioorganic & medicinal chemistry letters, Oct-06, Volume: 8, Issue:19
Aryl sulfonamides as selective PDE4 inhibitors.
AID1420132Inhibition of human U937 cells-derived PDE4B using [3H]-cAMP as substrate measured after 30 mins2018Bioorganic & medicinal chemistry letters, 10-15, Volume: 28, Issue:19
Synthesis and bioactivity of 3,5-dimethylpyrazole derivatives as potential PDE4 inhibitors.
AID1261707Antioxidant activity assessed as trolox equivalent of AAPH radical scavenging activity preincubated for 10 mins followed by AAPH challenge measured every min for 120 mins by ORAC-FL assay2015Journal of medicinal chemistry, Nov-12, Volume: 58, Issue:21
Design, Synthesis, and Evaluation of Orally Available Clioquinol-Moracin M Hybrids as Multitarget-Directed Ligands for Cognitive Improvement in a Rat Model of Neurodegeneration in Alzheimer's Disease.
AID159067Inhibition of phosphodiesterase 2 (PDE2) from porcine platelets2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
4-(3-Chloro-4-methoxybenzyl)aminophthalazines: synthesis and inhibitory activity toward phosphodiesterase 5.
AID1160998Inhibition of human recombinant PDE4B1 activity assessed as residual cAMP concentration by HTRF assay2014Bioorganic & medicinal chemistry letters, Sep-15, Volume: 24, Issue:18
Novel Roflumilast analogs as soft PDE4 inhibitors.
AID1370515Cytotoxicity against human A549 cells assessed as cell viability at 1 uM by MTT assay relative to control2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Identification of novel small-molecule inhibitors of Zika virus infection.
AID363099Inhibition of human PDE4D4 in cytosolic fraction of lung2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Recent advances on phosphodiesterase 4 inhibitors for the treatment of asthma and chronic obstructive pulmonary disease.
AID1593012Inhibition of human N-terminal GST-tagged PDE4D7 (2 to 748 residues) expressed in baculovirus infected Sf9 cells using cAMP as substrate after 1 hr by fluorescence polarization assay2019European journal of medicinal chemistry, Apr-15, Volume: 168Discovery of arylbenzylamines as PDE4 inhibitors with potential neuroprotective effect.
AID473492Antiinflammatory activity in mouse assessed as inhibition of phorbol ester-induced ear edema at 3 mg/ear2010Bioorganic & medicinal chemistry letters, Apr-01, Volume: 20, Issue:7
Design and synthesis of boron-containing PDE4 inhibitors using soft-drug strategy for potential dermatologic anti-inflammatory application.
AID1370514Cytotoxicity against human A549 cells assessed as cell viability at 0.1 uM by MTT assay relative to control2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Identification of novel small-molecule inhibitors of Zika virus infection.
AID1743664Inhibition of human U-937 cells derived PDE4D using [3H] cAMP as substrate measured after 30 mins2020European journal of medicinal chemistry, Dec-01, Volume: 207Synthesis and bioactivity of phenyl substituted furan and oxazole carboxylic acid derivatives as potential PDE4 inhibitors.
AID1623076Inhibition of human PDE4D2 (86 to 413 residues) catalytic domain using [3H]-cAMP as substrate after 15 mins by liquid scintillation counting method2019European journal of medicinal chemistry, Feb-01, Volume: 163Synthesis and evaluation of clioquinol-rolipram/roflumilast hybrids as multitarget-directed ligands for the treatment of Alzheimer's disease.
AID1543154Inhibition of PDE4D2 (unknown origin) by preincubated for 30 mins before substrate addition and measured after 60 mins by IMAP TR-FRET phosphodiesterase evaluation assay
AID159490Inhibition of Phosphodiesterase 31997Journal of medicinal chemistry, Jun-06, Volume: 40, Issue:12
9-Benzyladenines: potent and selective cAMP phosphodiesterase inhibitors.
AID349553Antiinflammatory activity in human PBMC assessed as inhibition of phytohemagglutininin-induced IL2 release after 24 hrs by FACS Array analysis2009Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8
Discovery and structure-activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis.
AID704144Antiinflammatory activity in A/J mouse assessed as inhibition of leukocyte accumulation in bronchoalveolar space at 45 umol/kg, po administered 1 hr prior to LPS-challenge measured after 18 hrs relative to vehicle-treated control2012Journal of medicinal chemistry, Sep-13, Volume: 55, Issue:17
Design, synthesis, and pharmacological evaluation of N-acylhydrazones and novel conformationally constrained compounds as selective and potent orally active phosphodiesterase-4 inhibitors.
AID158465Evaluated in vitro for its inhibitory activity on human monocyte cytosol Phosphodiesterase type 4 (PDE4).1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
Striking effect of hydroxamic acid substitution on the phosphodiesterase type 4 (PDE4) and TNF alpha inhibitory activity of two series of rolipram analogues: implications for a new active site model of PDE4.
AID1427215Inhibition of human U937 cells-derived PDE4D using [3H]cAMP as substrate after 30 mins
AID704148Antiinflammatory activity in A/J mouse lung assessed as inhibition of LPS-induced TNFalpha production at 45 umol/kg, po administered 1 hr prior to LPS-challenge measured after 18 hrs relative to vehicle-treated control2012Journal of medicinal chemistry, Sep-13, Volume: 55, Issue:17
Design, synthesis, and pharmacological evaluation of N-acylhydrazones and novel conformationally constrained compounds as selective and potent orally active phosphodiesterase-4 inhibitors.
AID425681Inhibition of PDE3A2009Bioorganic & medicinal chemistry letters, Jul-01, Volume: 19, Issue:13
Exploration and optimization of substituted triazolothiadiazines and triazolopyridazines as PDE4 inhibitors.
AID75783In vivo bronchodilator effect on histamine-induced bronchospasm in anaesthetized guinea pigs at 50 ug intravenous dose1994Journal of medicinal chemistry, May-27, Volume: 37, Issue:11
Selective type IV phosphodiesterase inhibitors as antiasthmatic agents. The syntheses and biological activities of 3-(cyclopentyloxy)-4-methoxybenzamides and analogues.
AID1773166Induction of apoptosis in human A549 cells assessed as increase in necrotic cells at 500 nM measured after 24 hrs by PI/FITC analysis (Rvb = 0.365%)2021European journal of medicinal chemistry, Nov-15, Volume: 224Discovery of novel trimethoxyphenylbenzo[d]oxazoles as dual tubulin/PDE4 inhibitors capable of inducing apoptosis at G2/M phase arrest in glioma and lung cancer cells.
AID215076TNF-alpha production in PBMC by ELISA method1996Journal of medicinal chemistry, Jan-05, Volume: 39, Issue:1
Substituted xanthines, pteridinediones, and related compounds as potential antiinflammatory agents. Synthesis and biological evaluation of inhibitors of tumor necrosis factor alpha.
AID1421679Inhibition of recombinant human PDE7A using cAMP as substrate after 10 mins by PDE-Glo Phosphodiesterase Assay2018European journal of medicinal chemistry, Oct-05, Volume: 158Novel amide derivatives of 1,3-dimethyl-2,6-dioxopurin-7-yl-alkylcarboxylic acids as multifunctional TRPA1 antagonists and PDE4/7 inhibitors: A new approach for the treatment of pain.
AID1623112Cognition enhancement activity in amyloid beta (25 to 35 residues) induced C57BL/6J mouse model of Alzheimer's disease assessed as swimming time in effective region at 4 mg/kg/day, ig administered for 26 consecutive days by Morris water maze test (4.3 +/-2019European journal of medicinal chemistry, Feb-01, Volume: 163Synthesis and evaluation of clioquinol-rolipram/roflumilast hybrids as multitarget-directed ligands for the treatment of Alzheimer's disease.
AID1545627Inhibition of human recombinant full length N-terminal GST-tagged PDE4B1 expressed in baculovirus infected Sf9 cells at 10'-5 M using cAMP as substrate incubated for 20 mins followed by substrate addition by luciferase assay relative to control2019Bioorganic & medicinal chemistry, 09-15, Volume: 27, Issue:18
Novel multitarget 5-arylidenehydantoins with arylpiperazinealkyl fragment: Pharmacological evaluation and investigation of cytotoxicity and metabolic stability.
AID440711Selectivity ratio of Ki for human PDE4D1 to Ki for human PDE4D32009Journal of medicinal chemistry, Nov-12, Volume: 52, Issue:21
New selective phosphodiesterase 4D inhibitors differently acting on long, short, and supershort isoforms.
AID260836Inhibition of release of LTE4 in human whole blood2006Bioorganic & medicinal chemistry letters, Feb, Volume: 16, Issue:3
A new chemical tool for exploring the role of the PDE4D isozyme in leukocyte function.
AID650863Inhibition of PDE4B expressed in HEK293 cells assessed as fold reduction in forskolin-stimulated cAMP production pretreated for 30 mins measured 4 hrs after forskolin challenge by luciferase reporter gene assay2012Bioorganic & medicinal chemistry, Apr-01, Volume: 20, Issue:7
C-C bond formation at C-2 of a quinoline ring: synthesis of 2-(1H-indol-3-yl)quinoline-3-carbonitrile derivatives as a new class of PDE4 inhibitors.
AID425678Inhibition of PDE1B2009Bioorganic & medicinal chemistry letters, Jul-01, Volume: 19, Issue:13
Exploration and optimization of substituted triazolothiadiazines and triazolopyridazines as PDE4 inhibitors.
AID1351564Inhibition of human PDE4D2 catalytic domain (86 to 413 residues) expressed in Escherichia coli strain BL21 using [3H]cAMP as substrate after 15 mins by liquid scintillation counter analysis2018European journal of medicinal chemistry, Jan-20, Volume: 144Prenylated flavonoids as potent phosphodiesterase-4 inhibitors from Morus alba: Isolation, modification, and structure-activity relationship study.
AID1480257Decrease in self-motivated exploration of LPS-induced Sprague-Dawley rat inflammatory pain model at 3 mg/kg administered via oral gavage measured after 1 hr by open field assay2018Journal of medicinal chemistry, 04-26, Volume: 61, Issue:8
Orally Available Soluble Epoxide Hydrolase/Phosphodiesterase 4 Dual Inhibitor Treats Inflammatory Pain.
AID1773137Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay2021European journal of medicinal chemistry, Nov-15, Volume: 224Discovery of novel trimethoxyphenylbenzo[d]oxazoles as dual tubulin/PDE4 inhibitors capable of inducing apoptosis at G2/M phase arrest in glioma and lung cancer cells.
AID766610Inhibition of Hartley guinea pig eosinophil PDE4 assessed as cAMP hydrolysis by two-step radioisotope method2013Bioorganic & medicinal chemistry, Sep-15, Volume: 21, Issue:18
Identification of 2,3-disubstituted pyridines as potent, orally active PDE4 inhibitors.
AID159214In vitro inhibition of Phosphodiesterase 3 activity from guinea pig cardiac ventricle1999Journal of medicinal chemistry, Mar-25, Volume: 42, Issue:6
Novel, potent, and selective phosphodiesterase-4 inhibitors as antiasthmatic agents: synthesis and biological activities of a series of 1-pyridylnaphthalene derivatives.
AID78148Inhibition of superoxide O2-generation from guinea pig peritoneal eosinophils1994Journal of medicinal chemistry, May-27, Volume: 37, Issue:11
Selective type IV phosphodiesterase inhibitors as antiasthmatic agents. The syntheses and biological activities of 3-(cyclopentyloxy)-4-methoxybenzamides and analogues.
AID1727190Hepatoprotective activity in ConA-induced BALB/c hepatitis mouse model assessed as decrease in serum IL-6 level at 50 mg/kg, ip administration and measured after 8 hrs relative to control2021European journal of medicinal chemistry, Jan-01, Volume: 209New imidazopyridines with phosphodiesterase 4 and 7 inhibitory activity and their efficacy in animal models of inflammatory and autoimmune diseases.
AID159810Inhibition of cAMP hydrolysis by human Phosphodiesterase 41995Journal of medicinal chemistry, Dec-22, Volume: 38, Issue:26
Introduction of a conformational switching element on a pyrrolidine ring. Synthesis and evaluation of (R*,R*)-(+/-)-methyl 3-acetyl-4-[3- (cyclopentyloxy)-4-methoxyphenyl]-3-methyl-1-pyrrolidinecarboxylate, a potent and selective inhibitor of cAMP-specifi
AID155790Inhibition of anti-CD3 induced IL-4 release by human peripheral blood mononuclear cells.1998Bioorganic & medicinal chemistry letters, Nov-17, Volume: 8, Issue:22
N-arylrolipram derivatives as potent and selective PDE4 inhibitors.
AID45803Inhibition of phosphodiesterase 4 from guinea pig lung1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Structure-activity relationship of quinazolinedione inhibitors of calcium-independent phosphodiesterase.
AID159648Displacement of [3H]- rolipram binding to guinea pig brain1999Journal of medicinal chemistry, Mar-25, Volume: 42, Issue:6
Novel, potent, and selective phosphodiesterase-4 inhibitors as antiasthmatic agents: synthesis and biological activities of a series of 1-pyridylnaphthalene derivatives.
AID260824Inhibition of PDE4B2006Bioorganic & medicinal chemistry letters, Feb, Volume: 16, Issue:3
A new chemical tool for exploring the role of the PDE4D isozyme in leukocyte function.
AID260829Inhibition of PDE8B2006Bioorganic & medicinal chemistry letters, Feb, Volume: 16, Issue:3
A new chemical tool for exploring the role of the PDE4D isozyme in leukocyte function.
AID662986Inhibition of rabbit corpus cavernosum PDE62012Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
Identification of chalcones as potent and selective PDE5A1 inhibitors.
AID1177596Inhibition of human PDE4D2 catalytic domain (86 to 413 amino acids) expressed in Escherichia coli strain BL21 after 15 mins using [3H]-cAMP by liquid scintillation counting2014Journal of natural products, Aug-22, Volume: 77, Issue:8
Prostaglandin Derivatives: Nonaromatic Phosphodiesterase-4 Inhibitors from the Soft Coral Sarcophyton ehrenbergi.
AID1727198Antiinflammatory activity in LPS-induced Wistar rat endotoxemia model assessed as decrease in plasma TNFalpha level at 5 mg/kg, ip measured after 1.5 hr2021European journal of medicinal chemistry, Jan-01, Volume: 209New imidazopyridines with phosphodiesterase 4 and 7 inhibitory activity and their efficacy in animal models of inflammatory and autoimmune diseases.
AID702890Inhibition of Trypanosoma brucei recombinant TbrPDEB1 expressed in Sf21 insect cells assessed as reduction of [3H]-cAMP hydrolysis by scintillation proximity assay2012Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20
Catechol pyrazolinones as trypanocidals: fragment-based design, synthesis, and pharmacological evaluation of nanomolar inhibitors of trypanosomal phosphodiesterase B1.
AID157758Inhibition of rolipram binding to phosphodiesterase 42003Bioorganic & medicinal chemistry letters, Jul-21, Volume: 13, Issue:14
Synthesis and biological activities of 1-pyridylisoquinoline and 1-pyridyldihydroisoquinoline derivatives as PDE4 inhibitors.
AID110206Inhibition of LPS-induced TNF-alpha production in mice after 30 min peroral dose2003Bioorganic & medicinal chemistry letters, Jul-21, Volume: 13, Issue:14
Synthesis and biological activities of 1-pyridylisoquinoline and 1-pyridyldihydroisoquinoline derivatives as PDE4 inhibitors.
AID77844Change in heart rate in guinea pigs after 1 mg/kg intravenous dose1996Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14
Novel selective PDE IV inhibitors as antiasthmatic agents. Synthesis and biological activities of a series of 1-aryl-2,3-bis(hydroxymethyl)naphthalene lignans.
AID363097Inhibition of human PDE4D3 in cytosolic fraction of lung2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Recent advances on phosphodiesterase 4 inhibitors for the treatment of asthma and chronic obstructive pulmonary disease.
AID1703894Vasorelaxant activity in non-sensitized guinea pig-derived trachea assessed as decrease in CCh-induced tracheal tonic contraction in absence of functional epithelium treated with compound after contraction stabilised2020European journal of medicinal chemistry, Oct-15, Volume: 204Discovery of sulfonyl hydrazone derivative as a new selective PDE4A and PDE4D inhibitor by lead-optimization approach on the prototype LASSBio-448: In vitro and in vivo preclinical studies.
AID425684Inhibition of PDE4B12009Bioorganic & medicinal chemistry letters, Jul-01, Volume: 19, Issue:13
Exploration and optimization of substituted triazolothiadiazines and triazolopyridazines as PDE4 inhibitors.
AID117193Evaluated for antiinflammatory activity in the TPA induced ear inflammation model at a dose 1 mg/kg (25 ug)2002Bioorganic & medicinal chemistry letters, Feb-25, Volume: 12, Issue:4
Synthesis and biological evaluation of imidazol-2-one and 2-cyanoiminoimidazole derivatives: novel series of PDE4 inhibitors.
AID389802Inhibition of LPS-induced TNFalpha production in human PBMC2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Design, synthesis, and structure-activity relationship, molecular modeling, and NMR studies of a series of phenyl alkyl ketones as highly potent and selective phosphodiesterase-4 inhibitors.
AID155791Inhibition of anti-CD3 induced T-cell proliferation in human peripheral blood mononuclear cells.1998Bioorganic & medicinal chemistry letters, Nov-17, Volume: 8, Issue:22
N-arylrolipram derivatives as potent and selective PDE4 inhibitors.
AID159065Inhibition of cGMP hydrolysis by human Phosphodiesterase 21995Journal of medicinal chemistry, Apr-28, Volume: 38, Issue:9
Phosphodiesterase type IV inhibition. Structure-activity relationships of 1,3-disubstituted pyrrolidines.
AID152781Inhibitory concentration against TNF-alpha production from human peripheral blood mononuclear cells stimulated by LPS2001Bioorganic & medicinal chemistry letters, Feb-26, Volume: 11, Issue:4
Structure-activity relationships of quinazoline derivatives: dual-acting compounds with inhibitory activities toward both TNF-alpha production and T cell proliferation.
AID1231637Toxicity in mouse assessed as sedative effect by measuring reduction of total distance traveled at 10 mg/kg, po measured over 60 mins by open-field test2015Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13
Synthesis, biological activities and pharmacokinetic properties of new fluorinated derivatives of selective PDE4D inhibitors.
AID1381682Inhibition of human GST-tagged PDE7A expressed in baculovirus infected Sf9 insect cells using cAMP as substrate after 10 mins by PDE-Glo Phosphodiesterase Assay2018European journal of medicinal chemistry, Feb-25, Volume: 146Novel butanehydrazide derivatives of purine-2,6-dione as dual PDE4/7 inhibitors with potential anti-inflammatory activity: Design, synthesis and biological evaluation.
AID1623077Antioxidant activity assessed as trolox equivalent of AAPH-induced radical scavenging activity at 10 to 20 uM preincubated for 10 mins followed by AAPH addition measured every minute for 120 mins by ORAC fluorescein assay2019European journal of medicinal chemistry, Feb-01, Volume: 163Synthesis and evaluation of clioquinol-rolipram/roflumilast hybrids as multitarget-directed ligands for the treatment of Alzheimer's disease.
AID1187755Inhibition of PDE4D2 (unknown origin) at 10 uM2014Journal of medicinal chemistry, Aug-28, Volume: 57, Issue:16
Synthesis, biological evaluation, and molecular modeling of new 3-(cyclopentyloxy)-4-methoxybenzaldehyde O-(2-(2,6-dimethylmorpholino)-2-oxoethyl) Oxime (GEBR-7b) related phosphodiesterase 4D (PDE4D) inhibitors.
AID156982Inhibition of cAMP PDE from canine brain1993Journal of medicinal chemistry, Apr-16, Volume: 36, Issue:8
(Imidazolylphenyl)pyrrol-2-one inhibitors of cardiac cAMP phosphodiesterase.
AID662985Inhibition of bovine platelet PDE52012Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
Identification of chalcones as potent and selective PDE5A1 inhibitors.
AID1773142Cell cycle arrest in human A549 cells assessed as G0/G1 phase at 500 nM incubated for 24 hrs by propidium iodide staining based flow cytometry analysis (Rvb = 79.14%)2021European journal of medicinal chemistry, Nov-15, Volume: 224Discovery of novel trimethoxyphenylbenzo[d]oxazoles as dual tubulin/PDE4 inhibitors capable of inducing apoptosis at G2/M phase arrest in glioma and lung cancer cells.
AID1783046Inhibition of TNF-alpha (unknown origin) at 0.1 uM relative to control2021European journal of medicinal chemistry, Oct-05, Volume: 221PdCl
AID1724983Effect on TNFalpha production in C57BL/6 mouse bone marrow derived Macrophage at 1 to 10 uM incubated for 30 mins by ELISA2020ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10
Synthesis and SAR Studies of 1
AID78168Eosinophil infiltration in passively-sensitized guinea pig at 30 mg/kg peroral dose 90 min prior to challenge2003Bioorganic & medicinal chemistry letters, Jul-21, Volume: 13, Issue:14
Improvement of therapeutic index of phosphodiesterase type IV inhibitors as anti-Asthmatics.
AID704134Antiinflammatory activity in A/J mouse assessed as inhibition of LPS-induced airway elastance provoked by methacholine at 45 umol/kg, po administered 1 hr prior to LPS-challenge measured after 18 hrs relative to vehicle-treated control2012Journal of medicinal chemistry, Sep-13, Volume: 55, Issue:17
Design, synthesis, and pharmacological evaluation of N-acylhydrazones and novel conformationally constrained compounds as selective and potent orally active phosphodiesterase-4 inhibitors.
AID210147In vitro inhibition of TNF-alpha release from human peripheral blood monocytes2000Journal of medicinal chemistry, Dec-14, Volume: 43, Issue:25
Synthesis, structure-activity relationships, and pharmacological profile of 9-amino-4-oxo-1-phenyl-3,4,6,7-tetrahydro[1,4]diazepino[6, 7,1-hi]indoles: discovery of potent, selective phosphodiesterase type 4 inhibitors.
AID260840Inhibition of PAF mediated human eosinophil chemotaxis2006Bioorganic & medicinal chemistry letters, Feb, Volume: 16, Issue:3
A new chemical tool for exploring the role of the PDE4D isozyme in leukocyte function.
AID1421678Inhibition of recombinant human PDE4B using cAMP as substrate after 10 mins by PDE-Glo Phosphodiesterase Assay2018European journal of medicinal chemistry, Oct-05, Volume: 158Novel amide derivatives of 1,3-dimethyl-2,6-dioxopurin-7-yl-alkylcarboxylic acids as multifunctional TRPA1 antagonists and PDE4/7 inhibitors: A new approach for the treatment of pain.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1797296Phosphodiesterase (PDE) Inhibition Assay from Article 10.1016/j.str.2004.10.004: \\Structural basis for the activity of drugs that inhibit phosphodiesterases.\\2004Structure (London, England : 1993), Dec, Volume: 12, Issue:12
Structural basis for the activity of drugs that inhibit phosphodiesterases.
AID1797212PDE Activity Assay from Article 10.1021/jm030603w: \\8-Substituted analogues of 3-(3-cyclopentyloxy-4-methoxy-benzyl)-8-isopropyladenine: highly potent and selective PDE4 inhibitors.\\2005Journal of medicinal chemistry, Feb-24, Volume: 48, Issue:4
8-Substituted analogues of 3-(3-cyclopentyloxy-4-methoxy-benzyl)-8-isopropyl-adenine: highly potent and selective PDE4 inhibitors.
AID1799753Enzymatic Assay from Article 10.1074/jbc.M111.326777: \\Biological and structural characterization of Trypanosoma cruzi phosphodiesterase C and Implications for design of parasite selective inhibitors.\\2012The Journal of biological chemistry, Apr-06, Volume: 287, Issue:15
Biological and structural characterization of Trypanosoma cruzi phosphodiesterase C and Implications for design of parasite selective inhibitors.
AID1799063PDE4 Enzyme Assay from Article 10.1021/jm8010993: \\Dual inhibitors of phosphodiesterase-4 and serotonin reuptake.\\2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
Dual inhibitors of phosphodiesterase-4 and serotonin reuptake.
AID1345234Human phosphodiesterase 4B (Phosphodiesterases, 3',5'-cyclic nucleotide (PDEs))1997Biochemical and biophysical research communications, May-19, Volume: 234, Issue:2
Expression, purification, and characterization of human cAMP-specific phosphodiesterase (PDE4) subtypes A, B, C, and D.
AID1345251Human phosphodiesterase 4A (Phosphodiesterases, 3',5'-cyclic nucleotide (PDEs))1997Biochemical and biophysical research communications, May-19, Volume: 234, Issue:2
Expression, purification, and characterization of human cAMP-specific phosphodiesterase (PDE4) subtypes A, B, C, and D.
AID1345281Human phosphodiesterase 4C (Phosphodiesterases, 3',5'-cyclic nucleotide (PDEs))1997Biochemical and biophysical research communications, May-19, Volume: 234, Issue:2
Expression, purification, and characterization of human cAMP-specific phosphodiesterase (PDE4) subtypes A, B, C, and D.
AID1345239Human phosphodiesterase 4D (Phosphodiesterases, 3',5'-cyclic nucleotide (PDEs))1997Biochemical and biophysical research communications, May-19, Volume: 234, Issue:2
Expression, purification, and characterization of human cAMP-specific phosphodiesterase (PDE4) subtypes A, B, C, and D.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,590)

TimeframeStudies, This Drug (%)All Drugs %
pre-199087 (5.47)18.7374
1990's494 (31.07)18.2507
2000's552 (34.72)29.6817
2010's380 (23.90)24.3611
2020's77 (4.84)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials17 (1.06%)5.53%
Reviews0 (0.00%)6.00%
Reviews38 (2.37%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies2 (0.12%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other26 (100.00%)84.16%
Other1,547 (96.45%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (6)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Antidepressant Effects on cAMP Specific Phosphodiesterase (PDE 4) in Depressed Patients[NCT00369798]Phase 1100 participants (Actual)Interventional2006-08-02Completed
PET Imaging of Phosphodiesterase-4 (PDE4) in Brain and Peripheral Organs of Mccune-Albright Syndrome[NCT02743377]Phase 1/Phase 216 participants (Actual)Interventional2018-04-04Completed
An Open Label Positron Emission Tomography Study in Healthy Male Subjects to Investigate Brain PDE4 Engagement, Pharmacokinetics and Safety of Single Oral Doses of GSK356278, Using 11C-(R)-Rolipram as a PET Ligand(s)[NCT01602900]Phase 18 participants (Actual)Interventional2011-11-22Completed
Safety, Tolerability & Effects of Rolipram on Inflammatory Activity in the Central Nervous System in Multiple Sclerosis. A Phase II, Open Label Crossover Trial Using MRI as an Outcome Measure[NCT00011375]Phase 252 participants Interventional2001-02-28Completed
PET Whole Body Biodistribution and Test Retest Brain Imaging Studies Using a Phosphodiesterase 4 Inhibitor (R)-[11C]Rolipram[NCT00250172]Phase 126 participants (Actual)Interventional2005-10-31Completed
[11C]-(R)-Rolipram to Measure cAMP Signaling Before and After Ketamine[NCT05522673]Phase 135 participants (Anticipated)Interventional2023-02-08Enrolling by invitation
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

MAS Affected Bone SUV AUC(60-120min) - Blocked

To assess whether uptake in dysplastic bone reflects parent radioligand binding to the enzyme or merely accumulation of radiometabolites (NCT02743377)
Timeframe: 120 minutes

InterventionSUV x min (Mean)
Subjects With McCune-Albright Syndrome (MAS)11.1

MAS Affected Bone SUV AUC(60-120min) - for Baseline and Blocked Subjects With MAS

Determine if PDE4 levels are different in areas of fibrous dysplasia as compared to unaffected bones in patients with MAS (NCT02743377)
Timeframe: 120 minutes

InterventionSUV x min (Mean)
Subjects With McCune-Albright Syndrome (MAS)13.5

MAS Affected Bone SUV AUC(60-120min) at Baseline

To assess whether uptake in dysplastic bone reflects parent radioligand binding to the enzyme or merely accumulation of radiometabolites (NCT02743377)
Timeframe: 120 minutes

InterventionSUV x min (Mean)
Subjects With McCune-Albright Syndrome (MAS)11.2

Normal Bone SUV AUC (60-120min) - for Healthy Controls

Determine if PDE4 levels are different in areas of fibrous dysplasia as compared to unaffected bones in patients with MAS (NCT02743377)
Timeframe: 120 minutes after the start of the scan

InterventionSUV x min (Mean)
Healthy Control4.2

Standard UptakeValue (SUV) Area Under the Curve (AUC) (30-120min) - Bladder

Determine if there is a difference in PDE4 levels (measured using [11C]rolipram) in the periphery of patients with McCune-Albright Syndrome (MAS) compared to healthy controls. (NCT02743377)
Timeframe: 120 minutes

InterventionSUV x min (Mean)
Healthy Control575.1
Subjects With McCune-Albright Syndrome (MAS)650.8

Standard UptakeValue (SUV) Area Under the Curve (AUC) (30-120min) - Heart

Determine if there is a difference in PDE4 levels (measured using [11C]rolipram) in the periphery of patients with McCune-Albright Syndrome (MAS) compared to healthy controls. (NCT02743377)
Timeframe: 120 minutes

InterventionSUV x min (Mean)
Healthy Control27.4
Subjects With McCune-Albright Syndrome (MAS)25.4

Standard UptakeValue (SUV) Area Under the Curve (AUC) (30-120min) - Kidneys

Determine if there is a difference in PDE4 levels (measured using [11C]rolipram) in the periphery of patients with McCune-Albright Syndrome (MAS) compared to healthy controls. (NCT02743377)
Timeframe: 120 minutes

InterventionSUV x min (Mean)
Healthy Control63.3
Subjects With McCune-Albright Syndrome (MAS)80.4

Standard UptakeValue (SUV) Area Under the Curve (AUC) (30-120min) - Liver

Determine if there is a difference in PDE4 levels (measured using [11C]rolipram) in the periphery of patients with McCune-Albright Syndrome (MAS) compared to healthy controls (NCT02743377)
Timeframe: 120 minutes

InterventionSUV x min (Mean)
Healthy Control47.6
Subjects With McCune-Albright Syndrome (MAS)52.4

Standard UptakeValue (SUV) Area Under the Curve (AUC) (30-120min) - Lungs

Determine if there is a difference in PDE4 levels (measured using [11C]rolipram) in the periphery of patients with McCune-Albright Syndrome (MAS) compared to healthy controls (NCT02743377)
Timeframe: 120 minutes

InterventionSUV x min (Mean)
Healthy Control10.2
Subjects With McCune-Albright Syndrome (MAS)9.6

Standard UptakeValue (SUV) Area Under the Curve (AUC) (30-120min) - Stomach

Determine if there is a difference in PDE4 levels (measured using [11C]rolipram) in the periphery of patients with McCune-Albright Syndrome (MAS) compared to healthy controls (NCT02743377)
Timeframe: 120 minutes

InterventionSUV x min (Mean)
Healthy Control39.4
Subjects With McCune-Albright Syndrome (MAS)34.1

Standard UptakeValue (SUV) Area Under the Curve (AUC) (30-120min) -Gallbladder

Determine if there is a difference in PDE4 levels (measured using [11C]rolipram) in the periphery of patients with McCune-Albright Syndrome (MAS) compared to healthy controls. (NCT02743377)
Timeframe: 120 minutes

InterventionSUV x min (Mean)
Healthy Control581.2
Subjects With McCune-Albright Syndrome (MAS)417.9

Standard UptakeValue (SUV) Area Under the Curve (AUC) (30-120min) -Spleen

Determine if there is a difference in PDE4 levels (measured using [11C]rolipram) in the periphery of patients with McCune-Albright Syndrome (MAS) compared to healthy controls (NCT02743377)
Timeframe: 120 minutes

InterventionSUV x min (Mean)
Healthy Control20.1
Subjects With McCune-Albright Syndrome (MAS)18.7

Whole Brain Total Distribution Volume (VT)

Determine if there is a difference in PDE4 levels (measured using [11C]rolipram) in the brain of patients with McCune-Albright Syndrome (MAS) compared to healthy controls (NCT02743377)
Timeframe: 90 minutes

InterventionmL x cm-3 (Mean)
Healthy Control0.67
Subjects With McCune-Albright Syndrome (MAS)0.52

SubstanceDescriptionRelationhip StrengthStudiesTrialsClassesRoles
(+)-rolipram[no description available]medium50rolipram
cilomilast[no description available]medium70methoxybenzenes
2,5-diphenylfuran[no description available]medium10diphenylfuran
cdp 840[no description available]medium10
nevirapine[no description available]medium10cyclopropanes;
dipyridodiazepine		antiviral drug;
HIV-1 reverse transcriptase inhibitor
efavirenz[no description available]medium10acetylenic compound;
benzoxazine;
cyclopropanes;
organochlorine compound;
organofluorine compound		antiviral drug;
HIV-1 reverse transcriptase inhibitor
rolipram[no description available]medium50pyrrolidin-2-onesantidepressant;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor
rp 73401[no description available]medium20aromatic ether;
benzamides;
chloropyridine;
monocarboxylic acid amide		anti-asthmatic drug;
anti-inflammatory agent;
bronchodilator agent;
phosphodiesterase IV inhibitor
roflumilast[no description available]medium60aromatic ether;
benzamides;
chloropyridine;
cyclopropanes;
organofluorine compound		anti-asthmatic drug;
phosphodiesterase IV inhibitor
gsk 256066[no description available]medium10
rs 25344[no description available]medium30
ibudilast[no description available]medium10pyrazolopyridine
4-(3-butoxy-4-methoxybenzyl)-2-imidazolidinone[no description available]medium10methoxybenzenes
cipamfylline[no description available]medium10oxopurine
rs 14203[no description available]medium10
isoproterenol[no description available]medium30catechols;
secondary alcohol;
secondary amino compound		beta-adrenergic agonist;
bronchodilator agent;
cardiotonic drug;
sympathomimetic agent
1-hydroxyphthalazine[no description available]medium10phthalazines
arformoterol[no description available]medium10N-[2-hydroxy-5-(1-hydroxy-2-{[1-(4-methoxyphenyl)propan-2-yl]amino}ethyl)phenyl]formamideanti-asthmatic drug;
beta-adrenergic agonist;
bronchodilator agent
1-methyl-3-isobutylxanthine[no description available]medium103-isobutyl-1-methylxanthine
papaverine[no description available]medium10benzylisoquinoline alkaloid;
dimethoxybenzene;
isoquinolines		antispasmodic drug;
vasodilator agent
pentoxifylline[no description available]medium10oxopurine
zardaverine[no description available]medium10organofluorine compound;
pyridazinone		anti-asthmatic drug;
bronchodilator agent;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
peripheral nervous system drug
5-nitroquinoline[no description available]medium10
2-amino-4,6-dimethyl pyrimidine[no description available]medium10aminopyrimidine
5-nitroindazole[no description available]medium10
7-chloro-4-hydroxyquinoline[no description available]medium10
9-(2-hydroxy-3-nonyl)adenine[no description available]medium10EHNAEC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
EC 3.5.4.4 (adenosine deaminase) inhibitor
2-amino-4-methyl-3-nitropyridine[no description available]medium10
mesopram[no description available]medium20
cyclic nucleotide phosphodiesterases, type 4[no description available]medium10
baohuoside i[no description available]medium10glycosyloxyflavoneanti-inflammatory agent;
antineoplastic agent;
apoptosis inducer;
plant metabolite
sildenafil[no description available]medium10piperazines;
pyrazolopyrimidine;
sulfonamide		EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor;
vasodilator agent
2-methyl-4(3h)-quinazolinone[no description available]medium10
4-hydroxyquinazoline[no description available]medium10quinazolines
bay 73-6691[no description available]medium10
bay 60-7550[no description available]medium10
n-methylpyrrolidone[no description available]medium10lactam;
N-alkylpyrrolidine;
pyrrolidin-2-ones		polar aprotic solvent
zm 241385[no description available]medium10diamino-1,3,5-triazine
2-(2-furanyl)-7-(2-(4-(4-(2-methoxyethoxy)phenyl)-1-piperazinyl)ethyl)-7h-pyrazolo(4,3-e)(1,2,4)triazolo(1,5-c)pyrimidine-5-amine[no description available]medium10
sch 442416[no description available]medium10triazolopyrimidines
psb603[no description available]medium10
apremilast[no description available]medium10aromatic ether;
N-acetylarylamine;
phthalimides;
sulfone		non-steroidal anti-inflammatory drug;
phosphodiesterase IV inhibitor
theophylline[no description available]high780dimethylxanthineadenosine receptor antagonist;
anti-asthmatic drug;
anti-inflammatory agent;
bronchodilator agent;
drug metabolite;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
fungal metabolite;
human blood serum metabolite;
immunomodulator;
muscle relaxant;
vasodilator agent
aminophylline[no description available]medium130mixturebronchodilator agent;
cardiotonic drug
4-(3-butoxy-4-methoxybenzyl)-2-imidazolidinone[no description available]medium680methoxybenzenes
nitraquazone[no description available]medium50
caffeine[no description available]high220purine alkaloid;
trimethylxanthine		adenosine A2A receptor antagonist;
adenosine receptor antagonist;
adjuvant;
central nervous system stimulant;
diuretic;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
environmental contaminant;
food additive;
fungal metabolite;
geroprotector;
human blood serum metabolite;
mouse metabolite;
mutagen;
plant metabolite;
psychotropic drug;
ryanodine receptor agonist;
xenobiotic
cgs 15943[no description available]medium40aromatic amine;
biaryl;
furans;
organochlorine compound;
primary amino compound;
quinazolines;
triazoloquinazoline		adenosine A1 receptor antagonist;
adenosine A2A receptor antagonist;
antineoplastic agent;
central nervous system stimulant
imipramine[no description available]high173dibenzoazepineadrenergic uptake inhibitor;
antidepressant;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor
imipramine[no description available]high170dibenzoazepineadrenergic uptake inhibitor;
antidepressant;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor
1-methyl-3-isobutylxanthine[no description available]medium10503-isobutyl-1-methylxanthine
1-methyl-3-isobutylxanthine[no description available]medium10513-isobutyl-1-methylxanthine
adenosine[no description available]medium490adenosines;
purines D-ribonucleoside		analgesic;
anti-arrhythmia drug;
fundamental metabolite;
human metabolite;
vasodilator agent
phenylisopropyladenosine[no description available]medium40aromatic amine;
benzenes;
hydrocarbyladenosine;
purine nucleoside;
secondary amino compound		adenosine A1 receptor agonist;
neuroprotective agent
n(6)-phenyladenosine[no description available]medium30purine nucleoside
cp 66713[no description available]medium10
heart[no description available]medium10
adenosine-5'-(n-ethylcarboxamide)[no description available]high160adenosines;
monocarboxylic acid amide		adenosine A1 receptor agonist;
adenosine A2A receptor agonist;
antineoplastic agent;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
vasodilator agent
n(6)-cyclopentyladenosine[no description available]medium50
n-(1-methyl-2-phenylethyl)adenosine, (s)-isomer[no description available]medium10
n(6)-cyclohexyladenosine[no description available]medium60
trequinsin[no description available]medium120pyridopyrimidine
4-phenylpyrrolidone-2[no description available]medium10
quinacrine[no description available]medium30acridines;
aromatic ether;
organochlorine compound;
tertiary amino compound		antimalarial;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor
gallopamil[no description available]medium20benzenes;
organic amino compound
4-aminopyridine[no description available]medium60aminopyridine;
aromatic amine		avicide;
orphan drug;
potassium channel blocker
phenytoin[no description available]medium50imidazolidine-2,4-dioneanticonvulsant;
drug allergen;
sodium channel blocker;
teratogenic agent
8-(4-sulfophenyl)theophylline[no description available]medium30
8-phenyltheophylline[no description available]medium50
amitriptyline[no description available]high62carbotricyclic compound;
tertiary amine		adrenergic uptake inhibitor;
antidepressant;
environmental contaminant;
tropomyosin-related kinase B receptor agonist;
xenobiotic
amitriptyline[no description available]high60carbotricyclic compound;
tertiary amine		adrenergic uptake inhibitor;
antidepressant;
environmental contaminant;
tropomyosin-related kinase B receptor agonist;
xenobiotic
anisindione[no description available]medium20aromatic ketone;
beta-diketone		anticoagulant;
vitamin K antagonist
baclofen[no description available]medium70amino acid zwitterion;
gamma-amino acid;
monocarboxylic acid;
monochlorobenzenes;
primary amino compound		central nervous system depressant;
GABA agonist;
muscle relaxant
benzocaine[no description available]medium10benzoate ester;
substituted aniline		allergen;
antipruritic drug;
sensitiser;
topical anaesthetic
bepridil[no description available]medium20pyrrolidines;
tertiary amine		anti-arrhythmia drug;
antihypertensive agent;
calcium channel blocker;
vasodilator agent
biperiden[no description available]medium10piperidines;
tertiary alcohol;
tertiary amino compound		antidote to sarin poisoning;
antidyskinesia agent;
antiparkinson drug;
muscarinic antagonist;
parasympatholytic
bupivacaine[no description available]medium20aromatic amide;
piperidinecarboxamide;
tertiary amino compound
buspirone[no description available]medium10azaspiro compound;
N-alkylpiperazine;
N-arylpiperazine;
organic heteropolycyclic compound;
piperidones;
pyrimidines		anxiolytic drug;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
sedative;
serotonergic agonist
butacaine[no description available]medium20benzoate ester
butamben[no description available]medium20amino acid ester;
benzoate ester;
primary amino compound;
substituted aniline		local anaesthetic
verapamil[no description available]medium60aromatic ether;
nitrile;
polyether;
tertiary amino compound
carbamazepine[no description available]medium30dibenzoazepine;
ureas		analgesic;
anticonvulsant;
antimanic drug;
drug allergen;
EC 3.5.1.98 (histone deacetylase) inhibitor;
environmental contaminant;
glutamate transporter activator;
mitogen;
non-narcotic analgesic;
sodium channel blocker;
xenobiotic
chlordiazepoxide[no description available]medium30benzodiazepine
chlorpheniramine[no description available]medium10monochlorobenzenes;
pyridines;
tertiary amino compound		anti-allergic agent;
antidepressant;
antipruritic drug;
H1-receptor antagonist;
histamine antagonist;
serotonin uptake inhibitor
chlorpromazine[no description available]medium40organochlorine compound;
phenothiazines;
tertiary amine		anticoronaviral agent;
antiemetic;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
phenothiazine antipsychotic drug
cimetidine[no description available]medium80aliphatic sulfide;
guanidines;
imidazoles;
nitrile		adjuvant;
analgesic;
anti-ulcer drug;
H2-receptor antagonist;
P450 inhibitor
clomipramine[no description available]medium20dibenzoazepineanticoronaviral agent;
antidepressant;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor;
serotonergic antagonist;
serotonergic drug;
serotonin uptake inhibitor
cyproheptadine[no description available]medium20piperidines;
tertiary amine		anti-allergic agent;
antipruritic drug;
gastrointestinal drug;
H1-receptor antagonist;
serotonergic antagonist
desipramine[no description available]high151dibenzoazepine;
secondary amino compound		adrenergic uptake inhibitor;
alpha-adrenergic antagonist;
antidepressant;
cholinergic antagonist;
drug allergen;
EC 3.1.4.12 (sphingomyelin phosphodiesterase) inhibitor;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
H1-receptor antagonist;
serotonin uptake inhibitor
desipramine[no description available]high150dibenzoazepine;
secondary amino compound		adrenergic uptake inhibitor;
alpha-adrenergic antagonist;
antidepressant;
cholinergic antagonist;
drug allergen;
EC 3.1.4.12 (sphingomyelin phosphodiesterase) inhibitor;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
H1-receptor antagonist;
serotonin uptake inhibitor
diazepam[no description available]medium1401,4-benzodiazepinone;
organochlorine compound		anticonvulsant;
anxiolytic drug;
environmental contaminant;
sedative;
xenobiotic
diazoxide[no description available]medium30benzothiadiazine;
organochlorine compound;
sulfone		antihypertensive agent;
beta-adrenergic agonist;
bronchodilator agent;
cardiotonic drug;
diuretic;
K-ATP channel agonist;
sodium channel blocker;
sympathomimetic agent;
vasodilator agent
dibucaine[no description available]medium30aromatic ether;
monocarboxylic acid amide;
tertiary amino compound		topical anaesthetic
dicyclomine[no description available]medium10carboxylic ester;
tertiary amine		antispasmodic drug;
muscarinic antagonist;
parasympatholytic
diphenidol[no description available]medium10benzenes;
piperidines;
tertiary alcohol		antiemetic
dilazep[no description available]medium20benzoate ester;
diazepane;
diester;
methoxybenzenes		cardioprotective agent;
platelet aggregation inhibitor;
vasodilator agent
diphenhydramine[no description available]medium20ether;
tertiary amino compound		anti-allergic agent;
antidyskinesia agent;
antiemetic;
antiparkinson drug;
antipruritic drug;
antitussive;
H1-receptor antagonist;
local anaesthetic;
muscarinic antagonist;
oneirogen;
sedative
dipyridamole[no description available]medium230piperidines;
pyrimidopyrimidine;
tertiary amino compound;
tetrol		adenosine phosphodiesterase inhibitor;
EC 3.5.4.4 (adenosine deaminase) inhibitor;
platelet aggregation inhibitor;
vasodilator agent
doxepin[no description available]medium10dibenzooxepine;
tertiary amino compound		antidepressant
droperidol[no description available]medium30aromatic ketone;
benzimidazoles;
organofluorine compound		anaesthesia adjuvant;
antiemetic;
dopaminergic antagonist;
first generation antipsychotic
etazolate[no description available]high50ethyl ester;
hydrazone;
pyrazolopyridine		alpha-secretase activator;
antidepressant;
antipsychotic agent;
anxiolytic drug;
GABA agent;
neuroprotective agent;
phosphodiesterase IV inhibitor
felodipine[no description available]medium30dichlorobenzene;
dihydropyridine;
ethyl ester;
methyl ester		anti-arrhythmia drug;
antihypertensive agent;
calcium channel blocker;
vasodilator agent
flufenamic acid[no description available]medium20aromatic amino acid;
organofluorine compound		antipyretic;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
fluphenazine[no description available]medium20N-alkylpiperazine;
organofluorine compound;
phenothiazines		anticoronaviral agent;
dopaminergic antagonist;
phenothiazine antipsychotic drug
flumazenil[no description available]medium50ethyl ester;
imidazobenzodiazepine;
organofluorine compound		antidote to benzodiazepine poisoning;
GABA antagonist
haloperidol[no description available]medium120aromatic ketone;
hydroxypiperidine;
monochlorobenzenes;
organofluorine compound;
tertiary alcohol		antidyskinesia agent;
antiemetic;
dopaminergic antagonist;
first generation antipsychotic;
serotonergic antagonist
hydroxyzine[no description available]medium10hydroxyether;
monochlorobenzenes;
N-alkylpiperazine		anticoronaviral agent;
antipruritic drug;
anxiolytic drug;
dermatologic drug;
H1-receptor antagonist
lidocaine[no description available]medium40benzenes;
monocarboxylic acid amide;
tertiary amino compound		anti-arrhythmia drug;
drug allergen;
environmental contaminant;
local anaesthetic;
xenobiotic
ici 118551[no description available]medium10indanes
indomethacin[no description available]medium250aromatic ether;
indole-3-acetic acids;
monochlorobenzenes;
N-acylindole		analgesic;
drug metabolite;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
gout suppressant;
non-steroidal anti-inflammatory drug;
xenobiotic metabolite;
xenobiotic
loperamide[no description available]medium30monocarboxylic acid amide;
monochlorobenzenes;
piperidines;
tertiary alcohol		anticoronaviral agent;
antidiarrhoeal drug;
mu-opioid receptor agonist
mepivacaine[no description available]medium10piperidinecarboxamidedrug allergen;
local anaesthetic
benzoic acid [2-methyl-2-(propylamino)propyl] ester[no description available]medium10benzoate ester
metoprolol[no description available]medium10aromatic ether;
propanolamine;
secondary alcohol;
secondary amino compound		antihypertensive agent;
beta-adrenergic antagonist;
environmental contaminant;
geroprotector;
xenobiotic
mianserin[no description available]high30dibenzoazepineadrenergic uptake inhibitor;
alpha-adrenergic antagonist;
antidepressant;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
geroprotector;
H1-receptor antagonist;
histamine agonist;
sedative;
serotonergic antagonist
nifedipine[no description available]medium80C-nitro compound;
dihydropyridine;
methyl ester		calcium channel blocker;
human metabolite;
tocolytic agent;
vasodilator agent
nisoldipine[no description available]medium10C-nitro compound;
dicarboxylic acids and O-substituted derivatives;
diester;
dihydropyridine;
methyl ester
nitrendipine[no description available]medium40C-nitro compound;
dicarboxylic acids and O-substituted derivatives;
diester;
dihydropyridine;
ethyl ester;
methyl ester		antihypertensive agent;
calcium channel blocker;
geroprotector;
vasodilator agent
nortriptyline[no description available]medium20organic tricyclic compound;
secondary amine		adrenergic uptake inhibitor;
analgesic;
antidepressant;
antineoplastic agent;
apoptosis inducer;
drug metabolite
oxethazaine[no description available]medium20amino acid amide
benoxinate[no description available]medium10amino acid ester;
benzoate ester;
substituted aniline;
tertiary amino compound		drug allergen;
local anaesthetic;
topical anaesthetic
papaverine[no description available]medium270benzylisoquinoline alkaloid;
dimethoxybenzene;
isoquinolines		antispasmodic drug;
vasodilator agent
pentobarbital[no description available]medium40barbituratesGABAA receptor agonist
pheniramine[no description available]medium10pyridines;
tertiary amino compound
phenobarbital[no description available]medium30barbituratesanticonvulsant;
drug allergen;
excitatory amino acid antagonist;
sedative
phenoxybenzamine[no description available]medium20aromatic amine
practolol[no description available]medium10acetamides;
ethanolamines;
propanolamine;
secondary alcohol;
secondary amino compound		anti-arrhythmia drug;
beta-adrenergic antagonist
pramoxine[no description available]medium10aromatic ether;
morpholines		local anaesthetic
prazosin[no description available]medium80aromatic ether;
furans;
monocarboxylic acid amide;
piperazines;
quinazolines		alpha-adrenergic antagonist;
antihypertensive agent;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor
prilocaine[no description available]medium10amino acid amide;
monocarboxylic acid amide		anticonvulsant;
local anaesthetic
proadifen[no description available]medium10diarylmethane
procainamide[no description available]medium10benzamidesanti-arrhythmia drug;
platelet aggregation inhibitor;
sodium channel blocker
procaine[no description available]medium10benzoate ester;
substituted aniline;
tertiary amino compound		central nervous system depressant;
drug allergen;
local anaesthetic;
peripheral nervous system drug
promazine[no description available]medium30phenothiazines;
tertiary amine		antiemetic;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
H1-receptor antagonist;
muscarinic antagonist;
phenothiazine antipsychotic drug;
serotonergic antagonist
promethazine[no description available]medium20phenothiazines;
tertiary amine		anti-allergic agent;
anticoronaviral agent;
antiemetic;
antipruritic drug;
H1-receptor antagonist;
local anaesthetic;
sedative
proxymetacaine[no description available]medium10benzoate ester
protriptyline[no description available]medium20carbotricyclic compoundantidepressant
pyrilamine[no description available]medium30aromatic ether;
ethylenediamine derivative		H1-receptor antagonist
secobarbital[no description available]medium10barbituratesanaesthesia adjuvant;
GABA modulator;
sedative
sotalol[no description available]medium20ethanolamines;
secondary alcohol;
secondary amino compound;
sulfonamide		anti-arrhythmia drug;
beta-adrenergic antagonist;
environmental contaminant;
xenobiotic
spiperone[no description available]medium40aromatic ketone;
azaspiro compound;
organofluorine compound;
piperidines;
tertiary amino compound		alpha-adrenergic antagonist;
antipsychotic agent;
dopaminergic antagonist;
psychotropic drug;
serotonergic antagonist
tetracaine[no description available]medium10benzoate ester;
tertiary amino compound		local anaesthetic
thioridazine[no description available]medium10phenothiazines;
piperidines		alpha-adrenergic antagonist;
dopaminergic antagonist;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
first generation antipsychotic;
H1-receptor antagonist;
serotonergic antagonist
trazodone[no description available]medium10monochlorobenzenes;
N-alkylpiperazine;
N-arylpiperazine;
triazolopyridine		adrenergic antagonist;
antidepressant;
anxiolytic drug;
H1-receptor antagonist;
sedative;
serotonin uptake inhibitor
trifluoperazine[no description available]medium30N-alkylpiperazine;
N-methylpiperazine;
organofluorine compound;
phenothiazines		antiemetic;
calmodulin antagonist;
dopaminergic antagonist;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor;
EC 5.3.3.5 (cholestenol Delta-isomerase) inhibitor;
phenothiazine antipsychotic drug
reserpine[no description available]medium120alkaloid ester;
methyl ester;
yohimban alkaloid		adrenergic uptake inhibitor;
antihypertensive agent;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
environmental contaminant;
first generation antipsychotic;
plant metabolite;
xenobiotic
phentolamine[no description available]medium50imidazoles;
phenols;
substituted aniline;
tertiary amino compound		alpha-adrenergic antagonist;
vasodilator agent
hexobendine[no description available]medium10trihydroxybenzoic acid
dichloroisoproterenol[no description available]medium10
tetraethylammonium chloride[no description available]medium20organic chloride salt;
quaternary ammonium salt		potassium channel blocker
tetrabenazine[no description available]medium20benzoquinolizine;
cyclic ketone;
tertiary amino compound
piperoxan[no description available]medium20
nifenalol[no description available]medium10C-nitro compound
brompheniramine[no description available]medium10organobromine compound;
pyridines		anti-allergic agent;
H1-receptor antagonist
propoxycaine[no description available]medium10benzoate ester
dimethisoquin[no description available]medium10isoquinolines
parethoxycaine[no description available]medium10benzoate ester
yohimbine[no description available]medium80methyl 17-hydroxy-20xi-yohimban-16-carboxylatealpha-adrenergic antagonist;
dopamine receptor D2 antagonist;
serotonergic antagonist
2-chloroadenosine[no description available]medium110purine nucleoside
prenylamine[no description available]medium10diarylmethane
bicuculline[no description available]medium30benzylisoquinoline alkaloid;
isoquinoline alkaloid;
isoquinolines		agrochemical;
central nervous system stimulant;
GABA-gated chloride channel antagonist;
GABAA receptor antagonist;
neurotoxin
hexylcaine[no description available]medium10benzoate ester
piperocaine[no description available]medium10benzoate ester
diperodon[no description available]medium20carbamate ester
cyclomethycaine[no description available]medium10benzoate ester
carcainium chloride[no description available]medium10
azacyclonol[no description available]medium20diarylmethane
butoxamine[no description available]medium10
dexpropranolol[no description available]medium10propranolol
iprindole[no description available]medium10indoles
carticaine[no description available]medium10thiophenecarboxylic acid
timolol[no description available]medium10timololanti-arrhythmia drug;
antiglaucoma drug;
antihypertensive agent;
beta-adrenergic antagonist
butaclamol[no description available]medium10organic heteropentacyclic compound
etidocaine[no description available]medium10amino acid amidelocal anaesthetic
diltiazem[no description available]medium205-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetateantihypertensive agent;
calcium channel blocker;
vasodilator agent
Arbaclofen[no description available]medium10organonitrogen compound;
organooxygen compound
colforsin[no description available]medium1800acetate ester;
cyclic ketone;
labdane diterpenoid;
organic heterotricyclic compound;
tertiary alpha-hydroxy ketone;
triol		adenylate cyclase agonist;
anti-HIV agent;
antihypertensive agent;
plant metabolite;
platelet aggregation inhibitor;
protein kinase A agonist
opromazine[no description available]medium10phenothiazines
corynanthine[no description available]medium10yohimban alkaloid
w 7[no description available]medium10
2-n-butyl-3-(dimethylamino)-5,6-methylenedioxyindene[no description available]medium10
rac 109[no description available]medium10
atropine[no description available]medium70
strychnine[no description available]medium10monoterpenoid indole alkaloid;
organic heteroheptacyclic compound		avicide;
cholinergic antagonist;
glycine receptor antagonist;
neurotransmitter agent;
rodenticide
quinidine[no description available]medium20cinchona alkaloidalpha-adrenergic antagonist;
anti-arrhythmia drug;
antimalarial;
drug allergen;
EC 1.14.13.181 (13-deoxydaunorubicin hydroxylase) inhibitor;
EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor;
muscarinic antagonist;
P450 inhibitor;
potassium channel blocker;
sodium channel blocker
cocaine[no description available]medium90benzoate ester;
methyl ester;
tertiary amino compound;
tropane alkaloid		adrenergic uptake inhibitor;
central nervous system stimulant;
dopamine uptake inhibitor;
environmental contaminant;
local anaesthetic;
mouse metabolite;
plant metabolite;
serotonin uptake inhibitor;
sodium channel blocker;
sympathomimetic agent;
vasoconstrictor agent;
xenobiotic
diethylstilbestrol[no description available]medium30olefinic compound;
polyphenol		antifungal agent;
antineoplastic agent;
autophagy inducer;
calcium channel blocker;
carcinogenic agent;
EC 1.1.1.146 (11beta-hydroxysteroid dehydrogenase) inhibitor;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor;
endocrine disruptor;
xenoestrogen
rauwolscine[no description available]medium20methyl 17-hydroxy-20xi-yohimban-16-carboxylate
chlorprothixene[no description available]medium20chlorprothixene
flunarizine[no description available]medium10diarylmethane
thiothixene[no description available]medium20N-methylpiperazineanticoronaviral agent
cinnarizine[no description available]medium40diarylmethane;
N-alkylpiperazine;
olefinic compound		anti-allergic agent;
antiemetic;
calcium channel blocker;
geroprotector;
H1-receptor antagonist;
histamine antagonist;
muscarinic antagonist
quinine[no description available]medium20cinchona alkaloidantimalarial;
muscle relaxant;
non-narcotic analgesic
codeine[no description available]medium10morphinane alkaloid;
organic heteropentacyclic compound		antitussive;
drug allergen;
environmental contaminant;
opioid analgesic;
opioid receptor agonist;
prodrug;
xenobiotic
morphine[no description available]medium110morphinane alkaloid;
organic heteropentacyclic compound;
tertiary amino compound		anaesthetic;
drug allergen;
environmental contaminant;
geroprotector;
mu-opioid receptor agonist;
opioid analgesic;
plant metabolite;
vasodilator agent;
xenobiotic
levorphanol[no description available]medium10morphinane alkaloid
dextrorphan[no description available]medium10morphinane alkaloid
zimeldine[no description available]medium10styrenes
1-methyl-d-lysergic acid butanolamide[no description available]medium10ergot alkaloid;
monocarboxylic acid amide		serotonergic antagonist;
sympatholytic agent;
vasoconstrictor agent
scopolamine hydrobromide[no description available]medium100
my 5445[no description available]medium20pyridazines;
ring assembly
cilostamide[no description available]medium500quinolines
cilostazol[no description available]medium180lactam;
tetrazoles		anticoagulant;
bronchodilator agent;
EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor;
fibrin modulating drug;
neuroprotective agent;
platelet aggregation inhibitor;
vasodilator agent
amrinone[no description available]high130bipyridinesEC 3.1.4.* (phosphoric diester hydrolase) inhibitor
sulmazole[no description available]medium20imidazopyridine;
sulfoxide		adenosine A1 receptor antagonist;
cardiotonic drug;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor
eg 626[no description available]medium10phthalazines
enoximone[no description available]medium20aromatic ketone
piroximone[no description available]medium10
imazodan[no description available]medium50
bufrolin[no description available]medium10
y 590[no description available]medium10
4,5-dihydro-6-(4-(imidazol-1-yl)phenyl)-5-methyl-3(2h)-pyridazinone[no description available]medium110
zaprinast[no description available]medium880triazolopyrimidines
milrinone[no description available]medium680bipyridines;
nitrile;
pyridone		cardiotonic drug;
EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor;
platelet aggregation inhibitor;
vasodilator agent
N-(1,3-benzodioxol-5-ylmethyl)-6-chloro-4-quinazolinamine[no description available]medium10quinazolines
rp 73401[no description available]medium440aromatic ether;
benzamides;
chloropyridine;
monocarboxylic acid amide		anti-asthmatic drug;
anti-inflammatory agent;
bronchodilator agent;
phosphodiesterase IV inhibitor
pentoxifylline[no description available]medium330oxopurine
pentoxifylline[no description available]medium331oxopurine
cyclic gmp[no description available]medium8603',5'-cyclic purine nucleotide;
guanyl ribonucleotide		Escherichia coli metabolite;
human metabolite;
mouse metabolite;
plant metabolite;
Saccharomyces cerevisiae metabolite
9-benzyladenine[no description available]medium10
9-(2-hydroxy-3-nonyl)adenine[no description available]medium40EHNAEC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
EC 3.5.4.4 (adenosine deaminase) inhibitor
denbufylline[no description available]medium150oxopurine
cdp 840[no description available]medium60
cilomilast[no description available]medium460methoxybenzenes
cilomilast[no description available]medium461methoxybenzenes
thalidomide[no description available]medium160phthalimides;
piperidones
sildenafil citrate[no description available]medium190citrate saltEC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor;
vasodilator agent
ci 1044[no description available]medium50
ci 1044[no description available]medium51
sulfasalazine[no description available]medium20
penicillamine[no description available]medium40non-proteinogenic alpha-amino acid;
penicillamine		antirheumatic drug;
chelator;
copper chelator;
drug allergen
sophoflavescenol[no description available]medium10
kuraridin[no description available]medium10
kurarinol[no description available]medium104'-hydroxyflavanones;
monomethoxyflavanone;
trihydroxyflavanone		anti-inflammatory agent;
antioxidant;
plant metabolite
sildenafil[no description available]medium130piperazines;
pyrazolopyrimidine;
sulfonamide		EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor;
vasodilator agent
zardaverine[no description available]medium220organofluorine compound;
pyridazinone		anti-asthmatic drug;
bronchodilator agent;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
peripheral nervous system drug
tadalafil[no description available]medium70benzodioxoles;
pyrazinopyridoindole		EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor;
vasodilator agent
(+)-rolipram[no description available]medium30rolipram
mesopram[no description available]medium50
mesopram[no description available]medium51
roflumilast[no description available]medium440aromatic ether;
benzamides;
chloropyridine;
cyclopropanes;
organofluorine compound		anti-asthmatic drug;
phosphodiesterase IV inhibitor
vardenafil[no description available]medium40imidazotriazine;
N-alkylpiperazine;
N-sulfonylpiperazine		EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
vasodilator agent
vinpocetine[no description available]medium210alkaloidgeroprotector
vinpocetine[no description available]medium211alkaloidgeroprotector
bay 60-7550[no description available]medium40
ag-1296[no description available]medium10quinoxaline derivative
albuterol[no description available]medium450phenols;
phenylethanolamines;
secondary amino compound		beta-adrenergic agonist;
bronchodilator agent;
environmental contaminant;
xenobiotic
aminoglutethimide[no description available]medium10dicarboximide;
piperidones;
substituted aniline		adrenergic agent;
anticonvulsant;
antineoplastic agent;
EC 1.14.14.14 (aromatase) inhibitor
bicalutamide[no description available]medium10(trifluoromethyl)benzenes;
monocarboxylic acid amide;
monofluorobenzenes;
nitrile;
sulfone;
tertiary alcohol
celecoxib[no description available]medium10organofluorine compound;
pyrazoles;
sulfonamide;
toluenes		cyclooxygenase 2 inhibitor;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
ciglitazone[no description available]medium10aromatic ether;
thiazolidinone		antineoplastic agent;
insulin-sensitizing drug
ciprofibrate[no description available]medium30cyclopropanes;
monocarboxylic acid;
organochlorine compound		antilipemic drug
clenbuterol[no description available]medium40amino alcohol;
dichlorobenzene;
ethanolamines;
primary arylamine;
secondary amino compound;
substituted aniline		beta-adrenergic agonist;
bronchodilator agent;
sympathomimetic agent
clofibrate[no description available]medium20aromatic ether;
ethyl ester;
monochlorobenzenes		anticholesteremic drug;
antilipemic drug;
geroprotector;
PPARalpha agonist
clotrimazole[no description available]medium20conazole antifungal drug;
imidazole antifungal drug;
imidazoles;
monochlorobenzenes		antiinfective agent;
environmental contaminant;
xenobiotic
fenofibrate[no description available]medium40aromatic ether;
chlorobenzophenone;
isopropyl ester;
monochlorobenzenes		antilipemic drug;
environmental contaminant;
geroprotector;
xenobiotic
gemfibrozil[no description available]medium20aromatic etherantilipemic drug
go 6976[no description available]medium10indolocarbazole;
organic heterohexacyclic compound		EC 2.7.11.13 (protein kinase C) inhibitor
isoproterenol[no description available]medium670catechols;
secondary alcohol;
secondary amino compound		beta-adrenergic agonist;
bronchodilator agent;
cardiotonic drug;
sympathomimetic agent
ketoconazole[no description available]medium20dichlorobenzene;
dioxolane;
ether;
imidazoles;
N-acylpiperazine;
N-arylpiperazine
beta-lapachone[no description available]medium20benzochromenone;
orthoquinones		anti-inflammatory agent;
antineoplastic agent;
plant metabolite
letrozole[no description available]medium10nitrile;
triazoles		antineoplastic agent;
EC 1.14.14.14 (aromatase) inhibitor
2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one[no description available]medium70chromones;
morpholines;
organochlorine compound		autophagy inhibitor;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
geroprotector
niclosamide[no description available]medium20benzamides;
C-nitro compound;
monochlorobenzenes;
salicylanilides;
secondary carboxamide		anthelminthic drug;
anticoronaviral agent;
antiparasitic agent;
apoptosis inducer;
molluscicide;
piscicide;
STAT3 inhibitor
patulin[no description available]medium10furopyran;
gamma-lactone;
lactol		antimicrobial agent;
Aspergillus metabolite;
carcinogenic agent;
mutagen;
mycotoxin;
Penicillium metabolite
pd 153035[no description available]medium20aromatic amine;
aromatic ether;
bromobenzenes;
quinazolines;
secondary amino compound		EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
epidermal growth factor receptor antagonist
pd 158780[no description available]medium10aromatic amine;
bromobenzenes;
diamine;
pyridopyrimidine;
secondary amino compound		antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
pd 98059[no description available]medium30aromatic amine;
monomethoxyflavone		EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
geroprotector
pioglitazone[no description available]high20aromatic ether;
pyridines;
thiazolidinediones		antidepressant;
cardioprotective agent;
EC 2.7.1.33 (pantothenate kinase) inhibitor;
EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor;
ferroptosis inhibitor;
geroprotector;
hypoglycemic agent;
insulin-sensitizing drug;
PPARgamma agonist;
xenobiotic
propranolol[no description available]medium190naphthalenes;
propanolamine;
secondary amine		anti-arrhythmia drug;
antihypertensive agent;
anxiolytic drug;
beta-adrenergic antagonist;
environmental contaminant;
human blood serum metabolite;
vasodilator agent;
xenobiotic
quetiapine[no description available]medium10dibenzothiazepine;
N-alkylpiperazine;
N-arylpiperazine		adrenergic antagonist;
dopaminergic antagonist;
histamine antagonist;
second generation antipsychotic;
serotonergic antagonist
raloxifene[no description available]medium101-benzothiophenes;
aromatic ketone;
N-oxyethylpiperidine;
phenols		bone density conservation agent;
estrogen antagonist;
estrogen receptor modulator
risperidone[no description available]medium401,2-benzoxazoles;
heteroarylpiperidine;
organofluorine compound;
pyridopyrimidine		alpha-adrenergic antagonist;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
H1-receptor antagonist;
psychotropic drug;
second generation antipsychotic;
serotonergic antagonist
rofecoxib[no description available]medium10butenolide;
sulfone		analgesic;
cyclooxygenase 2 inhibitor;
non-steroidal anti-inflammatory drug
imatinib[no description available]medium20aromatic amine;
benzamides;
N-methylpiperazine;
pyridines;
pyrimidines		antineoplastic agent;
apoptosis inducer;
tyrosine kinase inhibitor
terfenadine[no description available]medium30diarylmethane
troglitazone[no description available]medium10chromanes;
thiazolidinone		anticoagulant;
anticonvulsant;
antineoplastic agent;
antioxidant;
EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor;
ferroptosis inhibitor;
hypoglycemic agent;
platelet aggregation inhibitor;
vasodilator agent
zm 336372[no description available]medium10benzamides
zonisamide[no description available]medium101,2-benzoxazoles;
sulfonamide		anticonvulsant;
antioxidant;
central nervous system drug;
protective agent;
T-type calcium channel blocker
rotenone[no description available]medium20organic heteropentacyclic compound;
rotenones		antineoplastic agent;
metabolite;
mitochondrial NADH:ubiquinone reductase inhibitor;
phytogenic insecticide;
piscicide;
toxin
camptothecin[no description available]medium20delta-lactone;
pyranoindolizinoquinoline;
quinoline alkaloid;
tertiary alcohol		antineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
genotoxin;
plant metabolite
levamisole[no description available]medium206-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazoleantinematodal drug;
antirheumatic drug;
EC 3.1.3.1 (alkaline phosphatase) inhibitor;
immunological adjuvant;
immunomodulator
paclitaxel[no description available]medium40taxane diterpenoid;
tetracyclic diterpenoid		antineoplastic agent;
human metabolite;
metabolite;
microtubule-stabilising agent
paroxetine[no description available]high20aromatic ether;
benzodioxoles;
organofluorine compound;
piperidines		antidepressant;
anxiolytic drug;
hepatotoxic agent;
P450 inhibitor;
serotonin uptake inhibitor
lovastatin[no description available]medium40delta-lactone;
fatty acid ester;
hexahydronaphthalenes;
polyketide;
statin (naturally occurring)		anticholesteremic drug;
antineoplastic agent;
Aspergillus metabolite;
prodrug
simvastatin[no description available]medium10delta-lactone;
fatty acid ester;
hexahydronaphthalenes;
statin (semi-synthetic)		EC 1.1.1.34/EC 1.1.1.88 (hydroxymethylglutaryl-CoA reductase) inhibitor;
EC 3.4.24.83 (anthrax lethal factor endopeptidase) inhibitor;
ferroptosis inducer;
geroprotector;
prodrug
pravastatin[no description available]medium103-hydroxy carboxylic acid;
carbobicyclic compound;
carboxylic ester;
hydroxy monocarboxylic acid;
secondary alcohol;
statin (semi-synthetic)		anticholesteremic drug;
environmental contaminant;
metabolite;
xenobiotic
aromasil[no description available]medium1017-oxo steroid;
3-oxo-Delta(1),Delta(4)-steroid		antineoplastic agent;
EC 1.14.14.14 (aromatase) inhibitor;
environmental contaminant;
xenobiotic
atorvastatin[no description available]medium10aromatic amide;
dihydroxy monocarboxylic acid;
monofluorobenzenes;
pyrroles;
statin (synthetic)		environmental contaminant;
xenobiotic
ziprasidone[no description available]medium101,2-benzisothiazole;
indolones;
organochlorine compound;
piperazines		antipsychotic agent;
dopaminergic antagonist;
histamine antagonist;
muscarinic antagonist;
psychotropic drug;
serotonergic antagonist
mevastatin[no description available]medium202-pyranones;
carboxylic ester;
hexahydronaphthalenes;
polyketide;
statin (naturally occurring)		antifungal agent;
apoptosis inducer;
EC 3.4.24.83 (anthrax lethal factor endopeptidase) inhibitor;
fungal metabolite;
Penicillium metabolite
sertraline[no description available]high20dichlorobenzene;
secondary amino compound;
tetralins		antidepressant;
serotonin uptake inhibitor
rosiglitazone[no description available]medium20aminopyridine;
thiazolidinediones		EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor;
ferroptosis inhibitor;
insulin-sensitizing drug
fulvestrant[no description available]medium1017beta-hydroxy steroid;
3-hydroxy steroid;
organofluorine compound;
sulfoxide		antineoplastic agent;
estrogen antagonist;
estrogen receptor antagonist
valdecoxib[no description available]medium10isoxazoles;
sulfonamide		antipyretic;
antirheumatic drug;
cyclooxygenase 2 inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
cyc 202[no description available]medium202,6-diaminopurinesantiviral drug;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
angiotensin ii[no description available]medium30amino acid zwitterion;
angiotensin II		human metabolite
sb 203580[no description available]medium90imidazoles;
monofluorobenzenes;
pyridines;
sulfoxide		EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
geroprotector;
Hsp90 inhibitor;
neuroprotective agent
wortmannin[no description available]medium80acetate ester;
cyclic ketone;
delta-lactone;
organic heteropentacyclic compound		anticoronaviral agent;
antineoplastic agent;
autophagy inhibitor;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
geroprotector;
Penicillium metabolite;
radiosensitizing agent
acetylleucyl-leucyl-norleucinal[no description available]medium20aldehyde;
tripeptide		cysteine protease inhibitor
trichostatin a[no description available]medium10antibiotic antifungal agent;
hydroxamic acid;
trichostatin		bacterial metabolite;
EC 3.5.1.98 (histone deacetylase) inhibitor;
geroprotector
tretinoin[no description available]medium40retinoic acid;
vitamin A		anti-inflammatory agent;
antineoplastic agent;
antioxidant;
AP-1 antagonist;
human metabolite;
keratolytic drug;
retinoic acid receptor agonist;
retinoid X receptor agonist;
signalling molecule
cerivastatin[no description available]medium10dihydroxy monocarboxylic acid;
pyridines;
statin (synthetic)
rosuvastatin[no description available]medium10dihydroxy monocarboxylic acid;
monofluorobenzenes;
pyrimidines;
statin (synthetic);
sulfonamide		anti-inflammatory agent;
antilipemic drug;
cardioprotective agent;
CETP inhibitor;
environmental contaminant;
xenobiotic
y 27632[no description available]medium20aromatic amide
epothilone a[no description available]medium10epothilone;
epoxide		antineoplastic agent;
metabolite;
microtubule-stabilising agent;
tubulin modulator
h 89[no description available]medium290N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide
benzyloxycarbonylleucyl-leucyl-leucine aldehyde[no description available]medium30amino aldehyde;
carbamate ester;
tripeptide		proteasome inhibitor
tamoxifen[no description available]medium20stilbenoid;
tertiary amino compound		angiogenesis inhibitor;
antineoplastic agent;
bone density conservation agent;
EC 1.2.3.1 (aldehyde oxidase) inhibitor;
EC 2.7.11.13 (protein kinase C) inhibitor;
estrogen antagonist;
estrogen receptor antagonist;
estrogen receptor modulator
toremifene[no description available]medium10aromatic ether;
organochlorine compound;
tertiary amine		antineoplastic agent;
bone density conservation agent;
estrogen antagonist;
estrogen receptor modulator
sc 560[no description available]medium20aromatic ether;
monochlorobenzenes;
organofluorine compound;
pyrazoles		angiogenesis modulating agent;
antineoplastic agent;
apoptosis inducer;
cyclooxygenase 1 inhibitor;
non-steroidal anti-inflammatory drug
apigenin[no description available]medium20trihydroxyflavoneantineoplastic agent;
metabolite
genistein[no description available]medium307-hydroxyisoflavonesantineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
geroprotector;
human urinary metabolite;
phytoestrogen;
plant metabolite;
tyrosine kinase inhibitor
sirolimus[no description available]medium30antibiotic antifungal drug;
cyclic acetal;
cyclic ketone;
ether;
macrolide lactam;
organic heterotricyclic compound;
secondary alcohol		antibacterial drug;
anticoronaviral agent;
antineoplastic agent;
bacterial metabolite;
geroprotector;
immunosuppressive agent;
mTOR inhibitor
brefeldin a[no description available]medium30macrolide antibioticPenicillium metabolite
geldanamycin[no description available]medium101,4-benzoquinones;
ansamycin;
carbamate ester;
organic heterobicyclic compound		antimicrobial agent;
antineoplastic agent;
antiviral agent;
cysteine protease inhibitor;
Hsp90 inhibitor
lysophosphatidic acid[no description available]medium101-acyl-sn-glycerol 3-phosphate
bay 11-7082[no description available]medium10nitrile;
sulfone		apoptosis inducer;
EC 2.7.11.10 (IkappaB kinase) inhibitor;
EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor;
non-steroidal anti-inflammatory drug;
platelet aggregation inhibitor
(6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid[no description available]medium10dihydroxy monocarboxylic acid;
indoles;
organofluorine compound
tanespimycin[no description available]medium101,4-benzoquinones;
ansamycin;
carbamate ester;
organic heterobicyclic compound;
secondary amino compound		antineoplastic agent;
apoptosis inducer;
Hsp90 inhibitor
gw 1929[no description available]medium20benzophenones
2-[(3-iodophenyl)methylthio]-5-pyridin-4-yl-1,3,4-oxadiazole[no description available]medium10aryl sulfide
ci 940[no description available]medium10hydroxy polyunsaturated fatty acid;
leptomycin		antifungal agent;
bacterial metabolite
pifithrin-alpha[no description available]medium10
clozapine[no description available]medium40benzodiazepine;
N-arylpiperazine;
N-methylpiperazine;
organochlorine compound		adrenergic antagonist;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
environmental contaminant;
GABA antagonist;
histamine antagonist;
muscarinic antagonist;
second generation antipsychotic;
serotonergic antagonist;
xenobiotic
olanzapine[no description available]medium20benzodiazepine;
N-arylpiperazine;
N-methylpiperazine		antiemetic;
dopaminergic antagonist;
histamine antagonist;
muscarinic antagonist;
second generation antipsychotic;
serotonergic antagonist;
serotonin uptake inhibitor
rolipram(-)-rolipram : The (R)-enantiomer of rolipram.medium50rolipram
gamma-aminobutyric acid[no description available]medium100amino acid zwitterion;
gamma-amino acid;
monocarboxylic acid		human metabolite;
neurotransmitter;
Saccharomyces cerevisiae metabolite;
signalling molecule
acetamide[no description available]medium20acetamides;
carboximidic acid;
monocarboxylic acid amide;
N-acylammonia
catechol[no description available]medium10catecholsallelochemical;
genotoxin;
plant metabolite
taxifolin[no description available]medium103'-hydroxyflavanones;
4'-hydroxyflavanones;
dihydroflavonols;
pentahydroxyflavanone;
secondary alpha-hydroxy ketone
phosphonoacetic acid[no description available]medium20monocarboxylic acid;
phosphonic acids		antiviral agent;
EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor
3,4-dihydroxyphenylacetic acid[no description available]medium30catechols;
dihydroxyphenylacetic acid		human metabolite
aminocaproic acid[no description available]medium10amino acid zwitterion;
epsilon-amino acid;
omega-amino fatty acid		antifibrinolytic drug;
hematologic agent;
metabolite
diacetyl[no description available]medium10alpha-diketoneEscherichia coli metabolite;
Saccharomyces cerevisiae metabolite
hydroquinone[no description available]medium10benzenediol;
hydroquinones		antioxidant;
carcinogenic agent;
cofactor;
Escherichia coli metabolite;
human xenobiotic metabolite;
mouse metabolite;
skin lightening agent
melatonin[no description available]medium50acetamides;
tryptamines		anticonvulsant;
central nervous system depressant;
geroprotector;
hormone;
human metabolite;
immunological adjuvant;
mouse metabolite;
radical scavenger
n-acetylserotonin[no description available]medium10acetamides;
N-acylserotonin;
phenols		antioxidant;
human metabolite;
mouse metabolite;
tropomyosin-related kinase B receptor agonist
pyrazinamide[no description available]medium20monocarboxylic acid amide;
N-acylammonia;
pyrazines		antitubercular agent;
prodrug
quinolinic acid[no description available]medium40pyridinedicarboxylic acidEscherichia coli metabolite;
human metabolite;
mouse metabolite;
NMDA receptor agonist
taurine[no description available]medium20amino sulfonic acid;
zwitterion		antioxidant;
Escherichia coli metabolite;
glycine receptor agonist;
human metabolite;
mouse metabolite;
nutrient;
radical scavenger;
Saccharomyces cerevisiae metabolite
2-amino-5-phosphonovalerate[no description available]medium10non-proteinogenic alpha-amino acidNMDA receptor antagonist
alpha-methyl-4-carboxyphenylglycine[no description available]medium10
3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid[no description available]medium10
1-hydroxy-3-amino-2-pyrrolidone[no description available]medium10
ibotenic acid[no description available]medium10non-proteinogenic alpha-amino acidneurotoxin
n(8)-bromoacetyl-n(1)-3'-(4-indolyloxy)-2'-hydroxypropyl-1,8-diamino-4-menthane[no description available]medium10
sk&f-38393[no description available]medium10benzazepine;
catechols;
secondary amino compound
vanilmandelic acid[no description available]medium102-hydroxy monocarboxylic acid;
aromatic ether;
phenols		human metabolite
1,10-diaminodecane[no description available]medium10
1,3-diethyl-8-phenylxanthine[no description available]medium10
1,3-dipropyl-8-cyclopentylxanthine[no description available]medium80oxopurineadenosine A1 receptor antagonist;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor
1,3-dipropyl-8-(4-sulfophenyl)xanthine[no description available]medium10
1,5-dihydroxyisoquinoline[no description available]medium10isoquinolinolEC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor
pk 11195[no description available]medium30aromatic amide;
isoquinolines;
monocarboxylic acid amide;
monochlorobenzenes		antineoplastic agent
1-(2-trifluoromethylphenyl)imidazole[no description available]medium10imidazoles
1-aminobenzotriazole[no description available]medium10
1-methylimidazole[no description available]medium10imidazoles
edelfosine[no description available]medium10glycerophosphocholine
1h-(1,2,4)oxadiazolo(4,3-a)quinoxalin-1-one[no description available]medium40oxadiazoloquinoxalineEC 4.6.1.2 (guanylate cyclase) inhibitor
2,2'-dipyridyl[no description available]medium20bipyridinechelator;
ferroptosis inhibitor
2-hydroxysaclofen[no description available]medium10organochlorine compound
3,4-dichloroisocoumarin[no description available]medium20isocoumarins;
organochlorine compound		geroprotector;
serine protease inhibitor
phaclofen[no description available]medium10organophosphate oxoanion;
zwitterion
3-aminobenzamide[no description available]medium20benzamides;
substituted aniline		EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor
3-bromo-7-nitroindazole[no description available]medium10
enprofylline[no description available]medium50oxopurineanti-arrhythmia drug;
anti-asthmatic drug;
bronchodilator agent;
non-steroidal anti-inflammatory drug
3-nitropropionic acid[no description available]medium10C-nitro compoundantimycobacterial drug;
EC 1.3.5.1 [succinate dehydrogenase (quinone)] inhibitor;
mycotoxin;
neurotoxin
4-amino-1,8-naphthalimide[no description available]medium10benzoisoquinoline;
dicarboximide
homovanillic acid[no description available]medium20guaiacols;
monocarboxylic acid		human metabolite;
mouse metabolite
4-hydroxybenzoic acid hydrazide[no description available]medium10carbohydrazide;
phenols
4-phenyl-3-furoxancarbonitrile[no description available]medium101,2,5-oxadiazole;
benzenes;
N-oxide;
nitrile		geroprotector;
nitric oxide donor;
platelet aggregation inhibitor;
soluble guanylate cyclase activator;
vasodilator agent
5,5-dimethyl-1-pyrroline-1-oxide[no description available]medium101-pyrroline nitronesneuroprotective agent;
spin trapping reagent
5,7-dichlorokynurenic acid[no description available]medium10quinolines
5-(n,n-hexamethylene)amiloride[no description available]medium10aromatic amine;
azepanes;
guanidines;
monocarboxylic acid amide;
organochlorine compound;
pyrazines		antineoplastic agent;
apoptosis inducer;
odorant receptor antagonist;
sodium channel blocker
ethylisopropylamiloride[no description available]medium10aromatic amine;
guanidines;
monocarboxylic acid amide;
organochlorine compound;
pyrazines;
tertiary amino compound		anti-arrhythmia drug;
neuroprotective agent;
sodium channel blocker
5-fluoroindole-2-carboxylic acid[no description available]medium20indolyl carboxylic acid
hydroxyindoleacetic acid[no description available]medium10indole-3-acetic acidsdrug metabolite;
human metabolite;
mouse metabolite
phenanthridone[no description available]medium10lactam;
phenanthridines		EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor;
immunosuppressive agent;
mutagen
6-chloromelatonin[no description available]medium10acetamides
6-hydroxymelatonin[no description available]medium10acetamides;
tryptamines		metabolite;
mouse metabolite
6-methoxytryptoline[no description available]medium10
6-nitroso-1,2-benzopyrone[no description available]medium10
7-chlorokynurenic acid[no description available]medium10organochlorine compound;
quinolinemonocarboxylic acid		neuroprotective agent;
NMDA receptor antagonist
7-nitroindazole[no description available]medium20
8-cyclopentyl-1,3-dimethylxanthine[no description available]medium10oxopurine
acetazolamide[no description available]medium30monocarboxylic acid amide;
sulfonamide;
thiadiazoles		anticonvulsant;
diuretic;
EC 4.2.1.1 (carbonic anhydrase) inhibitor
acetohexamide[no description available]medium10acetophenones;
N-sulfonylurea		hypoglycemic agent;
insulin secretagogue
ag 127[no description available]medium10nitrophenol
rtki cpd[no description available]medium10aromatic ether;
monochlorobenzenes;
quinazolines		antineoplastic agent;
antiviral agent;
epidermal growth factor receptor antagonist;
geroprotector
tyrphostin a23[no description available]medium10catechols
tyrphostin 25[no description available]medium10benzenetriol
tyrphostin a1[no description available]medium10methoxybenzenesgeroprotector
1-aminoindan-1,5-dicarboxylic acid[no description available]medium10
alpha-methyltyrosine methyl ester[no description available]medium10
altretamine[no description available]medium20triamino-1,3,5-triazine
amfonelic acid[no description available]medium10
amifostine anhydrous[no description available]medium10diamine;
organic thiophosphate		antioxidant;
prodrug;
radiation protective agent
amoxapine[no description available]medium20dibenzooxazepineadrenergic uptake inhibitor;
antidepressant;
dopaminergic antagonist;
geroprotector;
serotonin uptake inhibitor
aniracetam[no description available]medium20N-acylpyrrolidine;
pyrrolidin-2-ones
2-amino-4-phosphonobutyric acid[no description available]medium10
aspirin[no description available]medium60benzoic acids;
phenyl acetates;
salicylates		anticoagulant;
antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
EC 1.1.1.188 (prostaglandin-F synthase) inhibitor;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
plant activator;
platelet aggregation inhibitor;
prostaglandin antagonist;
teratogenic agent
atenolol[no description available]medium60ethanolamines;
monocarboxylic acid amide;
propanolamine		anti-arrhythmia drug;
antihypertensive agent;
beta-adrenergic antagonist;
environmental contaminant;
sympatholytic agent;
xenobiotic
alpha-amino-3-hydroxy-5-tert-butyl-4-isoxazolepropionate[no description available]medium10alpha-amino acid
aurintricarboxylic acid[no description available]medium10monohydroxybenzoic acid;
quinomethanes;
tricarboxylic acid		fluorochrome;
histological dye;
insulin-like growth factor receptor 1 antagonist
azathioprine[no description available]medium10aryl sulfide;
C-nitro compound;
imidazoles;
thiopurine		antimetabolite;
antineoplastic agent;
carcinogenic agent;
DNA synthesis inhibitor;
hepatotoxic agent;
immunosuppressive agent;
prodrug
azelaic acid[no description available]medium20alpha,omega-dicarboxylic acid;
dicarboxylic fatty acid		antibacterial agent;
antineoplastic agent;
dermatologic drug;
plant metabolite
bay-k-8644[no description available]medium30(trifluoromethyl)benzenes;
C-nitro compound;
dihydropyridine;
methyl ester
benzamide[no description available]medium20benzamides
bml 190[no description available]medium10N-acylindole
brimonidine[no description available]medium20imidazoles;
quinoxaline derivative;
secondary amine		adrenergic agonist;
alpha-adrenergic agonist;
antihypertensive agent
bumetanide[no description available]medium30amino acid;
benzoic acids;
sulfonamide		diuretic;
EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor
carbetapentane[no description available]medium10benzenes
carisoprodol[no description available]medium20carbamate estermuscle relaxant
carmustine[no description available]medium10N-nitrosoureas;
organochlorine compound		alkylating agent;
antineoplastic agent
cgs 12066[no description available]medium10N-arylpiperazine;
organofluorine compound;
pyrroloquinoxaline		serotonergic agonist
chlorambucil[no description available]medium20aromatic amine;
monocarboxylic acid;
nitrogen mustard;
organochlorine compound;
tertiary amino compound		alkylating agent;
antineoplastic agent;
carcinogenic agent;
drug allergen;
immunosuppressive agent
chlormezanone[no description available]medium101,3-thiazine;
lactam;
monochlorobenzenes;
sulfone		antipsychotic agent;
anxiolytic drug;
muscle relaxant
chlorothiazide[no description available]medium10benzothiadiazineantihypertensive agent;
diuretic
chlorpropamide[no description available]medium20monochlorobenzenes;
N-sulfonylurea		hypoglycemic agent;
insulin secretagogue
chlorzoxazone[no description available]medium201,3-benzoxazoles;
heteroaryl hydroxy compound;
organochlorine compound		muscle relaxant;
sedative
cinoxacin[no description available]medium20cinnolines;
oxacycle;
oxo carboxylic acid		antibacterial drug;
antiinfective agent
cx546[no description available]medium10
cyclothiazide[no description available]medium10benzothiadiazineantihypertensive agent;
diuretic
dephostatin[no description available]medium10
nonivamide[no description available]medium10capsaicinoid;
phenols		lachrymator
r 59022[no description available]medium10diarylmethane
pentetic acid[no description available]medium10pentacarboxylic acidcopper chelator
diphenyleneiodonium[no description available]medium10organic cation
disopyramide[no description available]medium10monocarboxylic acid amide;
pyridines;
tertiary amino compound		anti-arrhythmia drug
disulfiram[no description available]medium30organic disulfide;
organosulfur acaricide		angiogenesis inhibitor;
antineoplastic agent;
apoptosis inducer;
EC 1.2.1.3 [aldehyde dehydrogenase (NAD(+))] inhibitor;
EC 3.1.1.1 (carboxylesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
ferroptosis inducer;
fungicide;
NF-kappaB inhibitor
2-amino-7-phosphonoheptanoic acid[no description available]medium10
thiorphan[no description available]medium10N-acyl-amino acid
2,3-dimethoxy-1,4-naphthoquinone[no description available]medium101,4-naphthoquinones
domperidone[no description available]medium20benzimidazoles;
heteroarylpiperidine		antiemetic;
dopaminergic antagonist
ebselen[no description available]medium30benzoselenazoleanti-inflammatory drug;
antibacterial agent;
anticoronaviral agent;
antifungal agent;
antineoplastic agent;
antioxidant;
apoptosis inducer;
EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
EC 1.3.1.8 [acyl-CoA dehydrogenase (NADP(+))] inhibitor;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor;
EC 2.5.1.7 (UDP-N-acetylglucosamine 1-carboxyvinyltransferase) inhibitor;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
EC 3.1.3.25 (inositol-phosphate phosphatase) inhibitor;
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor;
EC 3.5.4.1 (cytosine deaminase) inhibitor;
EC 5.1.3.2 (UDP-glucose 4-epimerase) inhibitor;
enzyme mimic;
ferroptosis inhibitor;
genotoxin;
hepatoprotective agent;
neuroprotective agent;
radical scavenger
ellipticine[no description available]medium20indole alkaloid;
organic heterotetracyclic compound;
organonitrogen heterocyclic compound;
polycyclic heteroarene		antineoplastic agent;
plant metabolite
emodin[no description available]medium10trihydroxyanthraquinoneantineoplastic agent;
laxative;
plant metabolite;
tyrosine kinase inhibitor
ethosuximide[no description available]medium20dicarboximide;
pyrrolidinone		anticonvulsant;
geroprotector;
T-type calcium channel blocker
etodolac[no description available]medium20monocarboxylic acid;
organic heterotricyclic compound		antipyretic;
cyclooxygenase 2 inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
felbamate[no description available]medium20carbamate esteranticonvulsant;
neuroprotective agent
fluorouracil[no description available]medium40nucleobase analogue;
organofluorine compound		antimetabolite;
antineoplastic agent;
environmental contaminant;
immunosuppressive agent;
radiosensitizing agent;
xenobiotic
fluspirilene[no description available]medium10diarylmethane
flutamide[no description available]medium10(trifluoromethyl)benzenes;
monocarboxylic acid amide		androgen antagonist;
antineoplastic agent
formoterol fumarate[no description available]medium10formamides;
phenols;
phenylethanolamines;
secondary alcohol;
secondary amino compound
fpl 64176[no description available]medium10carboxylic ester;
pyrroles		calcium channel agonist
furafylline[no description available]medium10oxopurine
furosemide[no description available]medium10chlorobenzoic acid;
furans;
sulfonamide		environmental contaminant;
loop diuretic;
xenobiotic
fusaric acid[no description available]medium10aromatic carboxylic acid;
pyridines
gabapentin[no description available]medium20gamma-amino acidanticonvulsant;
calcium channel blocker;
environmental contaminant;
xenobiotic
4-amino-5-hexynoic acid[no description available]medium10
glipizide[no description available]medium20aromatic amide;
monocarboxylic acid amide;
N-sulfonylurea;
pyrazines		EC 2.7.1.33 (pantothenate kinase) inhibitor;
hypoglycemic agent;
insulin secretagogue
glyburide[no description available]medium70monochlorobenzenes;
N-sulfonylurea		anti-arrhythmia drug;
EC 2.7.1.33 (pantothenate kinase) inhibitor;
EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor;
hypoglycemic agent
1-(5-isoquinolinesulfonyl)piperazine[no description available]medium10isoquinolines
hemicholinium 3[no description available]medium10morpholines
4-fluorohexahydrosiladifenidol[no description available]medium10
hydrochlorothiazide[no description available]medium30benzothiadiazine;
organochlorine compound;
sulfonamide		antihypertensive agent;
diuretic;
environmental contaminant;
xenobiotic
hydroxyurea[no description available]medium20one-carbon compound;
ureas		antimetabolite;
antimitotic;
antineoplastic agent;
DNA synthesis inhibitor;
EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor;
genotoxin;
immunomodulator;
radical scavenger;
teratogenic agent
ibudilast[no description available]medium50pyrazolopyridine
ibuprofen[no description available]medium30monocarboxylic acidantipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
environmental contaminant;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
radical scavenger;
xenobiotic
ic 261[no description available]medium10indoles
ifenprodil[no description available]medium10piperidines
indirubin-3'-monoxime[no description available]medium10
iodoacetamide[no description available]medium10
4-piperidinecarboxylic acid[no description available]medium10
4-(4'-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline[no description available]medium10
jl 18[no description available]medium10
nsc 664704[no description available]medium10indolobenzazepine;
lactam;
organobromine compound		cardioprotective agent;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor;
EC 2.7.11.26 (tau-protein kinase) inhibitor;
geroprotector
ketoprofen[no description available]medium30benzophenones;
oxo monocarboxylic acid		antipyretic;
drug allergen;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
non-steroidal anti-inflammatory drug;
xenobiotic
kynurenic acid[no description available]medium10monohydroxyquinoline;
quinolinemonocarboxylic acid		G-protein-coupled receptor agonist;
human metabolite;
neuroprotective agent;
nicotinic antagonist;
NMDA receptor antagonist;
Saccharomyces cerevisiae metabolite
2-amino-3-phosphonopropionic acid[no description available]medium10alanine derivative;
non-proteinogenic alpha-amino acid;
phosphonic acids		human metabolite;
metabotropic glutamate receptor antagonist
lamotrigine[no description available]medium201,2,4-triazines;
dichlorobenzene;
primary arylamine		anticonvulsant;
antidepressant;
antimanic drug;
calcium channel blocker;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
environmental contaminant;
excitatory amino acid antagonist;
geroprotector;
non-narcotic analgesic;
xenobiotic
lansoprazole[no description available]medium20benzimidazoles;
pyridines;
sulfoxide		anti-ulcer drug;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor
leflunomide[no description available]medium30(trifluoromethyl)benzenes;
isoxazoles;
monocarboxylic acid amide		antineoplastic agent;
antiparasitic agent;
EC 1.3.98.1 [dihydroorotate oxidase (fumarate)] inhibitor;
EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor;
hepatotoxic agent;
immunosuppressive agent;
non-steroidal anti-inflammatory drug;
prodrug;
pyrimidine synthesis inhibitor;
tyrosine kinase inhibitor
linopirdine[no description available]medium10indoles
loratadine[no description available]medium30benzocycloheptapyridine;
ethyl ester;
N-acylpiperidine;
organochlorine compound;
tertiary carboxamide		anti-allergic agent;
cholinergic antagonist;
geroprotector;
H1-receptor antagonist
loxoprofen[no description available]medium10cyclopentanones;
monocarboxylic acid		antipyretic;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
prodrug
meclofenamate sodium anhydrous[no description available]medium20organic sodium salt
methiothepin[no description available]medium20aryl sulfide;
dibenzothiepine;
N-alkylpiperazine;
tertiary amino compound		antipsychotic agent;
dopaminergic antagonist;
geroprotector;
serotonergic antagonist
methoctramine[no description available]medium10aromatic ether;
tetramine		muscarinic antagonist
nocodazole[no description available]medium30aromatic ketone;
benzimidazoles;
carbamate ester;
thiophenes		antimitotic;
antineoplastic agent;
microtubule-destabilising agent;
tubulin modulator
3-Hydroxy-alpha-methyl-DL-tyrosine[no description available]medium10benzenes;
monocarboxylic acid
metolazone[no description available]medium10organochlorine compound;
quinazolines;
sulfonamide		antihypertensive agent;
diuretic;
ion transport inhibitor
minoxidil[no description available]medium20dialkylarylamine;
tertiary amino compound
mitotane[no description available]medium10diarylmethane
mitoxantrone[no description available]medium30dihydroxyanthraquinoneanalgesic;
antineoplastic agent
ml 7[no description available]medium10N-sulfonyldiazepane;
organoiodine compound		EC 2.7.11.18 (myosin-light-chain kinase) inhibitor
n-(4-aminobutyl)-5-chloro-2-naphthalenesulfonamide[no description available]medium10naphthalenes;
organochlorine compound;
primary amino compound;
sulfonamide
n-bromoacetamide[no description available]medium10
ethylmaleimide[no description available]medium40maleimidesanticoronaviral agent;
EC 1.3.1.8 [acyl-CoA dehydrogenase (NADP(+))] inhibitor;
EC 2.1.1.122 [(S)-tetrahydroprotoberberine N-methyltransferase] inhibitor;
EC 2.7.1.1 (hexokinase) inhibitor
fg 7142[no description available]medium20beta-carbolines
fenamic acid[no description available]medium10aminobenzoic acid;
secondary amino compound		membrane transport modulator
n 0840[no description available]medium10
nialamide[no description available]medium20organonitrogen compound;
organooxygen compound
niflumic acid[no description available]medium20aromatic carboxylic acid;
pyridines
nilutamide[no description available]medium10(trifluoromethyl)benzenes;
C-nitro compound;
imidazolidinone		androgen antagonist;
antineoplastic agent
nimesulide[no description available]medium50aromatic ether;
C-nitro compound;
sulfonamide		cyclooxygenase 2 inhibitor;
non-steroidal anti-inflammatory drug
nimodipine[no description available]medium302-methoxyethyl ester;
C-nitro compound;
dicarboxylic acids and O-substituted derivatives;
diester;
dihydropyridine;
isopropyl ester		antihypertensive agent;
calcium channel blocker;
cardiovascular drug;
vasodilator agent
nipecotic acid[no description available]medium10beta-amino acid;
piperidinemonocarboxylic acid
masoprocol[no description available]medium10catechols;
lignan;
tetrol		antioxidant;
ferroptosis inhibitor;
geroprotector;
plant metabolite
5-nitro-2-(3-phenylpropylamino)benzoic acid[no description available]medium10nitrobenzoic acid
ns 2028[no description available]medium20
ns 1619[no description available]medium10(trifluoromethyl)benzenes;
benzimidazoles;
phenols		potassium channel opener
o(6)-benzylguanine[no description available]medium10
ofloxacin[no description available]medium403-oxo monocarboxylic acid;
N-arylpiperazine;
N-methylpiperazine;
organofluorine compound;
oxazinoquinoline
olomoucine[no description available]medium102,6-diaminopurines;
ethanolamines		EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
oxaprozin[no description available]medium101,3-oxazoles;
monocarboxylic acid		analgesic;
non-steroidal anti-inflammatory drug
oxatomide[no description available]medium10benzimidazoles;
diarylmethane;
N-alkylpiperazine		anti-allergic agent;
anti-inflammatory agent;
geroprotector;
H1-receptor antagonist;
serotonergic antagonist
oxiracetam[no description available]medium10organonitrogen compound;
organooxygen compound
oxolinic acid[no description available]medium10aromatic carboxylic acid;
organic heterotricyclic compound;
oxacycle;
quinolinemonocarboxylic acid;
quinolone antibiotic		antibacterial drug;
antifungal agent;
antiinfective agent;
antimicrobial agent;
enzyme inhibitor
quinone[no description available]medium101,4-benzoquinonescofactor;
human xenobiotic metabolite;
mouse metabolite
fenclonine[no description available]medium30phenylalanine derivative
palmidrol[no description available]medium20endocannabinoid;
N-(long-chain-acyl)ethanolamine;
N-(saturated fatty acyl)ethanolamine		anti-inflammatory drug;
anticonvulsant;
antihypertensive agent;
neuroprotective agent
1,7-dimethylxanthine[no description available]medium10dimethylxanthinecentral nervous system stimulant;
human blood serum metabolite;
human xenobiotic metabolite;
mouse metabolite
pentamidine[no description available]medium10aromatic ether;
carboxamidine;
diether		anti-inflammatory agent;
antifungal agent;
calmodulin antagonist;
chemokine receptor 5 antagonist;
EC 2.3.1.48 (histone acetyltransferase) inhibitor;
NMDA receptor antagonist;
S100 calcium-binding protein B inhibitor;
trypanocidal drug;
xenobiotic
perphenazine[no description available]medium20N-(2-hydroxyethyl)piperazine;
N-alkylpiperazine;
organochlorine compound;
phenothiazines		antiemetic;
dopaminergic antagonist;
phenothiazine antipsychotic drug
phenyl biguanide[no description available]medium10guanidinescentral nervous system drug
phenylbutazone[no description available]medium20pyrazolidinesantirheumatic drug;
EC 1.1.1.184 [carbonyl reductase (NADPH)] inhibitor;
metabolite;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
peripheral nervous system drug
phloretin[no description available]medium10dihydrochalconesantineoplastic agent;
plant metabolite
picotamide[no description available]medium10benzamides
pinacidil[no description available]medium20pyridines
pindolol[no description available]medium10indoles;
secondary amine		antiglaucoma drug;
antihypertensive agent;
beta-adrenergic antagonist;
serotonergic antagonist;
vasodilator agent
piperidine-4-sulfonic acid[no description available]medium10
piracetam[no description available]medium20organonitrogen compound;
organooxygen compound
pirenperone[no description available]medium20aromatic ketone
praziquantel[no description available]medium30isoquinolines
primidone[no description available]medium20pyrimidoneanticonvulsant;
environmental contaminant;
xenobiotic
proglumide[no description available]medium10benzamides;
dicarboxylic acid monoamide;
glutamine derivative;
racemate		anti-ulcer drug;
cholecystokinin antagonist;
cholinergic antagonist;
delta-opioid receptor agonist;
drug metabolite;
gastrointestinal drug;
opioid analgesic;
xenobiotic metabolite
propentofylline[no description available]medium30oxopurine
propofol[no description available]medium20phenolsanticonvulsant;
antiemetic;
intravenous anaesthetic;
radical scavenger;
sedative
pf 5901[no description available]medium20quinolines
riluzole[no description available]medium20benzothiazoles
ritanserin[no description available]medium20organofluorine compound;
piperidines;
thiazolopyrimidine		antidepressant;
antipsychotic agent;
anxiolytic drug;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
serotonergic antagonist
salmeterol xinafoate[no description available]medium10ether;
phenols;
primary alcohol;
secondary alcohol;
secondary amino compound
sb 202190[no description available]medium20imidazoles;
organofluorine compound;
phenols;
pyridines		apoptosis inducer;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
sobuzoxane[no description available]medium10organic molecular entity
spiroxatrine[no description available]medium10imidazolidines
sq 22536[no description available]medium20nucleoside analogue;
oxolanes		EC 4.6.1.1 (adenylate cyclase) inhibitor
sulfaphenazole[no description available]medium10primary amino compound;
pyrazoles;
substituted aniline;
sulfonamide antibiotic;
sulfonamide		antibacterial drug;
EC 1.14.13.181 (13-deoxydaunorubicin hydroxylase) inhibitor;
EC 1.14.13.67 (quinine 3-monooxygenase) inhibitor;
P450 inhibitor
sulpiride[no description available]medium10benzamides;
N-alkylpyrrolidine;
sulfonamide		antidepressant;
antiemetic;
antipsychotic agent;
dopaminergic antagonist
t0156[no description available]medium20naphthyridine derivative
1,4-bis(2-(3,5-dichloropyridyloxy))benzene[no description available]medium10
tetraisopropylpyrophosphamide[no description available]medium10phosphoramide
theobromine[no description available]medium10dimethylxanthineadenosine receptor antagonist;
bronchodilator agent;
food component;
human blood serum metabolite;
mouse metabolite;
plant metabolite;
vasodilator agent
8-(n,n-diethylamino)octyl-3,4,5-trimethoxybenzoate[no description available]medium20trihydroxybenzoic acid
tolazamide[no description available]medium20N-sulfonylureahypoglycemic agent;
potassium channel blocker
tolbutamide[no description available]medium20N-sulfonylureahuman metabolite;
hypoglycemic agent;
insulin secretagogue;
potassium channel blocker
(1,2,5,6-tetrahydropyridin-4-yl)methylphosphinic acid[no description available]medium10
ici 136,753[no description available]medium10pyrazolopyridine
triamterene[no description available]medium20pteridinesdiuretic;
sodium channel blocker
trimethoprim[no description available]medium30aminopyrimidine;
methoxybenzenes		antibacterial drug;
diuretic;
drug allergen;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
environmental contaminant;
xenobiotic
tropicamide[no description available]medium10acetamides
tyrphostin a9[no description available]medium20alkylbenzenegeroprotector
vigabatrin[no description available]medium10gamma-amino acidanticonvulsant;
EC 2.6.1.19 (4-aminobutyrate--2-oxoglutarate transaminase) inhibitor
8-(4-((2-aminoethyl)aminocarbonylmethyloxy)phenyl)-1,3-dipropylxanthine[no description available]medium10
3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole[no description available]medium10aromatic primary alcohol;
furans;
indazoles		antineoplastic agent;
apoptosis inducer;
platelet aggregation inhibitor;
soluble guanylate cyclase activator;
vasodilator agent
cortisone acetate[no description available]medium10corticosteroid hormone
corticosterone[no description available]medium10011beta-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone		human metabolite;
mouse metabolite
procaine hydrochloride[no description available]medium10organic molecular entity
isoproterenol hydrochloride[no description available]medium10catechols
histamine dihydrochloride[no description available]medium10
carbachol[no description available]medium140ammonium salt;
carbamate ester		cardiotonic drug;
miotic;
muscarinic agonist;
nicotinic acetylcholine receptor agonist;
non-narcotic analgesic
spironolactone[no description available]medium103-oxo-Delta(4) steroid;
oxaspiro compound;
steroid lactone;
thioester		aldosterone antagonist;
antihypertensive agent;
diuretic;
environmental contaminant;
xenobiotic
estrone[no description available]medium3017-oxo steroid;
3-hydroxy steroid;
phenolic steroid;
phenols		antineoplastic agent;
bone density conservation agent;
estrogen;
human metabolite;
mouse metabolite
androsterone[no description available]medium2017-oxo steroid;
3alpha-hydroxy steroid;
androstanoid;
C19-steroid		androgen;
anticonvulsant;
human blood serum metabolite;
human metabolite;
human urinary metabolite;
mouse metabolite;
pheromone
promazine hydrochloride[no description available]medium20hydrochloride
pilocarpine hydrochloride[no description available]medium20hydrochloride
dimethylphenylpiperazinium iodide[no description available]medium20N-arylpiperazine;
organic iodide salt;
piperazinium salt;
quaternary ammonium salt		nicotinic acetylcholine receptor agonist
pentylenetetrazole[no description available]medium10organic heterobicyclic compound;
organonitrogen heterocyclic compound
racepinephrine hydrochloride[no description available]medium10
(4-(m-chlorophenylcarbamoyloxy)-2-butynyl)trimethylammonium chloride[no description available]medium10
hexamethonium bromide[no description available]medium10
cystamine dihydrochloride[no description available]medium10
cantharidin[no description available]medium10cyclic dicarboxylic anhydride;
monoterpenoid		EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor;
herbicide
aspartic acid[no description available]medium30aspartate family amino acid;
aspartic acid;
L-alpha-amino acid;
proteinogenic amino acid		Escherichia coli metabolite;
mouse metabolite;
neurotransmitter
glutamine[no description available]medium10amino acid zwitterion;
glutamine family amino acid;
glutamine;
L-alpha-amino acid;
polar amino acid zwitterion;
proteinogenic amino acid		EC 1.14.13.39 (nitric oxide synthase) inhibitor;
Escherichia coli metabolite;
human metabolite;
metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite
vincristine[no description available]medium10acetate ester;
formamides;
methyl ester;
organic heteropentacyclic compound;
organic heterotetracyclic compound;
tertiary alcohol;
tertiary amino compound;
vinca alkaloid		antineoplastic agent;
drug;
microtubule-destabilising agent;
plant metabolite;
tubulin modulator
physostigmine[no description available]medium20carbamate ester;
indole alkaloid		antidote to curare poisoning;
EC 3.1.1.8 (cholinesterase) inhibitor;
miotic
apomorphine[no description available]medium40aporphine alkaloidalpha-adrenergic drug;
antidyskinesia agent;
antiparkinson drug;
dopamine agonist;
emetic;
serotonergic drug
promethazine hydrochloride[no description available]medium20hydrochlorideanti-allergic agent;
anticoronaviral agent;
antiemetic;
antipruritic drug;
geroprotector;
H1-receptor antagonist;
local anaesthetic;
sedative
bromodeoxyuridine[no description available]medium40pyrimidine 2'-deoxyribonucleosideantimetabolite;
antineoplastic agent
levodopa[no description available]medium30amino acid zwitterion;
dopa;
L-tyrosine derivative;
non-proteinogenic L-alpha-amino acid		allelochemical;
antidyskinesia agent;
antiparkinson drug;
dopaminergic agent;
hapten;
human metabolite;
mouse metabolite;
neurotoxin;
plant growth retardant;
plant metabolite;
prodrug
methoxamine hydrochloride[no description available]medium20dimethoxybenzene
papaverine hydrochloride[no description available]medium30
bretylium tosylate[no description available]medium20organosulfonate salt;
quaternary ammonium salt		adrenergic antagonist;
anti-arrhythmia drug;
antihypertensive agent
berlition[no description available]medium10dithiolanes;
heterocyclic fatty acid;
lipoic acid;
thia fatty acid		cofactor;
nutraceutical;
prosthetic group
methacholine chloride[no description available]medium100quaternary ammonium salt
androstenedione[no description available]medium2017-oxo steroid;
3-oxo-Delta(4) steroid;
androstanoid		androgen;
Daphnia magna metabolite;
human metabolite;
mouse metabolite
colchicine[no description available]medium20alkaloid;
colchicine		anti-inflammatory agent;
gout suppressant;
mutagen
yohimbine hydrochloride[no description available]medium10
gallamine triethiodide[no description available]medium10
cycloheximide[no description available]medium80antibiotic fungicide;
cyclic ketone;
dicarboximide;
piperidine antibiotic;
piperidones;
secondary alcohol		anticoronaviral agent;
bacterial metabolite;
ferroptosis inhibitor;
neuroprotective agent;
protein synthesis inhibitor
egtazic acid[no description available]medium30diether;
tertiary amino compound;
tetracarboxylic acid		chelator
cycloserine[no description available]medium104-amino-1,2-oxazolidin-3-one;
organonitrogen heterocyclic antibiotic;
organooxygen heterocyclic antibiotic;
zwitterion		antiinfective agent;
antimetabolite;
antitubercular agent;
metabolite;
NMDA receptor agonist
17-alpha-hydroxyprogesterone[no description available]medium2017alpha-hydroxy-C21-steroid;
17alpha-hydroxy steroid;
tertiary alpha-hydroxy ketone		human metabolite;
metabolite;
mouse metabolite;
progestin
quinacrine monohydrochloride[no description available]medium10
chlorpromazine hydrochloride[no description available]medium20hydrochloride;
phenothiazines		anticoronaviral agent;
phenothiazine antipsychotic drug
cytarabine hydrochloride[no description available]medium20
tryptophan[no description available]high30erythrose 4-phosphate/phosphoenolpyruvate family amino acid;
L-alpha-amino acid zwitterion;
L-alpha-amino acid;
proteinogenic amino acid;
tryptophan zwitterion;
tryptophan		antidepressant;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite
lidocaine hydrochloride[no description available]medium20hydrochlorideanti-arrhythmia drug;
local anaesthetic
arginine[no description available]medium30arginine;
glutamine family amino acid;
L-alpha-amino acid;
proteinogenic amino acid		biomarker;
Escherichia coli metabolite;
micronutrient;
mouse metabolite;
nutraceutical
synephrine[no description available]medium10ethanolamines;
phenethylamine alkaloid;
phenols		alpha-adrenergic agonist;
plant metabolite
pyridostigmine bromide[no description available]medium20pyridinium salt
imipramine hydrochloride[no description available]medium20hydrochlorideantidepressant
neostigmine bromide[no description available]medium30bromide salt
edrophonium chloride[no description available]medium20chloride salt;
quaternary ammonium salt		antidote;
diagnostic agent;
EC 3.1.1.8 (cholinesterase) inhibitor
suramin sodium[no description available]medium10organic sodium saltangiogenesis inhibitor;
antinematodal drug;
antineoplastic agent;
apoptosis inhibitor;
EC 2.7.11.13 (protein kinase C) inhibitor;
GABA antagonist;
GABA-gated chloride channel antagonist;
purinergic receptor P2 antagonist;
ryanodine receptor agonist;
trypanocidal drug
pyrazolanthrone[no description available]medium40anthrapyrazole;
aromatic ketone;
cyclic ketone		antineoplastic agent;
c-Jun N-terminal kinase inhibitor;
geroprotector
methapyrilene hydrochloride[no description available]medium20hydrochlorideanti-allergic agent;
carcinogenic agent;
H1-receptor antagonist;
sedative
tetrracaine hydrochloride[no description available]medium20benzoate ester
chelidamic acid[no description available]medium10
diphenhydramine hydrochloride[no description available]medium20hydrochloride;
organoammonium salt		anti-allergic agent;
antiemetic;
antiparkinson drug;
antipruritic drug;
H1-receptor antagonist;
local anaesthetic;
muscarinic antagonist;
sedative
cysteamine hydrochloride[no description available]medium10
propantheline bromide[no description available]medium20xanthenes
hydralazine hydrochloride[no description available]medium10hydrochlorideantihypertensive agent;
vasodilator agent
ethamivan[no description available]medium20methoxybenzenes;
phenols
pargyline hydrochloride[no description available]medium20
azacitidine[no description available]medium20N-glycosyl-1,3,5-triazine;
nucleoside analogue		antineoplastic agent
orphenadrine hydrochloride[no description available]medium20hydrochlorideantiparkinson drug;
H1-receptor antagonist;
muscarinic antagonist;
muscle relaxant;
NMDA receptor antagonist;
parasympatholytic
betamethasone[no description available]medium1011beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
fluorinated steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		anti-asthmatic agent;
anti-inflammatory drug;
immunosuppressive agent
benzenaminium, 4,4'-(3-oxo-1,5-pentanediyl)bis(n,n-dimethyl-n-2-propenyl-), dibromide[no description available]medium10
cyproterone acetate[no description available]medium1020-oxo steroid;
3-oxo-Delta(4) steroid;
acetate ester;
chlorinated steroid;
steroid ester		androgen antagonist;
geroprotector;
progestin
kainic acid[no description available]medium10dicarboxylic acid;
L-proline derivative;
non-proteinogenic L-alpha-amino acid;
pyrrolidinecarboxylic acid		antinematodal drug;
excitatory amino acid agonist
podophyllotoxin[no description available]medium20furonaphthodioxole;
lignan;
organic heterotetracyclic compound		antimitotic;
antineoplastic agent;
keratolytic drug;
microtubule-destabilising agent;
plant metabolite;
tubulin modulator
tetrahydrozoline hydrochloride[no description available]medium20hydrochloridenasal decongestant;
sympathomimetic agent;
vasoconstrictor agent
dequalinium chloride[no description available]medium10organic chloride saltantifungal agent;
antineoplastic agent;
antiseptic drug;
mitochondrial NADH:ubiquinone reductase inhibitor
decamethonium dibromide[no description available]medium10
amitriptyline hydrochloride[no description available]medium20organic tricyclic compound
naphazoline hydrochloride[no description available]medium20organic molecular entity
doxylamine succinate[no description available]medium20organic molecular entity
carbamylhydrazine monohydrochloride[no description available]medium10organic molecular entity
formestane[no description available]medium2017-oxo steroid;
3-oxo-Delta(4) steroid;
enol;
hydroxy steroid		antineoplastic agent;
EC 1.14.14.14 (aromatase) inhibitor
debrisoquin sulfate[no description available]medium10organic sulfate salt
betaine hydrochloride[no description available]medium10
bethanechol chloride[no description available]medium20carbamate ester;
chloride salt;
quaternary ammonium salt		muscarinic agonist
acetylcysteine[no description available]medium50acetylcysteine;
L-cysteine derivative;
N-acetyl-L-amino acid		antidote to paracetamol poisoning;
antiinfective agent;
antioxidant;
antiviral drug;
ferroptosis inhibitor;
geroprotector;
human metabolite;
mucolytic;
radical scavenger;
vulnerary
Mecamylamine hydrochloride[no description available]medium10monoterpenoid
vinblastine[no description available]medium10
cyproheptadine hydrochloride (anhydrous)[no description available]medium20hydrochloride
5 alpha-androstane-3 alpha,17 beta-diol[no description available]medium20androstane-3alpha,17beta-diolDaphnia magna metabolite;
human metabolite
pimozide[no description available]medium20benzimidazoles;
heteroarylpiperidine;
organofluorine compound		antidyskinesia agent;
dopaminergic antagonist;
first generation antipsychotic;
H1-receptor antagonist;
serotonergic antagonist
azetidyl-2-carboxylic acid[no description available]medium10azetidine-2-carboxylic acid
muscarine[no description available]medium10
antazoline hydrochloride[no description available]medium20
doxifluridine[no description available]medium10organofluorine compound;
pyrimidine 5'-deoxyribonucleoside		antimetabolite;
antineoplastic agent;
prodrug
meclofenoxate hydrochloride[no description available]medium10
clonidine hydrochloride[no description available]medium10dichlorobenzene
beclomethasone[no description available]medium2011beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
chlorinated steroid;
corticosteroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		anti-asthmatic drug;
anti-inflammatory drug
buthionine sulfoximine[no description available]medium20diastereoisomeric mixture;
homocysteines;
non-proteinogenic alpha-amino acid;
sulfoximide		EC 6.3.2.2 (glutamate--cysteine ligase) inhibitor;
ferroptosis inducer
mexiletine hydrochloride[no description available]medium10hydrochlorideanti-arrhythmia drug
cyclophosphamide[no description available]medium10hydratealkylating agent;
antineoplastic agent;
carcinogenic agent;
immunosuppressive agent
suxamethonium chloride[no description available]medium10chloride saltmuscle relaxant
cyclobenzaprine hydrochloride[no description available]medium10hydrochlorideantidepressant;
muscle relaxant
n-methylaspartate[no description available]medium50amino dicarboxylic acid;
D-alpha-amino acid;
D-aspartic acid derivative;
secondary amino compound		neurotransmitter agent
3-deazaadenosine[no description available]medium20
metoclopramide hydrochloride[no description available]medium20
isoetharine mesylate[no description available]medium20
zalcitabine[no description available]medium20pyrimidine 2',3'-dideoxyribonucleosideantimetabolite;
antiviral drug;
HIV-1 reverse transcriptase inhibitor
propionylpromazine hydrochloride[no description available]medium10
nsc-145,668[no description available]medium10hydrochlorideantimetabolite;
antineoplastic agent
clodronic acid[no description available]medium301,1-bis(phosphonic acid);
one-carbon compound;
organochlorine compound		antineoplastic agent;
bone density conservation agent
benserazide hydrochloride[no description available]medium20hydrochlorideantiparkinson drug;
dopaminergic agent;
EC 4.1.1.28 (aromatic-L-amino-acid decarboxylase) inhibitor
pancuronium bromide[no description available]medium10bromide saltcholinergic antagonist;
muscle relaxant;
nicotinic antagonist
tetradecanoylphorbol acetate[no description available]medium210acetate ester;
diester;
phorbol ester;
tertiary alpha-hydroxy ketone;
tetradecanoate ester		antineoplastic agent;
apoptosis inducer;
carcinogenic agent;
mitogen;
plant metabolite;
protein kinase C agonist;
reactive oxygen species generator
danazol[no description available]medium1017beta-hydroxy steroid;
terminal acetylenic compound		anti-estrogen;
estrogen antagonist;
geroprotector
metergoline[no description available]medium30carbamate ester;
ergoline alkaloid		dopamine agonist;
geroprotector;
serotonergic antagonist
lisuride[no description available]medium30monocarboxylic acid amideantidyskinesia agent;
antiparkinson drug;
dopamine agonist;
serotonergic agonist
lisuride[no description available]medium31monocarboxylic acid amideantidyskinesia agent;
antiparkinson drug;
dopamine agonist;
serotonergic agonist
disopyramide phosphate[no description available]medium10organoammonium phosphate
bromocriptine[no description available]medium10indole alkaloidantidyskinesia agent;
antiparkinson drug;
dopamine agonist;
hormone antagonist
ergocristine[no description available]medium10ergot alkaloid
triamcinolone[no description available]medium1011beta-hydroxy steroid;
16alpha-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
C21-steroid hormone;
fluorinated steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		anti-allergic agent;
anti-inflammatory drug
zidovudine[no description available]medium30azide;
pyrimidine 2',3'-dideoxyribonucleoside		antimetabolite;
antiviral drug;
HIV-1 reverse transcriptase inhibitor
buspirone hydrochloride[no description available]medium20hydrochlorideanxiolytic drug;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
sedative;
serotonergic agonist
etoposide[no description available]medium30beta-D-glucoside;
furonaphthodioxole;
organic heterotetracyclic compound		antineoplastic agent;
DNA synthesis inhibitor
propafenone hydrochloride[no description available]medium20hydrochlorideanti-arrhythmia drug
etazolate hydrochloride[no description available]medium10
butaclamol[no description available]medium20amino alcohol;
organic heteropentacyclic compound;
tertiary alcohol;
tertiary amino compound		dopaminergic antagonist
ribavirin[no description available]medium201-ribosyltriazole;
aromatic amide;
monocarboxylic acid amide;
primary carboxamide		anticoronaviral agent;
antiinfective agent;
antimetabolite;
antiviral agent;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
carbidopa[no description available]medium10catechols;
hydrate;
hydrazines;
monocarboxylic acid		antidyskinesia agent;
antiparkinson drug;
dopaminergic agent;
EC 4.1.1.28 (aromatic-L-amino-acid decarboxylase) inhibitor
cephradine[no description available]medium10beta-lactam antibiotic allergen;
cephalosporin		antibacterial drug
methyldopa[no description available]medium10L-tyrosine derivative;
non-proteinogenic L-alpha-amino acid		alpha-adrenergic agonist;
antihypertensive agent;
hapten;
peripheral nervous system drug;
sympatholytic agent
lonidamine[no description available]medium10dichlorobenzene;
indazoles;
monocarboxylic acid		antineoplastic agent;
antispermatogenic agent;
EC 2.7.1.1 (hexokinase) inhibitor;
geroprotector
dexibuprofen[no description available]medium10ibuprofennon-narcotic analgesic;
non-steroidal anti-inflammatory drug
quisqualic acid[no description available]medium10non-proteinogenic alpha-amino acid
pirfenidone[no description available]medium20pyridoneantipyretic;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
flecainide acetate[no description available]medium20acetate saltanti-arrhythmia drug
nicardipine hydrochloride[no description available]medium20dihydropyridinegeroprotector
idarubicin[no description available]medium10anthracycline antibiotic;
deoxy hexoside;
monosaccharide derivative
captopril[no description available]medium40alkanethiol;
L-proline derivative;
N-acylpyrrolidine;
pyrrolidinemonocarboxylic acid		antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
terazosin hydrochloride anhydrous[no description available]medium20
pergolide mesylate[no description available]medium20methanesulfonate saltantiparkinson drug;
dopamine agonist;
geroprotector
ranitidine hydrochloride[no description available]medium10
cefaclor anhydrous[no description available]medium10cephalosporinantibacterial drug;
drug allergen
alo 2145[no description available]medium10hydrochloridealpha-adrenergic agonist;
antiglaucoma drug
atomoxetine[no description available]medium10aromatic ether;
secondary amino compound;
toluenes		adrenergic uptake inhibitor;
antidepressant;
environmental contaminant;
xenobiotic
raloxifene hydrochloride[no description available]medium20hydrochloridebone density conservation agent;
estrogen antagonist;
estrogen receptor modulator
mifepristone[no description available]medium603-oxo-Delta(4) steroid;
acetylenic compound;
tertiary amino compound		abortifacient;
contraceptive drug;
hormone antagonist;
synthetic oral contraceptive
quinpirole hydrochloride[no description available]medium10
mibefradil dihydrochloride[no description available]medium10
aptiganel hydrochloride[no description available]medium10
phenelzine sulfate[no description available]medium10organic molecular entity
fluoxetine hydrochloride[no description available]medium20hydrochloride;
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine
propranolol hydrochloride[no description available]medium10hydrochloride
bupropion hydrochloride[no description available]medium10aromatic ketone
diltiazem hydrochloride[no description available]medium20hydrochlorideantihypertensive agent;
calcium channel blocker;
vasodilator agent
trazodone hydrochloride[no description available]medium30hydrochlorideadrenergic antagonist;
antidepressant;
H1-receptor antagonist;
sedative;
serotonin uptake inhibitor
verapamil hydrochloride[no description available]medium20
doxazosin mesylate[no description available]medium20methanesulfonate saltgeroprotector
terfenadine[no description available]medium10diarylmethane
amantadine hydrochloride[no description available]medium20hydrochlorideantiviral agent;
dopamine agonist;
NMDA receptor antagonist
chloroquine diphosphate[no description available]medium10
dobutamine hydrochloride[no description available]medium10hydrochloridebeta-adrenergic agonist;
cardiotonic drug;
sympathomimetic agent
desipramine hydrochloride[no description available]medium30hydrochloridedrug allergen
dopamine hydrochloride[no description available]medium20catecholamine
proadifen hydrochloride[no description available]medium10
4-nitrobenzylthioinosine[no description available]medium10purine nucleoside
metrifudil[no description available]medium10
rutecarpine[no description available]medium10beta-carbolines
trihexyphenidyl hydrochloride[no description available]medium20aralkylamine
thioridazine hydrochloride[no description available]medium20hydrochloridefirst generation antipsychotic;
geroprotector
procainamide hydrochloride[no description available]medium20hydrochlorideanti-arrhythmia drug
siquil[no description available]medium20hydrochlorideanticoronaviral agent
sotalol hydrochloride[no description available]medium10hydrochlorideanti-arrhythmia drug;
beta-adrenergic antagonist
oxymetazoline hydrochloride[no description available]medium20hydrochloridealpha-adrenergic agonist;
nasal decongestant;
sympathomimetic agent;
vasoconstrictor agent
alprenolol hydrochloride[no description available]medium20hydrochloride
2-methoxyestradiol[no description available]medium2017beta-hydroxy steroid;
3-hydroxy steroid		angiogenesis modulating agent;
antimitotic;
antineoplastic agent;
human metabolite;
metabolite;
mouse metabolite
fluphenazine hydrochloride[no description available]medium10phenothiazinesanticoronaviral agent
tryptamine monohydrochloride[no description available]medium10
clomipramine hydrochloride[no description available]medium20hydrochlorideanticoronaviral agent;
antidepressant;
serotonergic antagonist;
serotonergic drug
amiloride hydrochloride[no description available]medium10hydratediuretic;
sodium channel blocker
prazosin hydrochloride[no description available]medium20hydrochloride
mianserin hydrochloride[no description available]medium20hydrochloridegeroprotector
lomefloxacin hydrochloride[no description available]medium10hydrochlorideantimicrobial agent;
antitubercular agent;
photosensitizing agent
fenspiride hydrochloride[no description available]medium10
nilverm[no description available]medium10organic molecular entity
sanguinarine chloride[no description available]medium10
ropinirole hydrochloride[no description available]medium10indoles
plasmenylserine[no description available]medium10O-phosphoserineEC 1.4.7.1 [glutamate synthase (ferredoxin)] inhibitor;
EC 2.5.1.49 (O-acetylhomoserine aminocarboxypropyltransferase) inhibitor;
EC 4.3.1.10 (serine-sulfate ammonia-lyase) inhibitor;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
5-aminovaleric acid hydrochloride[no description available]medium10
n-acetyltryptamine[no description available]medium10acetamides;
indoles
D-serine[no description available]medium10D-alpha-amino acid;
serine zwitterion;
serine		Escherichia coli metabolite;
human metabolite;
NMDA receptor agonist
dihydroergotamine mesylate[no description available]medium10methanesulfonate saltnon-narcotic analgesic;
serotonergic agonist;
vasoconstrictor agent
ranolazine hydrochloride[no description available]medium10
loxapine succinate[no description available]medium20succinate saltgeroprotector
guanfacine hydrochloride[no description available]medium20acetamidesgeroprotector
pirenzepine dihydrochloride[no description available]medium10hydrochloride
labetalol hydrochloride[no description available]medium20salicylamides
acecainide hydrochloride[no description available]medium20
loperamide hydrochloride[no description available]medium20hydrochlorideanticoronaviral agent;
antidiarrhoeal drug;
mu-opioid receptor agonist
maprotiline hydrochloride[no description available]medium20anthracenes
protoporphyrin ix, disodium salt[no description available]medium10
siguazodan[no description available]medium220pyridazinone
3-octadecanamido-2-ethoxypropylphosphocholine[no description available]medium10
chelerythrine chloride[no description available]medium10
tosyllysine chloromethyl ketone[no description available]medium10
5-(n-methyl-n-isobutyl)amiloride[no description available]medium10
1-(5-isoquinolinesulfonyl)-2-methylpiperazine dihydrochloride[no description available]medium10hydrochlorideEC 2.7.11.13 (protein kinase C) inhibitor
amperozide hydrochloride[no description available]medium10hydrochlorideanxiolytic drug;
dopamine uptake inhibitor;
geroprotector;
second generation antipsychotic;
serotonergic antagonist
pyrrolidine dithiocarbamic acid[no description available]medium10
agroclavine[no description available]medium10ergot alkaloid
s-methylisothiourea sulfate[no description available]medium10
p-Aminobenzamidine dihydrochloride[no description available]medium10organic molecular entity
benzamidine hydrochloride[no description available]medium10
ketorolac tromethamine[no description available]medium10organoammonium saltanalgesic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor
methionine sulfoximine[no description available]medium10L-alpha-amino acid zwitterion;
L-methionine derivative;
methionine sulfoximine;
non-proteinogenic L-alpha-amino acid		EC 6.3.1.2 (glutamate--ammonia ligase) inhibitor;
geroprotector
tretazicar[no description available]medium10
carbetapentane citrate[no description available]medium10carbonyl compound
phentolamine mesylate[no description available]medium20
mephentermine[no description available]medium102-aminooctadecane-1,3-diolEC 2.7.11.13 (protein kinase C) inhibitor;
human metabolite;
mouse metabolite
oxybutynin hydrochloride[no description available]medium20hydrochloride
nimustine[no description available]medium10hydrochlorideantineoplastic agent
cordium[no description available]medium10hydrate;
hydrochloride
L-2-aminoadipic acid[no description available]medium102-aminoadipic acidEscherichia coli metabolite;
human metabolite
prilocaine hydrochloride[no description available]medium20hydrochloridelocal anaesthetic
mor-14[no description available]medium10hydroxypiperidine;
piperidine alkaloid;
tertiary amino compound		anti-HIV agent;
cardioprotective agent;
EC 3.2.1.20 (alpha-glucosidase) inhibitor;
plant metabolite
brexanolone[no description available]medium103-hydroxy-5alpha-pregnan-20-oneantidepressant;
GABA modulator;
human metabolite;
intravenous anaesthetic;
sedative
hexamethonium chloride[no description available]medium10
6-(4-nitrobenzylthio)guanosine[no description available]medium10
3-aminopropylphosphonic acid[no description available]medium10phosphonic acids;
primary amino compound;
zwitterion		GABAB receptor agonist
5'-n-methylcarboxamideadenosine[no description available]medium10
3,7-dimethyl-1-propargylxanthine[no description available]medium10
zpck[no description available]medium10
tetrahydrodeoxycorticosterone[no description available]medium1021-hydroxy steroid
n-methyladenosine[no description available]medium20methyladenosine
mizoribine[no description available]medium20imidazolesanticoronaviral agent
1-amino-1,3-dicarboxycyclopentane[no description available]medium10
u 73122[no description available]medium20aromatic ether;
aza-steroid;
maleimides		EC 3.1.4.11 (phosphoinositide phospholipase C) inhibitor
alphaxalone[no description available]medium20corticosteroid hormone
s-nitrosoglutathione[no description available]medium20glutathione derivative;
nitrosothio compound		bronchodilator agent;
nitric oxide donor;
platelet aggregation inhibitor;
signalling molecule
cp-55,940[no description available]medium10
vanoxerine[no description available]medium10hydrochloridedopamine uptake inhibitor
methyl 6,7-dimethoxy-4-ethyl-beta-carboline-3-carboxylate[no description available]medium20beta-carbolines
u 69593[no description available]medium10monocarboxylic acid amide;
N-alkylpyrrolidine;
organic heterobicyclic compound;
oxaspiro compound		anti-inflammatory agent;
diuretic;
kappa-opioid receptor agonist
cv 3988[no description available]medium10
beta-carboline-3-carboxylic acid methyl ester[no description available]medium10beta-carbolines
methoctramine[no description available]medium20hydrochloridemuscarinic antagonist
hypotaurine[no description available]medium10aminosulfinic acid;
zwitterion		human metabolite;
metabolite;
mouse metabolite
dihydrokainate[no description available]medium10dicarboxylic acid
gabazine[no description available]medium10
cl 218872[no description available]medium10pyridazines;
ring assembly
betaxolol hydrochloride[no description available]medium20hydrochlorideantihypertensive agent;
beta-adrenergic antagonist
catechin[no description available]medium10hydrategeroprotector
1-(2-methoxyphenyl)-4-(4-(2-phthalimido)butyl)piperazine[no description available]medium10hydrobromideserotonergic antagonist
s-methylthiocitrulline[no description available]medium10imidothiocarbamic ester;
L-arginine derivative;
L-ornithine derivative;
non-proteinogenic L-alpha-amino acid		EC 1.14.13.39 (nitric oxide synthase) inhibitor;
neuroprotective agent
dihydrocapsaicin[no description available]medium10capsaicinoid
ml 9[no description available]medium20
parthenolide[no description available]medium10germacranolide
3',4'-dichlorobenzamil[no description available]medium10guanidines;
pyrazines
1-(carboxymethylthio)tetradecane[no description available]medium10straight-chain fatty acid
2-iodomelatonin[no description available]medium10acetamides
arcaine, sulfate[no description available]medium10
gr 113808[no description available]medium10indolyl carboxylate ester;
piperidines;
sulfonamide		serotonergic antagonist
gallopamil hydrochloride[no description available]medium20
gamma-glutamylaminomethylsulfonic acid[no description available]medium10
buthionine sulfoximine[no description available]medium102-amino-4-(S-butylsulfonimidoyl)butanoic acidEC 6.3.2.2 (glutamate--cysteine ligase) inhibitor;
ferroptosis inducer
sb 204070a[no description available]medium10
1-(2-(4-aminophenyl)ethyl)-4-(3-trifluoromethylphenyl)piperazine[no description available]medium10(trifluoromethyl)benzenes;
N-alkylpiperazine;
N-arylpiperazine;
primary arylamine;
substituted aniline		geroprotector;
serotonergic agonist
l 655240[no description available]medium10methylindole
san 58035[no description available]medium10
nnc 711[no description available]medium10
4-(alpha-(4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl)-n,n-diethylbenzamide[no description available]medium10diarylmethane
e 64[no description available]medium20dicarboxylic acid monoamide;
epoxy monocarboxylic acid;
guanidines;
L-leucine derivative;
zwitterion		antimalarial;
antiparasitic agent;
protease inhibitor
azetidine-2,4-dicarboxylic acid[no description available]medium10
pre 084[no description available]medium10morpholines
methotrexate[no description available]medium40dicarboxylic acid;
monocarboxylic acid amide;
pteridines		abortifacient;
antimetabolite;
antineoplastic agent;
antirheumatic drug;
dermatologic drug;
DNA synthesis inhibitor;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
immunosuppressive agent
1-(2-allylphenoxy)-3-((8-bromoacetylamino-4-menthane-1-yl)amino)-1-propanol[no description available]medium10
sr 2640[no description available]medium10quinolines
ici 204448[no description available]medium10
4-amino-1-(6-chloro-2-pyridyl)piperidine hydrochloride[no description available]medium10
n,n-di-n-hexyl-2-(4-fluorophenyl)indole-3-acetamide[no description available]medium10phenylindole
3,5-bis(trifluoromethyl)benzyl n-acetyltryptophan[no description available]medium10
8-cyclopentyl-3-(3-((4-(fluorosulfonyl)benzoyl)oxy)propyl)-1-propylxanthine[no description available]medium10
l 741626[no description available]medium10piperidines
nisoxetine hydrochloride[no description available]medium10
ng-nitroarginine methyl ester[no description available]medium10hydrochlorideEC 1.14.13.39 (nitric oxide synthase) inhibitor
tilarginine acetate[no description available]medium10
alpha-guanidinoglutaric acid[no description available]medium10L-glutamic acid derivative
3,4-dichloro-n-methyl-n-(2-(1-pyrrolidinyl)cyclohexyl)-benzeneacetamide, (trans)-(+-)-isomer[no description available]medium20
imidazole-4-acetic acid hydrochloride[no description available]medium10
nsc-141549[no description available]medium10
2-chloro-2-deoxyglucose[no description available]medium10
idazoxan hydrochloride[no description available]medium20
isoguvacine hydrochloride[no description available]medium10
8-methoxymethyl-3-isobutyl-1-methylxanthine[no description available]medium40oxopurine
Serotonin hydrochloride[no description available]medium10tryptamines
n-phthaloylglutamic acid[no description available]medium10L-glutamic acid derivative;
phthalimides
1,3-dipropyl-7-methylxanthine[no description available]medium10
ag 3-5[no description available]medium10C-nitro compound
n-n-propylnorapomorphine[no description available]medium10aporphine alkaloid
urapidil monohydrochloride[no description available]medium10
aminopterin[no description available]medium10dicarboxylic acidEC 1.5.1.3 (dihydrofolate reductase) inhibitor;
mutagen
azepexole, dihydrochloride[no description available]medium10
2,5-dimethoxy-4-iodoamphetamine hydrochloride[no description available]medium10
abt 980[no description available]medium10
sk&f 75670[no description available]medium10
esatenolol[no description available]medium10atenololbeta-adrenergic antagonist
nbi 27914[no description available]medium10dialkylarylamine;
tertiary amino compound
sb 216763[no description available]medium10indoles;
maleimides
(R)-atenolol[no description available]medium10atenolol
memantine hydrochloride[no description available]medium10hydrochlorideantidepressant;
antiparkinson drug;
dopaminergic agent;
neuroprotective agent;
NMDA receptor antagonist
pefabloc[no description available]medium10
pongidae[no description available]medium10
succinylproline[no description available]medium10N-acyl-amino acid
sb 205384[no description available]medium10thienopyridine
hydrastine[no description available]medium10isoquinolinesmetabolite
gabaculine hydrochloride[no description available]medium10
etiron monohydrobromide[no description available]medium10
bmy 7378[no description available]medium10
vesamicol[no description available]medium10
cortisone[no description available]medium2011-oxo steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		human metabolite;
mouse metabolite
vincristine sulfate[no description available]medium10organic sulfate saltantineoplastic agent;
geroprotector
n-methylserotonin oxalate salt[no description available]medium10
nsc 95397[no description available]medium101,4-naphthoquinones
lithium chloride[no description available]medium20inorganic chloride;
lithium salt		antimanic drug;
geroprotector
canavanine[no description available]medium10amino acid zwitterion;
non-proteinogenic L-alpha-amino acid		phytogenic insecticide;
plant metabolite
5-hydroxytryptophan[no description available]medium105-hydroxytryptophan;
amino acid zwitterion;
hydroxy-L-tryptophan;
non-proteinogenic L-alpha-amino acid		human metabolite;
mouse metabolite;
plant metabolite
ouabain[no description available]medium3011alpha-hydroxy steroid;
14beta-hydroxy steroid;
5beta-hydroxy steroid;
alpha-L-rhamnoside;
cardenolide glycoside;
steroid hormone		anti-arrhythmia drug;
cardiotonic drug;
EC 2.3.3.1 [citrate (Si)-synthase] inhibitor;
EC 3.1.3.41 (4-nitrophenylphosphatase) inhibitor;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor;
EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor;
ion transport inhibitor;
plant metabolite
tosylphenylalanyl chloromethyl ketone[no description available]medium20alpha-chloroketone;
sulfonamide		alkylating agent;
serine proteinase inhibitor
monoiodotyrosine[no description available]medium20amino acid zwitterion;
L-tyrosine derivative;
monoiodotyrosine;
non-proteinogenic L-alpha-amino acid		EC 1.14.16.2 (tyrosine 3-monooxygenase) inhibitor;
human metabolite;
mouse metabolite
nitroarginine[no description available]medium10guanidines;
L-arginine derivative;
N-nitro compound;
non-proteinogenic L-alpha-amino acid
willardiine[no description available]medium10amino acid zwitterion;
L-alanine derivative;
non-proteinogenic L-alpha-amino acid
cortodoxone[no description available]medium20deoxycortisol;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		human metabolite;
mouse metabolite
amiodarone hydrochloride[no description available]medium20aromatic ketone
dicyclomine hydrochloride[no description available]medium20hydrochlorideantispasmodic drug;
muscarinic antagonist
metyrosine[no description available]medium10L-tyrosine derivative;
non-proteinogenic L-alpha-amino acid		antihypertensive agent;
EC 1.14.16.2 (tyrosine 3-monooxygenase) inhibitor
nortriptyline hydrochloride[no description available]medium20organic tricyclic compoundgeroprotector
paromomycin sulfate[no description available]medium10
Dubinidine[no description available]medium10organic heterotricyclic compound;
organonitrogen heterocyclic compound;
oxacycle
cyclopamine[no description available]medium10piperidinesglioma-associated oncogene inhibitor
s-(4-azidophenacyl)glutathione[no description available]medium10peptide
hydroxylamine hydrochloride[no description available]medium10organic molecular entity
sb 228357[no description available]medium10indolyl carboxylic acid
3,5-dihydroxyphenylglycine[no description available]medium10amino acid zwitterion;
non-proteinogenic L-alpha-amino acid;
resorcinols
actinonin[no description available]medium10
dihydroergocristine monomesylate[no description available]medium20methanesulfonate saltalpha-adrenergic antagonist;
geroprotector;
vasodilator agent
resveratrol[no description available]medium90resveratrolantioxidant;
phytoalexin;
plant metabolite;
quorum sensing inhibitor;
radical scavenger
oleic acid[no description available]medium10octadec-9-enoic acidantioxidant;
Daphnia galeata metabolite;
EC 3.1.1.1 (carboxylesterase) inhibitor;
Escherichia coli metabolite;
mouse metabolite;
plant metabolite;
solvent
thapsigargin[no description available]medium70butyrate ester;
organic heterotricyclic compound;
sesquiterpene lactone		calcium channel blocker;
EC 3.6.3.8 (Ca(2+)-transporting ATPase) inhibitor
brivudine[no description available]medium10
5,11-diethyl-5,6,11,12-tetrahydrochrysene-2,8-diol[no description available]medium10carbotetracyclic compound;
polyphenol		estrogen receptor agonist;
estrogen receptor antagonist;
geroprotector;
neuroprotective agent
2-amino-3-(5-tert-butyl-3-(phosphonomethoxy)-4-isoxazolyl)propionic acid[no description available]medium10
L-cycloserine[no description available]medium204-amino-1,2-oxazolidin-3-oneanti-HIV agent;
anticonvulsant;
EC 2.3.1.50 (serine C-palmitoyltransferase) inhibitor
1,4-dideoxy-1,4-imino-d-arabinitol[no description available]medium10
purvalanol a[no description available]medium10purvalanol
melphalan[no description available]medium10L-phenylalanine derivative;
nitrogen mustard;
non-proteinogenic L-alpha-amino acid;
organochlorine compound		alkylating agent;
antineoplastic agent;
carcinogenic agent;
drug allergen;
immunosuppressive agent
isoliquiritigenin[no description available]medium20chalconesantineoplastic agent;
biological pigment;
EC 1.14.18.1 (tyrosinase) inhibitor;
GABA modulator;
geroprotector;
metabolite;
NMDA receptor antagonist
gw9662[no description available]medium20benzamides
calmidazolium[no description available]medium10organic chloride saltapoptosis inducer;
calmodulin antagonist
tropisetron hydrochloride[no description available]medium10
Reactive blue 2[no description available]medium10anthraquinone
5,6-dichloro-1-ethyl-1,3-dihydro-2h-benzimidazol-2-one[no description available]medium10dichlorobenzene
quinidine sulfate[no description available]medium10
ipratropium bromide anhydrous[no description available]medium20
methamilane methiodide[no description available]medium20
pilocarpine nitrate[no description available]medium20
r 59949[no description available]medium10diarylmethane
methylatropine nitrate[no description available]medium20
sb 366791[no description available]medium10
ag-213[no description available]medium10
3,3',4,5'-tetrahydroxystilbene[no description available]medium10catechols;
polyphenol;
resorcinols;
stilbenol		antineoplastic agent;
apoptosis inducer;
geroprotector;
hypoglycemic agent;
plant metabolite;
protein kinase inhibitor;
tyrosine kinase inhibitor
bemesetron[no description available]medium30
(S)-(-)-pindolol[no description available]medium10pindolol
levosulpiride[no description available]medium10sulpirideantidepressant;
antiemetic;
antipsychotic agent;
dopaminergic antagonist
caffeic acid[no description available]medium20caffeic acidgeroprotector;
mouse metabolite
4-fluorophenyl-L-alanine[no description available]medium104-fluorophenylalanine;
L-phenylalanine derivative;
non-proteinogenic L-alpha-amino acid
urocanic acid[no description available]medium20urocanic acidhuman metabolite
cotinine[no description available]high10N-alkylpyrrolidine;
pyridines;
pyrrolidin-2-ones;
pyrrolidine alkaloid		antidepressant;
biomarker;
human xenobiotic metabolite;
plant metabolite
sulindac[no description available]medium10monocarboxylic acid;
organofluorine compound;
sulfoxide		analgesic;
antineoplastic agent;
antipyretic;
apoptosis inducer;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
prodrug;
tocolytic agent
cysteine sulfinic acid[no description available]medium10organosulfinic acid;
S-substituted L-cysteine		Escherichia coli metabolite;
human metabolite;
metabotropic glutamate receptor agonist;
mouse metabolite
d-ap7[no description available]medium10
(1R,2S)-tranylcypromine hydrochloride[no description available]medium10hydrochloride
tacrine hydrochloride[no description available]medium20
4-bromotetramisole, oxalate (1:1), salt(s)-isomer[no description available]medium10
3-hydroxybenzylhydrazine hydrochloride[no description available]medium10
1-(3-chlorophenyl)biguanide hydrochloride[no description available]medium10
4-chlorophenylalanine methyl ester, hydrochloride, (dl)-isomer[no description available]medium10
capsazepine[no description available]medium10benzazepine;
catechols;
monochlorobenzenes;
thioureas		capsaicin receptor antagonist
diphenyleneiodium chloride[no description available]medium10organic chloride saltEC 1.6.3.1. [NAD(P)H oxidase (H2O2-forming)] inhibitor;
G-protein-coupled receptor agonist
azetidine-2,4-dicarboxylic acid, (cis)-isomer[no description available]medium10
tamoxifen citrate[no description available]medium10citrate saltangiogenesis inhibitor;
anticoronaviral agent
pimagedine hydrochloride[no description available]medium10
Betaine Aldehyde Chloride[no description available]medium10quaternary ammonium salt
eskazine[no description available]medium20
monastrol[no description available]medium10enoate ester;
ethyl ester;
phenols;
racemate;
thioureas		antileishmanial agent;
antimitotic;
antineoplastic agent;
EC 3.5.1.5 (urease) inhibitor
u 0126[no description available]medium40aryl sulfide;
dinitrile;
enamine;
substituted aniline		antineoplastic agent;
antioxidant;
apoptosis inducer;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
osteogenesis regulator;
vasoconstrictor agent
4-diphenylacetoxy-n-methylpiperidine methiodide[no description available]medium30iodide salt;
quaternary ammonium salt		cholinergic antagonist;
muscarinic antagonist
1-(4-hydroxybenzyl)imidazole-2-thiol[no description available]medium10
2-chloro-n(6)-(3-iodobenzyl)adenosine-5'-n-methyluronamide[no description available]medium20
bp 897[no description available]medium10naphthalenecarboxamide
trequinsin hydrochloride[no description available]medium10
neboglamine[no description available]medium10
benzatropine methanesulfonate[no description available]medium10
sb 203186[no description available]medium10indolyl carboxylic acid
n-(1-methyl-5-indolyl)-n'-(3-methyl-5-isothiazolyl)urea[no description available]medium101,2-thiazoles;
indoles;
ureas		receptor modulator;
serotonergic antagonist
gw 7647[no description available]medium10aryl sulfide;
monocarboxylic acid;
ureas		PPARalpha agonist
ro 41-0960[no description available]medium10
cgp 13501[no description available]medium10alkylbenzene
n-(2-(4-(4-chlorophenyl)piperazin-1-yl)ethyl)-3-methoxybenzamide[no description available]medium10
brl 15572[no description available]medium10monochlorobenzenes;
N-alkylpiperazine;
N-arylpiperazine;
secondary alcohol		geroprotector;
serotonergic antagonist
mrs 1523[no description available]medium20
or486[no description available]medium10
fg 9041[no description available]medium10quinoxaline derivative
iik7[no description available]medium10
sb 415286[no description available]medium20C-nitro compound;
maleimides;
monochlorobenzenes;
phenols;
secondary amino compound;
substituted aniline		antioxidant;
apoptosis inducer;
EC 2.7.11.26 (tau-protein kinase) inhibitor;
neuroprotective agent
dm 235[no description available]medium10
jhw 015[no description available]medium10indolecarboxamide
bw 723c86[no description available]medium10tryptamines
sc-19220[no description available]medium10aromatic ether
le 300[no description available]medium10indoles
ly 367265[no description available]medium10dihydropyridine;
fluoroindole;
tertiary amino compound;
thiadiazoloquinoline		antidepressant;
geroprotector;
serotonergic antagonist;
serotonin uptake inhibitor
diclofenac sodium[no description available]medium30organic sodium salt
cgp 7930[no description available]medium10alkylbenzene
1,3,5-tris(4-hydroxyphenyl)-4-propyl-1h-pyrazole[no description available]medium10phenols;
pyrazoles		estrogen receptor agonist
sib 1757[no description available]medium10
sphingosine[no description available]medium30sphing-4-eninehuman metabolite;
mouse metabolite
luteolin[no description available]medium203'-hydroxyflavonoid;
tetrahydroxyflavone		angiogenesis inhibitor;
anti-inflammatory agent;
antineoplastic agent;
apoptosis inducer;
c-Jun N-terminal kinase inhibitor;
EC 2.3.1.85 (fatty acid synthase) inhibitor;
immunomodulator;
nephroprotective agent;
plant metabolite;
radical scavenger;
vascular endothelial growth factor receptor antagonist
daphnetin[no description available]medium10hydroxycoumarin
pulmicort[no description available]medium7011beta-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
cyclic acetal;
glucocorticoid;
primary alpha-hydroxy ketone		anti-inflammatory drug;
bronchodilator agent;
drug allergen
timolol maleate[no description available]medium20maleate saltanti-arrhythmia drug;
antiglaucoma drug;
antihypertensive agent;
beta-adrenergic antagonist
brompheniramine maleate[no description available]medium20maleate saltanti-allergic agent
chlorpheniramine maleate[no description available]medium10organic molecular entity
clemastine fumarate[no description available]medium10fumarate saltanti-allergic agent;
antipruritic drug;
H1-receptor antagonist;
muscarinic antagonist
methylergonovine maleate[no description available]medium10ergoline alkaloidgeroprotector
astaxanthine[no description available]medium10carotenol;
carotenone		animal metabolite;
anticoagulant;
antioxidant;
food colouring;
plant metabolite
harman[no description available]medium10harmala alkaloid;
indole alkaloid fundamental parent;
indole alkaloid		anti-HIV agent;
EC 1.4.3.4 (monoamine oxidase) inhibitor;
plant metabolite
morin[no description available]medium107-hydroxyflavonol;
pentahydroxyflavone		angiogenesis modulating agent;
anti-inflammatory agent;
antibacterial agent;
antihypertensive agent;
antineoplastic agent;
antioxidant;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
hepatoprotective agent;
metabolite;
neuroprotective agent
myricetin[no description available]medium107-hydroxyflavonol;
hexahydroxyflavone		antineoplastic agent;
antioxidant;
cyclooxygenase 1 inhibitor;
food component;
geroprotector;
hypoglycemic agent;
plant metabolite
daidzein[no description available]medium107-hydroxyisoflavonesantineoplastic agent;
EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor;
EC 3.2.1.20 (alpha-glucosidase) inhibitor;
phytoestrogen;
plant metabolite
caffeic acid phenethyl ester[no description available]medium10alkyl caffeate esteranti-inflammatory agent;
antibacterial agent;
antineoplastic agent;
antioxidant;
antiviral agent;
immunomodulator;
metabolite;
neuroprotective agent
rottlerin[no description available]medium10aromatic ketone;
benzenetriol;
chromenol;
enone;
methyl ketone		anti-allergic agent;
antihypertensive agent;
antineoplastic agent;
apoptosis inducer;
K-ATP channel agonist;
metabolite
flupenthixol[no description available]medium10flupenthixoldopaminergic antagonist
n-oleoyldopamine[no description available]medium10catechols;
fatty amide;
N-(fatty acyl)-dopamine;
secondary carboxamide		TRPV1 agonist
pheniramine maleate[no description available]medium10organic molecular entity
tranilast[no description available]medium30amidobenzoic acid;
cinnamamides;
dimethoxybenzene;
secondary carboxamide		anti-allergic agent;
anti-asthmatic drug;
antineoplastic agent;
aryl hydrocarbon receptor agonist;
calcium channel blocker;
hepatoprotective agent;
nephroprotective agent
trimipramine maleate[no description available]medium10maleate saltantidepressant
isotretinoin[no description available]medium10retinoic acidantineoplastic agent;
keratolytic drug;
teratogenic agent
xylometazoline hydrochloride[no description available]medium20
flunarizine hydrochloride[no description available]medium10diarylmethane
ketotifen fumarate[no description available]medium20organoammonium saltanti-asthmatic drug;
H1-receptor antagonist
cis-flupenthixol dihydrochloride[no description available]medium10hydrochloridegeroprotector
n-arachidonylglycine[no description available]medium10fatty amide;
N-acylglycine
n-oleoylethanolamine[no description available]medium10endocannabinoid;
N-(long-chain-acyl)ethanolamine;
N-acylethanolamine 18:1		EC 3.5.1.23 (ceramidase) inhibitor;
geroprotector;
PPARalpha agonist
cyclosporine[no description available]medium10homodetic cyclic peptideanti-asthmatic drug;
anticoronaviral agent;
antifungal agent;
antirheumatic drug;
carcinogenic agent;
dermatologic drug;
EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor;
geroprotector;
immunosuppressive agent;
metabolite
phenoxybenzamine hydrochloride[no description available]medium20organic molecular entity
phenylephrine hydrochloride[no description available]medium20hydrochloride
mepyramine maleate[no description available]medium20
fenretinide[no description available]medium10monocarboxylic acid amide;
retinoid		antineoplastic agent;
antioxidant
4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid[no description available]medium10benzoic acids;
naphthalenes;
retinoid		antineoplastic agent;
retinoic acid receptor agonist;
teratogenic agent
l-2-(carboxypropyl)glycine[no description available]medium10
4-aminocrotonic acid[no description available]medium10
denopamine[no description available]medium20dimethoxybenzene
l 655,708[no description available]medium10
ro 41-1049[no description available]medium10
sb 200646a[no description available]medium10
seglitide[no description available]medium10
sib 1893[no description available]medium10
su 6656[no description available]medium10
tyrphostin ag 555[no description available]medium30
tyrphostin ag-494[no description available]medium10
tyrphostin b44[no description available]medium10
ag-490[no description available]medium10catechols;
enamide;
monocarboxylic acid amide;
nitrile;
secondary carboxamide		anti-inflammatory agent;
antioxidant;
apoptosis inducer;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
geroprotector;
STAT3 inhibitor
ag 112[no description available]medium10
ag 183[no description available]medium10
semaxinib[no description available]medium10olefinic compound;
oxindoles;
pyrroles		angiogenesis modulating agent;
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
vascular endothelial growth factor receptor antagonist
8-(3-chlorostyryl)caffeine[no description available]medium20monochlorobenzenes;
trimethylxanthine		adenosine A2A receptor antagonist;
EC 1.4.3.4 (monoamine oxidase) inhibitor
bay 11-7085[no description available]medium10benzenes;
nitrile;
sulfone		anti-inflammatory agent;
antibacterial agent;
antineoplastic agent;
apoptosis inducer;
autophagy inducer;
EC 2.7.11.10 (IkappaB kinase) inhibitor;
ferroptosis inducer;
NF-kappaB inhibitor
molsidomine[no description available]medium20ethyl ester;
morpholines;
oxadiazole;
zwitterion		antioxidant;
apoptosis inhibitor;
cardioprotective agent;
nitric oxide donor;
vasodilator agent
diamide[no description available]medium101,1'-azobis(N,N-dimethylformamide)
nomifensine maleate[no description available]medium10
nalbuphine hydrochloride[no description available]medium10hydrochloride
isoalloxazine[no description available]medium10benzo[g]pteridine-2,4-dione
vinblastine sulfate[no description available]medium20
n-methylscopolamine bromide[no description available]medium20
dextromethorphan hydrobromide[no description available]medium10hydrate;
hydrobromide
naloxone hydrochloride[no description available]medium10hydrochlorideantidote to opioid poisoning;
central nervous system depressant;
mu-opioid receptor antagonist
s-trans,trans-farnesylthiosalicylic acid[no description available]medium10sesquiterpenoid
sulindac sulfone[no description available]medium10monocarboxylic acid;
organofluorine compound;
sulfone		apoptosis inducer;
cyclooxygenase 2 inhibitor;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor
naltrexone hydrochloride[no description available]medium20hydrochlorideantidote to opioid poisoning;
central nervous system depressant;
mu-opioid receptor antagonist
guanabenz acetate[no description available]medium20dichlorobenzenegeroprotector
nylidrin hydrochloride[no description available]medium20alkylbenzene
triprolidine hydrochloride anhydrous[no description available]medium20hydrochlorideH1-receptor antagonist
famotidine[no description available]medium101,3-thiazoles;
guanidines;
sulfonamide		anti-ulcer drug;
H2-receptor antagonist;
P450 inhibitor
fenoterol[no description available]medium10hydrobromidebeta-adrenergic agonist;
bronchodilator agent;
sympathomimetic agent
tiapridex[no description available]medium20benzamides
quipazine maleate[no description available]medium10
n-(2-aminoethyl)-4-chlorobenzamide hydrochloride[no description available]medium10
tulobuterol hydrochloride[no description available]medium20organic molecular entity
hp 029[no description available]medium10
n,n,n-trimethyl-1-(4-stilbenoxy)-2-propylammonium iodide[no description available]medium10
6-(bromomethylene)tetrahydro-3-(1-naphthaleneyl)-2h-pyran-2-one[no description available]medium10naphthalenes
nf023[no description available]medium10
nf 449[no description available]medium10
7-chloro-4-hydroxy-2-phenyl-1,8-naphthyridine[no description available]medium10
gr 46611[no description available]medium10
diacetylmonoxime[no description available]medium10
homatropine hydrobromide, (endo-(+-)-isomer)[no description available]medium10
vancomycin hydrochloride[no description available]medium10
moxisylyte hydrochloride[no description available]medium20monoterpenoid
dizocilpine maleate[no description available]medium120maleate salt;
tetracyclic antidepressant		anaesthetic;
anticonvulsant;
neuroprotective agent;
nicotinic antagonist;
NMDA receptor antagonist
beta-aminopropionitrile fumarate[no description available]medium10
flupirtine[no description available]medium10
zimelidine hydrochloride[no description available]medium10
pregna-4,17-diene-3,16-dione, (17z)-isomer[no description available]medium10
su 4312[no description available]medium10
protriptyline hydrochloride[no description available]medium20hydrochlorideantidepressant
n(4)-chloroacetylcytosine arabinoside[no description available]medium10
n-(3-(cyclohexylidene-(1h-imidazol-4-ylmethyl))phenyl)ethanesulfonamide[no description available]medium10
n-(4-amino-2-chlorophenyl)phthalimide[no description available]medium10
cb 34[no description available]medium10
b 43[no description available]medium10aromatic amine;
aromatic ether;
cyclopentanes;
primary amino compound;
pyrrolopyrimidine		EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
geroprotector
(8R)-7-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-2,13,14-triol[no description available]medium10aporphine alkaloid
(8R)-7-propyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-2,13,14-triol[no description available]medium10aporphine alkaloid
3-(6-chloro-3-pyridazinyl)-3,8-diazabicyclo(3.2.1)octane[no description available]medium10
2-(3,3-diphenylpropylamino)acetamide[no description available]medium10diarylmethane
4-(2-(phenylsulfonylamino)ethylthio)-2,6-difluorophenoxyacetamide[no description available]medium10
gw2974[no description available]medium10pyridopyrimidine
l 162313[no description available]medium10
l-165041[no description available]medium10aromatic ketone
mrs 1754[no description available]medium10oxopurine
s-nitroso-n-acetylpenicillamine[no description available]medium20nitroso compound;
nitrosothio compound		nitric oxide donor;
vasodilator agent
pd 404182[no description available]medium10
sb 222200[no description available]medium10quinolines
dantrolene sodium[no description available]medium10
cr 2945[no description available]medium10
sb 218795[no description available]medium10quinolines
dihydroceramide[no description available]medium10N-acylsphinganine
epinephrine bitartrate[no description available]medium20
bicuculline methobromide[no description available]medium20
butylscopolammonium bromide[no description available]medium20
butaclamol hydrochloride[no description available]medium20
a 38503[no description available]medium10
8-hydroxy-2-(di-n-propylamino)tetralin hydrobromide[no description available]medium10
sk&f 89976-a[no description available]medium10
cv 1808[no description available]medium20purine nucleoside
fluvoxamine maleate[no description available]medium10(trifluoromethyl)benzenes
naloxone benzoylhydrazone[no description available]medium10
2-methyl-6-(phenylethynyl)pyridine hydrochloride[no description available]medium10hydrochlorideanxiolytic drug;
metabotropic glutamate receptor antagonist
amiprilose[no description available]medium10
(R)-fluoxetine hydrochloride[no description available]medium10hydrochlorideantidepressant;
serotonin uptake inhibitor
desmethylselegiline hydrochloride[no description available]medium10
3-morpholino-sydnonimine monohydrochloride[no description available]medium20
t 1032[no description available]medium10
qx-314 bromide[no description available]medium10
(S)-fluoxetine hydrochloride[no description available]medium10hydrochlorideantidepressant;
serotonin uptake inhibitor
sr 59230a[no description available]medium10
u 74389g[no description available]medium10
1-(2-methoxyphenyl)piperazine hydrochloride[no description available]medium10
y 27632, dihydrochloride, (4(r)-trans)-isomer[no description available]medium10
noscapine hydrochloride[no description available]medium10
a 77636[no description available]medium10hydrochlorideantiparkinson drug;
dopamine agonist
cgp 20712a[no description available]medium20
levodopa methyl ester hydrochloride[no description available]medium10
benalfocin hydrochloride[no description available]medium10
lu 19005[no description available]medium10
benoxathian hydrochloride[no description available]medium10
((2-n-butyl-6,7-dichloro-2-cyclopentyl-2,3-dihydro-1-oxo-1h-inden-5-yl)oxy)acetic acid, (+)-isomer[no description available]medium10
n-cyclopropyl adenosine-5'-carboxamide[no description available]medium10
cefotaxime sodium[no description available]medium20organic sodium salt
calpain inhibitor iii[no description available]medium10
GR 127935 hydrochloride[no description available]medium10hydrochlorideserotonergic antagonist
mrs 1845[no description available]medium10
1-aminocyclopropane-1-carboxylic acid hydrochloride[no description available]medium10
alaproclate hydrochloride[no description available]medium10
ubenimex[no description available]medium10peptide
3-chloroalanine hydrochloride, (l-ala)-isomer[no description available]medium10
dsp 4 hydrochloride[no description available]medium10
calcimycin[no description available]medium70benzoxazole
(2-(2',6'-dimethoxy)phenoxyethylamino)methylbenzodioxan hydrochloride[no description available]medium10hydrochloridealpha-adrenergic antagonist
2-cyclooctyl-2-hydroxyethylamine hydrochloride[no description available]medium10
cirazoline monohydrochloride[no description available]medium10
adtn[no description available]medium10
apocodeine hydrochloride, (r)-isomer[no description available]medium10
Dihydro-beta-erythroidine hydrobromide[no description available]medium10indoles
lilly 78335[no description available]medium10
efaroxan hydrochloride[no description available]medium10
fenoldopam hydrobromide[no description available]medium10
1-[2-(benzhydryloxy)ethyl]-4-(3-phenylpropyl)piperazine dihydrochloride[no description available]medium10hydrochloridedopamine uptake inhibitor
guvacine hydrochloride[no description available]medium10
7-hydroxy-2-n,n-dipropylaminotetralin hydrobromide[no description available]medium10
8-hydroxy-2-(di-n-propylamino)tetralin hydrobromide, (r)-isomer,[no description available]medium10organic molecular entity
1-(2-(4-(4-fluoro-benzoyl)-piperidin-1-yl)-ethyl)-3,3-dimethyl-1,2-dihydro-indol-2-one[no description available]medium10hydrochloridereceptor modulator;
serotonergic antagonist
4-iodoclonidine[no description available]medium10
4-methylpyrazole monohydrochloride[no description available]medium10
tele-methylhistamine[no description available]medium10
alpha-methyltyrosine methyl ester, monohydrochloride[no description available]medium10
octoclothepine maleate[no description available]medium10
2-(n-phenethyl-n-propyl)amino-5-hydroxytetralin hydrochloride[no description available]medium10
du 24565[no description available]medium10
2-methoxyidazoxan hydrochloride[no description available]medium10
ro 25-6981[no description available]medium10
sk&f 77434[no description available]medium10hydrobromidedopamine agonist;
prodrug
3-[(6aR,9R,10aR)-7-methyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline-9-yl]-1,1-diethylurea[no description available]medium10organic heterotetracyclic compound;
organonitrogen heterocyclic compound
demethylcantharidin[no description available]medium10
atropine sulfate[no description available]medium10
1-deoxynojirimycin hydrochloride[no description available]medium10
win 62577[no description available]medium10
quinine sulfate[no description available]medium10hydrate
quercetin[no description available]medium10
rv 538, (r-(r*,r*))-isomer[no description available]medium10
3,4-dichloro-n-methyl-n-(2-(1-pyrrolidinyl)cyclohexyl)-benzeneacetamide, (1s-cis)-isomer[no description available]medium10
valproate sodium[no description available]medium10organic sodium saltgeroprotector
u 63557a[no description available]medium10
taurocholic acid, monosodium salt[no description available]medium10bile salt
cefmetazole sodium[no description available]medium10organic sodium saltantimicrobial agent
fusidate sodium[no description available]medium10
cephapirin sodium[no description available]medium10cephalosporin;
organic sodium salt		antibacterial drug
sodium cephalothin[no description available]medium10organic sodium salt
cefazolin sodium[no description available]medium20organic sodium salt
5-hydroxydecanoic acid, monosodium salt[no description available]medium10
ro13-9904[no description available]medium20
phenytoin sodium[no description available]medium10
cr 1409[no description available]medium10
cortisol succinate, sodium salt[no description available]medium10organic molecular entity
piroxicam[no description available]medium30benzothiazine;
monocarboxylic acid amide;
pyridines		analgesic;
antirheumatic drug;
cyclooxygenase 1 inhibitor;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-steroidal anti-inflammatory drug
lfm a13[no description available]medium10aromatic amide;
dibromobenzene;
enamide;
enol;
nitrile;
secondary carboxamide		antineoplastic agent;
apoptosis inducer;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
EC 2.7.11.21 (polo kinase) inhibitor;
geroprotector;
platelet aggregation inhibitor
l 701324[no description available]medium10quinolines
hispidin[no description available]medium102-pyranones;
catechols		antioxidant;
EC 2.7.11.13 (protein kinase C) inhibitor;
fungal metabolite
minocycline hydrochloride[no description available]medium10
demeclocycline hydrochloride[no description available]medium20
acyclovir[no description available]medium402-aminopurines;
oxopurine		antimetabolite;
antiviral drug
sepiapterin[no description available]medium10sepiapterin
isoxanthopterin[no description available]medium10dihydroxypteridine
ganciclovir[no description available]medium302-aminopurines;
oxopurine		antiinfective agent;
antiviral drug
allopurinol[no description available]medium20nucleobase analogue;
organic heterobicyclic compound		antimetabolite;
EC 1.17.3.2 (xanthine oxidase) inhibitor;
gout suppressant;
radical scavenger
thiolactomycin[no description available]medium10
2,4-diaminohypoxanthine[no description available]medium10hydroxypyrimidine
quazinone[no description available]medium60
8-bromocyclic gmp, sodium salt[no description available]medium10organic sodium saltmuscle relaxant;
protein kinase G agonist
ag-879[no description available]medium10
cephalexin[no description available]medium10beta-lactam antibiotic allergen;
cephalosporin;
semisynthetic derivative		antibacterial drug
nevirapine[no description available]medium30cyclopropanes;
dipyridodiazepine		antiviral drug;
HIV-1 reverse transcriptase inhibitor
3-(2,5-dimethoxyphenyl)-6-(3,4-dimethoxyphenyl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine[no description available]medium20triazoles
thymol[no description available]medium10monoterpenoid;
phenols		volatile oil component
2-hydroxychavicol[no description available]medium10
8-hydroxy-2-(di-n-propylamino)tetralin[no description available]medium20phenols;
tertiary amino compound;
tetralins		serotonergic antagonist
astemizole[no description available]medium30benzimidazoles;
piperidines		anti-allergic agent;
anticoronaviral agent;
H1-receptor antagonist
diclofenac[no description available]medium30amino acid;
aromatic amine;
dichlorobenzene;
monocarboxylic acid;
secondary amino compound		antipyretic;
drug allergen;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic
vanoxerine[no description available]medium10ether;
N-alkylpiperazine;
organofluorine compound;
tertiary amino compound		dopamine uptake inhibitor
ketanserin[no description available]medium20aromatic ketone;
organofluorine compound;
piperidines;
quinazolines		alpha-adrenergic antagonist;
antihypertensive agent;
cardiovascular drug;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
serotonergic antagonist
clorgyline[no description available]medium10aromatic ether;
dichlorobenzene;
terminal acetylenic compound;
tertiary amino compound		antidepressant;
EC 1.4.3.4 (monoamine oxidase) inhibitor
n-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide[no description available]medium10aromatic ether;
C-nitro compound;
sulfonamide		antineoplastic agent;
cyclooxygenase 2 inhibitor
pirenzepine[no description available]medium10pyridobenzodiazepineanti-ulcer drug;
antispasmodic drug;
muscarinic antagonist
veratridine[no description available]medium10steroidsodium channel modulator
framycetin[no description available]medium10aminoglycosideallergen;
antibacterial drug;
Escherichia coli metabolite
selegiline[no description available]medium10selegiline;
terminal acetylenic compound		geroprotector
staurosporine[no description available]medium10indolocarbazole alkaloid;
organic heterooctacyclic compound		apoptosis inducer;
bacterial metabolite;
EC 2.7.11.13 (protein kinase C) inhibitor;
geroprotector
arg-3-hyp-7-phe-bradykinin[no description available]medium10oligopeptidebradykinin receptor antagonist
n(6)-(3-iodobenzyl)-5'-n-methylcarboxamidoadenosine[no description available]medium20adenosines;
monocarboxylic acid amide;
organoiodine compound		adenosine A3 receptor agonist
1-(1-(2-benzo(b)thienyl)cyclohexyl)piperidine[no description available]medium101-benzothiophenes;
piperidines;
tertiary amino compound		dopamine uptake inhibitor
omega-n-methylarginine[no description available]medium20amino acid zwitterion;
arginine derivative;
guanidines;
L-arginine derivative;
non-proteinogenic L-alpha-amino acid
picrotoxinin[no description available]medium10epoxide;
gamma-lactone;
organic heteropentacyclic compound;
picrotoxane sesquiterpenoid;
tertiary alcohol		GABA antagonist;
plant metabolite;
serotonergic antagonist
devazepide[no description available]medium101,4-benzodiazepinone;
indolecarboxamide		antineoplastic agent;
apoptosis inducer;
cholecystokinin antagonist;
gastrointestinal drug
phosphoramidon[no description available]medium10deoxyaldohexose phosphate;
dipeptide		bacterial metabolite;
EC 3.4.24.11 (neprilysin) inhibitor;
EC 3.4.24.71 (endothelin-converting enzyme 1) inhibitor
u-50488[no description available]medium20dichlorobenzene;
monocarboxylic acid amide;
N-alkylpyrrolidine		analgesic;
antitussive;
calcium channel blocker;
diuretic;
kappa-opioid receptor agonist
sch 23390[no description available]medium40benzazepine
enkephalin, ala(2)-mephe(4)-gly(5)-[no description available]medium20peptide
pepstatin[no description available]medium20pentapeptide;
secondary carboxamide		bacterial metabolite;
EC 3.4.23.* (aspartic endopeptidase) inhibitor
saralasin[no description available]medium10oligopeptide
somatostatin[no description available]medium10heterodetic cyclic peptide;
peptide hormone
nociceptin[no description available]medium10organic molecular entity;
polypeptide		human metabolite;
rat metabolite
neurotensin[no description available]medium10peptide hormonehuman metabolite;
mitogen;
neurotransmitter;
vulnerary
endothelins[no description available]medium20
sch 351591[no description available]medium20
sch 351591[no description available]medium21
l-791943[no description available]medium10
rs 14203[no description available]medium40
l-454,560[no description available]medium20
l-826,141[no description available]medium20
fluoxetine[no description available]medium50(trifluoromethyl)benzenes;
aromatic ether;
secondary amino compound
methylinositol[no description available]medium10
3-(n,n-dimethylsulfonamido)-4-methyl-nitrobenzene[no description available]medium80C-nitro compound;
sulfonamide;
toluenes		bone density conservation agent;
EC 3.1.4.53 (3',5'-cyclic-AMP phosphodiesterase) inhibitor;
geroprotector
an2728[no description available]medium20aromatic ether;
benzoxaborole;
nitrile		antipsoriatic;
non-steroidal anti-inflammatory drug;
phosphodiesterase IV inhibitor
6-(3-cyclopentyloxy-4-methoxyphenyl)-3-(2-methoxyphenyl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine[no description available]medium10triazoles
3-(2-chlorophenyl)-6-(3-cyclopentyloxy-4-methoxyphenyl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine[no description available]medium10triazoles
6-(3-cyclopentyloxy-4-methoxyphenyl)-3-(2,5-dimethoxyphenyl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine[no description available]medium10triazoles
6-[3-(cyclopropylmethoxy)-4-methoxyphenyl]-3-(2-methoxyphenyl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine[no description available]medium10triazoles
3-(2-chlorophenyl)-6-[3-(cyclopropylmethoxy)-4-methoxyphenyl]-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine[no description available]medium10triazoles
6-[3-(cyclopropylmethoxy)-4-methoxyphenyl]-3-(2,5-dimethoxyphenyl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine[no description available]medium10triazoles
6-[3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl]-3-(2-methoxyphenyl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine[no description available]medium10triazoles
3-(2-chlorophenyl)-6-[3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl]-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine[no description available]medium10triazoles
6-[3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl]-3-(2-fluorophenyl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine[no description available]medium10triazoles
6-[3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl]-3-(2,5-dimethoxyphenyl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine[no description available]medium10triazoles
6-[4-methoxy-3-(3-oxolanyloxy)phenyl]-3-(2-methoxyphenyl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine[no description available]medium10triazoles
3-(2-chlorophenyl)-6-[4-methoxy-3-(3-oxolanyloxy)phenyl]-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine[no description available]medium10triazoles
3-(2-fluorophenyl)-6-[4-methoxy-3-(3-oxolanyloxy)phenyl]-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine[no description available]medium10triazoles
6-[4-methoxy-3-(3-oxolanyloxy)phenyl]-3-[2-(trifluoromethyl)phenyl]-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine[no description available]medium10triazoles
3-(2,5-dimethoxyphenyl)-6-[4-methoxy-3-(3-oxolanyloxy)phenyl]-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine[no description available]medium10triazoles
flurbiprofen[no description available]medium30fluorobiphenyl;
monocarboxylic acid		antipyretic;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
sb 220025[no description available]medium10aminopyrimidine;
imidazoles;
organofluorine compound;
piperidines		angiogenesis inhibitor;
anti-inflammatory agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
sb 216995[no description available]medium10
3,4-dihydro-2(1h)-quinolinone[no description available]medium10quinolines
cipamfylline[no description available]medium50oxopurine
coronopilin[no description available]medium10sesquiterpene lactone
parthenin[no description available]medium10sesquiterpene lactone
angiotensin amide[no description available]medium10
bay 19-8004[no description available]medium10
9-(2-hydroxy-3-nonyl)adenine[no description available]medium120
terferol[no description available]medium10
betulinan a[no description available]medium10
epibatidine[no description available]medium10alkaloid
no 711[no description available]medium10diarylmethane
triiodothyronine[no description available]medium102-halophenol;
amino acid zwitterion;
iodophenol;
iodothyronine		human metabolite;
mouse metabolite;
thyroid hormone
glutamic acid[no description available]medium30glutamic acid;
glutamine family amino acid;
L-alpha-amino acid;
proteinogenic amino acid		Escherichia coli metabolite;
ferroptosis inducer;
micronutrient;
mouse metabolite;
neurotransmitter;
nutraceutical
tiotidine[no description available]medium10thiazoles
idazoxan[no description available]medium20benzodioxine;
imidazolines		alpha-adrenergic antagonist
alpha,beta-methyleneadenosine 5'-triphosphate[no description available]medium10nucleoside triphosphate analogue
1-hexadecyl-2-acetyl-glycero-3-phosphocholine[no description available]medium1702-acetyl-1-alkyl-sn-glycero-3-phosphocholineantihypertensive agent;
beta-adrenergic antagonist;
bronchoconstrictor agent;
hematologic agent;
vasodilator agent
kallidin, des-arg(10)-[no description available]medium10
alpha-methylhistamine[no description available]medium10aralkylamino compound;
imidazoles		H3-receptor agonist
bradykinin[no description available]medium110oligopeptidehuman blood serum metabolite;
vasodilator agent
dinoprostone[no description available]medium410prostaglandins Ehuman metabolite;
mouse metabolite;
oxytocic
leukotriene d4[no description available]medium30dipeptide;
leukotriene;
organic sulfide		bronchoconstrictor agent;
human metabolite;
mouse metabolite
(3r)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone[no description available]medium10morpholines;
naphthyl ketone;
organic heterotricyclic compound;
synthetic cannabinoid		analgesic;
apoptosis inhibitor;
neuroprotective agent
naltrindole[no description available]medium10isoquinolines
mdl 105519[no description available]medium10
ranitidine[no description available]medium10aralkylamine
clioquinol[no description available]medium20monohydroxyquinoline;
organochlorine compound;
organoiodine compound		antibacterial agent;
antifungal agent;
antimicrobial agent;
antineoplastic agent;
antiprotozoal drug;
chelator;
copper chelator
donepezil[no description available]medium100aromatic ether;
indanones;
piperidines;
racemate		EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
nootropic agent
moracin m[no description available]medium10benzofurans
curcumin[no description available]medium60aromatic ether;
beta-diketone;
diarylheptanoid;
enone;
polyphenol		anti-inflammatory agent;
antifungal agent;
antineoplastic agent;
biological pigment;
contraceptive drug;
dye;
EC 1.1.1.205 (IMP dehydrogenase) inhibitor;
EC 1.1.1.21 (aldehyde reductase) inhibitor;
EC 1.1.1.25 (shikimate dehydrogenase) inhibitor;
EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor;
EC 1.8.1.9 (thioredoxin reductase) inhibitor;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
EC 3.5.1.98 (histone deacetylase) inhibitor;
flavouring agent;
food colouring;
geroprotector;
hepatoprotective agent;
immunomodulator;
iron chelator;
ligand;
lipoxygenase inhibitor;
metabolite;
neuroprotective agent;
nutraceutical;
radical scavenger
curcumin[no description available]medium61aromatic ether;
beta-diketone;
diarylheptanoid;
enone;
polyphenol		anti-inflammatory agent;
antifungal agent;
antineoplastic agent;
biological pigment;
contraceptive drug;
dye;
EC 1.1.1.205 (IMP dehydrogenase) inhibitor;
EC 1.1.1.21 (aldehyde reductase) inhibitor;
EC 1.1.1.25 (shikimate dehydrogenase) inhibitor;
EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor;
EC 1.8.1.9 (thioredoxin reductase) inhibitor;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
EC 3.5.1.98 (histone deacetylase) inhibitor;
flavouring agent;
food colouring;
geroprotector;
hepatoprotective agent;
immunomodulator;
iron chelator;
ligand;
lipoxygenase inhibitor;
metabolite;
neuroprotective agent;
nutraceutical;
radical scavenger
quercetin[no description available]medium207-hydroxyflavonol;
pentahydroxyflavone		antibacterial agent;
antineoplastic agent;
antioxidant;
Aurora kinase inhibitor;
chelator;
EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor;
geroprotector;
phytoestrogen;
plant metabolite;
protein kinase inhibitor;
radical scavenger
d159687[no description available]medium30
boswellic acid[no description available]medium10triterpenoid
11-keto-boswellic acid[no description available]medium10
acetyl-11-ketoboswellic acid[no description available]medium10triterpenoid
3-o-acetyl-beta-boswellic acid[no description available]medium10
4-hydroxyquinazoline[no description available]medium20quinazolines
bay 73-6691[no description available]medium20
9-xylosyladenine[no description available]medium10purine nucleoside
coumarin[no description available]medium30coumarinsfluorescent dye;
human metabolite;
plant metabolite
salicylic acid[no description available]medium30monohydroxybenzoic acidalgal metabolite;
antifungal agent;
antiinfective agent;
EC 1.11.1.11 (L-ascorbate peroxidase) inhibitor;
keratolytic drug;
plant hormone;
plant metabolite
malic acid[no description available]medium102-hydroxydicarboxylic acid;
C4-dicarboxylic acid		food acidity regulator;
fundamental metabolite
histamine[no description available]medium390aralkylamino compound;
imidazoles		human metabolite;
mouse metabolite;
neurotransmitter
naringenin[no description available]medium104'-hydroxyflavanones;
trihydroxyflavanone
niacinamide[no description available]medium60pyridine alkaloid;
pyridinecarboxamide;
vitamin B3		anti-inflammatory agent;
antioxidant;
cofactor;
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor;
EC 3.5.1.98 (histone deacetylase) inhibitor;
Escherichia coli metabolite;
geroprotector;
human urinary metabolite;
metabolite;
mouse metabolite;
neuroprotective agent;
Saccharomyces cerevisiae metabolite;
Sir2 inhibitor
niacinamide[no description available]medium61pyridine alkaloid;
pyridinecarboxamide;
vitamin B3		anti-inflammatory agent;
antioxidant;
cofactor;
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor;
EC 3.5.1.98 (histone deacetylase) inhibitor;
Escherichia coli metabolite;
geroprotector;
human urinary metabolite;
metabolite;
mouse metabolite;
neuroprotective agent;
Saccharomyces cerevisiae metabolite;
Sir2 inhibitor
niacin[no description available]medium10pyridine alkaloid;
pyridinemonocarboxylic acid;
vitamin B3		antidote;
antilipemic drug;
EC 3.5.1.19 (nicotinamidase) inhibitor;
Escherichia coli metabolite;
human urinary metabolite;
metabolite;
mouse metabolite;
plant metabolite;
vasodilator agent
pyrazinoic acid[no description available]medium10pyrazinecarboxylic acidantitubercular agent;
drug metabolite
1,10-phenanthroline[no description available]medium10phenanthrolineEC 2.7.1.1 (hexokinase) inhibitor;
EC 3.4.19.3 (pyroglutamyl-peptidase I) inhibitor
ro 5-4864[no description available]medium10
5,8,11,14-eicosatetraynoic acid[no description available]medium10long-chain fatty acid
etofylline[no description available]medium10oxopurine
aa 861[no description available]medium101,4-benzoquinones;
acetylenic compound;
primary alcohol		EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
ferroptosis inhibitor
acetarsol[no description available]medium10acetamides;
anilide
bendroflumethiazide[no description available]medium10benzothiadiazine;
sulfonamide		antihypertensive agent;
diuretic
benzbromarone[no description available]medium101-benzofurans;
aromatic ketone		uricosuric drug
benzothiazide[no description available]medium10benzothiadiazine;
sulfonamide		antihypertensive agent;
diuretic
bay h 4502[no description available]medium10biphenyls;
imidazoles
bisacodyl[no description available]medium10diarylmethane
bufexamac[no description available]medium10aromatic ether;
hydroxamic acid		antipyretic;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
chlorthalidone[no description available]medium10isoindoles;
monochlorobenzenes;
sulfonamide
4-chloro-N-(2,6-dimethyl-1-piperidinyl)-3-sulfamoylbenzamide[no description available]medium10sulfonamide
dapsone[no description available]medium10substituted aniline;
sulfone		anti-inflammatory drug;
antiinfective agent;
antimalarial;
leprostatic drug
deferiprone[no description available]medium204-pyridonesiron chelator;
protective agent
dichlorophen[no description available]medium10bridged diphenyl fungicide;
diarylmethane
diflunisal[no description available]medium10monohydroxybenzoic acid;
organofluorine compound		non-narcotic analgesic;
non-steroidal anti-inflammatory drug
dipropizine[no description available]medium10piperazines
dyphylline[no description available]medium10oxopurine;
propane-1,2-diols		bronchodilator agent;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
muscle relaxant;
vasodilator agent
epirizole[no description available]medium10aromatic ether
ethacrynic acid[no description available]medium10aromatic ether;
aromatic ketone;
dichlorobenzene;
monocarboxylic acid		EC 2.5.1.18 (glutathione transferase) inhibitor;
ion transport inhibitor;
loop diuretic
myambutol[no description available]medium10amino alcohol
ethoxzolamide[no description available]medium10aromatic ether;
benzothiazoles;
sulfonamide		antiglaucoma drug;
diuretic;
EC 4.2.1.1 (carbonic anhydrase) inhibitor
4-biphenylylacetic acid[no description available]medium10biphenyls;
monocarboxylic acid		non-steroidal anti-inflammatory drug
fenbufen[no description available]medium104-oxo monocarboxylic acid;
biphenyls		non-steroidal anti-inflammatory drug
flucytosine[no description available]medium10aminopyrimidine;
nucleoside analogue;
organofluorine compound;
pyrimidine antifungal drug;
pyrimidone		prodrug
flumequine[no description available]medium103-oxo monocarboxylic acid;
organofluorine compound;
pyridoquinoline;
quinolone antibiotic
fluorometholone[no description available]medium10
1-(5-isoquinolinesulfonyl)-2-methylpiperazine[no description available]medium30isoquinolines;
N-sulfonylpiperazine		EC 2.7.11.13 (protein kinase C) inhibitor
harmaline[no description available]medium10harmala alkaloidoneirogen
hexachlorophene[no description available]medium10bridged diphenyl fungicide;
polyphenol;
trichlorobenzene		acaricide;
antibacterial agent;
antifungal agrochemical;
antiseptic drug
hexamethylene bisacetamide[no description available]medium10acetamides
hycanthone[no description available]medium20thioxanthenesmutagen;
schistosomicide drug
hydroflumethiazide[no description available]medium10benzothiadiazine;
thiazide		antihypertensive agent;
diuretic
indapamide[no description available]medium10indoles;
organochlorine compound;
sulfonamide		antihypertensive agent;
diuretic
indoprofen[no description available]medium10gamma-lactam;
isoindoles;
monocarboxylic acid		EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
ipriflavone[no description available]medium10aromatic ether;
isoflavones		bone density conservation agent
isoniazid[no description available]medium10carbohydrazideantitubercular agent;
drug allergen
itraconazole[no description available]medium20piperazines
khellin[no description available]medium10furanochromone;
organic heterotricyclic compound;
oxacycle		anti-asthmatic agent;
bronchodilator agent;
cardiovascular drug;
vasodilator agent
ly 171883[no description available]medium10acetophenones;
aromatic ether;
phenols;
tetrazoles		anti-asthmatic drug;
leukotriene antagonist
edaravone[no description available]medium10pyrazoloneantioxidant;
radical scavenger
mefenamic acid[no description available]medium20aminobenzoic acid;
secondary amino compound		analgesic;
antipyretic;
antirheumatic drug;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
non-steroidal anti-inflammatory drug;
xenobiotic
vitamin k 3[no description available]medium201,4-naphthoquinones;
vitamin K		angiogenesis inhibitor;
antineoplastic agent;
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor;
human urinary metabolite;
nutraceutical
methazolamide[no description available]medium20sulfonamide;
thiadiazoles
methocarbamol[no description available]medium20aromatic ether;
carbamate ester;
secondary alcohol
metronidazole[no description available]medium10C-nitro compound;
imidazoles;
primary alcohol		antiamoebic agent;
antibacterial drug;
antimicrobial agent;
antiparasitic agent;
antitrichomonal drug;
environmental contaminant;
prodrug;
radiosensitizing agent;
xenobiotic
moclobemide[no description available]high20benzamides;
monochlorobenzenes;
morpholines		antidepressant;
environmental contaminant;
xenobiotic
acecainide[no description available]medium10acetamides;
benzamides		anti-arrhythmia drug
nabumetone[no description available]medium20methoxynaphthalene;
methyl ketone		cyclooxygenase 2 inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
prodrug
nalidixic acid[no description available]medium101,8-naphthyridine derivative;
monocarboxylic acid;
quinolone antibiotic		antibacterial drug;
antimicrobial agent;
DNA synthesis inhibitor
norfloxacin[no description available]medium10fluoroquinolone antibiotic;
N-arylpiperazine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone		antibacterial drug;
DNA synthesis inhibitor;
environmental contaminant;
xenobiotic
cm 7116[no description available]medium10benzodiazepine
omeprazole[no description available]medium40aromatic ether;
benzimidazoles;
pyridines;
sulfoxide
aminosalicylic acid[no description available]medium10aminobenzoic acid;
phenols		antitubercular agent
phenindione[no description available]medium10aromatic ketone;
beta-diketone		anticoagulant
phenolphthalein[no description available]medium10phenols
4-phenylbutyric acid[no description available]medium20monocarboxylic acidantineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor;
prodrug
pipemidic acid[no description available]medium10amino acid;
monocarboxylic acid;
N-arylpiperazine;
pyridopyrimidine;
quinolone antibiotic		antibacterial drug;
DNA synthesis inhibitor
probenecid[no description available]medium40benzoic acids;
sulfonamide		uricosuric drug
probucol[no description available]medium20dithioketal;
polyphenol		anti-inflammatory drug;
anticholesteremic drug;
antilipemic drug;
antioxidant;
cardiovascular drug
prochlorperazine[no description available]medium10N-alkylpiperazine;
N-methylpiperazine;
organochlorine compound;
phenothiazines		alpha-adrenergic antagonist;
antiemetic;
cholinergic antagonist;
dopamine receptor D2 antagonist;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
first generation antipsychotic
proxyphylline[no description available]medium10oxopurine
pyrimethamine[no description available]medium10aminopyrimidine;
monochlorobenzenes		antimalarial;
antiprotozoal drug;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor
ronidazole[no description available]medium10C-nitro compound;
carbamate ester;
imidazoles		antiparasitic agent;
antiprotozoal drug
salicylamide[no description available]medium10phenols;
salicylamides		antirheumatic drug;
non-narcotic analgesic
aldactazide[no description available]medium10steroid lactone
streptonigrin[no description available]medium10pyridines;
quinolone		antimicrobial agent;
antineoplastic agent
sulfabenzamide[no description available]medium10benzenes;
sulfonamide antibiotic;
sulfonamide		antibacterial drug;
antimicrobial drug
sulfacetamide[no description available]medium10N-sulfonylcarboxamide;
substituted aniline		antibacterial drug;
antiinfective agent;
antimicrobial agent;
EC 2.5.1.15 (dihydropteroate synthase) inhibitor
sulfadimethoxine[no description available]medium10aromatic ether;
pyrimidines;
substituted aniline;
sulfonamide antibiotic;
sulfonamide		antiinfective agent;
antimicrobial agent;
drug allergen;
environmental contaminant;
xenobiotic
sulfamerazine[no description available]medium10pyrimidines;
sulfonamide antibiotic;
sulfonamide		antiinfective agent;
drug allergen
sulfamethazine[no description available]medium10pyrimidines;
sulfonamide antibiotic;
sulfonamide		antibacterial drug;
antiinfective agent;
antimicrobial agent;
carcinogenic agent;
drug allergen;
EC 2.5.1.15 (dihydropteroate synthase) inhibitor;
environmental contaminant;
ligand;
xenobiotic
sulfamethizole[no description available]medium10sulfonamide antibiotic;
sulfonamide;
thiadiazoles		antiinfective agent;
antimicrobial agent;
drug allergen;
EC 2.5.1.15 (dihydropteroate synthase) inhibitor
sulfamethoxazole[no description available]medium10isoxazoles;
substituted aniline;
sulfonamide antibiotic;
sulfonamide		antibacterial agent;
antiinfective agent;
antimicrobial agent;
drug allergen;
EC 1.1.1.153 [sepiapterin reductase (L-erythro-7,8-dihydrobiopterin forming)] inhibitor;
EC 2.5.1.15 (dihydropteroate synthase) inhibitor;
environmental contaminant;
epitope;
P450 inhibitor;
xenobiotic
sulfamethoxypyridazine[no description available]medium10pyridazines;
sulfonamide antibiotic;
sulfonamide		antiinfective agent;
drug allergen;
EC 2.5.1.15 (dihydropteroate synthase) inhibitor
tegafur[no description available]medium10organohalogen compound;
pyrimidines
terazosin[no description available]medium10furans;
piperazines;
primary amino compound;
quinazolines		alpha-adrenergic antagonist;
antihypertensive agent;
antineoplastic agent
thiabendazole[no description available]medium101,3-thiazoles;
benzimidazole fungicide;
benzimidazoles		antifungal agrochemical;
antinematodal drug
tinidazole[no description available]medium10imidazolesantiamoebic agent;
antibacterial drug;
antiparasitic agent;
antiprotozoal drug
tolnaftate[no description available]medium10monothiocarbamic esterantifungal drug
trapidil[no description available]medium10triazolopyrimidines
trichlormethiazide[no description available]medium10benzothiadiazine;
sulfonamide antibiotic		antihypertensive agent;
diuretic
tyramine[no description available]medium10monoamine molecular messenger;
primary amino compound;
tyramines		EC 3.1.1.8 (cholinesterase) inhibitor;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
neurotransmitter
vesamicol[no description available]medium10piperidines
xylazine[no description available]medium301,3-thiazine;
methylbenzene;
secondary amino compound		alpha-adrenergic agonist;
analgesic;
emetic;
muscle relaxant;
sedative
zopiclone[no description available]medium10monochloropyridine;
pyrrolopyrazine		central nervous system depressant;
sedative
hydrocortisone acetate[no description available]medium10cortisol ester;
tertiary alpha-hydroxy ketone
oxyphenonium bromide[no description available]medium10
floxuridine[no description available]medium10nucleoside analogue;
organofluorine compound;
pyrimidine 2'-deoxyribonucleoside		antimetabolite;
antineoplastic agent;
antiviral drug;
radiosensitizing agent
neostigmine methylsulfate[no description available]medium10arylammonium sulfate saltEC 3.1.1.8 (cholinesterase) inhibitor
prednisolone acetate[no description available]medium10corticosteroid hormone
trichlorfon[no description available]medium10organic phosphonate;
organochlorine compound;
phosphonic ester		agrochemical;
anthelminthic drug;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
insecticide
azauridine[no description available]medium10N-glycosyl-1,2,4-triazineantimetabolite;
antineoplastic agent;
drug metabolite
desoxycorticosterone acetate[no description available]medium20corticosteroid hormone
benzyltrimethylammonium chloride[no description available]medium10
ethinyl estradiol[no description available]medium2017-hydroxy steroid;
3-hydroxy steroid;
terminal acetylenic compound		xenoestrogen
uridine[no description available]medium20uridinesdrug metabolite;
fundamental metabolite;
human metabolite
tolazoline hydrochloride[no description available]medium10benzenes
acetylcholine chloride[no description available]medium10quaternary ammonium salt
desoxycorticosterone[no description available]medium1020-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
mineralocorticoid;
primary alpha-hydroxy ketone		human metabolite;
mouse metabolite
fluocinolone acetonide[no description available]medium2011beta-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
cyclic ketal;
fluorinated steroid;
glucocorticoid;
organic heteropentacyclic compound;
primary alpha-hydroxy ketone		anti-inflammatory drug;
antipruritic drug
norethynodrel[no description available]medium10oxo steroid
ampicillin[no description available]medium10beta-lactam antibiotic;
penicillin allergen;
penicillin		antibacterial drug
trifluridine[no description available]medium20nucleoside analogue;
organofluorine compound;
pyrimidine 2'-deoxyribonucleoside		antimetabolite;
antineoplastic agent;
antiviral drug;
EC 2.1.1.45 (thymidylate synthase) inhibitor
4-hydroxypropiophenone[no description available]medium10acetophenones
medroxyprogesterone acetate[no description available]medium1020-oxo steroid;
3-oxo-Delta(4) steroid;
acetate ester;
corticosteroid;
steroid ester		adjuvant;
androgen;
antineoplastic agent;
antioxidant;
female contraceptive drug;
inhibitor;
progestin;
synthetic oral contraceptive
isopropamide iodide[no description available]medium10diarylmethane
mestranol[no description available]medium1017beta-hydroxy steroid;
aromatic ether;
terminal acetylenic compound		prodrug;
xenoestrogen
triamcinolone acetonide[no description available]medium1011beta-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
cyclic ketal;
fluorinated steroid;
glucocorticoid;
primary alpha-hydroxy ketone		anti-allergic agent;
anti-inflammatory drug
dehydrocholic acid[no description available]medium1012-oxo steroid;
3-oxo-5beta-steroid;
7-oxo steroid;
oxo-5beta-cholanic acid		gastrointestinal drug
methylprednisolone[no description available]medium506-methylprednisolone;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		adrenergic agent;
anti-inflammatory drug;
antiemetic;
environmental contaminant;
neuroprotective agent;
xenobiotic
9,10-phenanthrenequinone[no description available]medium10phenanthrenes
phenothiazine[no description available]medium10phenothiazineferroptosis inhibitor;
plant metabolite;
radical scavenger
mecoprop[no description available]medium10aromatic ether;
monocarboxylic acid;
monochlorobenzenes
2-methyl-4-chlorophenoxyacetic acid[no description available]medium10chlorophenoxyacetic acid;
monochlorobenzenes		environmental contaminant;
phenoxy herbicide;
synthetic auxin
arsanilic acid[no description available]medium10organoarsonic acid
3-aminobenzoic acid[no description available]medium10aminobenzoic acid
thiodipropionic acid[no description available]medium10dicarboxylic acid
maltol[no description available]medium104-pyranonesmetabolite
cinchophen[no description available]medium10quinolines
phenazopyridine hydrochloride[no description available]medium10hydrochloridecarcinogenic agent;
local anaesthetic;
non-narcotic analgesic
protocatechualdehyde[no description available]medium10dihydroxybenzaldehyde
20-alpha-dihydroprogesterone[no description available]medium1020-hydroxypregn-4-en-3-onehuman metabolite;
mouse metabolite
quinestrol[no description available]medium1017-hydroxy steroid;
terminal acetylenic compound		xenoestrogen
tripelennamine hydrochloride[no description available]medium10
chlormadinone acetate[no description available]medium20corticosteroid hormone
fluocinonide[no description available]medium10organic molecular entity
fluorometholone[no description available]medium1011beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
3-oxo-Delta(1),Delta(4)-steroid;
fluorinated steroid;
glucocorticoid;
tertiary alpha-hydroxy ketone		anti-inflammatory drug
xanthinol niacinate[no description available]medium10
glycyrrhetinic acid[no description available]medium10cyclic terpene ketone;
hydroxy monocarboxylic acid;
pentacyclic triterpenoid		immunomodulator;
plant metabolite
medroxyprogesterone[no description available]medium1017alpha-hydroxy steroid;
20-oxo steroid;
3-oxo-Delta(4) steroid;
tertiary alpha-hydroxy ketone		contraceptive drug;
progestin;
synthetic oral contraceptive
1,2-naphthoquinone[no description available]medium101,2-naphthoquinonesaryl hydrocarbon receptor agonist;
carcinogenic agent
4,4'-bipyridyl[no description available]medium10bipyridine
monoacetyldapsone[no description available]medium10acetamides;
anilide;
secondary carboxamide;
sulfone
chlorotrianisene[no description available]medium10chloroalkeneantineoplastic agent;
estrogen receptor modulator;
xenoestrogen
aminacrine[no description available]medium10
isoxsuprine hydrochloride[no description available]medium10alkylbenzene
megestrol acetate[no description available]medium2020-oxo steroid;
3-oxo-Delta(4) steroid;
acetate ester;
steroid ester		antineoplastic agent;
appetite enhancer;
contraceptive drug;
progestin;
synthetic oral contraceptive
2-hydroxyacetanilide[no description available]medium10acetamides;
phenols		anti-inflammatory agent;
antineoplastic agent;
antirheumatic drug;
apoptosis inducer;
platelet aggregation inhibitor;
xenobiotic metabolite
clopamide[no description available]medium10sulfonamide
phosmet[no description available]medium10organic thiophosphate;
organothiophosphate insecticide;
phthalimides		acaricide;
agrochemical;
EC 3.1.1.7 (acetylcholinesterase) inhibitor
levonorgestrel[no description available]medium2017beta-hydroxy steroid;
3-oxo-Delta(4) steroid;
terminal acetylenic compound		contraceptive drug;
female contraceptive drug;
progestin;
synthetic oral contraceptive
malononitrile dimer[no description available]medium10
diphenyl disulfide[no description available]medium10benzenes
estradiol valerate[no description available]medium10steroid ester
tetramethylpyrazine[no description available]medium10alkaloid;
pyrazines		antineoplastic agent;
apoptosis inhibitor;
bacterial metabolite;
neuroprotective agent;
platelet aggregation inhibitor;
vasodilator agent
2,2'-dipyridylamine[no description available]medium10
pregnenolone carbonitrile[no description available]medium10aliphatic nitrile
flurandrenolone[no description available]medium1021-hydroxy steroid
diethylcarbamazine citrate[no description available]medium10piperazinecarboxamide
guaiacoxyacetic acid[no description available]medium10
methylene diphosphonate[no description available]medium101,1-bis(phosphonic acid)bone density conservation agent;
chelator
amiloride hydrochloride, anhydrous[no description available]medium10hydrochloridediuretic;
sodium channel blocker
flumethasone[no description available]medium1011beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
fluorinated steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		anti-inflammatory drug
azaribine[no description available]medium10acetate ester;
N-glycosyl-1,2,4-triazine		antipsoriatic;
prodrug
hydrocortisone hemisuccinate[no description available]medium10dicarboxylic acid monoester;
hemisuccinate;
tertiary alpha-hydroxy ketone
mebeverine hydrochloride[no description available]medium10
stavudine[no description available]medium20dihydrofuran;
nucleoside analogue;
organic molecular entity		antimetabolite;
antiviral agent;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
clidinium bromide[no description available]medium10
diloxanide furoate[no description available]medium10carboxylic ester;
furans;
organochlorine compound;
tertiary carboxamide		antiamoebic agent;
prodrug
nitroxoline[no description available]medium10C-nitro compound;
monohydroxyquinoline		antifungal agent;
antiinfective agent;
antimicrobial agent;
renal agent
cladribine[no description available]medium10organochlorine compound;
purine 2'-deoxyribonucleoside		antineoplastic agent;
immunosuppressive agent
alverine citrate[no description available]medium10citrate salt;
organoammonium salt		antispasmodic drug;
cholinergic antagonist
cyclogyl[no description available]medium10
6-nitroindazole[no description available]medium10
hydrocortisone-17-butyrate[no description available]medium10butyrate ester;
cortisol ester;
primary alpha-hydroxy ketone		dermatologic drug;
drug allergen
pentamethylmelamine[no description available]medium10
eedq[no description available]medium10
ornidazole[no description available]medium10C-nitro compound;
imidazoles;
organochlorine compound;
secondary alcohol		antiamoebic agent;
antibacterial drug;
antiinfective agent;
antiprotozoal drug;
antitrichomonal drug;
epitope
tetridamin[no description available]medium10
capobenic acid[no description available]medium10benzamides
thymolphthalein[no description available]medium10terpene lactone
clobetasol propionate[no description available]medium1011beta-hydroxy steroid;
20-oxo steroid;
3-oxo-Delta(1),Delta(4)-steroid;
chlorinated steroid;
fluorinated steroid;
glucocorticoid		anti-inflammatory drug
frentizole[no description available]medium10
eterobarb[no description available]medium10barbiturates
oxcarbazepine[no description available]medium10cyclic ketone;
dibenzoazepine		anticonvulsant;
drug allergen
moricizine hydrochloride[no description available]medium10hydrochlorideanti-arrhythmia drug
proroxan hydrochloride[no description available]medium10
etomidate[no description available]medium10imidazoles
bezafibrate[no description available]medium10aromatic ether;
monocarboxylic acid amide;
monocarboxylic acid;
monochlorobenzenes		antilipemic drug;
environmental contaminant;
geroprotector;
xenobiotic
sq-11725[no description available]medium40
picobenzide[no description available]medium10
triadimenol[no description available]medium10aromatic ether;
conazole fungicide;
hemiaminal ether;
monochlorobenzenes;
secondary alcohol;
triazole fungicide		antifungal agrochemical;
EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor;
xenobiotic metabolite
cerm-1978[no description available]medium10hydrochloride
dazoxiben hydrochloride[no description available]medium10
tobramycin sulfate[no description available]medium10
benzylaminopurine[no description available]medium106-aminopurinescytokinin;
plant metabolite
norharman[no description available]medium10beta-carbolines;
mancude organic heterotricyclic parent		fungal metabolite;
marine metabolite
ticlopidine hydrochloride[no description available]medium10hydrochloride
sulconazole, mononitrate, (+-)-isomer[no description available]medium10conazole antifungal drug;
imidazole antifungal drug;
organic nitrate salt
acetylcholine bromide[no description available]medium10bromide salt;
quaternary ammonium salt
aloxistatin[no description available]medium20epoxide;
ethyl ester;
L-leucine derivative;
monocarboxylic acid amide		anticoronaviral agent;
cathepsin B inhibitor
tryptamide[no description available]medium10
oxyphencyclimine hydrochloride[no description available]medium10pyrimidines
diphenylpyraline hydrochloride[no description available]medium10hydrochloridecholinergic antagonist;
H1-receptor antagonist
mepivacaine hydrochloride[no description available]medium10hydrochloride;
piperidinecarboxamide		local anaesthetic
diphenidol hydrochloride[no description available]medium10diarylmethane
edoxudin[no description available]medium10pyrimidine 2'-deoxyribonucleoside
6-ketoestradiol[no description available]medium10
17 beta-estradiol hemisuccinate[no description available]medium10
amizyl[no description available]medium10
salicylhydroxamic acid[no description available]medium10hydroxamic acid;
phenols		antibacterial drug;
EC 1.11.2.2 (myeloperoxidase) inhibitor;
EC 3.5.1.5 (urease) inhibitor;
trypanocidal drug
1,7-phenanthroline[no description available]medium10phenanthroline
3-fluoro-4-hydroxyphenylacetic acid[no description available]medium10
dyclonine hydrochloride[no description available]medium10hydrochloridetopical anaesthetic
miconazole nitrate[no description available]medium10
econazole nitrate[no description available]medium10
2,4-dimethoxybenzaldehyde[no description available]medium10
enrofloxacin[no description available]medium10cyclopropanes;
N-alkylpiperazine;
N-arylpiperazine;
organofluorine compound;
quinolinemonocarboxylic acid;
quinolone		antibacterial agent;
antimicrobial agent;
antineoplastic agent
clobetasone butyrate[no description available]medium10organic molecular entity
diflorasone diacetate[no description available]medium1011beta-hydroxy steroid;
20-oxo steroid;
3-oxo-Delta(1),Delta(4)-steroid;
acetate ester;
fluorinated steroid;
glucocorticoid		anti-inflammatory drug;
antipruritic drug
hydroxyzine dihydrochloride[no description available]medium10
betamipron[no description available]medium10organonitrogen compound;
organooxygen compound
secnidazole[no description available]medium10C-nitro compound;
imidazoles;
secondary alcohol		epitope
ergocornine[no description available]medium10ergot alkaloid
pramoxine hydrochloride[no description available]medium10aromatic ether
butyrylcholine chloride[no description available]medium10
1-benzylimidazole[no description available]medium10
chloropyramine hydrochloride[no description available]medium10
6-aminoindazole[no description available]medium10indazoles
5-aminoindazole[no description available]medium10
2-methylhippuric acid[no description available]medium10N-acylglycinemetabolite
meclizine hydrochloride[no description available]medium10
11-hydroxyprogesterone, (11alpha)-isomer[no description available]medium1011alpha-hydroxy steroid;
20-oxo steroid;
3-oxo-Delta(4) steroid
malic acid, (r)-isomer[no description available]medium10malic acid
21-deoxycortisol[no description available]medium1011beta-hydroxy steroid;
17alpha-hydroxy-C21-steroid;
deoxycortisol;
tertiary alpha-hydroxy ketone		human blood serum metabolite;
mouse metabolite
estrone 3-methyl ether[no description available]medium10
e-250[no description available]medium10
rac-glycerol 1-monodecanoate[no description available]medium10rac-1-monoacylglycerol
nipecotic acid amide[no description available]medium10piperidinecarboxamide
levcromakalim[no description available]medium101-benzopyran
tachistin[no description available]medium10
cortisol octanoate[no description available]medium10corticosteroid hormone
armepavine[no description available]medium10
bicuculline methiodide[no description available]medium10
beta-carboline-3-carboxylic acid ethyl ester[no description available]medium10beta-carbolines
tryptoline[no description available]medium10beta-carbolines
gamma-fagarine[no description available]medium10organic heterotricyclic compound;
organonitrogen heterocyclic compound;
oxacycle
Zearalanone[no description available]medium10macrolide;
resorcinols
butethamate citrate[no description available]medium10
4-(4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)-1-butanol[no description available]medium10piperidines
1,3-dimethylbenzimidazoline-2-thione[no description available]medium10
n-(n-(3-carboxyoxirane-2-carbonyl)leucyl)isoamylamine[no description available]medium20leucine derivative
desloratadine[no description available]medium10benzocycloheptapyridineanti-allergic agent;
cholinergic antagonist;
drug metabolite;
H1-receptor antagonist
dichloro-1,2-diaminocyclohexane platinum complex[no description available]medium10
1,4-di(2'-thienyl)-1,4-butadione[no description available]medium10
methyl 5-aminolevulinate hydrochloride[no description available]medium10hydrochlorideantineoplastic agent;
dermatologic drug;
photosensitizing agent;
prodrug
antazoline phosphate[no description available]medium10
pridinol mesylate[no description available]medium10
17 alpha-hydroxyprogesterone caproate[no description available]medium10corticosteroid hormone
5-fluorotryptamine monohydrochloride[no description available]medium10
piribedil mesylate[no description available]medium10
serc[no description available]medium10
procyclidine hydrochloride[no description available]medium10hydrochloride
(7R)-7,15,17-trihydroxy-11-methyl-12-oxabicyclo[12.4.0]octadeca-1(14),15,17-trien-13-one[no description available]medium10macrolide
equilin[no description available]medium1017-oxo steroid;
3-hydroxy steroid
adrenosterone[no description available]medium1011-oxo steroid;
17-oxo steroid;
3-oxo-Delta(4) steroid;
androstanoid		androgen;
EC 1.1.1.146 (11beta-hydroxysteroid dehydrogenase) inhibitor;
human urinary metabolite;
marine metabolite
gossypol acetic acid[no description available]medium10
epinastine[no description available]medium10corticosteroid hormone
4',6-dihydroxy-5,7-dimethoxyflavone[no description available]medium10dihydroxyflavone;
dimethoxyflavone
2-hydroxyestradiol[no description available]medium2017beta-hydroxy steroid;
2-hydroxy steroid		carcinogenic agent;
human metabolite;
metabolite;
mouse metabolite;
prodrug
medrysone[no description available]medium10corticosteroid hormone
artisone acetate[no description available]medium10corticosteroid hormone
chondocurine (1beta)-(+-)-isomer[no description available]medium10aromatic ether
4-methoxyxanthone[no description available]medium10
2-methyl-N-[4-(propan-2-ylamino)phenyl]-2-propenamide[no description available]medium10amine
mandelic acid, (s)-isomer[no description available]medium10(2S)-2-hydroxy monocarboxylic acid;
mandelic acid
acebutolol hydrochloride[no description available]medium10hydrochlorideanti-arrhythmia drug;
antihypertensive agent;
beta-adrenergic antagonist;
sympathomimetic agent
difluprednate[no description available]medium10butyrate ester;
corticosteroid hormone
dironyl[no description available]medium10organic molecular entity
amcinonide[no description available]medium1011beta-hydroxy steroid;
20-oxo steroid;
3-oxo-Delta(1),Delta(4)-steroid;
acetate ester;
corticosteroid;
fluorinated steroid;
spiroketal		anti-inflammatory drug
flumethasone pivalate[no description available]medium1011beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
3-oxo-Delta(1),Delta(4)-steroid;
fluorinated steroid;
glucocorticoid;
pivalate ester;
tertiary alpha-hydroxy ketone		anti-inflammatory drug;
antipruritic drug
histidyl-proline diketopiperazine[no description available]medium10dipeptide;
homodetic cyclic peptide;
imidazoles;
pyrrolopyrazine		anti-inflammatory agent;
dopamine uptake inhibitor;
human blood serum metabolite
afimoxifene[no description available]medium10phenols;
tertiary amino compound		antineoplastic agent;
estrogen receptor antagonist;
metabolite
ketoconazole[no description available]medium20cis-1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine
aphidicolin[no description available]medium10tetracyclic diterpenoidantimicrobial agent;
antimitotic;
antineoplastic agent;
antiviral drug;
apoptosis inducer;
Aspergillus metabolite;
DNA synthesis inhibitor;
EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor;
fungal metabolite
azaserine[no description available]medium10carboxylic ester;
diazo compound;
L-serine derivative;
non-proteinogenic L-alpha-amino acid		antifungal agent;
antimetabolite;
antimicrobial agent;
antineoplastic agent;
glutamine antagonist;
immunosuppressive agent;
metabolite
maltitol[no description available]medium10alpha-D-glucoside;
glycosyl alditol		laxative;
metabolite;
sweetening agent
chalcone[no description available]medium30chalconeEC 3.2.1.1 (alpha-amylase) inhibitor
thermospine[no description available]medium10
dibenzylidene acetone[no description available]medium10
4-methoxy-1,3-dimethyl-6-thiophen-2-yl-8-cyclohepta[c]furanone[no description available]medium10cycloheptafuran
5-[(5-methoxycarbonyl-2-methyl-3-furanyl)methoxy]-2-methyl-3-benzofurancarboxylic acid 2-methoxyethyl ester[no description available]medium102-methoxyethyl ester;
benzofurans
5,6,7-trimethoxy-1-methyl-2-indolecarboxylic acid[no description available]medium10indolyl carboxylic acid
haplamine[no description available]medium10organic heterotricyclic compound;
organonitrogen heterocyclic compound;
oxacycle
octotropine methylbromide[no description available]medium20
diethylstilbestrol dipropionate[no description available]medium10
(1S,2R)-2-(octylamino)-1-[4-(propan-2-ylthio)phenyl]-1-propanol[no description available]medium10alkylbenzene
glycerylphosphorylcholine[no description available]medium10phosphocholines;
sn-glycerol 3-phosphates		Escherichia coli metabolite;
human metabolite;
mouse metabolite;
neuroprotective agent;
parasympatholytic;
Saccharomyces cerevisiae metabolite
n-methylscopolamine nitrate[no description available]medium10
propylthiouracil[no description available]medium10pyrimidinethioneantidote to paracetamol poisoning;
antimetabolite;
antioxidant;
antithyroid drug;
carcinogenic agent;
EC 1.14.13.39 (nitric oxide synthase) inhibitor;
hormone antagonist
nsc 4347[no description available]medium10
4-methoxy-N1,N3-bis(3-pyridinyl)benzene-1,3-dicarboxamide[no description available]medium10benzamides
physostigmine salicylate[no description available]medium10azaheterocycle salicylate salt;
salicylates
1-[1-oxo-2-[(4-oxo-2,3-dihydro-1H-cyclopenta[c][1]benzopyran-7-yl)oxy]ethyl]-4-piperidinecarboxylic acid[no description available]medium10coumarins
prothionamide[no description available]medium10pyridines
2-(2,3,4-trimethoxyphenyl)-2,3-dihydro-1,3-benzoxazin-4-one[no description available]medium10benzoxazine
dienestrol[no description available]medium10
methylthiouracil[no description available]medium10pyrimidone
4-methoxy-N-(3-pyridinylmethyl)benzamide[no description available]medium10benzamides
5-methyl-4-[(2-oxo-1-benzopyran-7-yl)oxymethyl]-2-furancarboxylic acid methyl ester[no description available]medium10coumarins
2-(1,3-dioxo-2-isoindolyl)-N-(3-nitrophenyl)acetamide[no description available]medium10phthalimides
2-(3,4-dimethoxyphenyl)-1-(2,4,6-trihydroxyphenyl)ethanone[no description available]medium10stilbenoid
3-(4-methoxyphenyl)-5-(2-phenylethyl)-1,2,4-oxadiazole[no description available]medium10oxadiazole;
ring assembly
3-(3,5-dimethyl-7-oxo-6-furo[3,2-g][1]benzopyranyl)propanoic acid[no description available]medium10psoralens
1,6-dimethyl-3-(2-pyridinyl)pyrimido[5,4-e][1,2,4]triazine-5,7-dione[no description available]medium10pyrimidotriazine
9-hydroxy-4-[1-oxo-2-[4-(phenylmethyl)-1-piperazinyl]ethyl]-2,3-dihydro-1H-[1]benzopyrano[3,4-b]pyridin-5-one[no description available]medium10pyridochromene
5-bromo-3-pyridinecarboxylic acid [3-(3-methylphenoxy)-4-oxo-1-benzopyran-7-yl] ester[no description available]medium10chromones
5-methyl-4-[(3-methyl-6-oxo-7,8,9,10-tetrahydrobenzo[c][1]benzopyran-1-yl)oxymethyl]-2-furancarboxylic acid[no description available]medium10coumarins
4-methyl-3-(phenylmethyl)-7-[(3,4,5-trimethoxyphenyl)methoxy]-1-benzopyran-2-one[no description available]medium10coumarins
[2-(4-methoxyphenyl)-6-methyl-4-quinolinyl]-(4-morpholinyl)methanone[no description available]medium10quinolines
5-(3,3-dimethyl-2-oxobutoxy)-3,4,7-trimethyl-1-benzopyran-2-one[no description available]medium10coumarins
N-[4-(4-morpholinyl)phenyl]-5-(2-nitrophenyl)-2-furancarboxamide[no description available]medium10aromatic amide;
furans
2-(8-methoxy-2-methyl-4-oxo-1-quinolinyl)-N-(2-methoxyphenyl)acetamide[no description available]medium10quinolines
N-[(6-methoxy-2-oxo-1H-quinolin-3-yl)methyl]-N-propan-2-yl-2-furancarboxamide[no description available]medium10quinolines
2-(4-bromophenyl)-1-(2,4-dihydroxyphenyl)ethanone[no description available]medium10stilbenoid
1-cyclohexyl-3-(6-ethoxy-1,3-benzothiazol-2-yl)urea[no description available]medium10benzothiazoles
N-[(3,5-dimethoxyphenyl)methyl]-1-(2,3,4-trimethoxyphenyl)methanamine[no description available]medium10dimethoxybenzene
2-[[5-[2-[(2-methylpropan-2-yl)oxy]-2-oxoethoxy]-4-oxo-2-phenyl-1-benzopyran-7-yl]oxy]acetic acid tert-butyl ester[no description available]medium10flavones;
tert-butyl ester
ethylenethiourea[no description available]medium10imidazolidines
p-aminosalicylic acid monosodium salt[no description available]medium10organic molecular entity
digoxin[no description available]medium10cardenolide glycoside;
steroid saponin		anti-arrhythmia drug;
cardiotonic drug;
EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor;
epitope
mecysteine hydrochloride[no description available]medium10alpha-amino acid ester
ethionamide[no description available]medium10pyridines;
thiocarboxamide		antilipemic drug;
antitubercular agent;
fatty acid synthesis inhibitor;
leprostatic drug;
prodrug
2-(2-furanyl)-4-thiazolidinecarboxylic acid[no description available]medium10organonitrogen compound;
organooxygen compound
dihydrosamidine[no description available]medium10
N-(2-methoxycyclohexyl)-3,4-dimethylaniline[no description available]medium10methylbenzene
2-(3,4-dimethylphenyl)-5-ethyl-5-phenyl-1,2,4-triazolidine-3-thione[no description available]medium10methylbenzene
2-[3-oxo-1-[[[oxo(thiophen-2-yl)methyl]amino]-sulfanylidenemethyl]-2-piperazinyl]acetic acid propan-2-yl ester[no description available]medium10isopropyl ester;
piperazines
zeranol[no description available]medium10macrolide
monooctanoin[no description available]medium101-monoglyceride;
octanoate ester;
rac-1-monoacylglycerol
trimethoprim[no description available]medium10
4-hydroxy-1-[1-oxo-2-(phenylmethoxycarbonylamino)propyl]-2-pyrrolidinecarboxylic acid[no description available]medium10peptide
N-(2,3-dihydro-1,4-benzodioxin-3-ylmethyl)-2-(2,3-dimethoxyphenyl)acetamide[no description available]medium10dimethoxybenzene
3-acetyl-6-methyl-1H-quinolin-4-one[no description available]medium10quinolines
3-(phenylthio)-1-(1-pyrrolidinyl)-1-propanone[no description available]medium10aryl sulfide
N-(3-chlorophenyl)-5-oxo-9b-phenyl-2,3-dihydroimidazo[2,1-a]isoindole-1-carboxamide[no description available]medium10imidazolidines
Anthraniloyllycoctonine[no description available]medium10diterpene alkaloid
N-[4-[(cyclohexylamino)-oxomethyl]phenyl]-3-pyridinecarboxamide[no description available]medium10aromatic amide
1-[3-[[4-(4-fluorophenyl)-1-piperazinyl]methyl]-4-methoxyphenyl]-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carboxylic acid[no description available]medium10harmala alkaloid
biochanin a[no description available]medium104'-methoxyisoflavones;
7-hydroxyisoflavones		antineoplastic agent;
EC 3.5.1.99 (fatty acid amide hydrolase) inhibitor;
phytoestrogen;
plant metabolite;
tyrosine kinase inhibitor
prostaglandin b1[no description available]medium10prostaglandins Bhuman metabolite
prostaglandin f1[no description available]medium10prostaglandins Falphahuman metabolite
zearalenone[no description available]medium10macrolide;
resorcinols		fungal metabolite;
mycoestrogen
estriol 17-glucuronide[no description available]medium10steroid saponin
4-hydroxyestradiol[no description available]medium104-hydroxy steroidmetabolite
menatetrenone[no description available]medium10menaquinoneanti-inflammatory agent;
antioxidant;
bone density conservation agent;
human metabolite;
neuroprotective agent
dinoprost tromethamine[no description available]medium10organic molecular entity
hydrocortisone valerate[no description available]medium10cortisol ester;
glucocorticoid;
primary alpha-hydroxy ketone;
valerate ester
prostaglandin f2 methyl ester[no description available]medium10prostanoid
2-bromoergocryptine mesylate[no description available]medium10
perhexiline maleate[no description available]medium10
ethisterone[no description available]medium1017beta-hydroxy steroid;
3-oxo-Delta(4) steroid;
terminal acetylenic compound;
tertiary alcohol		drug metabolite;
progestin
nalmefene[no description available]medium20morphinane alkaloid
6alpha-hydroxy-17beta-estradiol[no description available]medium106alpha-hydroxy steroid
desoximetasone[no description available]medium1011beta-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
fluorinated steroid;
glucocorticoid;
primary alpha-hydroxy ketone		anti-inflammatory drug;
antipruritic drug
cytochalasin b[no description available]medium30cytochalasin;
lactam;
lactone;
organic heterotricyclic compound		actin polymerisation inhibitor;
metabolite;
mycotoxin;
platelet aggregation inhibitor
u-44619[no description available]medium10
furazolidone[no description available]medium10
nifuroxazide[no description available]medium10benzoic acids
rg 13022[no description available]medium10
styrylquinoline[no description available]medium102-styrylquinoline
kavain[no description available]medium10racemateglycine receptor antagonist
enalapril maleate[no description available]medium10maleate saltantihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
prodrug
trimebutine maleate salt[no description available]medium10trihydroxybenzoic acid
vincristine sulfate[no description available]medium10
3-(3,4-dihydro-2H-1,5-benzodioxepin-7-yl)-5,7-dihydroxy-2-methyl-1-benzopyran-4-one[no description available]medium10isoflavones
(2R)-2-[[(2R,3R,4R)-2-amino-4-hydroxy-4-(5-hydroxy-2-pyridinyl)-3-methyl-1-oxobutyl]amino]-2-[(2S,3R,4S,5S)-5-(2,4-dioxo-1-pyrimidinyl)-3,4-dihydroxy-2-oxolanyl]acetic acid[no description available]medium10peptide
phentolamine[no description available]medium10
fendiline hydrochloride[no description available]medium10
nab-365[no description available]medium10hydrochloridebeta-adrenergic agonist;
bronchodilator agent;
sympathomimetic agent
dithiazanine iodide[no description available]medium10benzothiazoles;
organic iodide salt		anthelminthic drug;
fluorochrome
sinequan[no description available]medium10dibenzooxazepine
buflomedil hydrochloride[no description available]medium10aromatic ketone
dirithromycin[no description available]medium10macrolide antibioticprodrug
fluphenazine[no description available]medium10
homochlorocyclizine monohydrochloride[no description available]medium10
butoxamine hydrochloride[no description available]medium10
scopolamine hydrobromide[no description available]medium10
emetine hydrochloride[no description available]medium10
6 beta-hydroxycortisol[no description available]medium1011beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
6beta-hydroxy steroid;
C21-steroid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		human metabolite;
mammalian metabolite;
probe
androst-16-en-3-one[no description available]medium103-oxo steroid;
androstanoid		mammalian metabolite;
pheromone
dihydroouabain[no description available]medium10cardenolide glycosideEC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor;
radiosensitizing agent
LSM-6455[no description available]medium10peptide ergot alkaloid
estradiol 17-acetate[no description available]medium10steroid ester
(3aR,6aR)-5-(3-methoxyphenyl)-3-[oxo(2-pyrazinyl)methyl]-3a,6a-dihydro-1H-pyrrolo[3,4-c]pyrazole-4,6-dione[no description available]medium10pyrrolidines
N-[[3-(2-chlorophenyl)-1-(4-fluorophenyl)-4-pyrazolyl]methyl]-2-(2-pyridinyl)ethanamine[no description available]medium10pyrazoles;
ring assembly
bucladesine[no description available]medium6503',5'-cyclic purine nucleotide
ampicillin sodium[no description available]medium10organic sodium salt
penicillin g potassium[no description available]medium10organic potassium salt
piperacillin sodium[no description available]medium10organic sodium salt
cefoxitin sodium[no description available]medium10organic molecular entity
nafcillin sodium[no description available]medium10organic sodium salt
cefamandole nafate[no description available]medium10organic sodium saltantibacterial drug
sodium diatrizoate[no description available]medium10organic sodium salt;
organoiodine compound		radioopaque medium
estrone sulfate, potassium salt[no description available]medium10
naproxen sodium[no description available]medium10organic sodium saltantipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
oxytetracycline, anhydrous[no description available]medium10
acenocoumarol[no description available]medium10C-nitro compound;
hydroxycoumarin;
methyl ketone		anticoagulant;
EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor
mobic[no description available]medium201,3-thiazoles;
benzothiazine;
monocarboxylic acid amide		analgesic;
antirheumatic drug;
cyclooxygenase 2 inhibitor;
non-steroidal anti-inflammatory drug
mobiflex[no description available]medium10heteroaryl hydroxy compound;
monocarboxylic acid amide;
pyridines;
thienothiazine		antipyretic;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
inosine[no description available]medium20inosines;
purines D-ribonucleoside		Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
kf38789[no description available]medium10
pralidoxime iodide[no description available]medium10organic iodide salt;
pyridinium salt		cholinergic drug;
cholinesterase reactivator
pralidoxime chloride[no description available]medium10organic chloride salt;
pyridinium salt		cholinergic drug;
cholinesterase reactivator
spd-304[no description available]medium10
zm 241385[no description available]medium40diamino-1,3,5-triazine
morusin[no description available]medium10extended flavonoid;
trihydroxyflavone		antineoplastic agent;
plant metabolite
cudraflavone c[no description available]medium10tetrahydroxyflavoneantibacterial agent;
antineoplastic agent;
plant metabolite
licoflavone c[no description available]medium10
artemisinin[no description available]medium20organic peroxide;
sesquiterpene lactone		antimalarial;
plant metabolite
artenimol[no description available]medium10
gsk2256294[no description available]medium10
hc 030031[no description available]medium10
pregabalin[no description available]medium10gamma-amino acidanticonvulsant;
calcium channel blocker
clonidine[no description available]medium50clonidine;
imidazoline
lomefloxacin[no description available]medium10fluoroquinolone antibiotic;
N-arylpiperazine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone		antimicrobial agent;
antitubercular agent;
photosensitizing agent
apremilast[no description available]medium70aromatic ether;
N-acetylarylamine;
phthalimides;
sulfone		non-steroidal anti-inflammatory drug;
phosphodiesterase IV inhibitor
fingolimod[no description available]medium10aminodiol;
primary amino compound		antineoplastic agent;
CB1 receptor antagonist;
immunosuppressive agent;
prodrug;
sphingosine-1-phosphate receptor agonist
4-amino-5-chloro-N-[(3R,4S)-1-[3-(4-fluorophenoxy)propyl]-3-methoxy-4-piperidinyl]-2-methoxybenzamide[no description available]medium10benzamides
tacrine[no description available]medium10acridines;
aromatic amine		EC 3.1.1.7 (acetylcholinesterase) inhibitor
nan 190[no description available]medium10N-alkylpiperazine;
N-arylpiperazine;
phthalimides		serotonergic antagonist
sb 269970[no description available]medium10sulfonamide
betulinic acid[no description available]medium20hydroxy monocarboxylic acid;
pentacyclic triterpenoid		anti-HIV agent;
anti-inflammatory agent;
antimalarial;
antineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
plant metabolite
mangostin[no description available]medium20aromatic ether;
phenols;
xanthones		antimicrobial agent;
antineoplastic agent;
antioxidant;
plant metabolite
9-Hydroxycalabaxanthone[no description available]medium20xanthones
enoxacin[no description available]medium101,8-naphthyridine derivative;
amino acid;
fluoroquinolone antibiotic;
monocarboxylic acid;
N-arylpiperazine;
quinolone antibiotic		antibacterial drug;
DNA synthesis inhibitor
prednisone[no description available]medium1011-oxo steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		adrenergic agent;
anti-inflammatory drug;
antineoplastic agent;
immunosuppressive agent;
prodrug
4-nitrobenzenesulfonyl chloride[no description available]medium10
ranitidine[no description available]medium20C-nitro compound;
furans;
organic sulfide;
tertiary amino compound		anti-ulcer drug;
drug allergen;
environmental contaminant;
H2-receptor antagonist;
xenobiotic
9-(2-hydroxy-3-nonyl)adenine[no description available]medium10EHNA
dimethyl sulfoxide[no description available]medium30sulfoxide;
volatile organic compound		alkylating agent;
antidote;
Escherichia coli metabolite;
geroprotector;
MRI contrast agent;
non-narcotic analgesic;
polar aprotic solvent;
radical scavenger
uracil[no description available]medium10pyrimidine nucleobase;
pyrimidone		allergen;
Daphnia magna metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
prodrug;
Saccharomyces cerevisiae metabolite
uridine monophosphate[no description available]medium10pyrimidine ribonucleoside 5'-monophosphate;
uridine 5'-phosphate		Escherichia coli metabolite;
human metabolite;
mouse metabolite
hydantoins[no description available]medium10imidazolidine-2,4-dione
succinimide[no description available]medium10dicarboximide;
pyrrolidinone
1-methyluracil[no description available]medium10nucleobase analogue;
pyrimidone		metabolite
1-methylhydantoin[no description available]medium10imidazolidine-2,4-dionebacterial metabolite
1-aminohydantoin[no description available]medium10imidazolidine-2,4-dione
pomalidomide[no description available]medium10aromatic amine;
dicarboximide;
isoindoles;
piperidones		angiogenesis inhibitor;
antineoplastic agent;
immunomodulator
lenalidomide[no description available]medium10aromatic amine;
dicarboximide;
isoindoles;
piperidones		angiogenesis inhibitor;
antineoplastic agent;
immunomodulator
thiohydantoins[no description available]medium10
nitrofurantoin[no description available]medium10imidazolidine-2,4-dione;
nitrofuran antibiotic;
organonitrogen heterocyclic antibiotic;
organooxygen heterocyclic antibiotic		antibacterial drug;
antiinfective agent;
hepatotoxic agent
furagin[no description available]medium10
azumolene[no description available]medium10
cc-122[no description available]medium10
sofosbuvir[no description available]medium20isopropyl ester;
L-alanyl ester;
nucleotide conjugate;
organofluorine compound;
phosphoramidate ester		antiviral drug;
hepatitis C protease inhibitor;
prodrug
abt-333[no description available]medium20aromatic ether;
naphthalenes;
pyrimidone;
sulfonamide		antiviral drug;
nonnucleoside hepatitis C virus polymerase inhibitor
a 867744[no description available]medium10
fosbretabulin[no description available]medium10stilbenoid
pf-2545920[no description available]medium10
(2R,3S)-EHNA hydrochloride[no description available]medium10hydrochlorideEC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
EC 3.5.4.4 (adenosine deaminase) inhibitor
6-((3s,4s)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl)-1-(tetrahydro-2h-pyran-4-yl)-1,5-dihydro-4h-pyrazolo(3,4-d)pyrimidin-4-one[no description available]medium10
aminolevulinic acid[no description available]medium104-oxo monocarboxylic acid;
amino acid zwitterion;
delta-amino acid		antineoplastic agent;
dermatologic drug;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
photosensitizing agent;
plant metabolite;
prodrug;
Saccharomyces cerevisiae metabolite
thioctic acid[no description available]medium10dithiolanes;
heterocyclic fatty acid;
thia fatty acid		fundamental metabolite;
geroprotector
picolinic acid[no description available]medium10pyridinemonocarboxylic acidhuman metabolite;
MALDI matrix material
thiamine[no description available]medium10primary alcohol;
vitamin B1		Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
pleconaril[no description available]medium10
4-(2-aminoethyl)benzenesulfonylfluoride[no description available]medium10
alprenolol[no description available]medium10secondary alcohol;
secondary amino compound		anti-arrhythmia drug;
antihypertensive agent;
beta-adrenergic antagonist;
sympatholytic agent
amantadine[no description available]medium10adamantanes;
primary aliphatic amine		analgesic;
antiparkinson drug;
antiviral drug;
dopaminergic agent;
NMDA receptor antagonist;
non-narcotic analgesic
2-aminothiazole[no description available]medium101,3-thiazoles;
primary amino compound
amodiaquine[no description available]medium10aminoquinoline;
organochlorine compound;
phenols;
secondary amino compound;
tertiary amino compound		anticoronaviral agent;
antimalarial;
drug allergen;
EC 2.1.1.8 (histamine N-methyltransferase) inhibitor;
non-steroidal anti-inflammatory drug;
prodrug
camostat[no description available]medium10benzoate ester;
carboxylic ester;
diester;
guanidines;
tertiary carboxamide		anti-inflammatory agent;
anticoronaviral agent;
antifibrinolytic drug;
antihypertensive agent;
antineoplastic agent;
antiviral agent;
serine protease inhibitor
camphor, (+-)-isomer[no description available]medium10bornane monoterpenoid;
cyclic monoterpene ketone		plant metabolite
candesartan[no description available]medium10benzimidazolecarboxylic acid;
biphenylyltetrazole		angiotensin receptor antagonist;
antihypertensive agent;
environmental contaminant;
xenobiotic
cetylpyridinium[no description available]medium10pyridinium ion
chloroxylenol[no description available]medium10monochlorobenzenes;
phenols		antiseptic drug;
disinfectant;
molluscicide
danthron[no description available]medium10dihydroxyanthraquinoneapoptosis inducer;
plant metabolite
valproic acid[no description available]medium20branched-chain fatty acid;
branched-chain saturated fatty acid		anticonvulsant;
antimanic drug;
EC 3.5.1.98 (histone deacetylase) inhibitor;
GABA agent;
neuroprotective agent;
psychotropic drug;
teratogenic agent
doxazosin[no description available]medium10aromatic amine;
benzodioxine;
monocarboxylic acid amide;
N-acylpiperazine;
N-arylpiperazine;
quinazolines		alpha-adrenergic antagonist;
antihyperplasia drug;
antihypertensive agent;
antineoplastic agent;
vasodilator agent
etidronate[no description available]medium101,1-bis(phosphonic acid)antineoplastic agent;
bone density conservation agent;
chelator
2-hexyloxybenzamide[no description available]medium10aromatic ether;
benzamides		antifungal agent
brl 42810[no description available]medium102-aminopurines;
acetate ester		antiviral drug;
prodrug
gabexate[no description available]medium10benzoate ester
glutaral[no description available]medium10dialdehydecross-linking reagent;
disinfectant;
fixative
fasudil[no description available]medium10isoquinolines;
N-sulfonyldiazepane		antihypertensive agent;
calcium channel blocker;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
geroprotector;
neuroprotective agent;
nootropic agent;
vasodilator agent
miltefosine[no description available]medium10phosphocholines;
phospholipid		anti-inflammatory agent;
anticoronaviral agent;
antifungal agent;
antineoplastic agent;
antiprotozoal drug;
apoptosis inducer;
immunomodulator;
protein kinase inhibitor
hexylresorcinol[no description available]medium10resorcinols
beta-thujaplicin[no description available]medium10cyclic ketone;
enol;
monoterpenoid		antibacterial agent;
antifungal agent;
antineoplastic agent;
antiplasmodial drug;
plant metabolite
avapro[no description available]medium10azaspiro compound;
biphenylyltetrazole		angiotensin receptor antagonist;
antihypertensive agent;
environmental contaminant;
xenobiotic
kojic acid[no description available]medium104-pyranones;
enol;
primary alcohol		Aspergillus metabolite;
EC 1.10.3.1 (catechol oxidase) inhibitor;
EC 1.10.3.2 (laccase) inhibitor;
EC 1.13.11.24 (quercetin 2,3-dioxygenase) inhibitor;
EC 1.14.18.1 (tyrosinase) inhibitor;
EC 1.4.3.3 (D-amino-acid oxidase) inhibitor;
NF-kappaB inhibitor;
skin lightening agent
lapachol[no description available]medium10
losartan[no description available]medium10biphenylyltetrazole;
imidazoles		angiotensin receptor antagonist;
anti-arrhythmia drug;
antihypertensive agent;
endothelin receptor antagonist
4-(dimethylamino)-n-(7-(hydroxyamino)-7-oxoheptyl)benzamide[no description available]medium10benzamides;
hydroxamic acid;
secondary carboxamide;
tertiary amino compound		antineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor
mafenide[no description available]medium10aromatic amine
entinostat[no description available]medium10benzamides;
carbamate ester;
primary amino compound;
pyridines;
substituted aniline		antineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor
nafamostat[no description available]medium10benzoic acids;
guanidines
osalmide[no description available]medium10organic molecular entity
perhexiline[no description available]medium10piperidinescardiovascular drug
phenazopyridine[no description available]medium10diaminopyridine;
monoazo compound		anticoronaviral agent;
carcinogenic agent;
local anaesthetic;
non-narcotic analgesic
phenylmethylsulfonyl fluoride[no description available]medium10acyl fluorideserine proteinase inhibitor
pimobendan[no description available]medium30benzimidazoles;
pyridazinone		cardiotonic drug;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
vasodilator agent
pj-34[no description available]medium10phenanthridines;
secondary carboxamide;
tertiary amino compound		angiogenesis inhibitor;
anti-inflammatory agent;
antiatherosclerotic agent;
antineoplastic agent;
apoptosis inducer;
cardioprotective agent;
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor;
neuroprotective agent
rimantadine[no description available]medium10alkylamine
scriptaid[no description available]medium10isoquinolines
sebacic acid[no description available]medium10alpha,omega-dicarboxylic acid;
dicarboxylic fatty acid		human metabolite;
plant metabolite
fenofibrate[no description available]medium10benzochromenone;
delta-lactone;
naphtho-alpha-pyrone		platelet aggregation inhibitor;
Sir2 inhibitor
suprofen[no description available]medium10aromatic ketone;
monocarboxylic acid;
thiophenes		antirheumatic drug;
drug allergen;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
peripheral nervous system drug
ticlopidine[no description available]medium10monochlorobenzenes;
thienopyridine		anticoagulant;
fibrin modulating drug;
hematologic agent;
P2Y12 receptor antagonist;
platelet aggregation inhibitor
triflupromazine[no description available]medium10organofluorine compound;
phenothiazines;
tertiary amine		anticoronaviral agent;
antiemetic;
dopaminergic antagonist;
first generation antipsychotic
trigonelline[no description available]medium10alkaloid;
iminium betaine		food component;
human urinary metabolite;
plant metabolite
trimethobenzamide[no description available]medium10benzamides;
tertiary amino compound		antiemetic
delavirdine[no description available]medium10aminopyridine;
indolecarboxamide;
N-acylpiperazine;
sulfonamide		antiviral drug;
HIV-1 reverse transcriptase inhibitor
vesnarinone[no description available]medium50organic molecular entity
idoxuridine[no description available]medium10organoiodine compound;
pyrimidine 2'-deoxyribonucleoside		antiviral drug;
DNA synthesis inhibitor
chloramphenicol[no description available]medium10C-nitro compound;
carboxamide;
diol;
organochlorine compound		antibacterial drug;
antimicrobial agent;
Escherichia coli metabolite;
geroprotector;
Mycoplasma genitalium metabolite;
protein synthesis inhibitor
lysine[no description available]medium10aspartate family amino acid;
L-alpha-amino acid zwitterion;
L-alpha-amino acid;
lysine;
organic molecular entity;
proteinogenic amino acid		algal metabolite;
anticonvulsant;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite
phenylethyl alcohol[no description available]medium10benzenes;
primary alcohol		Aspergillus metabolite;
fragrance;
plant growth retardant;
plant metabolite;
Saccharomyces cerevisiae metabolite
zoxazolamine[no description available]medium10benzoxazole
ficusin[no description available]medium10psoralensplant metabolite
tubercidin[no description available]medium10antibiotic antifungal agent;
N-glycosylpyrrolopyrimidine;
ribonucleoside		antimetabolite;
antineoplastic agent;
bacterial metabolite
9,10-anthraquinone[no description available]medium10anthraquinone
salicylanilide[no description available]medium10benzanilide fungicide;
salicylamides;
salicylanilides
gramine[no description available]medium10aminoalkylindole;
indole alkaloid;
tertiary amino compound		antibacterial agent;
antiviral agent;
plant metabolite;
serotonergic antagonist
aminacrine[no description available]medium10aminoacridines;
primary amino compound		acid-base indicator;
antiinfective agent;
antiseptic drug;
fluorescent dye;
MALDI matrix material;
mutagen
methyl gallate[no description available]medium10gallate esteranti-inflammatory agent;
antioxidant;
plant metabolite
monobenzone[no description available]medium10benzyl etherallergen;
dermatologic drug;
melanin synthesis inhibitor
ditiocarb[no description available]medium10dithiocarbamic acidschelator;
copper chelator
catechin[no description available]medium10catechinantioxidant;
plant metabolite
lucanthone[no description available]medium10thioxanthenesadjuvant;
antineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
mutagen;
photosensitizing agent;
prodrug;
schistosomicide drug
cepharanthine[no description available]medium10bisbenzylisoquinoline alkaloid;
isoquinolines
aloe emodin[no description available]medium10aromatic primary alcohol;
dihydroxyanthraquinone		antineoplastic agent;
plant metabolite
chrysophanic acid[no description available]medium10dihydroxyanthraquinoneanti-inflammatory agent;
antiviral agent;
plant metabolite
emetine[no description available]medium20isoquinoline alkaloid;
pyridoisoquinoline		antiamoebic agent;
anticoronaviral agent;
antiinfective agent;
antimalarial;
antineoplastic agent;
antiprotozoal drug;
antiviral agent;
autophagy inhibitor;
emetic;
expectorant;
plant metabolite;
protein synthesis inhibitor
osthol[no description available]medium10botanical anti-fungal agent;
coumarins		metabolite
flavanone[no description available]medium10flavanones
phloretic acid[no description available]medium10hydroxy monocarboxylic acidplant metabolite
oleanolic acid[no description available]medium10hydroxy monocarboxylic acid;
pentacyclic triterpenoid		plant metabolite
angelicin[no description available]medium10furanocoumarin
hydroxychloroquine sulfate[no description available]medium10
ethambutol[no description available]medium10ethanolamines;
ethylenediamine derivative		antitubercular agent;
environmental contaminant;
xenobiotic
metformin hydrochloride[no description available]medium10hydrochlorideenvironmental contaminant;
hypoglycemic agent;
xenobiotic
antimycin a[no description available]medium10benzamides;
formamides;
macrodiolide;
phenols		antifungal agent;
mitochondrial respiratory-chain inhibitor;
piscicide
5,5'-dimethyl-2,2'-bipyridyl[no description available]medium10bipyridines
dichlorobenzyl alcohol[no description available]medium10benzyl alcohols;
dichlorobenzene		antiseptic drug
dideoxyadenosine[no description available]medium40adenosines;
purine 2',3'-dideoxyribonucleoside		EC 3.5.4.4 (adenosine deaminase) inhibitor;
EC 4.6.1.1 (adenylate cyclase) inhibitor
vidarabine[no description available]medium30beta-D-arabinoside;
purine nucleoside		antineoplastic agent;
bacterial metabolite;
nucleoside antibiotic
vidarabine[no description available]medium31beta-D-arabinoside;
purine nucleoside		antineoplastic agent;
bacterial metabolite;
nucleoside antibiotic
ancitabine[no description available]medium10diol;
organic heterotricyclic compound		antimetabolite;
antineoplastic agent;
prodrug
chloropyramine[no description available]medium10aminopyridine
n'-nitrosonornicotine[no description available]medium10pyridines;
pyrrolidines
daunorubicin[no description available]medium10aminoglycoside antibiotic;
anthracycline;
p-quinones;
tetracenequinones		antineoplastic agent;
bacterial metabolite
pyridoxal phosphate[no description available]medium10pyridinecarbaldehyde
nitazoxanide[no description available]medium10benzamides;
carboxylic ester
oltipraz[no description available]medium101,2-dithiole;
pyrazines		angiogenesis modulating agent;
antimutagen;
antineoplastic agent;
antioxidant;
EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor;
neurotoxin;
protective agent;
schistosomicide drug
fiacitabine[no description available]medium10
ranolazine[no description available]medium10aromatic amide;
monocarboxylic acid amide;
monomethoxybenzene;
N-alkylpiperazine;
secondary alcohol
brequinar[no description available]medium10biphenyls;
monocarboxylic acid;
monofluorobenzenes;
quinolinemonocarboxylic acid		anticoronaviral agent;
antimetabolite;
antineoplastic agent;
antiviral agent;
EC 1.3.5.2 [dihydroorotate dehydrogenase (quinone)] inhibitor;
immunosuppressive agent;
pyrimidine synthesis inhibitor
imiquimod[no description available]medium10imidazoquinolineantineoplastic agent;
interferon inducer
adefovir[no description available]medium106-aminopurines;
ether;
phosphonic acids		antiviral drug;
DNA synthesis inhibitor;
drug metabolite;
HIV-1 reverse transcriptase inhibitor;
nephrotoxic agent
cidofovir anhydrous[no description available]medium10phosphonic acids;
pyrimidone		anti-HIV agent;
antineoplastic agent;
antiviral drug;
photosensitizing agent
celgosivir[no description available]medium10
gemcitabine[no description available]medium10organofluorine compound;
pyrimidine 2'-deoxyribonucleoside		antimetabolite;
antineoplastic agent;
antiviral drug;
DNA synthesis inhibitor;
EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor;
environmental contaminant;
immunosuppressive agent;
photosensitizing agent;
prodrug;
radiosensitizing agent;
xenobiotic
lamivudine[no description available]medium10monothioacetal;
nucleoside analogue;
oxacycle;
primary alcohol		allergen;
anti-HBV agent;
antiviral drug;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor;
HIV-1 reverse transcriptase inhibitor;
prodrug
valsartan[no description available]medium10biphenylyltetrazole;
monocarboxylic acid amide;
monocarboxylic acid		angiotensin receptor antagonist;
antihypertensive agent;
environmental contaminant;
xenobiotic
zanamivir[no description available]medium10guanidinesantiviral agent;
EC 3.2.1.18 (exo-alpha-sialidase) inhibitor
adefovir dipivoxil[no description available]medium106-aminopurines;
carbonate ester;
ether;
organic phosphonate		antiviral drug;
DNA synthesis inhibitor;
HIV-1 reverse transcriptase inhibitor;
nephrotoxic agent;
prodrug
emtricitabine[no description available]medium10monothioacetal;
nucleoside analogue;
organofluorine compound;
pyrimidone		antiviral drug;
HIV-1 reverse transcriptase inhibitor
octyl gallate[no description available]medium10gallate esterfood antioxidant;
hypoglycemic agent;
plant metabolite
nelfinavir[no description available]medium10aryl sulfide;
benzamides;
organic heterobicyclic compound;
phenols;
secondary alcohol;
tertiary amino compound		antineoplastic agent;
HIV protease inhibitor
arctigenin[no description available]medium10lignan
baicalin[no description available]medium20dihydroxyflavone;
glucosiduronic acid;
glycosyloxyflavone;
monosaccharide derivative		antiatherosclerotic agent;
antibacterial agent;
anticoronaviral agent;
antineoplastic agent;
antioxidant;
cardioprotective agent;
EC 2.7.7.48 (RNA-directed RNA polymerase) inhibitor;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
ferroptosis inhibitor;
neuroprotective agent;
non-steroidal anti-inflammatory drug;
plant metabolite;
prodrug
plerixafor[no description available]medium10azacycloalkane;
azamacrocycle;
benzenes;
crown amine;
secondary amino compound;
tertiary amino compound		anti-HIV agent;
antineoplastic agent;
C-X-C chemokine receptor type 4 antagonist;
immunological adjuvant
amprenavir[no description available]medium10carbamate ester;
sulfonamide;
tetrahydrofuryl ester		antiviral drug;
HIV protease inhibitor
oseltamivir[no description available]medium10acetamides;
amino acid ester;
cyclohexenecarboxylate ester;
primary amino compound		antiviral drug;
EC 3.2.1.18 (exo-alpha-sialidase) inhibitor;
environmental contaminant;
prodrug;
xenobiotic
epigallocatechin gallate[no description available]medium10flavans;
gallate ester;
polyphenol		antineoplastic agent;
antioxidant;
apoptosis inducer;
geroprotector;
Hsp90 inhibitor;
neuroprotective agent;
plant metabolite
1,2,3,4,6-pentakis-O-galloyl-beta-D-glucose[no description available]medium10gallate ester;
galloyl beta-D-glucose		anti-inflammatory agent;
antineoplastic agent;
geroprotector;
hepatoprotective agent;
plant metabolite;
radiation protective agent;
radical scavenger
cephalotaxine[no description available]medium10benzazepine alkaloid fundamental parent;
benzazepine alkaloid;
cyclic acetal;
enol ether;
organic heteropentacyclic compound;
secondary alcohol;
tertiary amino compound
mefloquine hydrochloride[no description available]medium10hydrochloride
propazole[no description available]medium10benzimidazoles
prulifloxacin[no description available]medium10fluoroquinolone antibiotic;
quinolone antibiotic
telmisartan[no description available]medium10benzimidazoles;
biphenyls;
carboxybiphenyl		angiotensin receptor antagonist;
antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
environmental contaminant;
xenobiotic
bergenin[no description available]medium10trihydroxybenzoic acidmetabolite
zoledronic acid[no description available]medium101,1-bis(phosphonic acid);
imidazoles		bone density conservation agent
brinzolamide[no description available]medium10sulfonamide;
thienothiazine		antiglaucoma drug;
EC 4.2.1.1 (carbonic anhydrase) inhibitor
dipropylacetamide[no description available]medium10fatty amidegeroprotector;
metabolite;
teratogenic agent
oxprenolol hydrochloride[no description available]medium10
opipramol hydrochloride[no description available]medium10
moroxydine[no description available]medium10biguanides
thioxolone[no description available]medium10benzoxathioleantiseborrheic
honokiol[no description available]medium10biphenyls
nobiletin[no description available]medium10methoxyflavoneantineoplastic agent;
plant metabolite
lycorine[no description available]medium10indolizidine alkaloidanticoronaviral agent;
antimalarial;
plant metabolite;
protein synthesis inhibitor
leupeptin[no description available]medium10aldehyde;
tripeptide		bacterial metabolite;
calpain inhibitor;
cathepsin B inhibitor;
EC 3.4.21.4 (trypsin) inhibitor;
serine protease inhibitor
tetrandrine[no description available]medium10bisbenzylisoquinoline alkaloid;
isoquinolines
calpeptin[no description available]medium10amino acid amide
fangchinoline[no description available]medium10aromatic ether;
bisbenzylisoquinoline alkaloid;
macrocycle		anti-HIV-1 agent;
anti-inflammatory agent;
antineoplastic agent;
antioxidant;
neuroprotective agent;
plant metabolite
maslinic acid[no description available]medium10dihydroxy monocarboxylic acid;
pentacyclic triterpenoid		anti-inflammatory agent;
antineoplastic agent;
antioxidant;
plant metabolite
atovaquone[no description available]medium10hydroxy-1,2-naphthoquinone
loganin[no description available]medium10beta-D-glucoside;
cyclopentapyran;
enoate ester;
iridoid monoterpenoid;
methyl ester;
monosaccharide derivative;
secondary alcohol		anti-inflammatory agent;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.2.1.20 (alpha-glucosidase) inhibitor;
EC 3.4.23.46 (memapsin 2) inhibitor;
neuroprotective agent;
plant metabolite
moexipril[no description available]medium10peptide
aucubin[no description available]medium10organic molecular entitymetabolite
catalpol[no description available]medium10organic molecular entitymetabolite
lekoptin[no description available]medium102-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile
sivelestat[no description available]medium20N-acylglycine;
pivalate ester
pyronaridine[no description available]medium10aminoquinoline
geniposide[no description available]medium10terpene glycoside
daidzin[no description available]medium107-hydroxyisoflavones 7-O-beta-D-glucoside;
hydroxyisoflavone;
monosaccharide derivative		plant metabolite
sophocarpine[no description available]medium10
marimastat[no description available]medium20hydroxamic acid;
secondary carboxamide		antineoplastic agent;
matrix metalloproteinase inhibitor
elacridar[no description available]medium10
celastrol[no description available]medium10monocarboxylic acid;
pentacyclic triterpenoid		anti-inflammatory drug;
antineoplastic agent;
antioxidant;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
Hsp90 inhibitor;
metabolite
vadimezan[no description available]medium10monocarboxylic acid;
xanthones		antineoplastic agent
umifenovir[no description available]medium10indolyl carboxylic acid
safinamide[no description available]medium10amino acid amide
ilomastat[no description available]medium10hydroxamic acid;
L-tryptophan derivative;
N-acyl-amino acid		anti-inflammatory agent;
antibacterial agent;
antineoplastic agent;
EC 3.4.24.24 (gelatinase A) inhibitor;
neuroprotective agent
atazanavir[no description available]medium10carbohydrazideantiviral drug;
HIV protease inhibitor
vx 497[no description available]medium10
bcx 1812[no description available]medium103-hydroxy monocarboxylic acid;
acetamides;
cyclopentanols;
guanidines		antiviral drug;
EC 3.2.1.18 (exo-alpha-sialidase) inhibitor
naproxen[no description available]medium30methoxynaphthalene;
monocarboxylic acid		antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
environmental contaminant;
gout suppressant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic
olmesartan[no description available]medium10biphenylyltetrazoleangiotensin receptor antagonist;
antihypertensive agent
telbivudine[no description available]medium10pyrimidine 2'-deoxyribonucleosideantiviral drug;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
celastrol methyl ester[no description available]medium10carboxylic ester
resiquimod[no description available]medium10imidazoquinoline
tanshinone ii a[no description available]medium10abietane diterpenoid
anacardic acid[no description available]medium10hydroxy monocarboxylic acid;
hydroxybenzoic acid		anti-inflammatory agent;
antibacterial agent;
anticoronaviral agent;
apoptosis inducer;
EC 2.3.1.48 (histone acetyltransferase) inhibitor;
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor;
neuroprotective agent;
plant metabolite
migalastat[no description available]medium10piperidines
erlotinib[no description available]medium10aromatic ether;
quinazolines;
secondary amino compound;
terminal acetylenic compound		antineoplastic agent;
epidermal growth factor receptor antagonist;
protein kinase inhibitor
limonin[no description available]medium10epoxide;
furans;
hexacyclic triterpenoid;
lactone;
limonoid;
organic heterohexacyclic compound		inhibitor;
metabolite;
volatile oil component
scutellarin[no description available]medium10glucosiduronic acid;
glycosyloxyflavone;
monosaccharide derivative;
trihydroxyflavone		antineoplastic agent;
proteasome inhibitor
etravirine[no description available]medium10aminopyrimidine;
aromatic ether;
dinitrile;
organobromine compound		antiviral agent;
HIV-1 reverse transcriptase inhibitor
chelidonine[no description available]medium10alkaloid antibiotic;
alkaloid fundamental parent;
benzophenanthridine alkaloid
4-n-butylresorcinol[no description available]medium10resorcinols
darunavir[no description available]medium10carbamate ester;
furofuran;
sulfonamide		antiviral drug;
HIV protease inhibitor
dapivirine[no description available]medium10
nsc 74859[no description available]medium10amidobenzoic acid;
monohydroxybenzoic acid;
tosylate ester		STAT3 inhibitor
berbamine[no description available]medium10bisbenzylisoquinoline alkaloid;
isoquinolines
u-104[no description available]medium10
7-hydroxy-5-methyl-2-(2-oxopropyl)-8-[3,4,5-trihydroxy-6-(hydroxymethyl)-2-oxanyl]-1-benzopyran-4-one[no description available]medium10glycoside
bortezomib[no description available]medium10amino acid amide;
L-phenylalanine derivative;
pyrazines		antineoplastic agent;
antiprotozoal drug;
protease inhibitor;
proteasome inhibitor
ritonavir[no description available]medium101,3-thiazoles;
carbamate ester;
carboxamide;
L-valine derivative;
ureas		antiviral drug;
environmental contaminant;
HIV protease inhibitor;
xenobiotic
tizoxanide[no description available]medium10salicylamides
arbutin[no description available]medium10beta-D-glucoside;
monosaccharide derivative		Escherichia coli metabolite;
plant metabolite
conessine[no description available]medium10steroid alkaloid;
tertiary amino compound		antibacterial agent;
antimalarial;
H3-receptor antagonist;
plant metabolite
saquinavir[no description available]medium10L-asparagine derivative;
quinolines		antiviral drug;
HIV protease inhibitor
abacavir[no description available]medium102,6-diaminopurinesantiviral drug;
drug allergen;
HIV-1 reverse transcriptase inhibitor
linezolid[no description available]medium10acetamides;
morpholines;
organofluorine compound;
oxazolidinone		antibacterial drug;
protein synthesis inhibitor
cephaelin[no description available]medium10pyridoisoquinoline
(-)-usnic acid[no description available]medium10usnic acidEC 1.13.11.27 (4-hydroxyphenylpyruvate dioxygenase) inhibitor
tacrolimus[no description available]medium30macrolide lactambacterial metabolite;
immunosuppressive agent
lycopene[no description available]medium10acyclic caroteneantioxidant;
plant metabolite
zithromax[no description available]medium20macrolide antibioticantibacterial drug;
environmental contaminant;
xenobiotic
bevirimat[no description available]medium10dicarboxylic acid monoester;
monocarboxylic acid;
pentacyclic triterpenoid		HIV-1 maturation inhibitor;
metabolite
tenofovir[no description available]medium10nucleoside analogue;
phosphonic acids		antiviral drug;
drug metabolite;
HIV-1 reverse transcriptase inhibitor
posaconazole[no description available]medium10aromatic ether;
conazole antifungal drug;
N-arylpiperazine;
organofluorine compound;
oxolanes;
triazole antifungal drug;
triazoles		trypanocidal drug
gw 257406x[no description available]medium10
shikonin[no description available]medium10hydroxy-1,4-naphthoquinone
4,4-difluoro-N-[(1S)-3-[3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-phenylpropyl]-1-cyclohexanecarboxamide[no description available]medium10tropane alkaloid
cmx 001[no description available]medium10
amd 8664[no description available]medium10
bay 41-4109[no description available]medium10
bay 57-1293[no description available]medium10
2'-c-methylcytidine[no description available]medium10
isoxanthohumol[no description available]medium10flavanones
4-(4-chloro-2-methylphenoxy)-n-hydroxybutanamide[no description available]medium10aromatic ether
mecarbinate[no description available]medium10
acetyl-aspartyl-glutamyl-valyl-aspartal[no description available]medium10tetrapeptideprotease inhibitor
mercaptopurine[no description available]medium10aryl thiol;
purines;
thiocarbonyl compound		anticoronaviral agent;
antimetabolite;
antineoplastic agent
jrf 12[no description available]medium10
3,4'-dihydroxyflavone[no description available]medium10
3-(3,4-dimethoxyphenyl)propenoic acid[no description available]medium10methoxycinnamic acid
isoferulic acid[no description available]medium10ferulic acidsantioxidant;
biomarker;
metabolite
cyclouridine[no description available]medium10
zucapsaicin[no description available]medium10methoxybenzenes;
phenols
nbd 556[no description available]medium10
thioguanine anhydrous[no description available]medium102-aminopurinesanticoronaviral agent;
antimetabolite;
antineoplastic agent
4,5,6,7-tetrachloroindan-1,3-dione[no description available]medium10
srpin340[no description available]medium10
pr-619[no description available]medium10
p5091[no description available]medium10
trovirdine[no description available]medium10
fti 277[no description available]medium10
vicriviroc[no description available]medium10(trifluoromethyl)benzenes
telaprevir[no description available]medium10cyclopentapyrrole;
cyclopropanes;
oligopeptide;
pyrazines		antiviral drug;
hepatitis C protease inhibitor;
peptidomimetic
orlistat[no description available]medium10beta-lactone;
carboxylic ester;
formamides;
L-leucine derivative		anti-obesity agent;
bacterial metabolite;
EC 2.3.1.85 (fatty acid synthase) inhibitor;
EC 3.1.1.3 (triacylglycerol lipase) inhibitor
dasatinib[no description available]medium101,3-thiazoles;
aminopyrimidine;
monocarboxylic acid amide;
N-(2-hydroxyethyl)piperazine;
N-arylpiperazine;
organochlorine compound;
secondary amino compound;
tertiary amino compound		anticoronaviral agent;
antineoplastic agent;
tyrosine kinase inhibitor
yya-021[no description available]medium10
sitagliptin[no description available]medium10triazolopyrazine;
trifluorobenzene		EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor;
environmental contaminant;
hypoglycemic agent;
serine proteinase inhibitor;
xenobiotic
tak-220[no description available]medium10
jtk-303[no description available]medium10aromatic ether;
monochlorobenzenes;
organofluorine compound;
quinolinemonocarboxylic acid;
quinolone		HIV-1 integrase inhibitor
nbd 557[no description available]medium10
5'-o-caffeoylquinic acid[no description available]medium10cinnamate ester;
cyclitol carboxylic acid		plant metabolite
luteolin-7-glucoside[no description available]medium10beta-D-glucoside;
glycosyloxyflavone;
monosaccharide derivative;
trihydroxyflavone		antioxidant;
plant metabolite
cyclosporine[no description available]medium10
harmine[no description available]medium10harmala alkaloidanti-HIV agent;
EC 1.4.3.4 (monoamine oxidase) inhibitor;
metabolite
eprosartan[no description available]medium10dicarboxylic acid;
imidazoles;
thiophenes		angiotensin receptor antagonist;
antihypertensive agent;
environmental contaminant;
xenobiotic
mycophenolate mofetil[no description available]medium10carboxylic ester;
ether;
gamma-lactone;
phenols;
tertiary amino compound		anticoronaviral agent;
EC 1.1.1.205 (IMP dehydrogenase) inhibitor;
immunosuppressive agent;
prodrug
entacapone[no description available]medium102-nitrophenols;
catechols;
monocarboxylic acid amide;
nitrile		antidyskinesia agent;
antiparkinson drug;
central nervous system drug;
EC 2.1.1.6 (catechol O-methyltransferase) inhibitor
amentoflavone[no description available]medium10biflavonoid;
hydroxyflavone;
ring assembly		angiogenesis inhibitor;
antiviral agent;
cathepsin B inhibitor;
P450 inhibitor;
plant metabolite
baicalein[no description available]medium10trihydroxyflavoneangiogenesis inhibitor;
anti-inflammatory agent;
antibacterial agent;
anticoronaviral agent;
antifungal agent;
antineoplastic agent;
antioxidant;
apoptosis inducer;
EC 1.13.11.31 (arachidonate 12-lipoxygenase) inhibitor;
EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor;
EC 4.1.1.17 (ornithine decarboxylase) inhibitor;
ferroptosis inhibitor;
geroprotector;
hormone antagonist;
plant metabolite;
prostaglandin antagonist;
radical scavenger
genkwanin[no description available]medium10dihydroxyflavone;
monomethoxyflavone		metabolite
hyperoside[no description available]medium10beta-D-galactoside;
monosaccharide derivative;
quercetin O-glycoside;
tetrahydroxyflavone		hepatoprotective agent;
plant metabolite
3-methylquercetin[no description available]medium107-hydroxyflavonol;
monomethoxyflavone;
tetrahydroxyflavone		anticoagulant;
EC 1.14.18.1 (tyrosinase) inhibitor;
metabolite
kaempferide[no description available]medium107-hydroxyflavonol;
monomethoxyflavone;
trihydroxyflavone		antihypertensive agent;
metabolite
orientin[no description available]medium103'-hydroxyflavonoid;
C-glycosyl compound;
tetrahydroxyflavone		antioxidant;
metabolite
scutellarein[no description available]medium10tetrahydroxyflavonemetabolite
trans-2,3',4,5'-tetrahydroxystilbene[no description available]medium10stilbenoid
polydatin[no description available]medium10beta-D-glucoside;
monosaccharide derivative;
polyphenol;
stilbenoid		anti-arrhythmia drug;
antioxidant;
geroprotector;
hepatoprotective agent;
metabolite;
nephroprotective agent;
potassium channel modulator
chicoric acid[no description available]medium10organooxygen compoundgeroprotector;
HIV-1 integrase inhibitor
acteoside[no description available]medium10catechols;
cinnamate ester;
disaccharide derivative;
glycoside;
polyphenol		anti-inflammatory agent;
antibacterial agent;
antileishmanial agent;
neuroprotective agent;
plant metabolite
dorzolamide[no description available]medium10sulfonamide;
thiophenes		antiglaucoma drug;
antihypertensive agent;
EC 4.2.1.1 (carbonic anhydrase) inhibitor
topiramate[no description available]medium10cyclic ketal;
ketohexose derivative;
sulfamate ester		anticonvulsant;
sodium channel blocker
benzyloxycarbonyl-phe-ala-fluormethylketone[no description available]medium10
n-(n-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester[no description available]medium10carboxylic ester;
difluorobenzene;
dipeptide;
tert-butyl ester		EC 3.4.23.46 (memapsin 2) inhibitor
casticin[no description available]medium10dihydroxyflavone;
tetramethoxyflavone		apoptosis inducer;
plant metabolite
5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one[no description available]medium10dihydroxyflavone;
monomethoxyflavone		antineoplastic agent;
EC 1.14.13.39 (nitric oxide synthase) inhibitor
(E)-2,3,5,4'-tetrahydroxystilbene-2-O-beta-D-glucoside[no description available]medium10beta-D-glucoside;
resorcinols;
stilbenoid		anti-inflammatory agent;
antioxidant;
apoptosis inhibitor;
cardioprotective agent;
cyclooxygenase 2 inhibitor;
platelet aggregation inhibitor
pd 151746[no description available]medium10
lisinopril[no description available]medium10dipeptideEC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
verteporfin[no description available]medium10
batimastat[no description available]medium10hydroxamic acid;
L-phenylalanine derivative;
organic sulfide;
secondary carboxamide;
thiophenes;
triamide		angiogenesis inhibitor;
antineoplastic agent;
matrix metalloproteinase inhibitor
indinavir sulfate[no description available]medium10dicarboxylic acid diamide;
N-(2-hydroxyethyl)piperazine;
piperazinecarboxamide		HIV protease inhibitor
solanesol[no description available]medium10nonaprenol;
primary alcohol		plant metabolite
l 685458[no description available]medium10carbamate ester;
monocarboxylic acid amide;
peptide;
secondary alcohol		EC 3.4.23.46 (memapsin 2) inhibitor;
peptidomimetic
bms 806[no description available]medium10
benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone[no description available]medium10
salubrinal[no description available]medium10aminal;
organochlorine compound;
quinolines;
secondary carboxamide;
thioureas
germacrone[no description available]medium10germacrane sesquiterpenoid;
olefinic compound		androgen antagonist;
anti-inflammatory agent;
antifeedant;
antifungal agent;
antimicrobial agent;
antineoplastic agent;
antioxidant;
antitussive;
antiviral agent;
apoptosis inducer;
autophagy inducer;
hepatoprotective agent;
insecticide;
neuroprotective agent;
plant metabolite;
volatile oil component
(2e,4e,6e,10e)-3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid[no description available]medium10
lithospermic acid[no description available]medium10
laq824[no description available]medium10
ekb 569[no description available]medium10aminoquinoline;
monocarboxylic acid amide;
monochlorobenzenes;
nitrile		protein kinase inhibitor
rilpivirine[no description available]medium10aminopyrimidine;
nitrile		EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor;
HIV-1 reverse transcriptase inhibitor
(1Ar,7aS,10aS,10bS)-1a,5-dimethyl-8-methylidene-2,3,6,7,7a,8,10a,10b-octahydrooxireno[9,10]cyclodeca[1,2-b]furan-9(1aH)-one[no description available]medium10germacranolide
4,5-di-O-caffeoylquinic acid[no description available]medium10quinic acid
indigo carmine[no description available]medium10
artesunate[no description available]medium10artemisinin derivative;
cyclic acetal;
dicarboxylic acid monoester;
hemisuccinate;
semisynthetic derivative;
sesquiterpenoid		antimalarial;
antineoplastic agent;
ferroptosis inducer
(3S,6S,9S,12R)-3-[(2S)-Butan-2-yl]-6-[(1-methoxyindol-3-yl)methyl]-9-(6-oxooctyl)-1,4,7,10-tetrazabicyclo[10.4.0]hexadecane-2,5,8,11-tetrone[no description available]medium10oligopeptide
vildagliptin[no description available]medium10amino acid amide
belinostat[no description available]medium10hydroxamic acid;
olefinic compound;
sulfonamide		antineoplastic agent;
EC 3.5.1.98 (histone deacetylase) inhibitor
hdac-42[no description available]medium10amidobenzoic acid
chlorhexidine[no description available]medium10biguanides;
monochlorobenzenes		antibacterial agent;
antiinfective agent
gs-7340[no description available]medium106-aminopurines;
ether;
isopropyl ester;
L-alanine derivative;
phosphoramidate ester		antiviral drug;
HIV-1 reverse transcriptase inhibitor;
prodrug
iniparib[no description available]medium10carbonyl compound;
organohalogen compound
n-(2-amino-5-fluorobenzyl)-4-(n-(pyridine-3-acrylyl)aminomethyl)benzamide[no description available]medium10
pri-2205[no description available]medium10
mk 0752[no description available]medium10
givinostat[no description available]medium10carbamate ester
pd 144418[no description available]medium10
bicyclol[no description available]medium10
midostaurin[no description available]medium10benzamides;
gamma-lactam;
indolocarbazole;
organic heterooctacyclic compound		antineoplastic agent;
EC 2.7.11.13 (protein kinase C) inhibitor
ly 450139[no description available]medium10peptide
mocetinostat[no description available]medium170aminopyrimidine;
benzamides;
pyridines;
secondary amino compound;
secondary carboxamide;
substituted aniline		antineoplastic agent;
apoptosis inducer;
autophagy inducer;
cardioprotective agent;
EC 3.5.1.98 (histone deacetylase) inhibitor;
hepatotoxic agent
rivaroxaban[no description available]medium10aromatic amide;
lactam;
monocarboxylic acid amide;
morpholines;
organochlorine compound;
oxazolidinone;
thiophenes		anticoagulant;
EC 3.4.21.6 (coagulation factor Xa) inhibitor
sb 3ct compound[no description available]medium10aromatic ether
ginsenoside rb1[no description available]medium10ginsenoside;
glycoside;
tetracyclic triterpenoid		anti-inflammatory drug;
anti-obesity agent;
apoptosis inhibitor;
neuroprotective agent;
plant metabolite;
radical scavenger
rucaparib[no description available]medium10azepinoindole;
caprolactams;
organofluorine compound;
secondary amino compound		antineoplastic agent;
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor
6h-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetamide, 4-(4-chlorophenyl)-n-(4-hydroxyphenyl)-2,3,9-trimethyl-, (6s)-[no description available]medium10organonitrogen heterocyclic compound;
organosulfur heterocyclic compound
cetilistat[no description available]medium10benzoxazine
ym 201636[no description available]medium10aromatic amide
linagliptin[no description available]medium10aminopiperidine;
quinazolines		EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor;
hypoglycemic agent
azd 6244[no description available]medium10benzimidazoles;
bromobenzenes;
hydroxamic acid ester;
monochlorobenzenes;
organofluorine compound;
secondary amino compound		anticoronaviral agent;
antineoplastic agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
odanacatib[no description available]medium10
apilimod[no description available]medium10
apixaban[no description available]medium10aromatic ether;
lactam;
piperidones;
pyrazolopyridine		anticoagulant;
EC 3.4.21.6 (coagulation factor Xa) inhibitor
betrixaban[no description available]medium10benzamides;
guanidines;
monochloropyridine;
monomethoxybenzene;
secondary carboxamide		anticoagulant;
EC 3.4.21.6 (coagulation factor Xa) inhibitor
edoxaban[no description available]medium10chloropyridine;
monocarboxylic acid amide;
tertiary amino compound;
thiazolopyridine		anticoagulant;
EC 3.4.21.6 (coagulation factor Xa) inhibitor;
platelet aggregation inhibitor
saracatinib[no description available]medium10aromatic ether;
benzodioxoles;
diether;
N-methylpiperazine;
organochlorine compound;
oxanes;
quinazolines;
secondary amino compound		anticoronaviral agent;
antineoplastic agent;
apoptosis inducer;
autophagy inducer;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
radiosensitizing agent
n-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide[no description available]medium10tripeptide;
ureas		antiviral drug;
hepatitis C protease inhibitor;
peptidomimetic
ly 411575[no description available]medium10dibenzoazepine;
difluorobenzene;
lactam;
secondary alcohol		EC 3.4.23.46 (memapsin 2) inhibitor
galidesivir[no description available]medium10
PB28[no description available]medium10aromatic ether;
piperazines;
tetralins		anticoronaviral agent;
antineoplastic agent;
apoptosis inducer;
sigma-2 receptor agonist
degrasyn[no description available]medium10
epoxomicin[no description available]medium10morpholines;
tripeptide		proteasome inhibitor
bms 477118[no description available]medium10adamantanes;
azabicycloalkane;
monocarboxylic acid amide;
nitrile;
tertiary alcohol		EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor;
hypoglycemic agent
pha 680632[no description available]medium10
tmc 353121[no description available]medium10
amd 070[no description available]medium10aminoquinoline
danoprevir[no description available]medium10
bms-626529[no description available]medium10
bms-663068[no description available]medium10
amenamevir[no description available]medium10
vx 765[no description available]medium10dipeptide
Dihydrotanshinone I[no description available]medium10abietane diterpenoidanticoronaviral agent
alogliptin[no description available]medium10nitrile;
piperidines;
primary amino compound;
pyrimidines		EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor;
hypoglycemic agent
fr 180204[no description available]medium10pyrazoles;
ring assembly
quisinostat[no description available]medium10indoles
carfilzomib[no description available]medium10epoxide;
morpholines;
tetrapeptide		antineoplastic agent;
proteasome inhibitor
hcv 796[no description available]medium10
resminostat[no description available]medium10
zk 756326[no description available]medium10aromatic ether
balapiravir[no description available]medium10
trametinib[no description available]medium10acetamides;
aromatic amine;
cyclopropanes;
organofluorine compound;
organoiodine compound;
pyridopyrimidine;
ring assembly		anticoronaviral agent;
antineoplastic agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
geroprotector
deoxyarbutin[no description available]medium10
abexinostat[no description available]medium10benzofurans
silvestrol[no description available]medium10dioxanes;
ether;
methyl ester;
organic heterotricyclic compound		antineoplastic agent;
metabolite
narlaprevir[no description available]medium10azabicyclohexane;
cyclopropanes;
pyrrolidinecarboxamide;
secondary carboxamide;
sulfone;
tertiary carboxamide;
ureas		anticoronaviral agent;
antiviral drug;
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor;
hepatitis C protease inhibitor
teneligliptin[no description available]medium10amino acid amide
dextrothyroxine[no description available]medium10
veliparib[no description available]medium10benzimidazolesEC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor
pf 03491390[no description available]medium10
alloin[no description available]medium10anthracenes;
C-glycosyl compound;
cyclic ketone;
phenols		laxative;
metabolite
mdv 3100[no description available]medium10(trifluoromethyl)benzenes;
benzamides;
imidazolidinone;
monofluorobenzenes;
nitrile;
thiocarbonyl compound		androgen antagonist;
antineoplastic agent
bms-650032[no description available]medium10oligopeptide
rg 7128[no description available]medium10
oritavancin[no description available]medium10disaccharide derivative;
glycopeptide;
semisynthetic derivative		antibacterial drug;
antimicrobial agent
pevonedistat[no description available]medium10cyclopentanols;
indanes;
pyrrolopyrimidine;
secondary amino compound;
sulfamidate		antineoplastic agent;
apoptosis inducer
uk 453,061[no description available]medium10aromatic ether
N-(2-aminophenyl)-2-pyrazinecarboxamide[no description available]medium10aromatic amide
tegobuvir[no description available]medium10
pf-429242[no description available]medium10
olaparib[no description available]medium10cyclopropanes;
monofluorobenzenes;
N-acylpiperazine;
phthalazines		antineoplastic agent;
apoptosis inducer;
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor
cx 4945[no description available]medium10
pci 34051[no description available]medium10indolecarboxamide
lomibuvir[no description available]medium10thiophenecarboxylic acid
delanzomib[no description available]medium10C-terminal boronic acid peptide;
phenylpyridine;
secondary alcohol;
threonine derivative		antineoplastic agent;
apoptosis inducer;
proteasome inhibitor
pitavastatin(1-)[no description available]medium10hydroxy monocarboxylic acid anion
GRL-0617[no description available]medium10benzamides;
naphthalenes;
secondary carboxamide;
substituted aniline		anticoronaviral agent;
protease inhibitor
N-[4-[3-[[[7-(hydroxyamino)-7-oxoheptyl]amino]-oxomethyl]-5-isoxazolyl]phenyl]carbamic acid tert-butyl ester[no description available]medium10carbamate ester
niraparib[no description available]medium102-[4-(piperidin-3-yl)phenyl]-2H-indazole-7-carboxamideantineoplastic agent;
apoptosis inducer;
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor;
radiosensitizing agent
jzl 184[no description available]medium10benzodioxoles
gsk 650394[no description available]medium10phenylpyridine
oprozomib[no description available]medium10
az 960[no description available]medium10
golgicide a[no description available]medium10diastereoisomeric mixturecis-Golgi ArfGEF GBF inhibitor
cobicistat[no description available]medium101,3-thiazoles;
carbamate ester;
monocarboxylic acid amide;
morpholines;
ureas		P450 inhibitor
bms-790052[no description available]medium10biphenyls;
carbamate ester;
carboxamide;
imidazoles;
valine derivative		antiviral drug;
nonstructural protein 5A inhibitor
ixazomib[no description available]medium10benzamides;
boronic acids;
dichlorobenzene;
glycine derivative		antineoplastic agent;
apoptosis inducer;
drug metabolite;
orphan drug;
proteasome inhibitor
ucph 101[no description available]medium10
5-(3-methylsulfonylphenyl)-4-[(1-methyl-5-tetrazolyl)thio]thieno[2,3-d]pyrimidine[no description available]medium10aryl sulfide;
thienopyrimidine
baricitinib[no description available]medium10azetidines;
nitrile;
pyrazoles;
pyrrolopyrimidine;
sulfonamide		anti-inflammatory agent;
antirheumatic drug;
antiviral agent;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
immunosuppressive agent
KOM70144[no description available]medium10acetamides;
benzamides;
naphthalenes;
secondary carboxamide		anticoronaviral agent;
protease inhibitor
e-52862[no description available]medium10
ly2811376[no description available]medium10
anagliptin[no description available]medium10amino acid amide
gardiquimod[no description available]medium10
grazoprevir[no description available]medium10aromatic ether;
azamacrocycle;
carbamate ester;
cyclopropanes;
lactam;
N-sulfonylcarboxamide;
quinoxaline derivative		antiviral drug;
hepatitis C protease inhibitor;
hepatoprotective agent
abt-450[no description available]medium10
letermovir[no description available]medium10
5-(4-amino-1-propan-2-yl-3-pyrazolo[3,4-d]pyrimidinyl)-1,3-benzoxazol-2-amine[no description available]medium10benzoxazole
blz 945[no description available]medium10
azd3839[no description available]medium10
pf 3084014[no description available]medium10
unc 0638[no description available]medium10quinazolines
gs-9620[no description available]medium10
n-((5-(methanesulfonyl)pyridin-2-yl)methyl)-6-methyl-5-(1-methyl-1h-pyrazol-5-yl)-2-oxo-1-(3-(trifluoromethyl)phenyl)-1,2-dihydropyridine-3-carboxamide[no description available]medium10
bms 708163[no description available]medium10oxadiazole;
ring assembly
jq1 compound[no description available]medium10carboxylic ester;
organochlorine compound;
tert-butyl ester;
thienotriazolodiazepine		angiogenesis inhibitor;
anti-inflammatory agent;
antineoplastic agent;
apoptosis inducer;
bromodomain-containing protein 4 inhibitor;
cardioprotective agent;
ferroptosis inducer
1-(5-((2,4-difluorophenyl)thio)-4-nitrothiophen-2-yl)ethanone[no description available]medium10
gsk525762a[no description available]medium10benzodiazepine
ML240[no description available]medium10aromatic amine;
aromatic ether;
benzimidazoles;
primary amino compound;
quinazolines;
secondary amino compound		antineoplastic agent
birinapant[no description available]medium10dipeptide
ly2886721[no description available]medium10
nms-p118[no description available]medium10
tubastatin a[no description available]medium10hydroxamic acid;
pyridoindole;
tertiary amino compound		EC 3.5.1.98 (histone deacetylase) inhibitor
pracinostat[no description available]medium10benzimidazole;
hydroxamic acid;
olefinic compound;
tertiary amino compound		antimalarial;
antineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor
spautin-1[no description available]medium10
ldn 57444[no description available]medium10
gsk1210151a[no description available]medium10imidazoquinoline
i-bet726[no description available]medium10
acy-1215[no description available]medium10pyrimidinecarboxylic acid
cudc-907[no description available]medium10
tipranavir[no description available]medium10sulfonamideantiviral drug;
HIV protease inhibitor
tasquinimod[no description available]medium10
gsk1265744[no description available]medium10difluorobenzene;
monocarboxylic acid amide;
organic heterotricyclic compound;
secondary carboxamide		HIV-1 integrase inhibitor
abt-267[no description available]medium10aromatic amide;
carbamate ester;
dipeptide;
pyrrolidines		antiviral drug;
hepatitis C virus nonstructural protein 5A inhibitor
rgfp966[no description available]medium10
rg2833[no description available]medium10
pi-1840[no description available]medium10
acy-738[no description available]medium10
pelabresib[no description available]medium10monochlorobenzenes;
organic heterotricyclic compound;
primary carboxamide		antineoplastic agent;
bromodomain-containing protein 4 inhibitor
gs-5806[no description available]medium10
doravirine[no description available]medium10
gn6958[no description available]medium10
vx-787[no description available]medium10
ledipasvir[no description available]medium10azaspiro compound;
benzimidazole;
bridged compound;
carbamate ester;
carboxamide;
fluorenes;
imidazoles;
L-valine derivative;
N-acylpyrrolidine;
organofluorine compound		antiviral drug;
hepatitis C protease inhibitor
gs-5816[no description available]medium10carbamate ester;
ether;
imidazoles;
L-valine derivative;
N-acylpyrrolidine;
organic heteropentacyclic compound;
ring assembly		antiviral drug;
hepatitis C virus nonstructural protein 5A inhibitor
g007-lk[no description available]medium10
4-((1-butyl-3-phenylureido)methyl)-n-hydroxybenzamide[no description available]medium10
selinexor[no description available]medium10
verdinexor[no description available]medium10
cb-839[no description available]medium10
mk-8742[no description available]medium10carbamate ester;
imidazoles;
L-valine derivative;
N-acylpyrrolidine;
organic heterotetracyclic compound;
ring assembly		antiviral drug;
hepatitis C virus nonstructural protein 5A inhibitor;
hepatoprotective agent
atglistatin[no description available]medium10
xen445[no description available]medium10
santacruzamate a[no description available]medium10organonitrogen compound;
organooxygen compound
ldc4297[no description available]medium10aromatic ether;
piperidines;
pyrazoles;
pyrazolotriazine;
secondary amino compound		antineoplastic agent;
antiviral agent;
apoptosis inducer;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
enasidenib[no description available]medium101,3,5-triazines;
aminopyridine;
aromatic amine;
organofluorine compound;
secondary amino compound;
tertiary alcohol		antineoplastic agent;
EC 1.1.1.42 (isocitrate dehydrogenase) inhibitor
s 8932[no description available]medium10aromatic amine;
C-nucleoside;
carboxylic ester;
nitrile;
phosphoramidate ester;
pyrrolotriazine		anticoronaviral agent;
antiviral drug;
prodrug
entecavir[no description available]medium102-aminopurines;
oxopurine;
primary alcohol;
secondary alcohol		antiviral drug;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
nu 1025[no description available]medium10phenols;
quinazolines		EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor
didanosine[no description available]medium10purine 2',3'-dideoxyribonucleosideantimetabolite;
antiviral drug;
EC 2.4.2.1 (purine-nucleoside phosphorylase) inhibitor;
geroprotector;
HIV-1 reverse transcriptase inhibitor
valacyclovir[no description available]medium10L-valyl esterantiviral drug
penciclovir[no description available]medium102-aminopurines;
propane-1,3-diols		antiviral drug
tegaserod[no description available]medium10carboxamidine;
guanidines;
hydrazines;
indoles		gastrointestinal drug;
serotonergic agonist
norclozapine[no description available]medium10dibenzodiazepine;
organochlorine compound;
piperazines		delta-opioid receptor agonist;
metabolite;
serotonergic antagonist
pemetrexed[no description available]medium10N-acyl-L-glutamic acid;
pyrrolopyrimidine		antimetabolite;
antineoplastic agent;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
EC 2.1.1.45 (thymidylate synthase) inhibitor;
EC 2.1.2.2 (phosphoribosylglycinamide formyltransferase) inhibitor
aprepitant[no description available]medium10(trifluoromethyl)benzenes;
cyclic acetal;
morpholines;
triazoles		antidepressant;
antiemetic;
neurokinin-1 receptor antagonist;
peripheral nervous system drug;
substance P receptor antagonist
azilsartan[no description available]medium101,2,4-oxadiazole;
aromatic ether;
benzimidazolecarboxylic acid		angiotensin receptor antagonist;
antihypertensive agent
hesperadin[no description available]medium10
6-bromoindirubin-3'-acetoxime[no description available]medium10
n'-(3,4-dihydroxybenzylidene)-3-hydroxy-2-naphthahydrazide[no description available]medium10catechols;
hydrazide;
hydrazone;
naphthols		EC 3.6.5.5 (dynamin GTPase) inhibitor
XL413[no description available]medium10benzofuropyrimidine;
organochlorine compound;
pyrrolidines		antineoplastic agent;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor
me0328[no description available]medium10
nvp-tnks656[no description available]medium10
triazoles[no description available]medium601,2,3-triazole
alpha-aminopyridine[no description available]medium260
ceefourin 1[no description available]medium10
melitten[no description available]medium10
hc-067047[no description available]medium10
adenosine monophosphate[no description available]medium80adenosine 5'-phosphate;
purine ribonucleoside 5'-monophosphate		adenosine A1 receptor agonist;
cofactor;
EC 3.1.3.1 (alkaline phosphatase) inhibitor;
EC 3.1.3.11 (fructose-bisphosphatase) inhibitor;
fundamental metabolite;
micronutrient;
nutraceutical
simendan[no description available]medium30
cytochrome c-t[no description available]medium20
temozolomide[no description available]medium20imidazotetrazine;
monocarboxylic acid amide;
triazene derivative		alkylating agent;
antineoplastic agent;
prodrug
perillyl alcohol[no description available]medium20limonene monoterpenoidplant metabolite;
volatile oil component
chloroquine[no description available]medium10aminoquinoline;
organochlorine compound;
secondary amino compound;
tertiary amino compound		anticoronaviral agent;
antimalarial;
antirheumatic drug;
autophagy inhibitor;
dermatologic drug
vardenafil dihydrochloride[no description available]medium90
tesaglitazar[no description available]medium10
alprostadil[no description available]medium90prostaglandins Eanticoagulant;
human metabolite;
platelet aggregation inhibitor;
vasodilator agent
adenine[no description available]medium2006-aminopurines;
purine nucleobase		Daphnia magna metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
butaprost[no description available]medium10
8-bromocyclic gmp[no description available]medium903',5'-cyclic purine nucleotide;
organobromine compound		muscle relaxant;
protein kinase G agonist
9-(tetrahydro-2-furyl)-adenine[no description available]medium60
8-bromo cyclic adenosine monophosphate[no description available]medium4003',5'-cyclic purine nucleotide;
adenyl ribonucleotide;
organobromine compound		antidepressant;
protein kinase agonist
carbostyril[no description available]medium500monohydroxyquinoline;
quinolone		bacterial xenobiotic metabolite
phenyl acetate[no description available]medium30benzenes;
phenyl acetates
angiotensin i[no description available]medium10angiotensin;
peptide zwitterion		human metabolite;
neurotransmitter agent
angiotensin ii, des-phe(8)-[no description available]medium10amino acid zwitterion;
angiotensin		vasodilator agent
protectin d1[no description available]medium10dihydroxydocosahexaenoic acid;
protectin;
secondary allylic alcohol		anti-inflammatory agent;
apoptosis inhibitor;
hepatoprotective agent;
human xenobiotic metabolite;
neuroprotective agent;
PPARgamma agonist;
specialised pro-resolving mediator
ym 976[no description available]medium50pyrimidines
pyrimidinones[no description available]medium70
ciprofloxacin[no description available]medium10aminoquinoline;
cyclopropanes;
fluoroquinolone antibiotic;
N-arylpiperazine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone;
zwitterion		antibacterial drug;
antiinfective agent;
antimicrobial agent;
DNA synthesis inhibitor;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
environmental contaminant;
topoisomerase IV inhibitor;
xenobiotic
calpain[no description available]medium10
sodium arsenite[no description available]medium10arsenic molecular entity;
inorganic sodium salt		antibacterial agent;
antifungal agent;
antineoplastic agent;
carcinogenic agent;
herbicide;
insecticide;
rodenticide
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine[no description available]medium10methylpyridines;
phenylpyridine;
tetrahydropyridine		neurotoxin
atrazine[no description available]medium20chloro-1,3,5-triazine;
diamino-1,3,5-triazine		environmental contaminant;
herbicide;
xenobiotic
hydrogen sulfide[no description available]medium10gas molecular entity;
hydracid;
mononuclear parent hydride;
sulfur hydride		Escherichia coli metabolite;
genotoxin;
metabolite;
signalling molecule;
toxin;
vasodilator agent
natriuretic peptide, c-type[no description available]medium20
sirtinol[no description available]medium10aldimine;
benzamides;
naphthols		anti-inflammatory agent;
EC 3.5.1.98 (histone deacetylase) inhibitor;
Sir2 inhibitor
2-naphthol[no description available]medium10naphtholantinematodal drug;
genotoxin;
human urinary metabolite;
human xenobiotic metabolite;
mouse metabolite;
radical scavenger
mk 2206[no description available]medium10organic heterotricyclic compoundEC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
malondialdehyde[no description available]medium50dialdehydebiomarker
ng-nitroarginine methyl ester[no description available]medium120alpha-amino acid ester;
L-arginine derivative;
methyl ester;
N-nitro compound		EC 1.14.13.39 (nitric oxide synthase) inhibitor
brl 37344[no description available]medium10monocarboxylic acid
glycine[no description available]medium40alpha-amino acid;
amino acid zwitterion;
proteinogenic amino acid;
serine family amino acid		EC 2.1.2.1 (glycine hydroxymethyltransferase) inhibitor;
fundamental metabolite;
hepatoprotective agent;
micronutrient;
neurotransmitter;
NMDA receptor agonist;
nutraceutical
leukotriene b4[no description available]medium60dihydroxy monocarboxylic acid;
hydroxy polyunsaturated fatty acid;
leukotriene;
long-chain fatty acid		human metabolite;
mouse metabolite;
plant metabolite;
vasoconstrictor agent
FR900359[no description available]medium10cyclodepsipeptide
sk&f 81297[no description available]medium20benzazepine
endothelin-1[no description available]medium50
propyl gallate[no description available]medium10trihydroxybenzoic acid
6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid[no description available]medium10chromanol;
monocarboxylic acid;
phenols		antioxidant;
ferroptosis inhibitor;
neuroprotective agent;
radical scavenger;
Wnt signalling inhibitor
stilbenes[no description available]medium50stilbene
3-(6-isobutyl-9-methoxy-1,4-dioxo-1,2,3,4,6,7,12,12a-octahydropyrazino(1',2'-1,6)pyrido(3,4-b)indol-3-yl)propionic acid tert-butyl ester[no description available]medium10
ovalbumin[no description available]medium260
verlukast[no description available]medium10
rifampin[no description available]medium10cyclic ketal;
hydrazone;
N-iminopiperazine;
N-methylpiperazine;
rifamycins;
semisynthetic derivative;
zwitterion		angiogenesis inhibitor;
antiamoebic agent;
antineoplastic agent;
antitubercular agent;
DNA synthesis inhibitor;
EC 2.7.7.6 (RNA polymerase) inhibitor;
Escherichia coli metabolite;
geroprotector;
leprostatic drug;
neuroprotective agent;
pregnane X receptor agonist;
protein synthesis inhibitor
hesperidin[no description available]medium203'-hydroxyflavanones;
4'-methoxyflavanones;
dihydroxyflavanone;
disaccharide derivative;
flavanone glycoside;
monomethoxyflavanone;
rutinoside		mutagen
amiloride[no description available]medium10aromatic amine;
guanidines;
organochlorine compound;
pyrazines		diuretic;
sodium channel blocker
chlorine[no description available]medium20halide anion;
monoatomic chlorine		cofactor;
Escherichia coli metabolite;
human metabolite
org 30029[no description available]medium30
arginine vasopressin[no description available]medium70vasopressincardiovascular drug;
hematologic agent;
mitogen
erythromycin[no description available]medium20cyclic ketone;
erythromycin
erythromycin propionate-n-acetylcysteinate[no description available]medium20
malachite green[no description available]medium10organic chloride saltantibacterial agent;
antifungal drug;
carcinogenic agent;
environmental contaminant;
fluorochrome;
histological dye;
teratogenic agent
c.i. 42510[no description available]medium10
emd 53998[no description available]medium10
warfarin[no description available]medium10benzenes;
hydroxycoumarin;
methyl ketone
carvedilol[no description available]medium10carbazoles;
secondary alcohol;
secondary amino compound		alpha-adrenergic antagonist;
antihypertensive agent;
beta-adrenergic antagonist;
cardiovascular drug;
vasodilator agent
phenylephrine[no description available]medium80phenols;
phenylethanolamines;
secondary amino compound		alpha-adrenergic agonist;
cardiotonic drug;
mydriatic agent;
nasal decongestant;
protective agent;
sympathomimetic agent;
vasoconstrictor agent
oxadiazoles[no description available]medium50
thiazoles[no description available]medium901,3-thiazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
heroin[no description available]medium10morphinane alkaloidmu-opioid receptor agonist;
opioid analgesic;
prodrug
3-cyclopentyloxy-4-methoxybenzaldehyde[no description available]medium20
2-piperidone[no description available]medium10delta-lactam;
piperidones		EC 1.2.1.88 (L-glutamate gamma-semialdehyde dehydrogenase) inhibitor
relcovaptan[no description available]medium10proline derivative
benzo(a)pyrene[no description available]medium10ortho- and peri-fused polycyclic arenecarcinogenic agent;
mouse metabolite
cyclin d1[no description available]medium10
ethyl pyruvate[no description available]medium10oxo carboxylic acid
metformin[no description available]medium10guanidinesenvironmental contaminant;
geroprotector;
hypoglycemic agent;
xenobiotic
formaldehyde[no description available]medium20aldehyde;
one-carbon compound		allergen;
carcinogenic agent;
disinfectant;
EC 3.5.1.4 (amidase) inhibitor;
environmental contaminant;
Escherichia coli metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
roflumilast n-oxide[no description available]medium20
4-amino-3-phenylbutyric acid[no description available]medium10organonitrogen compound;
organooxygen compound
docetaxel anhydrous[no description available]medium10secondary alpha-hydroxy ketone;
tetracyclic diterpenoid		antimalarial;
antineoplastic agent;
photosensitizing agent
1,2-distearoylphosphatidylethanolamine[no description available]medium10phosphatidylethanolamine zwitterion;
phosphatidylethanolamine		human metabolite
phosphatidylcholines[no description available]medium201,2-diacyl-sn-glycero-3-phosphocholine
rx 821002[no description available]medium10benzodioxine;
cyclic ketal;
imidazolines		alpha-adrenergic antagonist
naltrexone[no description available]medium20cyclopropanes;
morphinane-like compound;
organic heteropentacyclic compound		antidote to opioid poisoning;
central nervous system depressant;
environmental contaminant;
mu-opioid receptor antagonist;
xenobiotic
raclopride[no description available]medium20salicylamides
lisdexamfetamine dimesylate[no description available]medium10
serine[no description available]medium70L-alpha-amino acid;
proteinogenic amino acid;
serine family amino acid;
serine zwitterion;
serine		algal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
piperidines[no description available]medium100
epidermal growth factor[no description available]medium20
adamantane[no description available]medium30adamantanes;
polycyclic alkane
delta-philanthotoxin[no description available]medium10
iem 1460[no description available]medium10
ceruletide[no description available]medium50oligopeptidediagnostic agent;
gastrointestinal drug
chlorine[no description available]medium30diatomic chlorine;
gas molecular entity		bleaching agent
triptolide[no description available]medium10diterpenoid;
epoxide;
gamma-lactam;
organic heteroheptacyclic compound		antispermatogenic agent;
plant metabolite
phenanthrenes[no description available]medium20
sphingosine 1-phosphate[no description available]medium20sphingoid 1-phosphatemouse metabolite;
signalling molecule;
sphingosine-1-phosphate receptor agonist;
T-cell proliferation inhibitor;
vasodilator agent
uk 68798[no description available]medium10aromatic ether;
sulfonamide;
tertiary amino compound		anti-arrhythmia drug;
potassium channel blocker
3-aminopyridine-2-carboxaldehyde thiosemicarbazone[no description available]medium10
mannose-6-phosphate[no description available]medium10D-mannopyranose 6-phosphate
7-benzylamino-6-chloro-2-piperazino-4-pyrrolidinopteridine[no description available]medium40
pteridines[no description available]medium40azaarene;
mancude organic heterobicyclic parent;
ortho-fused heteroarene;
pteridines
picryl chloride[no description available]medium20C-nitro compound;
monochlorobenzenes		allergen;
epitope;
explosive;
hapten
pyrazolopyridine[no description available]medium10
brimonidine tartrate[no description available]medium20
quinoxalines[no description available]medium60mancude organic heterobicyclic parent;
naphthyridine;
ortho-fused heteroarene
rs 67333[no description available]medium10aromatic ketone
td-5108[no description available]medium10
dichlororibofuranosylbenzimidazole[no description available]medium10
durapatite[no description available]medium10
s-nitro-n-acetylpenicillamine[no description available]medium20
thiophenes[no description available]medium80mancude organic heteromonocyclic parent;
monocyclic heteroarene;
thiophenes;
volatile organic compound		non-polar solvent
cgp 12177[no description available]medium30aromatic ether;
benzimidazoles;
secondary alcohol;
secondary amino compound		beta-adrenergic antagonist
dacarbazine[no description available]medium10dacarbazine
taurocholic acid[no description available]medium10amino sulfonic acid;
bile acid taurine conjugate		human metabolite
8-bromoadenosine-3',5'-cyclic monophosphorothioate[no description available]medium20
oxytocin[no description available]medium20heterodetic cyclic peptide;
peptide hormone		oxytocic;
vasodilator agent
prednisolone[no description available]medium3011beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		adrenergic agent;
anti-inflammatory drug;
antineoplastic agent;
drug metabolite;
environmental contaminant;
immunosuppressive agent;
xenobiotic
biotin[no description available]medium10biotins;
vitamin B7		coenzyme;
cofactor;
Escherichia coli metabolite;
fundamental metabolite;
human metabolite;
mouse metabolite;
nutraceutical;
prosthetic group;
Saccharomyces cerevisiae metabolite
myelin basic protein[no description available]medium70
glucagon-like peptide 1[no description available]medium30
nsc 23766[no description available]medium10hydrochlorideantiviral agent;
apoptosis inducer;
EC 3.6.5.2 (small monomeric GTPase) inhibitor;
muscarinic antagonist
transforming growth factor beta[no description available]medium60
exendin (9-39)[no description available]medium10
2',5'-dideoxyadenosine[no description available]medium30deoxyribonucleoside
gastrin-releasing peptide[no description available]medium10
rc 3095[no description available]medium10
bleomycetin[no description available]medium10
hydroxyproline[no description available]medium104-hydroxyproline;
L-alpha-amino acid zwitterion		human metabolite;
mouse metabolite;
plant metabolite
cyclopentane[no description available]medium60cycloalkane;
cyclopentanes;
volatile organic compound		non-polar solvent
adenosine-3',5'-cyclic phosphorothioate[no description available]medium80nucleoside 3',5'-cyclic phosphorothioate
ketamine[no description available]medium30cyclohexanones;
monochlorobenzenes;
secondary amino compound		analgesic;
environmental contaminant;
intravenous anaesthetic;
neurotoxin;
NMDA receptor antagonist;
xenobiotic
ro 31-8220[no description available]medium10imidothiocarbamic ester;
indoles;
maleimides		EC 2.7.11.13 (protein kinase C) inhibitor
guanosine triphosphate[no description available]medium10guanosine 5'-phosphate;
purine ribonucleoside 5'-triphosphate		Escherichia coli metabolite;
mouse metabolite;
uncoupling protein inhibitor
pcera-1[no description available]medium10
amphetamine[no description available]medium30primary amine
bupropion[no description available]medium10aromatic ketone;
monochlorobenzenes;
secondary amino compound		antidepressant;
environmental contaminant;
xenobiotic
1-(2-(diphenylmethoxy)ethyl)-4-(3-phenyl-2-propenyl)piperazine[no description available]medium10
2-(4-(2-carboxyethyl)phenethylamino)-5'-n-ethylcarboxamidoadenosine[no description available]medium90adenosines;
dicarboxylic acid monoamide;
monocarboxylic acid		adenosine A2A receptor agonist;
anti-inflammatory agent
kf 17837s[no description available]medium10
dioclein[no description available]medium10
3-hydroxyephedrine[no description available]medium10
ephedrine[no description available]medium10phenethylamine alkaloid;
phenylethanolamines		bacterial metabolite;
environmental contaminant;
nasal decongestant;
plant metabolite;
sympathomimetic agent;
vasoconstrictor agent;
xenobiotic
terbutaline[no description available]medium70phenylethanolamines;
resorcinols		anti-asthmatic drug;
beta-adrenergic agonist;
bronchodilator agent;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
hypoglycemic agent;
sympathomimetic agent;
tocolytic agent
15-hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic acid[no description available]medium80
montelukast[no description available]medium10aliphatic sulfide;
monocarboxylic acid;
quinolines		anti-arrhythmia drug;
anti-asthmatic drug;
leukotriene antagonist
n-formylmethionine leucyl-phenylalanine[no description available]medium220tripeptide
fentanyl[no description available]medium10anilide;
monocarboxylic acid amide;
piperidines		adjuvant;
anaesthesia adjuvant;
anaesthetic;
intravenous anaesthetic;
mu-opioid receptor agonist;
opioid analgesic
enkephalin, ala(2)-mephe(4)-gly(5)-[no description available]medium10
cl 316243[no description available]medium10
granisetron[no description available]medium10aromatic amide;
indazoles
sibutramine[no description available]medium10organochlorine compound;
tertiary amino compound		anti-obesity agent;
serotonin uptake inhibitor
globotriaosylceramide[no description available]medium10
leupeptins[no description available]medium10
amyloid beta-peptides[no description available]medium20
atrial natriuretic factor[no description available]medium60polypeptide
staurosporine[no description available]medium40ammonium ion derivative
hydrogen carbonate[no description available]medium40carbon oxoanioncofactor;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
iloprost[no description available]medium51carbobicyclic compound;
monocarboxylic acid;
secondary alcohol		platelet aggregation inhibitor;
vasodilator agent
ucn 1028 c[no description available]medium20
amthamine[no description available]medium10thiazoles
rhodium[no description available]medium20cobalt group element atom
beta-lactams[no description available]medium10beta-lactam antibiotic allergen;
beta-lactam
n-(2-methoxybenzyl)-n-(4-phenoxypyridin-3-yl)acetamide[no description available]medium10
4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione[no description available]medium10benzenes;
thiadiazolidine		anti-inflammatory agent;
antineoplastic agent;
apoptosis inducer;
EC 2.7.11.26 (tau-protein kinase) inhibitor;
neuroprotective agent
motapizone[no description available]medium70
interleukin-8[no description available]medium110
propane[no description available]medium10alkane;
gas molecular entity		food propellant
viscolin[no description available]medium10
sucrose[no description available]medium10glycosyl glycosidealgal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
osmolyte;
Saccharomyces cerevisiae metabolite;
sweetening agent
tyrosine[no description available]medium20amino acid zwitterion;
erythrose 4-phosphate/phosphoenolpyruvate family amino acid;
L-alpha-amino acid;
proteinogenic amino acid;
tyrosine		EC 1.3.1.43 (arogenate dehydrogenase) inhibitor;
fundamental metabolite;
micronutrient;
nutraceutical
losartan potassium[no description available]medium11
pyruvic acid[no description available]medium102-oxo monocarboxylic acidcofactor;
fundamental metabolite
nad[no description available]medium20organophosphate oxoanioncofactor;
human metabolite;
hydrogen acceptor;
Saccharomyces cerevisiae metabolite
palladium[no description available]medium20metal allergen;
nickel group element atom;
platinum group metal atom
iodine[no description available]medium10halide anion;
monoatomic iodine		human metabolite
berotek[no description available]medium30resorcinols;
secondary alcohol;
secondary amino compound		beta-adrenergic agonist;
bronchodilator agent;
sympathomimetic agent;
tocolytic agent
memantine[no description available]medium10adamantanes;
primary aliphatic amine		antidepressant;
antiparkinson drug;
dopaminergic agent;
neuroprotective agent;
NMDA receptor antagonist
dextroamphetamine[no description available]medium201-phenylpropan-2-amineadrenergic agent;
adrenergic uptake inhibitor;
dopamine uptake inhibitor;
dopaminergic agent;
neurotoxin;
sympathomimetic agent
hexafluoroisopropanol[no description available]medium10organofluorine compound;
secondary alcohol		drug metabolite
lactic acid[no description available]medium202-hydroxy monocarboxylic acidalgal metabolite;
Daphnia magna metabolite
glucuronic acid[no description available]medium10D-glucuronic acidalgal metabolite
carbonyl cyanide p-trifluoromethoxyphenylhydrazone[no description available]medium10aromatic ether;
hydrazone;
nitrile;
organofluorine compound		ATP synthase inhibitor;
geroprotector;
ionophore
yessotoxin[no description available]medium10ciguatoxin
pyrroles[no description available]medium90pyrrole;
secondary amine
kt 5720[no description available]medium50carboxylic ester;
gamma-lactam;
hemiaminal;
indolocarbazole;
organic heterooctacyclic compound;
semisynthetic derivative;
tertiary alcohol		EC 2.7.11.11 (cAMP-dependent protein kinase) inhibitor
cuprizone[no description available]medium10organonitrogen compound;
organooxygen compound
lysophosphatidylcholines[no description available]medium101-O-acyl-sn-glycero-3-phosphocholine
citric acid, anhydrous[no description available]medium10tricarboxylic acidantimicrobial agent;
chelator;
food acidity regulator;
fundamental metabolite
thromboxane b2[no description available]medium20thromboxanes Bhuman metabolite;
mouse metabolite
6-ketoprostaglandin f1 alpha[no description available]medium10prostaglandins Falphahuman metabolite;
mouse metabolite
methane[no description available]medium20alkane;
gas molecular entity;
mononuclear parent hydride;
one-carbon compound		bacterial metabolite;
fossil fuel;
greenhouse gas
nitromethane[no description available]medium10primary nitroalkane;
volatile organic compound		EC 4.3.1.3 (histidine ammonia-lyase) inhibitor;
explosive;
NMR chemical shift reference compound;
polar aprotic solvent
6-methyl-2-(phenylethynyl)pyridine[no description available]medium10acetylenic compound;
methylpyridines		anxiolytic drug;
metabotropic glutamate receptor antagonist
alpha-synuclein[no description available]medium10
sodium dodecyl sulfate[no description available]medium10organic sodium saltdetergent;
protein denaturant
1-butanol[no description available]medium10alkyl alcohol;
primary alcohol;
short-chain primary fatty alcohol		human metabolite;
mouse metabolite;
protic solvent
org 9935[no description available]medium50
cyclosporine[no description available]medium60
deoxyglucose[no description available]medium20
3-n-methylspiperone[no description available]medium10aromatic ketone
thiazolyl blue[no description available]medium10organic bromide saltcolorimetric reagent;
dye
mycophenolic acid[no description available]medium102-benzofurans;
gamma-lactone;
monocarboxylic acid;
phenols		anticoronaviral agent;
antimicrobial agent;
antineoplastic agent;
EC 1.1.1.205 (IMP dehydrogenase) inhibitor;
environmental contaminant;
immunosuppressive agent;
mycotoxin;
Penicillium metabolite;
xenobiotic
pimagedine[no description available]medium10guanidines;
one-carbon compound		EC 1.14.13.39 (nitric oxide synthase) inhibitor;
EC 1.4.3.4 (monoamine oxidase) inhibitor
teriflunomide[no description available]medium10(trifluoromethyl)benzenes;
aromatic amide;
enamide;
enol;
nitrile;
secondary carboxamide		drug metabolite;
EC 1.3.98.1 [dihydroorotate oxidase (fumarate)] inhibitor;
hepatotoxic agent;
non-steroidal anti-inflammatory drug;
tyrosine kinase inhibitor
isoxazoles[no description available]medium10isoxazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
alkenes[no description available]medium10
iotrolan[no description available]medium11organic molecular entity
iopromide[no description available]medium11dicarboxylic acid diamide;
organoiodine compound		environmental contaminant;
nephrotoxic agent;
radioopaque medium;
xenobiotic
iohexol[no description available]medium11benzenedicarboxamide;
organoiodine compound		environmental contaminant;
radioopaque medium;
xenobiotic
diatrizoic acid[no description available]medium11acetamides;
benzoic acids;
organoiodine compound		environmental contaminant;
radioopaque medium;
xenobiotic
oxazoles[no description available]medium211,3-oxazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
edetic acid[no description available]medium30ethylenediamine derivative;
polyamino carboxylic acid;
tetracarboxylic acid		anticoagulant;
antidote;
chelator;
copper chelator;
geroprotector
fluorodeoxyglucose f18[no description available]medium102-deoxy-2-((18)F)fluoro-D-glucose;
2-deoxy-2-fluoro-aldehydo-D-glucose
thromboxanes[no description available]medium20
calca protein, human[no description available]medium10
arachidonyltrifluoromethane[no description available]medium10fatty acid derivative;
ketone;
olefinic compound;
organofluorine compound		EC 3.1.1.4 (phospholipase A2) inhibitor
dactinomycin[no description available]medium40actinomycinmutagen
alanine[no description available]medium20alanine zwitterion;
alanine;
L-alpha-amino acid;
proteinogenic amino acid;
pyruvate family amino acid		EC 4.3.1.15 (diaminopropionate ammonia-lyase) inhibitor;
fundamental metabolite
toluene[no description available]medium10methylbenzene;
toluenes;
volatile organic compound		cholinergic antagonist;
fuel additive;
neurotoxin;
non-polar solvent
hydrazine[no description available]medium10azane;
hydrazines		EC 4.3.1.10 (serine-sulfate ammonia-lyase) inhibitor
salmeterol xinafoate[no description available]medium80naphthoic acid
leukotriene c4[no description available]medium50leukotrienebronchoconstrictor agent;
human metabolite;
mouse metabolite
arachidonic acid[no description available]medium70icosa-5,8,11,14-tetraenoic acid;
long-chain fatty acid;
omega-6 fatty acid		Daphnia galeata metabolite;
EC 3.1.1.1 (carboxylesterase) inhibitor;
human metabolite;
mouse metabolite
potassium chloride[no description available]medium60inorganic chloride;
inorganic potassium salt;
potassium salt		fertilizer
phenanthrene[no description available]medium10ortho-fused polycyclic arene;
ortho-fused tricyclic hydrocarbon;
phenanthrenes		environmental contaminant;
mouse metabolite
stephenanthrine[no description available]medium10cyclic acetal;
organic heterotetracyclic compound;
tertiary amino compound
fluoromethyl 2,2-difluoro-1-(trifluoromethyl)vinyl ether[no description available]medium10organofluorine compound
guanosine diphosphate[no description available]medium10guanosine 5'-phosphate;
purine ribonucleoside 5'-diphosphate		Escherichia coli metabolite;
mouse metabolite;
uncoupling protein inhibitor
guanosine 5'-o-(3-thiotriphosphate)[no description available]medium20nucleoside triphosphate analogue
seryl-leucyl-isoleucyl-glycyl--arginyl-leucinamide[no description available]medium10
hoe 33342[no description available]medium10
pituitrin[no description available]medium40
neuropeptide y[no description available]medium10
vasoactive intestinal peptide[no description available]medium130
tetraethylammonium[no description available]medium20quaternary ammonium ion
capsaicin[no description available]medium20capsaicinoidnon-narcotic analgesic;
TRPV1 agonist;
voltage-gated sodium channel blocker
charybdotoxin[no description available]medium20
sq-23377[no description available]medium10cyclic ether;
enol;
polyunsaturated fatty acid;
very long-chain fatty acid		calcium ionophore;
metabolite
picrotoxin[no description available]medium20
keratan sulfate[no description available]medium10
tetrahydropapaveroline[no description available]medium10benzylisoquinoline alkaloid;
benzyltetrahydroisoquinoline;
isoquinolinol		human metabolite
leukotoxin[no description available]medium10
8-bromo-2'-amp[no description available]medium10
2-(2,3-dicarboxycyclopropyl)glycine[no description available]medium10
ly 341495[no description available]medium10
xanthenes[no description available]medium10xanthene
8-bromoadenosine 5'-triphosphate[no description available]medium10
thromboxane a2[no description available]medium30epoxy monocarboxylic acid;
thromboxanes A		mouse metabolite
mitomycin[no description available]medium10mitomycinalkylating agent;
antineoplastic agent
p-methoxy-n-methylphenethylamine[no description available]medium20aromatic ether;
secondary amino compound		metabolite
luminol[no description available]medium20
cromakalim[no description available]medium20
dynorphins[no description available]medium10
fluticasone[no description available]medium5011beta-hydroxy steroid;
17alpha-hydroxy steroid;
3-oxo-Delta(4) steroid;
corticosteroid;
fluorinated steroid;
thioester		anti-allergic agent;
anti-asthmatic drug
monobutyryl cyclic amp[no description available]medium103',5'-cyclic purine nucleotide;
adenyl ribonucleotide;
butanamides		protein kinase agonist
nicotine[no description available]medium103-(1-methylpyrrolidin-2-yl)pyridineanxiolytic drug;
biomarker;
immunomodulator;
mitogen;
neurotoxin;
nicotinic acetylcholine receptor agonist;
peripheral nervous system drug;
phytogenic insecticide;
plant metabolite;
psychotropic drug;
teratogenic agent;
xenobiotic
irsogladine[no description available]medium20dichlorobenzene
nitrites[no description available]medium30monovalent inorganic anion;
nitrogen oxoanion;
reactive nitrogen species		human metabolite
anisomycin[no description available]medium10monohydroxypyrrolidine;
organonitrogen heterocyclic antibiotic		anticoronaviral agent;
antimicrobial agent;
antineoplastic agent;
antiparasitic agent;
bacterial metabolite;
DNA synthesis inhibitor;
protein synthesis inhibitor
glucagon[no description available]medium50peptide hormone
dobutamine[no description available]medium30catecholamine;
secondary amine		beta-adrenergic agonist;
cardiotonic drug;
sympathomimetic agent
kn 62[no description available]medium10piperazines
atl 146e[no description available]medium40
thioacetamide[no description available]medium10thiocarboxamidehepatotoxic agent
azelastine[no description available]medium10monochlorobenzenes;
phthalazines;
tertiary amino compound		anti-allergic agent;
anti-asthmatic drug;
bronchodilator agent;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
H1-receptor antagonist;
platelet aggregation inhibitor
3,4-dehydroproline[no description available]medium10
proline[no description available]medium10amino acid zwitterion;
glutamine family amino acid;
L-alpha-amino acid;
proline;
proteinogenic amino acid		algal metabolite;
compatible osmolytes;
Escherichia coli metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite
lanthanum[no description available]medium10f-block element atom;
lanthanoid atom;
scandium group element atom
1-propanol[no description available]medium10propan-1-ols;
short-chain primary fatty alcohol		metabolite;
protic solvent
nefiracetam[no description available]medium20organonitrogen compound;
organooxygen compound
methamphetamine[no description available]medium70amphetamines;
secondary amine		central nervous system stimulant;
environmental contaminant;
neurotoxin;
psychotropic drug;
xenobiotic
1,2-dilinolenoyl-3-(4-aminobutyryl)propane-1,2,3-triol[no description available]medium10
trientine[no description available]medium10polyazaalkane;
tetramine		copper chelator
glyceryl 2-arachidonate[no description available]medium102-acylglycerol 20:4;
endocannabinoid		human metabolite
anandamide[no description available]medium10endocannabinoid;
N-acylethanolamine 20:4		human blood serum metabolite;
neurotransmitter;
vasodilator agent
arvanil[no description available]medium10methoxybenzenes;
phenols
am 404[no description available]medium10anilide
snx 230[no description available]medium10
6-anilino-5,8-quinolinedione[no description available]medium10aminoquinoline;
aromatic amine;
p-quinones;
quinolone		antineoplastic agent;
EC 4.6.1.2 (guanylate cyclase) inhibitor
zinterol[no description available]medium10
thioperamide[no description available]medium10primary aliphatic amine
tranylcypromine[no description available]medium202-phenylcyclopropan-1-amine
lixazinone[no description available]medium30
quinazolines[no description available]medium180azaarene;
mancude organic heterobicyclic parent;
ortho-fused heteroarene;
quinazolines
glucose, (beta-d)-isomer[no description available]medium90D-glucopyranoseepitope;
mouse metabolite
rmi 12330a[no description available]medium20
naloxone[no description available]medium40morphinane alkaloid;
organic heteropentacyclic compound;
tertiary alcohol		antidote to opioid poisoning;
central nervous system depressant;
mu-opioid receptor antagonist
gadolinium[no description available]medium10f-block element atom;
lanthanoid atom
fludarabine[no description available]medium21purine nucleoside
3,5-dihydroxyphenylglycine[no description available]medium10alpha-amino acid
pyrazines[no description available]medium210diazine;
pyrazines		Daphnia magna metabolite
osteoprotegerin[no description available]medium20long-chain fatty acid
sodium chlorate[no description available]medium10chlorate salt;
inorganic sodium salt		herbicide
4-nitrophenyl beta-d-xyloside[no description available]medium10C-nitro compound;
xyloside		chromogenic compound
chlorates[no description available]medium10chlorine oxoanion;
monovalent inorganic anion
glycosides[no description available]medium10
substance p[no description available]medium20peptideneurokinin-1 receptor agonist;
neurotransmitter;
vasodilator agent
tofisopam[no description available]medium10organic molecular entity
normetanephrine[no description available]medium10catecholamine
alendronate[no description available]medium101,1-bis(phosphonic acid);
primary amino compound		bone density conservation agent;
EC 2.5.1.1 (dimethylallyltranstransferase) inhibitor
tartaric acid[no description available]medium10tartaric acidEscherichia coli metabolite
cdp 840[no description available]medium90
(9R)-9-chloro-11,17-dihydroxy-17-(2-hydroxy-1-oxoethyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one[no description available]medium2021-hydroxy steroid
birb 796[no description available]medium10aromatic ether;
morpholines;
naphthalenes;
pyrazoles;
ureas		EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
immunomodulator
peroxynitrous acid[no description available]medium10nitrogen oxoacid
sodium nitrate[no description available]medium10inorganic nitrate salt;
inorganic sodium salt		fertilizer;
NMR chemical shift reference compound
sodium nitrite[no description available]medium10inorganic sodium salt;
nitrite salt		antidote to cyanide poisoning;
antihypertensive agent;
antimicrobial food preservative;
food antioxidant;
poison
meclofenamic acid[no description available]medium40aminobenzoic acid;
organochlorine compound;
secondary amino compound		analgesic;
anticonvulsant;
antineoplastic agent;
antipyretic;
antirheumatic drug;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-steroidal anti-inflammatory drug
u 37883a[no description available]medium20
nitrates[no description available]medium10monovalent inorganic anion;
nitrogen oxoanion;
reactive nitrogen species
ici 118551[no description available]medium30aromatic ether;
indanes;
secondary alcohol;
secondary amino compound		beta-adrenergic antagonist
n(6)-phenyl-camp[no description available]medium10
fura-2[no description available]medium50
malonic acid[no description available]medium10alpha,omega-dicarboxylic acidhuman metabolite
thiourea[no description available]medium10one-carbon compound;
thioureas;
ureas		antioxidant;
chromophore
choline[no description available]medium10cholinesallergen;
Daphnia magna metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
neurotransmitter;
nutrient;
plant metabolite;
Saccharomyces cerevisiae metabolite
tetrodotoxin[no description available]medium40azatetracycloalkane;
oxatetracycloalkane;
quinazoline alkaloid		animal metabolite;
bacterial metabolite;
marine metabolite;
neurotoxin;
voltage-gated sodium channel blocker
clonazepam[no description available]medium101,4-benzodiazepinone;
monochlorobenzenes		anticonvulsant;
anxiolytic drug;
GABA modulator
ro 05-4082[no description available]medium10
cromolyn sodium[no description available]medium10organic sodium saltanti-asthmatic drug;
drug allergen
2'-deoxy cyclic amp[no description available]medium103',5'-cyclic purine nucleotideSaccharomyces cerevisiae metabolite
ici 63197[no description available]medium30triazolopyrimidines
sodium fluoride[no description available]medium20fluoride saltmutagen
5,6-dihydroprostacyclin[no description available]medium10
fenfluramine[no description available]medium10(trifluoromethyl)benzenes;
secondary amino compound		appetite depressant;
serotonergic agonist;
serotonin uptake inhibitor
dinoprost[no description available]medium30monocarboxylic acid;
prostaglandins Falpha		human metabolite;
mouse metabolite
fura-2-am[no description available]medium10
5-(4-acetamidophenyl)pyrazin-2(1h)-one[no description available]medium170
thymidine[no description available]medium40pyrimidine 2'-deoxyribonucleosideEscherichia coli metabolite;
human metabolite;
metabolite;
mouse metabolite
manganese[no description available]medium20elemental manganese;
manganese group element atom		Escherichia coli metabolite;
micronutrient
tolafentrine[no description available]medium30
ah 21-132[no description available]medium20
sq 20006[no description available]medium10
methylene blue[no description available]medium10organic chloride saltacid-base indicator;
antidepressant;
antimalarial;
antimicrobial agent;
antioxidant;
cardioprotective agent;
EC 1.4.3.4 (monoamine oxidase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
EC 4.6.1.2 (guanylate cyclase) inhibitor;
fluorochrome;
histological dye;
neuroprotective agent;
physical tracer
vanadates[no description available]medium40trivalent inorganic anion;
vanadium oxoanion		EC 3.1.3.1 (alkaline phosphatase) inhibitor;
EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor;
EC 3.1.3.41 (4-nitrophenylphosphatase) inhibitor;
EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor
dibutyryl cyclic gmp[no description available]medium60
methionine[no description available]medium10aspartate family amino acid;
L-alpha-amino acid;
methionine zwitterion;
methionine;
proteinogenic amino acid		antidote to paracetamol poisoning;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical
phenidone[no description available]medium10
sk&f 86002[no description available]medium20imidazoles
1,2-bis(2-aminophenoxy)ethane n,n,n',n'-tetraacetic acid acetoxymethyl ester[no description available]medium10
2,5-di-tert-butylhydroquinone[no description available]medium10hydroquinones
inositol 1,4,5-trisphosphate[no description available]medium30myo-inositol trisphosphatemouse metabolite
adenosine diphosphate[no description available]medium20adenosine 5'-phosphate;
purine ribonucleoside 5'-diphosphate		fundamental metabolite;
human metabolite
inosine triphosphate[no description available]medium20inosine phosphate;
purine ribonucleoside 5'-triphosphate		Escherichia coli metabolite;
human metabolite;
mouse metabolite
nystatin a1[no description available]medium10nystatins
n-(2-(methylamino)ethyl)-5-isoquinolinesulfonamide[no description available]medium20isoquinolines;
sulfonamide
galactosamine[no description available]medium20D-galactosamine;
primary amino compound		toxin
gallic acid[no description available]medium10trihydroxybenzoic acidantineoplastic agent;
antioxidant;
apoptosis inducer;
astringent;
cyclooxygenase 2 inhibitor;
EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor;
geroprotector;
human xenobiotic metabolite;
plant metabolite
okadaic acid[no description available]medium30ketal
quin2[no description available]medium10
flosequinan[no description available]medium20quinolines
flosequinoxan[no description available]medium10
aminopyrine[no description available]medium10pyrazolone;
tertiary amino compound		antipyretic;
environmental contaminant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic
enkephalin, leucine[no description available]medium40pentapeptide;
peptide zwitterion		analgesic;
delta-opioid receptor agonist;
human metabolite;
mu-opioid receptor agonist;
neurotransmitter;
rat metabolite
cicaprost[no description available]medium70monoterpenoid
phorbol 12,13-dibutyrate[no description available]medium70butyrate ester;
phorbol ester;
tertiary alpha-hydroxy ketone
indolidan[no description available]medium30
evans blue[no description available]medium30organic sodium saltfluorochrome;
histological dye;
sodium channel blocker;
teratogenic agent
linsidomine[no description available]medium10morpholines
molsidomine[no description available]medium10ethyl ester;
morpholines;
oxadiazole;
zwitterion		antioxidant;
apoptosis inhibitor;
cardioprotective agent;
nitric oxide donor;
vasodilator agent
bemoradan[no description available]medium20
4,4'-diisothiocyanostilbene-2,2'-disulfonic acid[no description available]medium10
opc 3911[no description available]medium30
sk&f 96231[no description available]medium20
beta-endorphin[no description available]medium10
croton oil[no description available]medium10N-acyl-hexosamine
concanavalin a[no description available]medium40
aluminum oxide[no description available]medium10
8-bromoadenosine[no description available]medium10purine nucleoside
fluorescein-5-isothiocyanate[no description available]medium20fluorescein isothiocyanate
antioquine[no description available]medium10
taprostene[no description available]medium10benzoic acids
cardiovascular agents[no description available]medium10
sumatriptan[no description available]medium10sulfonamide;
tryptamines		serotonergic agonist;
vasoconstrictor agent
5-carboxamidotryptamine[no description available]medium10tryptamines
minocycline[no description available]medium10
oxidopamine[no description available]medium70benzenetriol;
catecholamine;
primary amino compound		drug metabolite;
human metabolite;
neurotoxin
muscimol[no description available]medium20alkaloid;
isoxazoles;
primary amino compound		fungal metabolite;
GABA agonist;
oneirogen;
psychotropic drug
deoxycholic acid[no description available]medium10bile acid;
C24-steroid;
dihydroxy-5beta-cholanic acid		human blood serum metabolite
ly 186126[no description available]medium10
5-hydroxy-6,8,11,14-eicosatetraenoic acid[no description available]medium10HETEhuman metabolite;
mouse metabolite
phosphatidylethanol[no description available]medium10
ici 118233[no description available]medium10
1-naphthylamine[no description available]medium10naphthylaminehuman xenobiotic metabolite
neopterin[no description available]medium10
fluparoxan[no description available]medium10
meclofenoxate[no description available]medium10monocarboxylic acid
guanosine monophosphate[no description available]medium10guanosine 5'-phosphate;
purine ribonucleoside 5'-monophosphate		biomarker;
Escherichia coli metabolite;
metabolite;
mouse metabolite
hydralazine[no description available]medium10azaarene;
hydrazines;
ortho-fused heteroarene;
phthalazines		antihypertensive agent;
vasodilator agent
thimerosal[no description available]medium10alkylmercury compoundantifungal drug;
antiseptic drug;
disinfectant;
drug allergen
6-bromo-8-methylaminoimidazo(1,2-a)pyrazine-2-carbonitrile[no description available]medium20
cp 80633[no description available]medium20
arsenic[no description available]medium10metalloid atom;
pnictogen		micronutrient
oxophenylarsine[no description available]medium10arsine oxidesantineoplastic agent;
apoptosis inducer;
EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor
dimercaprol[no description available]medium10dithiol;
primary alcohol		chelator
sk&f 95654[no description available]medium20
adrenomedullin[no description available]medium40
medetomidine[no description available]medium30imidazoles
nitrous oxide[no description available]medium10gas molecular entity;
nitrogen oxide		analgesic;
bacterial metabolite;
food packaging gas;
food propellant;
general anaesthetic;
greenhouse gas;
inhalation anaesthetic;
NMDA receptor antagonist;
raising agent;
refrigerant;
vasodilator agent
8-bromoguanosino-3',5'-cyclic monophosphorothioate[no description available]medium10
bmy 45778[no description available]medium10bisoxazolepartial prostacyclin agonist
bmy 42393[no description available]medium10
octimibate[no description available]medium10
sdz mks 492[no description available]medium10
folic acid[no description available]medium10folic acids;
N-acyl-amino acid		human metabolite;
mouse metabolite;
nutrient
neurokinin a[no description available]medium10
oxotremorine[no description available]medium30N-alkylpyrrolidine
t 440[no description available]medium10
ah 23848[no description available]medium10(4Z)-7-{5-[([1,1'-biphenyl]-4-yl)methoxy]-2-(morpholin-4-yl)-3-oxocyclopentyl}hept-4-enoic acid
thymic factor, circulating[no description available]medium10
cytochalasin d[no description available]medium10
guanylyl imidodiphosphate[no description available]medium10nucleoside triphosphate analogue
1,9-dideoxyforskolin[no description available]medium10acetate ester;
labdane diterpenoid;
organic heterotricyclic compound		plant metabolite
glycerol[no description available]medium10alditol;
triol		algal metabolite;
detergent;
Escherichia coli metabolite;
geroprotector;
human metabolite;
mouse metabolite;
osmolyte;
Saccharomyces cerevisiae metabolite;
solvent
dihydropyridines[no description available]medium20
lithium[no description available]medium20alkali metal atom
hypoxanthine[no description available]medium10nucleobase analogue;
oxopurine;
purine nucleobase		fundamental metabolite
menotropins[no description available]medium10
leptin[no description available]medium10
fluorescein[no description available]medium102-benzofurans;
gamma-lactone;
organic heteropentacyclic compound;
oxaspiro compound;
polyphenol;
xanthene dye		fluorescent dye;
radioopaque medium
isradipine[no description available]medium10benzoxadiazole;
dihydropyridine;
isopropyl ester;
methyl ester
bunazosin[no description available]medium10quinazolines
cp 99994[no description available]medium10
ondansetron[no description available]medium10carbazoles
8-((4-chlorophenyl)thio)cyclic-3',5'-amp[no description available]medium203',5'-cyclic purine nucleotide;
adenyl ribonucleotide;
aryl sulfide;
organochlorine compound		protein kinase agonist
rmp 7[no description available]medium10
binodenoson[no description available]medium10
org 4428[no description available]medium10
8-chloro-cyclic adenosine monophosphate[no description available]medium10
lavendustin a[no description available]medium10aromatic amine
drotaverin[no description available]medium10isoquinolines
metyrapone[no description available]medium10aromatic ketoneantimetabolite;
diagnostic agent;
EC 1.14.15.4 (steroid 11beta-monooxygenase) inhibitor
prostaglandin d2[no description available]medium10prostaglandins Dhuman metabolite;
mouse metabolite
gp 1-515[no description available]medium10
adenosine kinase[no description available]medium10
phencyclidine[no description available]medium10benzenes;
piperidines		anaesthetic;
neurotoxin;
NMDA receptor antagonist;
psychotropic drug
etonogestrel[no description available]medium1017beta-hydroxy steroid;
3-oxo-Delta(4) steroid;
terminal acetylenic compound		contraceptive drug;
female contraceptive drug;
progestin
desogestrel[no description available]medium1017beta-hydroxy steroid;
terminal acetylenic compound		contraceptive drug;
progestin;
synthetic oral contraceptive
gestodene[no description available]medium10steroidestrogen
benzofurans[no description available]medium10
2-methyl-5-ht[no description available]medium10tryptaminesserotonergic agonist
1-hydroxyphenazine[no description available]medium10phenazines
mrs 1191[no description available]medium10cinnamate ester
2,3-dioxo-6-nitro-7-sulfamoylbenzo(f)quinoxaline[no description available]medium10naphthalenes;
sulfonic acid derivative
acetic acid[no description available]medium10monocarboxylic acidantimicrobial food preservative;
Daphnia magna metabolite;
food acidity regulator;
protic solvent
histidine[no description available]medium10amino acid zwitterion;
histidine;
L-alpha-amino acid;
polar amino acid zwitterion;
proteinogenic amino acid		algal metabolite;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite
phenylalanine[no description available]medium10amino acid zwitterion;
erythrose 4-phosphate/phosphoenolpyruvate family amino acid;
L-alpha-amino acid;
phenylalanine;
proteinogenic amino acid		algal metabolite;
EC 3.1.3.1 (alkaline phosphatase) inhibitor;
Escherichia coli metabolite;
human xenobiotic metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite
methoxamine[no description available]medium10amphetaminesalpha-adrenergic agonist;
antihypotensive agent
leukotriene e4[no description available]medium10amino dicarboxylic acid;
L-cysteine thioether;
leukotriene;
non-proteinogenic L-alpha-amino acid;
secondary alcohol
cobalt[no description available]medium10cobalt group element atom;
metal allergen		micronutrient
formylmethionyl-leucyl-phenylalanine methyl ester[no description available]medium10peptide
uridine triphosphate[no description available]medium20pyrimidine ribonucleoside 5'-triphosphate;
uridine 5'-phosphate		Escherichia coli metabolite;
mouse metabolite
2-methylthio-atp[no description available]medium10
iberiotoxin[no description available]medium10
atrial natriuretic factor (4-23)nh2, de-gln(18)-de-ser(19)-de-gly(20,22)-de-leu(21)-[no description available]medium10
pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid[no description available]medium10arenesulfonic acid;
azobenzenes;
methylpyridines;
monohydroxypyridine;
organic phosphate;
pyridinecarbaldehyde		purinergic receptor P2X antagonist
pyridoxal phosphate[no description available]medium10methylpyridines;
monohydroxypyridine;
pyridinecarbaldehyde;
vitamin B6 phosphate		coenzyme;
cofactor;
EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
midazolam[no description available]medium10imidazobenzodiazepine;
monofluorobenzenes;
organochlorine compound		anticonvulsant;
antineoplastic agent;
anxiolytic drug;
apoptosis inducer;
central nervous system depressant;
GABAA receptor agonist;
general anaesthetic;
muscle relaxant;
sedative
thiopental[no description available]medium10barbituratesanticonvulsant;
drug allergen;
environmental contaminant;
intravenous anaesthetic;
sedative;
xenobiotic
vasoactive intestinal peptide[no description available]medium10
chelerythrine[no description available]medium10benzophenanthridine alkaloid;
organic cation		antibacterial agent;
antineoplastic agent;
EC 2.7.11.13 (protein kinase C) inhibitor
norbinaltorphimine[no description available]medium10isoquinolines
caseins[no description available]medium10
ozone[no description available]medium10elemental molecule;
gas molecular entity;
reactive oxygen species;
triatomic oxygen		antiseptic drug;
disinfectant;
electrophilic reagent;
greenhouse gas;
mutagen;
oxidising agent;
tracer
hydroxylamine[no description available]medium10hydroxylaminesalgal metabolite;
bacterial xenobiotic metabolite;
EC 1.1.3.13 (alcohol oxidase) inhibitor;
EC 4.2.1.22 (cystathionine beta-synthase) inhibitor;
EC 4.3.1.10 (serine-sulfate ammonia-lyase) inhibitor;
nitric oxide donor;
nucleophilic reagent
enkephalin, d-penicillamine (2,5)-[no description available]medium10heterodetic cyclic peptidedelta-opioid receptor agonist
heliodermin[no description available]medium10
ud cg 212 cl[no description available]medium10
minaprine[no description available]medium10morpholines;
pyridazines;
secondary amine		antidepressant;
antiparkinson drug;
cholinergic drug;
dopamine uptake inhibitor;
serotonin uptake inhibitor
bw-a 78u[no description available]medium10
barium[no description available]medium10alkaline earth metal atom;
elemental barium
sincalide[no description available]medium10oligopeptide
azepexole[no description available]medium10
2-phenylpyrazolo(4,3-c)quinolin-3(5h)-one[no description available]medium10
enkephalin, leucine-2-alanine[no description available]medium10
cadmium[no description available]medium10cadmium molecular entity;
zinc group element atom
valeramide[no description available]medium10monocarboxylic acid amide
valerates[no description available]medium10short-chain fatty acid anion;
straight-chain saturated fatty acid anion		plant metabolite
4-(3,4-dibutoxybenzyl)-2-imidazolidinone[no description available]medium10
alprazolam[no description available]medium10organochlorine compound;
triazolobenzodiazepine		anticonvulsant;
anxiolytic drug;
GABA agonist;
muscle relaxant;
sedative;
xenobiotic
gastrins[no description available]medium10
pargyline[no description available]medium10aromatic amine
racemetirosine[no description available]medium20
pilocarpine[no description available]medium10pilocarpineantiglaucoma drug
citalopram[no description available]medium202-benzofurans;
cyclic ether;
nitrile;
organofluorine compound;
tertiary amino compound
methotrimeprazine[no description available]medium10phenothiazines;
tertiary amine		anticoronaviral agent;
cholinergic antagonist;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
non-narcotic analgesic;
phenothiazine antipsychotic drug;
serotonergic antagonist
s,n,n'-tripropylthiocarbamate[no description available]medium30tertiary amine
pica[no description available]medium20
trolamine salicylate[no description available]medium30
2-propanol[no description available]medium20secondary alcohol;
secondary fatty alcohol		protic solvent
fomesafen[no description available]medium20aromatic ether;
C-nitro compound;
monochlorobenzenes;
N-sulfonylcarboxamide;
organofluorine compound;
phenols		agrochemical;
EC 1.3.3.4 (protoporphyrinogen oxidase) inhibitor;
herbicide
eye[no description available]medium10
7,8-dihydroxyflavone[no description available]low00dihydroxyflavoneantidepressant;
antineoplastic agent;
antioxidant;
plant metabolite;
tropomyosin-related kinase B receptor agonist
n-acetylphenylalanine[no description available]low00N-acetyl-amino acid;
phenylalanine derivative		antidepressant;
metabolite
am 251[no description available]low00amidopiperidine;
carbohydrazide;
dichlorobenzene;
organoiodine compound;
pyrazoles		antidepressant;
antineoplastic agent;
apoptosis inducer;
CB1 receptor antagonist
cyclobenzaprine[no description available]low00carbotricyclic compoundantidepressant;
muscle relaxant;
tranquilizing drug
lofepramine[no description available]low00aromatic ketone;
dibenzoazepine;
monochlorobenzenes;
tertiary amino compound		antidepressant
nefazodone[no description available]low00aromatic ether;
monochlorobenzenes;
N-alkylpiperazine;
N-arylpiperazine;
triazoles		alpha-adrenergic antagonist;
analgesic;
antidepressant;
serotonergic antagonist;
serotonin uptake inhibitor
nisoxetine[no description available]low00aromatic ether;
secondary amino compound		adrenergic uptake inhibitor;
antidepressant
trimipramine[no description available]low00dibenzoazepine;
tertiary amino compound		antidepressant;
environmental contaminant;
xenobiotic
venlafaxine[no description available]low00cyclohexanols;
monomethoxybenzene;
tertiary alcohol;
tertiary amino compound		adrenergic uptake inhibitor;
analgesic;
antidepressant;
dopamine uptake inhibitor;
environmental contaminant;
serotonin uptake inhibitor;
xenobiotic
thymoquinone[no description available]low001,4-benzoquinonesadjuvant;
anti-inflammatory agent;
antidepressant;
antineoplastic agent;
antioxidant;
cardioprotective agent;
plant metabolite
lofepramine hydrochloride[no description available]low00hydrochlorideantidepressant
amineptin[no description available]low00amino acid;
carbocyclic fatty acid;
carbotricyclic compound;
secondary amino compound		antidepressant;
dopamine uptake inhibitor
adinazolam[no description available]low00triazolobenzodiazepineanticonvulsant;
antidepressant;
anxiolytic drug;
sedative
atomoxetine hydrochloride[no description available]low00hydrochlorideadrenergic uptake inhibitor;
antidepressant
duloxetine hydrochloride[no description available]low00duloxetine hydrochlorideantidepressant
rubidium chloride[no description available]low00inorganic chloride;
rubidium molecular entity		antidepressant;
biomarker
paroxetine hydrochloride[no description available]low00hydrochlorideantidepressant;
anxiolytic drug;
hepatotoxic agent;
P450 inhibitor;
serotonin uptake inhibitor
sertraline hydrochloride[no description available]low00hydrochlorideantidepressant;
serotonin uptake inhibitor
secoisolariciresinol[no description available]low00secoisolariciresinolantidepressant;
phytoestrogen;
plant metabolite
lithium sulfate[no description available]low00metal sulfateantidepressant
dexamisole[no description available]low006-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazoleantidepressant
tandospirone[no description available]low00bridged compound;
dicarboximide;
N-alkylpiperazine;
N-arylpiperazine;
pyrimidines		antidepressant;
anxiolytic drug
desvenlafaxine[no description available]low00cyclohexanols;
phenols;
tertiary amino compound		antidepressant;
drug metabolite;
marine xenobiotic metabolite
escitalopram[no description available]low001-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrileantidepressant;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor
tetrindole[no description available]low00racemateantidepressant;
EC 1.4.3.4 (monoamine oxidase) inhibitor;
serotonergic agonist
eicosapentaenoic acid[no description available]low00icosapentaenoic acid;
omega-3 fatty acid		anticholesteremic drug;
antidepressant;
antineoplastic agent;
Daphnia galeata metabolite;
fungal metabolite;
micronutrient;
mouse metabolite;
nutraceutical
fluoxetine[no description available]low00N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amineantidepressant;
serotonin uptake inhibitor
(R)-fluoxetine[no description available]low00N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amineantidepressant;
serotonin uptake inhibitor
ANA-12[no description available]low001-benzothiophenes;
caprolactams;
secondary carboxamide		antidepressant;
anxiolytic drug;
tropomyosin-related kinase B receptor antagonist
quercetin 3-o-glucuronide[no description available]low00beta-D-glucosiduronic acid;
quercetin O-glycoside		antidepressant;
antioxidant;
metabolite
fluvoxamine[no description available]low00(trifluoromethyl)benzenes;
5-methoxyvalerophenone O-(2-aminoethyl)oxime		antidepressant;
anxiolytic drug;
serotonin uptake inhibitor
lespenefril[no description available]low00alpha-L-rhamnoside;
dihydroxyflavone;
glycosyloxyflavone;
monosaccharide derivative;
polyphenol		anti-inflammatory agent;
antidepressant;
antineoplastic agent;
apoptosis inducer;
bone density conservation agent;
hypoglycemic agent;
immunomodulator;
plant metabolite
clovoxamine[no description available]low005-methoxyvalerophenone O-(2-aminoethyl)oxime;
monochlorobenzenes		antidepressant
paroxetine maleate[no description available]low00maleate saltantidepressant;
anxiolytic drug;
hepatotoxic agent;
P450 inhibitor;
serotonin uptake inhibitor
salvianolic acid B[no description available]low001-benzofurans;
catechols;
dicarboxylic acid;
enoate ester;
polyphenol		anti-inflammatory agent;
antidepressant;
antineoplastic agent;
antioxidant;
apoptosis inducer;
autophagy inhibitor;
cardioprotective agent;
hepatoprotective agent;
hypoglycemic agent;
neuroprotective agent;
osteogenesis regulator;
plant metabolite
ro 25-6981[no description available]low00benzenes;
phenols;
piperidines;
secondary alcohol;
tertiary amino compound		anticonvulsant;
antidepressant;
neuroprotective agent;
NMDA receptor antagonist
flibanserin[no description available]low00benzimidazoles;
N-alkylpiperazine;
N-arylpiperazine;
organofluorine compound		antidepressant;
serotonergic agonist;
serotonergic antagonist
vilazodone hydrochloride[no description available]low00hydrochlorideantidepressant;
serotonergic agonist;
serotonin uptake inhibitor
vilazodone[no description available]low001-benzofurans;
indoles;
monocarboxylic acid amide;
N-alkylpiperazine;
N-arylpiperazine;
nitrile		antidepressant;
serotonergic agonist;
serotonin uptake inhibitor
vortioxetine[no description available]low00aryl sulfide;
N-arylpiperazine		antidepressant;
anxiolytic drug;
serotonergic agonist;
serotonergic antagonist
ginsenoside rb3[no description available]low0012beta-hydroxy steroid;
beta-D-glucoside;
disaccharide derivative;
ginsenoside;
tetracyclic triterpenoid		antidepressant;
antioxidant;
cardioprotective agent;
neuroprotective agent;
NMDA receptor antagonist;
plant metabolite
levomefolate calcium[no description available]low00organic calcium saltantidepressant
3-methylflavone-8-carboxylic acid[no description available]low00flavones;
oxo monocarboxylic acid		EC 3.1.4.* (phosphoric diester hydrolase) inhibitor
avanafil[no description available]low00aromatic amide;
monocarboxylic acid amide;
organochlorine compound;
prolinols;
pyrimidines		EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
vasodilator agent
pyrrolidonecarboxylic acid[no description available]low00oxoproline;
pyrrolidin-2-ones;
pyrrolidinemonocarboxylic acid		human metabolite
doxapram[no description available]low00morpholines;
pyrrolidin-2-ones		central nervous system stimulant
n-vinyl-2-pyrrolidinone[no description available]low00pyrrolidin-2-ones
2-pyrrolidone[no description available]low00pyrrolidin-2-onesmetabolite;
polar solvent
1-lauryl-2-pyrrolidone[no description available]low00pyrrolidin-2-onesepitope
fradafiban[no description available]low00carboxamidine;
monocarboxylic acid;
pyrrolidin-2-ones		platelet glycoprotein-IIb/IIIa receptor antagonist
hydroxycotinine[no description available]low00N-alkylpyrrolidine;
pyridines;
pyrrolidin-2-ones;
pyrrolidine alkaloid
1-[4-carboxy-2-(3-pentylamino)phenyl]-5,5-bis(hydroxymethyl)pyrrolidin-2-one[no description available]low00benzoic acids;
primary alcohol;
pyrrolidin-2-ones;
secondary amino compound
levetiracetam[no description available]low00pyrrolidin-2-onesanticonvulsant;
environmental contaminant;
xenobiotic
N-[(5-methyl-1,2-oxazol-3-yl)carbonyl]-L-alanyl-L-valyl-N-{(2S,3E)-5-(benzyloxy)-5-oxo-1-[(3S)-2-oxopyrrolidin-3-yl]pent-3-en-2-yl}-L-leucinamide[no description available]low00benzyl ester;
isoxazoles;
pyrrolidin-2-ones;
tripeptide		anticoronaviral agent;
antiviral agent;
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor
ik 682[no description available]low00hydroxamic acid;
pyrrolidin-2-ones;
quinolines
3,3-diethyl-2-pyrrolidinone[no description available]low00pyrrolidin-2-onesanticonvulsant;
geroprotector
rolapitant[no description available]low00azaspiro compound;
ether;
organofluorine compound;
piperidines;
pyrrolidin-2-ones		antiemetic;
neurokinin-1 receptor antagonist
vibrioferrin[no description available]low00carboxylic ester;
N-acyl hemiaminal;
pyrrolidin-2-ones;
tertiary alcohol;
tricarboxylic acid		marine metabolite;
siderophore
PF-00835231[no description available]low00aromatic ether;
indolecarboxamide;
L-leucine derivative;
primary alcohol;
pyrrolidin-2-ones;
secondary carboxamide		anticoronaviral agent;
drug metabolite;
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor
cay 10580[no description available]low00hydroxy monocarboxylic acid;
pyrrolidin-2-ones;
secondary alcohol		prostaglandin receptor agonist
ivosidenib[no description available]low00cyanopyridine;
monochlorobenzenes;
organofluorine compound;
pyrrolidin-2-ones;
secondary carboxamide;
tertiary carboxamide		antineoplastic agent;
EC 1.1.1.42 (isocitrate dehydrogenase) inhibitor
N-[(2S)-3-cyclohexyl-1-oxo-1-({(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}amino)propan-2-yl]-1H-indole-2-carboxamide[no description available]low00aldehyde;
indolecarboxamide;
oligopeptide;
pyrrolidin-2-ones;
secondary carboxamide		anticoronaviral agent;
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor
3-fluoro-Nalpha-(1H-indol-2-ylcarbonyl)-N-{(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}-L-phenylalaninamide[no description available]low00aldehyde;
indolecarboxamide;
monofluorobenzenes;
oligopeptide;
pyrrolidin-2-ones;
secondary carboxamide		anticoronaviral agent;
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor
PF-07304814[no description available]low00aromatic ether;
indolecarboxamide;
L-leucine derivative;
phosphate monoester;
pyrrolidin-2-ones;
secondary carboxamide		anticoronaviral agent;
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor;
prodrug
nirmatrelvir[no description available]low00azabicyclohexane;
nitrile;
organofluorine compound;
pyrrolidin-2-ones;
pyrrolidinecarboxamide;
secondary carboxamide;
tertiary carboxamide		anticoronaviral agent;
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor
ConditionIndicatedRelationship StrengthStudiesTrials
Airflow Obstruction, Chronic0low20
Anasarca0low10
Asthma0low10
Asthma, Bronchial0low10
Brain Diseases0low10
Brain Disorders0low10
Bronchial Asthma0low10
Central Nervous System Disorders, Intracranial0low10
Central Nervous System Intracranial Disorders0low10
Chronic Airflow Obstruction0low20
Chronic Obstructive Airway Disease0low20
Chronic Obstructive Lung Disease0low20
Chronic Obstructive Pulmonary Disease0low20
Chronic Obstructive Pulmonary Diseases0low20
CNS Disorders, Intracranial0low10
COAD0low20
Congenital Zika Syndrome0low20
Congenital Zika Virus Infection0low20
COPD0low20
Disease Models, Animal0low20
Dropsy0low10
Edema0low10
Emesis0low40
Encephalon Diseases0low10
Encephalopathy0low10
Fever, Zika0low20
Fra(X) Syndrome0low10
Fragile X Mental Retardation Syndrome0low10
Fragile X Syndrome0low10
Fragile X-F Mental Retardation Syndrome0low10
FRAXA Syndrome0low10
FRAXE Syndrome0low10
Hydrops0low10
Intracranial Central Nervous System Disorders0low10
Intracranial CNS Disorders0low10
Mar (X) Syndrome0low10
Marker X Syndrome0low10
Martin-Bell Syndrome0low10
Mental Retardation, X-Linked, Associated With Fragile Site Fraxe0low10
Mental Retardation, X-Linked, Associated With Marxq280low10
Pulmonary Disease, Chronic Obstructive0low20
Vomiting0low40
X-Linked Mental Retardation and Macroorchidism0low10
Zika Fever0low20
Zika Virus Disease0low20
Zika Virus Infection0low20
ZikV Infection0low20
(pPNET) Peripheral Primitive Neuroectodermal Tumors0low10
2019 Novel Coronavirus Disease0low10
2019 Novel Coronavirus Infection0low10
2019-nCoV Disease0low10
2019-nCoV Infection0low10
47,XX,+210low10
47,XY,+210low10
Abdominal Pain0low10
Absence Seizure0low30
Absence Seizures0low30
Academic Disorder, Developmental0low20
Ache0low60
Acquired Nephrogenic Diabetes Insipidus0low10
Acromegaly Due To Pituitary Adenoma0low10
Action Tremor0low20
Acute Brain Injuries0low80
Acute Confusional Senile Dementia0low130
Acute Disease0low60
Acute Edematous Pancreatitis0low50
Acute Hypercapnic Respiratory Failure0low10
Acute Hypoxemic Respiratory Failure0low10
Acute Kidney Failure0low20
Acute Kidney Injury0low20
Acute Kidney Insufficiency0low20
Acute Liver Injury, Drug-Induced0low20
Acute Lung Injury0low70
Acute Lymphoid Leukemia0low10
Acute Myelogenous Leukemia0low20
Acute Myeloid Leukemia0low20
Acute Myeloid Leukemia with Maturation0low20
Acute Myeloid Leukemia without Maturation0low20
Acute Onset Vascular Dementia0low20
Acute Pancreatitis0low50
Acute Post-Traumatic Stress Disorder0low10
Acute Promyelocytic Leukemia0low10
Acute Renal Failure0low20
Acute Renal Injury0low20
Acute Renal Insufficiency0low20
Acute Respiratory Distress Syndrome0low70
Acute-Phase Reaction0low10
Acute-Phase State0low10
Addison Disease and Cerebral Sclerosis0low20
Adenocarcinoma0low10
Adenocarcinoma, Basal Cell0low10
Adenocarcinoma, Granular Cell0low10
Adenocarcinoma, Oxyphilic0low10
Adenocarcinoma, Tubular0low10
Adenoma0low10
Adenoma, Basal Cell0low10
Adenoma, Follicular0low10
Adenoma, Malignant0low10
Adenoma, Microcystic0low10
Adenoma, Monomorphic0low10
Adenoma, Papillary0low10
Adenoma, Prolactin-Secreting, Pituitary0low10
Adenoma, Prostatic0low10
Adenoma, Trabecular0low10
ADH-Resistant Diabetes Insipidus0low10
Adhesions, Tissue0low20
Adjuvant Arthritis0low70
Adrenoleukodystrophy0low20
Adrenomyeloneuropathy0low20
Adult Learning Disabilities0low20
Adult Learning Disorders0low20
Adult Respiratory Distress Syndrome0low70
Adult Spinal Muscular Atrophy0low10
Adult-Onset Spinal Muscular Atrophy0low10
African Sleeping Sickness0low10
African Trypanosomiasis0low10
Age-Related Memory Disorders0low170
Age-Related Osteoporosis0low10
Aggression0low10
Aging0low220
AIDS-Related Opportunistic Infections0low10
Airflow Obstruction, Chronic0medium181
Airway Hyper-Responsiveness0low50
Airway Obstruction0low10
Airway Remodeling0low10
Airway Remodelling0low10
Airway Wall Remodelling0low10
Akinetic-Rigid Variant of Huntington Disease0low60
Albright Syndrome0low10
Albright-Mccune-Sternberg Syndrome0low10
Albright-Sternberg Syndrome0low10
Albright's Disease0low10
Albright's Disease of Bone0low10
Albright's Syndrome0low10
Albright's Syndrome with Precocious Puberty0low10
Alcohol Abuse0low10
Alcohol Addiction0low10
Alcohol Dependence0low10
Alcohol Drinking0low60
Alcohol Problem0low10
Alcohol Related Neurodevelopmental Disorder0low10
Alcohol Use Disorder0low10
Alcohol-Related Birth Defects0low10
Alcohol-Related Disorders0low10
Alcoholic Fatty Liver0low10
Alcoholic Intoxication0low10
Alcoholic Intoxication, Chronic0low10
Alcoholic Steatohepatitis0low10
Alcoholism0low10
ALD (Adrenoleukodystrophy)0low20
ALL, Childhood0low10
Allergic Encephalomyelitis0low160
Allergic Encephalomyelitis, Experimental0low160
Allergic Neuritis, Experimental0low20
Allergic Reaction0low70
Allergy0low70
Allodynia0low100
Allodynia, Mechanical0low100
Allodynia, Tactile0low100
Allodynia, Thermal0low100
Allotriophagy0low20
Alloxan Diabetes0low60
Alveolitis, Fibrosing0low20
Alzheimer Dementia0low130
Alzheimer Disease0low130
Alzheimer Disease, Early Onset0low130
Alzheimer Disease, Late Onset0low130
Alzheimer Sclerosis0low130
Alzheimer Syndrome0low130
Alzheimer Type Senile Dementia0low130
Alzheimer-Type Dementia (ATD)0low130
Alzheimer's Disease0low130
Alzheimer's Disease, Focal Onset0low130
Alzheimer's Diseases0low130
Ambulation Disorders, Neurologic0low10
Amentia0low20
AML M30low10
Amnesia0low10
Amnesia-Memory Loss0low10
Amnesia, Dissociative0low10
Amnesia, Global0low10
Amnesia, Hysterical0low10
Amnesia, Tactile0low10
Amnesia, Temporary0low10
Amnestic State0low10
Amnionitis0low10
Amyloid Deposits0low10
Amyloid Plaques0low10
Amyotrophy, Neurogenic Scapuloperoneal, New England Type0low10
Anaplastic Astrocytoma0low20
Anasarca0low130
Anemia0medium11
Anemia, Fanconi0low10
Anemia, Sickle Cell0low10
Anesthesia0low110
Angiogenesis, Pathologic0low20
Angiogenesis, Pathological0low20
ANLL0low20
Anochlesia0low20
Anorexia0low10
Anoxemia0low50
Anoxia0low50
Anoxia-Ischemia, Brain0low20
Anoxia-Ischemia, Cerebral0low20
Anoxia, Fetal0low10
Anoxic-Ischemic Encephalopathy0low20
Anterior Cerebral Circulation Infarction0low10
Anterior Circulation Brain Infarction0low10
Anterior Circulation Infarction, Brain0low10
Anterior Circulation Transient Ischemic Attack0low90
Anxiety0low70
Apoplexy0low30
Arachnoidal Cerebellar Sarcoma, Circumscribed0low30
ARDS, Human0low70
Arrhythmia0low30
Arrhythmia, Sinoatrial0low20
Arrhythmia, Sinus0low20
Arrhythmias, Cardiac0low30
Arrythmia0low30
Arteriosclerosis, Coronary0low10
Arteriosclerotic Dementia0low20
Arteriosclerotic Encephalopathy, Subcortical0low20
Arthritides, Bacterial0low20
Arthritis0low40
Arthritis, Adjuvant0low70
Arthritis, Adjuvant-Induced0low70
Arthritis, Bacterial0low20
Arthritis, Collagen-Induced0low70
Arthritis, Experimental0low70
Arthritis, Infectious0low20
Arthritis, Rheumatoid0low80
Arthritis, Septic0low20
Arthritis, Suppurative0low20
Arthritis, Viral0low20
Ascites0low10
Aspiration, Meconium0low10
Asthma0low460
Asthma, Bronchial0low460
Asthmatic Airway Remodeling0low10
Asthmatic Airway Remodelling0low10
Asthmatic Airway Wall Remodeling0low10
Asthmatic Airway Wall Remodelling0low10
Astrocytoma0low20
Astrocytoma, Grade I0low20
Astrocytoma, Grade II0low20
Astrocytoma, Grade III0low20
Astrocytoma, Grade IV0low50
Astrocytoma, Protoplasmic0low20
Astrocytoma, Subependymal Giant Cell0low20
Astroglioma0low20
Asymmetric Diabetic Proximal Motor Neuropathy0low20
Atherogenesis0low10
Atherosclerosis0low10
Atherosclerosis, Coronary0low10
Atonic Absence Seizure0low30
Atonic Absence Seizures0low30
Atonic Seizure0low30
Atonic Seizures0low30
Atopic Hypersensitivity0low20
Atrial Fibrillation0low20
Atrioventricular Nodal Re-Entrant Tachycardia0low10
Atrioventricular Reentrant Tachycardia0low10
Atrophy, Muscle0low30
Aura0low20
Auricular Fibrillation0low20
Autism-Dementia-Ataxia-Loss of Purposeful Hand Use Syndrome0low10
Autism, Dementia, Ataxia, and Loss of Purposeful Hand Use0low10
Autoimmune Diabetes0low20
Autoimmune Disease0low80
Autoimmune Diseases0low80
Autoimmune Encephalomyelitis, Experimental0low160
Autoimmune Experimental Encephalomyelitis0low160
Autoimmune Neuritis, Experimental0low20
Awakening Epilepsy0low20
B-Cell Chronic Lymphocytic Leukemia0medium111
B-Cell Leukemia, Chronic0medium111
B-Cell Malignancy, Low-Grade0medium111
B-Lymphocytic Leukemia, Chronic0medium111
Bacteremia0low10
Bacterial Arthritides0low20
Bacterial Arthritis0low20
Bacterial Disease0low10
Bacterial Infection0low10
Bacterial Infections0low10
Bacterial Meningitides0low10
Bacterial Meningitis0low10
Behavior Disorders0low10
Benign Cerebellar Neoplasms0low10
Benign Neoplasms0low50
Benign Neoplasms, Brain0low60
Benign Prostatic Hyperplasia0low10
Bile Duct Diseases0low10
Binge Alcohol Consumption0low10
Binge Drinking0low10
Binge Eating0low10
Binswanger Disease0low20
Binswanger Encephalopathy0low20
Binswanger's Disease0low20
Bladder, Overactive0low20
Bleeding0low10
Blood Clot0low10
Blood Poisoning0low70
Blood Pressure, High0low30
Bloodstream Infection0low70
Blunt Injuries0low10
Body Weight0low110
Bone Cancer0low20
Bone Diseases, Metabolic0low10
Bone Loss, Age-Related0low10
Bone Loss, Osteoclastic0low40
Bone Neoplasms0low20
Bone Resorption0low40
Bouillaud Disease0low10
Bouillaud's Disease0low10
Bowel Diseases, Inflammatory0low10
Bradyarrhythmia0low20
Bradyarrhythmias0low20
Bradycardia0low20
Brain Anoxia-Ischemia0low20
Brain Cancer0low60
Brain Diseases0low30
Brain Disorders0low30
Brain Edema0low30
Brain Hemorrhage, Cerebral0low20
Brain Hypoxia-Ischemia0low20
Brain Infarct0low10
Brain Infarction0low10
Brain Infarction, Anterior Circulation0low10
Brain Infarction, Posterior Circulation0low10
Brain Infarction, Venous0low10
Brain Inflammation0low50
Brain Injuries0low80
Brain Injuries, Acute0low80
Brain Injuries, Focal0low80
Brain Injuries, Traumatic0low30
Brain Ischemia0low100
Brain Ischemia-Anoxia0low20
Brain Ischemia-Hypoxia0low20
Brain Lacerations0low80
Brain Metastases0low60
Brain Neoplasm, Primary0low60
Brain Neoplasms0low60
Brain Neoplasms, Benign0low60
Brain Neoplasms, Malignant0low60
Brain Neoplasms, Malignant, Primary0low60
Brain Neoplasms, Primary Malignant0low60
Brain Stem Ischemia, Transient0low90
Brain Stem Transient Ischemic Attack0low90
Brain Swelling0low30
Brain TIA0low90
Brain Tumor, Primary0low60
Brain Tumor, Recurrent0low60
Brain Tumors0low60
Brainstem Ischemia, Transient0low90
Brainstem Transient Ischemic Attack0low90
Break-Bone Fever0low10
Breakbone Fever0low10
Breast Cancer0low40
Breast Carcinoma0low40
Breast Neoplasms0low40
Breast Tumors0low40
Bright Disease0low10
Broad Thumb-Hallux Syndrome0low10
Broad Thumbs and Great Toes, Characteristic Facies, and Mental Retardation0low10
Bronchial Asthma0low460
Bronchial Hyperreactivity0medium201
Bronchial Spasm0medium71
Bronchiolitis Obliterans0low10
Bronchiolitis, Exudative0low10
Bronchiolitis, Proliferative0low10
Bronchospasm0medium71
Bronze Schilder Disease0low20
Brucella Infection0low10
Brucellosis0low10
Brucellosis, Pulmonary0low10
Bruise0low20
Bulbospinal Neuronopathy0low10
Bulimia0low10
Cachexia0low10
Cacosmia0low10
Cadaver0low10
Cancer0low50
Cancer of Bone0low20
Cancer of Brain0low60
Cancer of Breast0low40
Cancer of Colon0low20
Cancer of Liver0low10
Cancer of Lung0low50
Cancer of Pituitary0low20
Cancer of Prostate0low20
Cancer of Skin0low20
Cancer of the Bone0low20
Cancer of the Brain0low60
Cancer of the Breast0low40
Cancer of the Colon0low20
Cancer of the Liver0low10
Cancer of the Lung0low50
Cancer of the Pituitary0low20
Cancer of the Prostate0low20
Cancer of the Skin0low20
Cancer Pain0low10
Cancer-Associated Pain0low10
Cancer-Related Pain0low10
Cancer, Hepatocellular0low10
Capillary Leak Syndrome0low10
Carcinogenesis0low10
Carcinoma0low10
Carcinoma, Anaplastic0low10
Carcinoma, Cribriform0low10
Carcinoma, Epidermoid0low10
Carcinoma, Granular Cell0low10
Carcinoma, Hepatocellular0low10
Carcinoma, Planocellular0low10
Carcinoma, Spindle-Cell0low10
Carcinoma, Squamous0low10
Carcinoma, Squamous Cell0low10
Carcinoma, Tubular0low10
Carcinoma, Undifferentiated0low10
Carcinomatosis0low10
Cardiac Arrhythmia0low30
Cardiac Arrhythmias0low30
Cardiac Dysrhythmia0low30
Cardiac Failure0low50
Cardiac Hypertrophy0low10
Cardiomegaly0low10
Cardiomyopathies0low20
Cardiomyopathies, Primary0low20
Cardiomyopathies, Secondary0low20
Cardiomyopathy, Hypertrophic0low10
Cardiomyopathy, Hypertrophic Obstructive0low10
Cardiovascular Stroke0low40
Carditis0low10
Carotid Artery Narrowing0low10
Carotid Artery Plaque0low10
Carotid Artery Stenosis0low10
Carotid Artery Thrombosis0low10
Carotid Artery Ulcerating Plaque0low10
Carotid Circulation Transient Ischemic Attack0low90
Carotid Stenosis0low10
Carotid Thrombosis0low10
Carotid Ulcer0low10
Catalepsy0low20
Cell Transformation, Neoplastic0low20
Central Nervous System Disorders, Intracranial0low30
Central Nervous System Intracranial Disorders0low30
Centriacinar Emphysema0low10
Centrilobular Emphysema0low10
Cerea Flexibilitas0low20
Cerebellar Cancer0low10
Cerebellar Neoplasms0low10
Cerebellar Neoplasms, Benign0low10
Cerebellar Neoplasms, Malignant0low10
Cerebellar Neoplasms, Primary0low10
Cerebellar Tumors0low10
Cerebral Anoxia-Ischemia0low20
Cerebral Arteriosclerosis0medium11
Cerebral Astrocytoma0low20
Cerebral Atherosclerosis0medium11
Cerebral Edema0low30
Cerebral Edema, Cytotoxic0low30
Cerebral Edema, Vasogenic0low30
Cerebral Hemorrhage0low20
Cerebral Hypoxia-Ischemia0low20
Cerebral Infarction, Middle Cerebral Artery0low10
Cerebral Ischemia0low100
Cerebral Ischemia-Anoxia0low20
Cerebral Ischemia-Hypoxia0low20
Cerebral Ischemia, Transient0low90
Cerebral Parenchymal Hemorrhage0low20
Cerebral Stroke0low30
Cerebroatrophic Hyperammonemia0low10
Cerebrovascular Accident0low30
Cerebrovascular Accident, Acute0low30
Cerebrovascular Apoplexy0low30
Cerebrovascular Stroke0low30
Charcot Gait0low10
Charcot's Gait0low10
Chemical and Drug Induced Liver Injury0low20
Chemical Dependence0low10
Chemically-Induced Liver Toxicity0low20
Childhood Cerebral Astrocytoma0low20
Choking0low10
Chondrodystrophic Myotonia0low10
Chorea, Chronic Progressive Hereditary (Huntington)0low60
Chorioamnionitis0low10
Choriocarcinoma0low10
Chromosomal Triplication0low10
Chromosome Deletion0low10
Chronic Airflow Obstruction0medium181
Chronic Disease0low40
Chronic Fatigue and Immune Dysfunction Syndrome0low10
Chronic Fatigue Disorder0low10
Chronic Fatigue Syndrome0low10
Chronic Fatigue-Fibromyalgia Syndrome0low10
Chronic Illness0low40
Chronic Lung Injury0low20
Chronic Lymphocytic Leukemia0medium111
Chronic Obstructive Airway Disease0medium181
Chronic Obstructive Lung Disease0medium181
Chronic Obstructive Pulmonary Disease0medium181
Chronic Obstructive Pulmonary Diseases0medium181
Chronic Post-Traumatic Stress Disorder0low10
Chronic Progressive Hereditary Chorea (Huntington)0low60
Chronic Progressive Subcortical Encephalopathy0low20
Chronically Ill0low40
Cirrhoses, Experimental Liver0low20
Cirrhosis0low70
Cirrhosis, Experimental Liver0low20
Cirrhosis, Liver0low10
Clarkson Disease0low10
Classical Dengue0low10
Classical Dengue Fever0low10
Clerambault Syndrome0medium11
Clinical Capillary Leak Syndrome0low10
Clinically Isolated CNS Demyelinating Syndrome0low40
Clinically Isolated Syndrome, CNS Demyelinating0low40
Clonic Seizure0low30
Clonic Seizures0low30
CNS Disorders, Intracranial0low30
Co-infection0low10
COAD0medium181
Coarse Tremor0low20
Cocaine Abuse0low10
Cocaine Addiction0low10
Cocaine Dependence0low10
Cocaine-Related Disorders0low10
Cochlear Hearing Loss0low10
Cognition Disorders0low110
Cognitive Decline0low20
Cognitive Dysfunction0low20
Cognitive Impairments0low20
Coinfection0low10
Colicky Pain0low10
Colitis0low30
Colitis, Granulomatous0low10
Colitis, Mucous0low20
Collagen Arthritis0low70
Colon Cancer0low20
Colon Neoplasms0low20
Colon, Irritable0low20
Colonic Cancer0low20
Colonic Neoplasms0low20
Colorectal Cancer0low10
Colorectal Carcinoma0low10
Colorectal Neoplasms0low10
Colorectal Tumors0low10
Common Carotid Artery Stenosis0low10
Common Carotid Artery Thrombosis0low10
Common Peroneal Nerve Entrapment0low10
Complex Partial Seizure0low30
Complex Partial Seizures0low30
Congenital Nephrogenic Diabetes Insipidus0low10
Congenital Zika Syndrome0low20
Congenital Zika Virus Infection0low20
Congestive Heart Failure0low50
Conjunctivitis0low10
Constrictive Bronchiolitis0low10
Contact Dermatitis0low20
Continuous Tremor0low20
Contusions0low20
Conus Medullaris Syndrome0low10
Convulsion0low30
Convulsion, Non-Epileptic0low30
Convulsions0low30
Convulsive Seizure0low30
Convulsive Seizures0low30
COPD0medium181
Coronary Arteriosclerosis0low10
Coronary Artery Disease0low10
Coronary Atherosclerosis0low10
Coronary Disease0low10
Coronary Heart Disease0low10
Coronavirus Disease 20190low10
Coronavirus Disease-190low10
Corpse0low10
Cortical Lewy Body Disease0low10
Cough0low10
COVID-190low10
COVID-19 Pandemic0low10
COVID-19 Pandemics0low10
COVID-19 Virus Disease0low10
COVID-19 Virus Infection0low10
COVID190low10
Cramp0low10
Crescendo Transient Ischemic Attacks0low90
Crohn Disease0low10
Crohn's Disease0low10
Crohn's Enteritis0low10
Cryptogenic Fibrosing Alveolitis0low20
CVA (Cerebrovascular Accident)0low30
Cyprus Fever0low10
Cystic Fibrosis0low20
Cystic Fibrosis of Pancreas0low20
Cystitis0low20
Cytotoxic Brain Edema0low30
Cytotoxic Cerebral Edema0low30
Darkness Tremor0low20
DDD MPGNII0low10
Deafness Neurosensory0low10
Deficiency, Mental0low10
Deficiency, Oxygen0low50
Delayed Effects, Prenatal Exposure0low10
Delayed Hypersensitivity0low10
Delayed Onset Post-Traumatic Stress Disorder0low10
Delirium, Dementia, Amnestic, Cognitive Disorders0medium11
Dementia0low20
Dementia Praecox0low50
Dementia, Alzheimer Type0low130
Dementia, Lewy Body0low10
Dementia, Presenile0low130
Dementia, Primary Senile Degenerative0low130
Dementia, Senile0low130
Dementia, Vascular0low20
Demyelinating Diseases0low40
Demyelinating Disorders0low40
Demyelination0low40
Dengue0low10
Dengue Fever0low10
Dense Deposit Disease0low10
Depression0low90
Depression, Endogenous0medium127
Depression, Involutional0medium71
Depression, Neurotic0medium127
Depression, Unipolar0medium127
Depressive Disorder0medium127
Depressive Syndrome0medium127
Dermatitis0low40
Dermatitis Venenata0low20
Dermatitis, Atopic0low20
Dermatitis, Contact0low20
Dermatoses0low10
Dermatosis0low10
Developmental Academic Disability0low20
Developmental Academic Disorder0low20
Developmental Disabilities of Scholastic Skills0low20
Developmental Disorders of Scholastic Skills0low20
Diabetes Insipidus0low40
Diabetes Insipidus Renalis0low10
Diabetes Insipidus, Nephrogenic0low10
Diabetes Insipidus, Nephrogenic, Autosomal0low10
Diabetes Insipidus, Nephrogenic, Type 10low10
Diabetes Insipidus, Nephrogenic, Type I0low10
Diabetes Insipidus, Nephrogenic, Type II0low10
Diabetes Insipidus, Nephrogenic, X-Linked0low10
Diabetes Mellitus0low10
Diabetes Mellitus, Adult-Onset0low10
Diabetes Mellitus, Brittle0low20
Diabetes Mellitus, Experimental0low60
Diabetes Mellitus, Insulin-Dependent0low20
Diabetes Mellitus, Insulin-Dependent, 10low20
Diabetes Mellitus, Juvenile-Onset0low20
Diabetes Mellitus, Ketosis-Prone0low20
Diabetes Mellitus, Ketosis-Resistant0low10
Diabetes Mellitus, Maturity-Onset0low10
Diabetes Mellitus, Non Insulin Dependent0low10
Diabetes Mellitus, Non-Insulin-Dependent0low10
Diabetes Mellitus, Noninsulin Dependent0low10
Diabetes Mellitus, Noninsulin-Dependent0low10
Diabetes Mellitus, Slow-Onset0low10
Diabetes Mellitus, Stable0low10
Diabetes Mellitus, Sudden-Onset0low20
Diabetes Mellitus, Type 10low20
Diabetes Mellitus, Type 20low10
Diabetes Mellitus, Type I0low20
Diabetes Mellitus, Type II0low10
Diabetes, Autoimmune0low20
Diabetic Amyotrophy0low20
Diabetic Asymmetric Polyneuropathy0low20
Diabetic Autonomic Neuropathy0low20
Diabetic Mononeuropathy0low20
Diabetic Mononeuropathy Simplex0low20
Diabetic Neuralgia0low20
Diabetic Neuropathies0low20
Diabetic Neuropathy, Painful0low20
Diabetic Polyneuropathy0low20
Diagnosis, Psychiatric0low10
Diathesis0low10
Diffuse Large B-Cell Lymphoma0low10
Diffuse Large-Cell Lymphoma0low10
Diffuse Lewy Body Disease0low10
Diffuse Well-Differentiated Lymphocytic Lymphoma0medium111
Diffuse, Large B-Cell, Lymphoma0low10
Disability, Intellectual0low10
Disease Exacerbation0low40
Disease Models, Animal0low1400
Disease Progression0low40
Disease Susceptibility0low10
Disease, Pulmonary0low60
Diseases, Metabolic0low10
Diseases, Pulmonary0low60
Disrupted In B-Cell Malignancy0medium111
Distal Spinal Muscular Atrophy0low10
Down Syndrome0low10
Down Syndrome, Partial Trisomy 210low10
Down's Syndrome0low10
Dropsy0low130
Drug Abuse0low10
Drug Addiction0low10
Drug Dependence0low10
Drug Habituation0low10
Drug Use Disorders0low10
Drug Withdrawal Symptoms0low70
Drug-Induced Acute Liver Injury0low20
Drug-Induced Liver Disease0low20
Drug-Induced Liver Injury0low20
Drunkenness0low10
Duck Gait0low10
Dyschondroplasia0low10
Dyschondroplasias0low10
Dyskinesia Syndromes0low20
Dyskinesia, Drug-Induced0low40
Dyskinesia, Medication-Induced0low40
Dysosmia0low10
Dysostoses0low10
Dysostosis0low10
E coli Infections0low20
E. coli Infection0low20
EAN (Experimental Allergic Neuritis)0low20
EAN (Experimental Autoimmune Neuritis)0low20
Ear Diseases0low10
Early Onset Alzheimer Disease0low130
Eczema, Atopic0low20
Eczema, Contact0low20
Eczema, Infantile0low20
Edema0low130
Edema, Pulmonary0low50
Edemas, Pulmonary0low50
Elevated Cholesterol0low10
Embolic Infarction, Middle Cerebral Artery0low10
Embolism0low10
Embolus0low10
Embolus, Middle Cerebral Artery0low10
Emesis0low250
Emphysema, Pulmonary0low10
Emphysemas, Pulmonary0low10
Encephalitis0low50
Encephalitis, Polio0low10
Encephalitis, Rasmussen0low50
Encephalomyelitis, Allergic0low160
Encephalomyelitis, Autoimmune, Experimental0low160
Encephalomyelitis, Experimental Autoimmune0low160
Encephalomyelitis, Myalgic0low10
Encephalon Diseases0low30
Encephalopathy0low30
Encephalopathy, Anoxic-Ischemic0low20
Encephalopathy, Binswanger0low20
Encephalopathy, Binswanger's0low20
Encephalopathy, Chronic Progressive Subcortical0low20
Encephalopathy, Hypoxic-Ischemic0low20
Encephalopathy, Ischemic0low100
Encephalopathy, Subcortical Arteriosclerotic0low20
Encephalopathy, Subcortical, Chronic Progressive0low20
Encephalopathy, Traumatic0low30
Endolymphatic Hydrops0low10
Endometrial Diseases0low10
Endomyocardial Fibrosis0low10
Endosteal Hyperostosis, Autosomal Recessive0low10
Endotoxemia0low50
Endotoxin Shock0low50
Enlarged Heart0low10
Enteritis, Granulomatous0low10
Enteritis, Regional0low10
Eosinophilia0low70
Eosinophilia, Pulmonary0low50
Eosinophilia, Tropical0low70
Eosinophilias, Pulmonary0low50
Eosinophilic Pneumonia0low50
Epidemic Acute Poliomyelitis0low10
Epilepsy0low20
Epilepsy, Cryptogenic0low20
Epileptic Seizure0low30
Epileptic Seizures0low30
Epithelial Neoplasms, Malignant0low10
Epithelial Tumors, Malignant0low10
Epithelioma0low10
Equine Diseases0low40
ER-Negative PR-Negative HER2-Negative Breast Cancer0low10
ER-Negative PR-Negative HER2-Negative Breast Neoplasms0low10
Erectile Dysfunction0low10
Escherichia coli Infections0low20
Etat Marbre0low20
Ethanol Abuse0low10
Experimental Allergic Encephalomyelitis0low160
Experimental Allergic Neuritis0low20
Experimental Autoimmune Encephalomyelitis0low160
Experimental Autoimmune Neuritis0low20
Experimental Autoimmune Neuropathy0low20
Experimental Diabetes Mellitus0low60
Experimental Liver Cirrhoses0low20
Experimental Liver Cirrhosis0low20
Experimental Lung Inflammation0low120
Experimental Mammary Neoplasms0low10
External Carotid Artery Stenosis0low10
External Carotid Artery Thrombosis0low10
External Popliteal Neuropathy0low10
Extracranial Primitive Neuroectodermal Tumor0low10
Extramedullary Spinal Cord Compression0low10
Exudative Bronchiolitis0low10
FAE (Fetal Alcohol Effects)0low10
Familial Alzheimer Disease (FAD)0low130
Familial Atrial Fibrillation0low20
Familial Dementia0low20
Familial Idiopathic Pulmonary Fibrosis0low20
Familial Spastic Paraparesis, Htlv-1-Associated0low10
Fanconi Anemia0low10
Fanconi Hypoplastic Anemia0low10
Fanconi Pancytopenia0low10
Fanconi Panmyelopathy0low10
Fanconi's Anemia0low10
FASD0low10
Fatigue Syndrome, Chronic0low10
Fatigue Syndrome, Postviral0low10
Fatty Liver, Alcoholic0low10
Fetal Alcohol Spectrum Disorder0low10
Fetal Alcohol Spectrum Disorders0low10
Fetal Alcohol Syndrome0low10
Fetal Anoxia0low10
Fetal Hypoxia0low10
Fever0low10
Fever, Zika0low20
Fibrillary Astrocytoma0low20
Fibrocystic Disease of Pancreas0low20
Fibrocystic Pulmonary Dysplasia0low20
Fibrosarcoma0low20
Fibroses, Pulmonary0low20
Fibrosing Alveolitis, Cryptogenic0low20
Fibrosis0low70
Fibrosis, Liver0low10
Fibrosis, Pulmonary0low20
Fibrous Dysplasia with Pigmentary Skin Changes and Precocious Puberty0low10
Fibrous Dysplasia, Polyostotic0low10
Fibular Nerve Diseases0low10
Fibular Neuropathy0low10
Fine Tremor0low20
Flexibility, Waxy0low20
Focal Brain Injuries0low80
Focal Emphysema0low10
Focal Onset Alzheimer's Disease0low130
Foot Drop0low10
Fra(X) Syndrome0low10
Fragile X Mental Retardation Syndrome0low10
Fragile X Syndrome0low10
Fragile X-F Mental Retardation Syndrome0low10
FRAXA Syndrome0low10
FRAXE Syndrome0low10
Funisitis0low10
Gait Disorder, Sensorimotor0low10
Gait Disorders, Neurologic0low10
Gait Dysfunction, Neurologic0low10
Gait, Athetotic0low10
Gait, Broadened0low10
Gait, Drop Foot0low10
Gait, Festinating0low10
Gait, Frontal0low10
Gait, Hemiplegic0low10
Gait, Hysterical0low10
Gait, Reeling0low10
Gait, Rigid0low10
Gait, Scissors0low10
Gait, Shuffling0low10
Gait, Spastic0low10
Gait, Stumbling0low10
Gait, Unsteady0low10
Gait, Widebased0low10
Gastric Diseases0low10
Gastric Stasis0low10
Gastric Ulcer0low20
Gastritis0low10
Gastroparesis0low10
Gemistocytic Astrocytoma0low20
Generalized Absence Seizure0low30
Generalized Absence Seizures0low30
Generalized Tonic-Clonic Seizures0low30
Geophagia0low20
GH-Secreting Pituitary Adenoma0low10
Giant Cell Glioblastoma0low50
Gibraltar Fever0low10
Glaucoma0low10
Glial Cell Tumors0low70
Glioblastoma0low50
Glioblastoma Multiforme0low50
Glioma0low70
Glioma, Astrocytic0low20
Glomerulonephritis0low10
Glomerulonephritis, Hypocomplementemic0low10
Glomerulonephritis, Membranoproliferative0low10
Glomerulonephritis, Mesangiocapillary0low10
Glucose Intolerance0low10
Graft vs Host Disease0low20
Graft-Versus-Host Disease0low20
Graft-vs-Host Disease0low20
Granulocytic Leukemia0low10
Grippe0low10
Group A Strep Infection0low10
Group A Streptococcal Infection0low10
Group A Streptococcal Infections0low10
Group B Strep Infection0low10
Group B Streptococcal Infection0low10
Group B Streptococcal Infections0low10
Growth Hormone-Secreting Pituitary Adenoma0low10
Growth Retardation, Facial Abnormalities, and Central Nervous System Dysfunction0low10
Haemophilus Infections0low10
Haemophilus influenzae Infection0low10
Haemophilus influenzae Type b Infection0low10
HbS Disease0low10
Hearing Loss, Cochlear0low10
Hearing Loss, Sensorineural0low10
Heart Attack0low40
Heart Decompensation0low50
Heart Disease, Ischemic0low10
Heart Enlargement0low10
Heart Failure0low50
Heart Failure, Congestive0low50
Heart Failure, Left-Sided0low50
Heart Failure, Right-Sided0low50
Heart Hypertrophy0low10
Heart Valve Diseases0low10
Heart Valvular Disease0low10
Hemoglobin S Disease0low10
Hemophilus Infections0low10
Hemorrhage0low10
Hemorrhage, Cerebral0low20
Hemorrhage, Cerebrum0low20
Hemorrhage, Subarachnoid0low30
Hepatic Cancer0low10
Hepatic Cirrhosis0low10
Hepatic Cirrhosis, Experimental0low20
Hepatic Neoplasms0low10
Hepatitis0low10
Hepatitis, Animal0low10
Hepatitis, Drug-Induced0low20
Hepatitis, Toxic0low20
Hepatocellular Cancer0low10
Hepatocellular Carcinoma0low10
Hepatoma0low10
Hereditary Motor Neuronopathy0low10
Heroin Abuse0low20
Heroin Addiction0low20
Heroin Dependence0low20
Heroin Smoking0low20
Hib Infection0low10
High Cholesterol Levels0low10
Histiocytic Lymphoma0low10
Histiocytic Lymphoma, Diffuse0low10
HIV0low10
HIV Coinfection0low20
HIV Infections0low20
HIV-Related Opportunistic Infections0low10
Homologous Wasting Disease0low20
Horse Diseases0low40
HTLV I Associated Myelopathies0low10
HTLV-I Infections0low20
HTLV-I-Associated Myelopathy0low10
HTLV-I-Associated Myelopathy-Tropical Spastic Paraparesis0low10
HTLV-III Infections0low20
HTLV-III-LAV Infections0low20
Human Flu0low10
Human Influenza0low10
Human Mammary Carcinoma0low40
Human T-lymphotropic Virus 1 Infection0low20
Human T-lymphotropic Virus 1 Infections0low20
Human T-Lymphotropic Virus Type 1 Associated Myelopathy0low10
Huntington Chorea0low60
Huntington Chronic Progressive Hereditary Chorea0low60
Huntington Disease, Akinetic-Rigid Variant0low60
Huntington Disease, Juvenile0low60
Huntington Disease, Juvenile-Onset0low60
Huntington Disease, Late Onset0low60
Huntington's Chorea0low60
Huntington's Disease0low60
Hydrops0low130
Hymenolepiasis0low10
Hymenolepis Infection0low10
Hyperactivity, Motor0low10
Hyperalgesia0low100
Hyperalgesia, Mechanical0low100
Hyperalgesia, Primary0low100
Hyperalgesia, Secondary0low100
Hyperalgesia, Tactile0low100
Hyperalgesia, Thermal0low100
Hyperalgesic Sensations0low100
Hyperalgia0low100
Hyperalgia, Mechanical0low100
Hyperalgia, Primary0low100
Hyperalgia, Secondary0low100
Hypercalcemia0low10
Hypercapnia0low10
Hypercapnic Acute Respiratory Failure0low10
Hypercapnic Respiratory Failure0low10
Hypercholesteremia0low10
Hypercholesterolemia0low10
Hyperkinesia0low10
Hyperkinesia, Generalized0low10
Hyperkinesis0low10
Hyperkinetic Movements0low10
Hyperlipemia0low10
Hyperlipidemia0low10
Hyperlipidemias0low10
Hyperostosis Corticalis Generalisata0low10
Hyperoxia0low10
Hyperphosphatasemia Tarda0low10
Hyperplasia0low10
Hypersensitivity0low70
Hypersensitivity, Atopic0low20
Hypersensitivity, Contact0low20
Hypersensitivity, Delayed0low10
Hypersensitivity, Immediate0low20
Hypersensitivity, Respiratory0low50
Hypersensitivity, Tuberculin-Type0low10
Hypersensitivity, Type I0low20
Hypersensitivity, Type IV0low10
Hypertension0low30
Hypertension, Pulmonary0low50
Hyperventilation0medium11
Hypoxemia0low50
Hypoxemic Acute Respiratory Failure0low10
Hypoxemic Respiratory Failure0low10
Hypoxia0low50
Hypoxia-Ischemia, Brain0low20
Hypoxia-Ischemia, Cerebral0low20
Hypoxic-Ischemic Encephalopathy0low20
IDDM0low20
Idiocy0low10
Idiopathic Diffuse Interstitial Pulmonary Fibrosis0low20
Idiopathic Fibrosing Alveolitis, Chronic Form0low20
Idiopathic Parkinson Disease0medium51
Idiopathic Parkinson's Disease0medium51
Idiopathic Pulmonary Fibrosis0low20
Idiopathic Pulmonary Fibrosis, Familial0low20
Idiopathic Ventricular Tachycardia0low10
IgE-Mediated Hypersensitivity0low20
Ileitis, Regional0low10
Ileitis, Terminal0low10
Ileocolitis0low10
Impaired Glucose Tolerance0low10
Impotence0low10
Inadequate Sleep0low20
Infantile Paralysis0low10
Infarction, Anterior Cerebral Circulation0low10
Infarction, Anterior Circulation, Brain0low10
Infarction, Brain, Anterior Circulation0low10
Infarction, Brain, Posterior Circulation0low10
Infarction, Middle Cerebral Artery0low10
Infarction, Posterior Circulation, Brain0low10
Infection, Bacterial0low10
Infections, Bacterial0low10
Infections, E coli0low20
Infections, Escherichia coli0low20
Infections, Haemophilus0low10
Infections, Hemophilus0low10
Infections, HTLV-I0low20
Infections, Klebsiella0low10
Infections, Orthomyxoviridae0low10
Infections, Orthomyxovirus0low10
Infections, Picornaviridae0low10
Infections, Picornavirus0low10
Infections, Respiratory Syncytial Virus0low10
Infections, Respirovirus0low10
Infections, Staphylococcal0low10
Infections, Streptococcal0low10
Infectious Arthritis0low20
Infectious Mononucleosis-Like Syndrome, Chronic0low10
Inflammation0medium541
Inflammation, Brain0low50
Inflammatory Bowel Disease 10low10
Inflammatory Bowel Diseases0low10
Inflammatory Response Syndrome, Systemic0low10
Influenza0low10
Influenza in Humans0low10
Influenza, Human0low10
Injuries, Acute Brain0low80
Injuries, Blunt0low10
Injuries, Brain0low80
Injuries, Nonpenetrating0low10
Injuries, Spinal Cord0low260
Injury, Brain, Traumatic0low30
Injury, Ischemia-Reperfusion0low90
Injury, Myocardial Reperfusion0low30
Injury, Reperfusion0low90
Innate Inflammatory Response0medium541
Insufficient Sleep0low20
Insufficient Sleep Syndrome0low20
Insulin-Dependent Diabetes Mellitus 10low20
Intellectual Development Disorder0low10
Intellectual Disability0low10
Intention Tremor0low20
Intermittent Tremor0low20
Internal Carotid Artery Stenosis0low10
Internal Carotid Artery Thrombosis0low10
Interstitial Pneumonitis, Usual0low20
Intoxication, Alcoholic0low10
Intracerebral Hemorrhage0low20
Intracranial Arteriosclerosis0medium11
Intracranial Astrocytoma0low20
Intracranial Atherosclerosis0medium11
Intracranial Central Nervous System Disorders0low30
Intracranial CNS Disorders0low30
Intracranial Edema0low30
Intracranial Neoplasms0low60
Intraocular Pressure0low10
Invasiveness, Neoplasm0low10
Involuntary Quiver0low20
Irritable Bowel Syndrome0low20
Ischemia-Anoxia, Brain0low20
Ischemia-Anoxia, Cerebral0low20
Ischemia-Hypoxia, Brain0low20
Ischemia-Hypoxia, Cerebral0low20
Ischemia-Reperfusion Injury0low90
Ischemia, Cerebral0low100
Ischemia, Myocardial0low10
Ischemic Attack, Transient0low90
Ischemic Encephalopathy0low100
Ischemic Heart Disease0low10
Ischemic-Hypoxic Encephalopathy0low20
Isolated Familial Somatotropinoma0low10
Itching0low10
Jacksonian Seizure0low30
Juvenile Huntington Disease0low60
Juvenile Pilocytic Astrocytoma0low20
Juvenile-Onset Diabetes0low20
Juvenile-Onset Huntington Disease0low60
Kahler Disease0low10
Kandinsky Syndrome0medium11
Kidney Diseases0low40
Kidney Failure, Acute0low20
Kidney Insufficiency, Acute0low20
Kidney Scarring0low10
Klebsiella Infections0low10
Koch's Disease0low10
Kochs Disease0low10
Labor, Premature0low20
Lactotroph Adenoma0low10
Large Lymphoid Lymphoma, Diffuse0low10
Large-Cell Lymphoma, Diffuse0low10
Late Effects, Prenatal Exposure0low10
Late Onset Alzheimer Disease0low130
Late-Onset Huntington Disease0low60
Late-Onset Spondyloepiphyseal Dysplasia0low10
Lateral Popliteal Neuropathy0low10
Learning Disabilities0low20
Learning Disorders0low20
Learning Disorders, Adult0low20
Learning Disturbance0low20
Left Main Coronary Artery Disease0low10
Left Main Coronary Disease0low10
Left Main Disease0low10
Left Middle Cerebral Artery Infarction0low10
Left-Sided Heart Failure0low50
Leukemia, Acute Lymphoblastic0low10
Leukemia, Acute Monocytic0low10
Leukemia, Acute Myelogenous0low20
Leukemia, Acute Myeloid0low20
Leukemia, Acute Promyelocytic0low10
Leukemia, B Cell, Chronic0medium111
Leukemia, B-Cell, Chronic0medium111
Leukemia, Chronic Lymphatic0medium111
Leukemia, Chronic Lymphocytic0medium111
Leukemia, Chronic Lymphocytic, B-Cell0medium111
Leukemia, Granulocytic0low10
Leukemia, Lymphoblastic0low10
Leukemia, Lymphoblastic, Acute0low10
Leukemia, Lymphoblastic, Acute, L10low10
Leukemia, Lymphoblastic, Acute, L20low10
Leukemia, Lymphoblastic, Acute, Philadelphia-Positive0low10
Leukemia, Lymphoblastic, Chronic0medium111
Leukemia, Lymphocytic, Acute0low10
Leukemia, Lymphocytic, Acute, L10low10
Leukemia, Lymphocytic, Acute, L20low10
Leukemia, Lymphocytic, Chronic0medium111
Leukemia, Lymphocytic, Chronic, B Cell0medium111
Leukemia, Lymphocytic, Chronic, B-Cell0medium111
Leukemia, Lymphoid, Acute0low10
Leukemia, Megakaryoblastic, Acute0low10
Leukemia, Megakaryocytic0low10
Leukemia, Megakaryocytic, Acute0low10
Leukemia, Monoblastic, Acute0low10
Leukemia, Monocytic, Acute0low10
Leukemia, Monocytic, Chronic0low10
Leukemia, Myeloblastic, Acute0low20
Leukemia, Myelocytic0low10
Leukemia, Myelocytic, Acute0low20
Leukemia, Myelogenous0low10
Leukemia, Myelogenous, Acute0low20
Leukemia, Myeloid0low10
Leukemia, Myeloid, Acute0low20
Leukemia, Myeloid, Acute, M10low20
Leukemia, Myeloid, Acute, M20low20
Leukemia, Myeloid, Acute, M30low10
Leukemia, Myeloid, Acute, M50low10
Leukemia, Myeloid, Acute, M70low10
Leukemia, Myeloid, Schilling Type0low10
Leukemia, Myeloid, Schilling-Type0low10
Leukemia, Nonlymphoblastic, Acute0low20
Leukemia, Nonlymphocytic, Acute0low20
Leukemia, Progranulocytic0low10
Leukemia, Promyelocytic, Acute0low10
Leukocytopenia0low10
Leukocytosis0low10
Leukoencephalopathy, Subcortical0low20
Leukopenia0low10
Lewy Body Dementia0low10
Lewy Body Disease0low10
Lewy Body Disease, Cortical0low10
Lewy Body Disease, Diffuse0low10
Lewy Body Parkinson Disease0medium51
Lewy Body Parkinson's Disease0medium51
Lewy Body Type Senile Dementia0low10
Limb Cramp0low10
Lipemia0low10
Lipidemia0low10
Liver Cancer0low10
Liver Cancer, Adult0low10
Liver Cell Carcinoma0low10
Liver Cell Carcinoma, Adult0low10
Liver Cirrhoses, Experimental0low20
Liver Cirrhosis0low10
Liver Cirrhosis, Experimental0low20
Liver Diseases0low10
Liver Dysfunction0low10
Liver Fibrosis0low10
Liver Injury, Drug-Induced0low20
Liver Injury, Drug-Induced, Acute0low20
Liver Neoplasms0low10
Lobar Pneumonia0low120
Locomotion Disorders, Neurologic0low10
Loeffler Syndrome0low50
Low Bone Density0low10
Low Bone Mineral Density0low10
Lung Cancer0low50
Lung Diseases0low60
Lung Diseases, Obstructive0low40
Lung Inflammation0low120
Lung Injuries0low20
Lung Injury0low20
Lung Injury, Acute0low70
Lung Neoplasms0low50
Lymphoblastic Leukemia0low10
Lymphoblastic Leukemia, Acute0low10
Lymphoblastic Leukemia, Acute, Adult0low10
Lymphoblastic Leukemia, Acute, Childhood0low10
Lymphoblastic Leukemia, Acute, L10low10
Lymphoblastic Leukemia, Acute, L20low10
Lymphoblastic Leukemia, Chronic0medium111
Lymphoblastic Lymphoma0low10
Lymphocytic Leukemia, Acute0low10
Lymphocytic Leukemia, Chronic0medium111
Lymphocytic Leukemia, Chronic, B Cell0medium111
Lymphocytic Leukemia, Chronic, B-Cell0medium111
Lymphocytic Leukemia, L10low10
Lymphocytic Leukemia, L20low10
Lymphocytic Lymphoma0medium111
Lymphocytic Lymphoma, Diffuse, Well Differentiated0medium111
Lymphocytic Lymphoma, Diffuse, Well-Differentiated0medium111
Lymphocytic Lymphoma, Well Differentiated0medium111
Lymphocytic Lymphoma, Well-Differentiated0medium111
Lymphoma, Diffuse Large-Cell0low10
Lymphoma, Histiocytic0low10
Lymphoma, Histiocytic, Diffuse0low10
Lymphoma, Large B-Cell, Diffuse0low10
Lymphoma, Large Cell, Diffuse0low10
Lymphoma, Large Lymphoid, Diffuse0low10
Lymphoma, Large-Cell, Diffuse0low10
Lymphoma, Lymphoblastic0low10
Lymphoma, Lymphocytic0medium111
Lymphoma, Lymphocytic, Diffuse, Well Differentiated0medium111
Lymphoma, Lymphocytic, Diffuse, Well-Differentiated0medium111
Lymphoma, Lymphocytic, Well Differentiated0medium111
Lymphoma, Lymphocytic, Well-Differentiated0medium111
Lymphoma, Lymphoplasmacytoid, CLL0medium111
Lymphoma, Small Lymphocytic0medium111
Lymphoma, Small Lymphocytic, Plasmacytoid0medium111
Lymphoma, Small-Cell0medium111
Lymphoplasmacytoid Lymphoma, CLL0medium111
M3 ANLL0low10
Macroprolactinoma0low10
Major Depressive Disorder0medium71
Malaria, Falciparum0low10
Male Impotence0low10
Male Sexual Impotence0low10
Malignancy0low50
Malignant Cerebellar Neoplasms0low10
Malignant Epithelial Neoplasms0low10
Malignant Glioma0low70
Malignant Melanoma0low30
Malignant Neoplasm of Breast0low40
Malignant Neoplasms0low50
Malignant Neoplasms, Brain0low60
Malignant Primary Brain Neoplasms0low60
Malignant Primary Brain Tumors0low60
Malignant Tumor of Breast0low40
Malta Fever0low10
Mammary Cancer0low40
Mammary Carcinoma, Human0low40
Mammary Neoplasm, Human0low40
Mammary Neoplasms, Experimental0low10
Mammary Neoplasms, Human0low40
Mar (X) Syndrome0low10
Marasmus0low10
Marche a Petit Pas0low10
Marker X Syndrome0low10
Martin-Bell Syndrome0low10
Massive Tremor0low20
Maturity-Onset Diabetes0low10
Maturity-Onset Diabetes Mellitus0low10
MCA Infarct0low10
MCA Infarction0low10
McCune-Albright Syndrome0low10
Mechanical Allodynia0low100
Mechanical Hyperalgesia0low100
Meconium Aspiration0low10
Meconium Aspiration Syndrome0low10
Meconium Inhalation0low10
Medication-Induced Dyskinesia0low40
Medulloblastoma0low30
Medulloblastoma, Adult0low30
Medulloblastoma, Childhood0low30
Medulloblastoma, Desmoplastic0low30
Medullomyoblastoma0low30
Megakaryoblastic Leukemia, Acute0low10
Megakaryocytic Leukemia0low10
Megakaryocytic Leukemia, Acute0low10
Melancholia0medium127
Melancholia, Involutional0medium71
Melanocytic Medulloblastoma0low30
Melanodermic Leukodystrophy0low20
Melanoma0low30
Melnick-Needles Osteodysplasty0low10
Melnick-Needles Syndrome0low10
Membranoproliferative Glomerulonephritis0low10
Membranoproliferative Glomerulonephritis Type II0low10
Membranoproliferative Glomerulonephritis, Type I0low10
Membranoproliferative Glomerulonephritis, Type II0low10
Membranoproliferative Glomerulonephritis, Type III0low10
Memory Deficits0low170
Memory Disorder, Semantic0low170
Memory Disorder, Spatial0low170
Memory Disorders0low170
Memory Disorders, Age-Related0low170
Memory Loss0low170
Meningitides, Bacterial0low10
Meningitis, Bacterial0low10
Mental Deficiency0low10
Mental Deterioration0low20
Mental Disorders0low10
Mental Disorders, Organic0medium11
Mental Disorders, Severe0low10
Mental Illness0low10
Mental Retardation0low10
Mental Retardation, Psychosocial0low10
Mental Retardation, X-Linked, Associated With Fragile Site Fraxe0low10
Mental Retardation, X-Linked, Associated With Marxq280low10
Mesangiocapillary Glomerulonephritis0low10
Mesangiocapillary Glomerulonephritis, Type I0low10
Mesangiocapillary Glomerulonephritis, Type II0low10
Metabolic Bone Diseases0low10
Metabolic Diseases0low10
Metaplasia0low10
Metastase0low10
Metastases, Neoplasm0low10
Metastasis0low10
Metastasis, Neoplasm0low10
Microprolactinoma0low10
Middle Cerebral Artery Circulation Infarction0low10
Middle Cerebral Artery Embolic Infarction0low10
Middle Cerebral Artery Embolus0low10
Middle Cerebral Artery Infarction0low10
Middle Cerebral Artery Occlusion0low10
Middle Cerebral Artery Stroke0low10
Middle Cerebral Artery Syndrome0low10
Middle Cerebral Artery Thrombosis0low10
Middle Cerebral Artery Thrombotic Infarction0low10
Mild Cognitive Impairment0low20
Mild Neurocognitive Disorder0low20
Milk-Alkali Syndrome0low10
Mixed Glioma0low70
Mixed Infection0low10
MODY0low10
Mongolism0low10
Monoblastic Leukemia, Acute0low10
Monocytic Leukemia, Acute0low10
Monocytic Leukemia, Chronic0low10
Mononeuropathy, Diabetic0low20
Monosomy, Partial0low10
Moral Injury0low10
Morphine Abuse0low30
Morphine Addiction0low30
Morphine Dependence0low30
Movement Disorder Syndromes0low20
Movement Disorders0low20
MPGN0low10
MPGNII0low10
MPTP Neurotoxicity Syndrome0low20
MPTP Poisoning0low20
MPTP-Induced Degeneration of the Striatum0low20
MPTP-Induced Parkinsonism0low20
MS (Multiple Sclerosis)0medium131
Mucoviscidosis0low20
Multiple Epiphyseal Dysplasia0low10
Multiple Myeloma0low10
Multiple Sclerosis, Acute Fulminating0medium131
Muscle Contraction0low470
Muscle Cramp0low10
Muscle Relaxation0low450
Muscle Spasm0low10
Muscular Atrophy0low30
Muscular Atrophy, Adult Spinal0low10
Muscular Atrophy, Spinal0low10
Muscular Cramp0low10
Muscular Spasm0low10
Myalgic Encephalomyelitis0low10
Mycobacterium tuberculosis Infection0low10
Myeloblastic Leukemia, Acute0low20
Myelocytic Leukemia0low10
Myelocytic Leukemia, Acute0low20
Myelogenous Leukemia0low10
Myelogenous Leukemia, Acute0low20
Myeloid Leukemia0low10
Myeloid Leukemia, Acute0low20
Myeloid Leukemia, Acute, M10low20
Myeloid Leukemia, Acute, M20low20
Myeloid Leukemia, Acute, M30low10
Myeloid Leukemia, Acute, M50low10
Myeloid Leukemia, Acute, M70low10
Myeloid Leukemia, Schilling-Type0low10
Myeloma-Multiple0low10
Myeloma, Multiple0low10
Myeloma, Plasma-Cell0low10
Myelomatosis0low10
Myelopathic Muscular Atrophy0low10
Myelopathic Muscular Atrophy, Progressive0low10
Myelopathies, HTLV I Associated0low10
Myelopathy, Compressive0low10
Myelopathy, Htlv-1-Associated0low10
Myelopathy, Human T-Lymphotropic Virus Type 1 Associated0low10
Myelopathy, Traumatic0low260
Myocardial Diseases0low20
Myocardial Diseases, Primary0low20
Myocardial Diseases, Secondary0low20
Myocardial Failure0low50
Myocardial Infarct0low40
Myocardial Infarction0low40
Myocardial Ischemia0low10
Myocardial Ischemic Reperfusion Injury0low30
Myocardial Reperfusion Injury0low30
Myocardiopathies0low20
Myocarditis0low10
Myoclonic Seizure0low30
Myoclonic Seizures0low30
Myotonic Chondrodystrophy0low10
Myotonic Myopathy, Dwarfism, Chondrodystrophy, And Ocular And Facial Abnormalities0low10
Nagana0low10
Nausea0low10
Necrosis0low20
Necrotizing Pyelonephritis0low10
Neoplasia0low50
Neoplasm0low50
Neoplasm Invasion0low10
Neoplasm Invasiveness0low10
Neoplasm Metastases0low10
Neoplasm Metastasis0low10
Neoplasm-Associated Pain0low10
Neoplasm-Related Pain0low10
Neoplasms0low50
Neoplasms, Benign0low50
Neoplasms, Bone0low20
Neoplasms, Brain0low60
Neoplasms, Brain, Benign0low60
Neoplasms, Brain, Malignant0low60
Neoplasms, Brain, Primary0low60
Neoplasms, Breast0low40
Neoplasms, Cerebellar0low10
Neoplasms, Cerebellar, Benign0low10
Neoplasms, Cerebellar, Malignant0low10
Neoplasms, Cerebellar, Primary0low10
Neoplasms, Colonic0low20
Neoplasms, Colorectal0low10
Neoplasms, Experimental Mammary0low10
Neoplasms, Hepatic0low10
Neoplasms, Intracranial0low60
Neoplasms, Liver0low10
Neoplasms, Lung0low50
Neoplasms, Malignant Epithelial0low10
Neoplasms, Prostate0low20
Neoplasms, Prostatic0low20
Neoplasms, Pulmonary0low50
Neoplasms, Skin0low20
Neoplastic Cell Transformation0low20
Neoplastic Transformation, Cell0low20
Neovascularization, Pathologic0low20
Neovascularization, Pathological0low20
Nephrogenic Diabetes Insipidus0low10
Nephrogenic Diabetes Insipidus, Type I0low10
Nephrogenic Diabetes Insipidus, Type II0low10
Nerve Degeneration0low40
Nerve Pain0low40
Nervous System Disorders0low10
Neuralgia0low40
Neuralgia, Atypical0low40
Neuralgia, Diabetic0low20
Neuralgia, Iliohypogastric Nerve0low40
Neuralgia, Ilioinguinal0low40
Neuralgia, Perineal0low40
Neuralgia, Stump0low40
Neuralgia, Supraorbital0low40
Neuralgia, Vidian0low40
Neuritic Plaques0low10
Neuritis, Autoimmune, Experimental0low20
Neuritis, Experimental Allergic0low20
Neuritis, Experimental Autoimmune0low20
Neuroblastoma0low60
Neurocognitive Disorders0medium11
Neurodermatitis, Atopic0low20
Neurodermatitis, Disseminated0low20
Neurodynia0low40
Neuroectodermal Neoplasm, Peripheral Primitive0low10
Neuroectodermal Tumor, Peripheral0low10
Neuroectodermal Tumor, Peripheral Primitive0low10
Neuroectodermal Tumors, Primitive, Peripheral0low10
Neuroepithelioma, Peripheral0low10
Neurogenic Muscular Atrophy0low30
Neurologic Ambulation Disorders0low10
Neurologic Disorders0low10
Neurologic Locomotion Disorders0low10
Neurological Disorders0low10
Neuron Degeneration0low40
Neuropathic Pain0low40
Neuropathy, Common Peroneal0low10
Neuropathy, Deep Peroneal0low10
Neuropathy, Superficial Peroneal0low10
Neuroretinitis0low10
Neuroses, Post-Traumatic0low10
Neuroses, Posttraumatic0low10
Neurosis, Depressive0medium127
Neurotoxicity Syndrome, MPTP0low20
Neurotrophic Muscular Atrophy0low30
Neutropenia0low10
NIDDM0low10
Non-Epileptic Seizure0low30
Non-Epileptic Seizures0low30
Nonepileptic Seizure0low30
Nonepileptic Seizures0low30
Noninsulin-Dependent Diabetes Mellitus0low10
Nonlymphoblastic Leukemia, Acute0low20
Nonlymphocytic Leukemia, Acute0low20
Nonpenetrating Injuries0low10
Nonpsychotic Organic Brain Syndrome0medium11
Nonsustained Ventricular Tachycardia0low10
Obesity0low50
Obstetric Labor, Premature0low20
Obstructive Lung Diseases0low40
Obstructive Pulmonary Diseases0low40
Occlusion, Middle Cerebral Artery0low10
Oculopharyngeal Spinal Muscular Atrophy0low10
Olfaction Disorders0low10
Olfactory Impairment0low10
Oligoastrocytoma, Mixed0low20
Oncogenesis0low10
Oncological Pain0low10
Oncology Pain0low10
Opportunistic Infections, AIDS-Related0low10
Opportunistic Infections, HIV-Related0low10
Organic Brain Syndrome, Nonpsychotic0medium11
Organic Mental Disorders0medium11
Organic Mental Disorders, Psychotic0medium11
Organic Mental Disorders, Substance-Induced0low10
Orthomyxoviridae Infections0low10
Orthomyxovirus Infections0low10
Osteochondrodysplasias0low10
Osteoclastic Bone Loss0low40
Osteodysplasty of Melnick and Needles0low10
Osteogenic Sarcoma0low10
Osteopenia0low10
Osteoporosis0low10
Osteoporosis, Age-Related0low10
Osteoporosis, Involutional0low10
Osteoporosis, Post-Traumatic0low10
Osteoporosis, Senile0low10
Osteosarcoma0low10
Osteosarcoma Tumor0low10
Otologic Diseases0low10
Otological Diseases0low10
Overactive Bladder0low20
Overactive Detrusor0low20
Overactive Detrusor Function0low20
Overactive Urinary Bladder0low20
Overinclusion0low110
Oxygen Deficiency0low50
Pain0low60
Pain, Burning0low60
Pain, Crushing0low60
Pain, Migratory0low60
Pain, Radiating0low60
Pain, Splitting0low60
Palmoplantaris Pustulosis0low20
Palsy0low10
Panacinar Emphysema0low10
Pancreatic Cystic Fibrosis0low20
Pancreatic Parenchyma with Edema0low50
Pancreatic Parenchymal Edema0low50
Pancreatitis0low50
Pancreatitis, Acute0low50
Pancreatitis, Acute Edematous0low50
Panlobular Emphysema0low10
Papilloma0low20
Papilloma, Squamous Cell0low20
Papillomatosis0low20
Paralysis0low10
Paralysis Agitans0medium51
Paraosmia0low10
Paraparesis, Tropical Spastic0low10
Paraphrenia, Involutional0medium71
Paraplegia, Tropical Spastic0low10
Parkinson Disease0medium51
Parkinson Disease, Idiopathic0medium51
Parkinson's Disease0medium51
Parkinson's Disease, Idiopathic0medium51
Parkinson's Disease, Lewy Body0medium51
Paroxysmal Atrial Fibrillation0low20
Paroxysmal Nerve Pain0low40
Paroxysmal Supraventricular Tachycardia0low10
Partial Fetal Alcohol Syndrome0low10
Partial Monosomy0low10
Partial Seizure0low30
Partial Seizures0low30
Partial Trisomy0low10
Partial Trisomy 21 Down Syndrome0low10
Passive Tremor0low20
Pathologic Angiogenesis0low20
Pathologic Neovascularization0low20
Pediatric Respiratory Distress Syndrome0low70
Perinatal Subarachnoid Hemorrhage0low30
Peripancreatic Fat Necrosis0low50
Peripheral Arterial Disease0medium11
Peripheral Arterial Diseases0medium11
Peripheral Artery Disease0medium11
Peripheral Nerve Diseases0low20
Peripheral Nerve Injuries0low10
Peripheral Nerve Injury0low10
Peripheral Nervous System Disease0low20
Peripheral Nervous System Diseases0low20
Peripheral Nervous System Disorders0low20
Peripheral Neuropathies0low20
Peripheral Primitive Neuroectodermal Neoplasm0low10
Peripheral Primitive Neuroectodermal Tumor0low10
Peripheral Primitive Neuroectodermal Tumors0low10
Peroneal Mononeuropathies0low10
Peroneal Nerve Diseases0low10
Peroneal Nerve Entrapment0low10
Peroneal Nerve Paralysis0low10
Peroneal Neuropathies0low10
Peroneal Palsy0low10
Persistent Atrial Fibrillation0low20
Persistent Tremor0low20
Petit Mal Convulsion0low30
Pica0low20
Picornaviridae Infections0low10
Picornavirus Infections0low10
Pill Rolling Tremor0low20
Pilocytic Astrocytoma0low20
Pink Eye0low10
Pituitary Adenoma0low20
Pituitary Adenoma, GH-Secreting0low10
Pituitary Adenoma, Growth Hormone-Secreting0low10
Pituitary Adenoma, Prolactin-Secreting0low10
Pituitary Cancer0low20
Pituitary Carcinoma0low20
Pituitary Growth Hormone-Secreting Adenoma0low10
Pituitary Neoplasms0low20
Pituitary Tumors0low20
Plaque, Amyloid0low10
Plaque, Ulcerating, Carotid Artery0low10
Plaques, Amyloid0low10
Plasma Cell Myeloma0low10
Plasmodium falciparum Malaria0low10
Plegia0low10
Pleocytosis0low10
Pleurisy0low10
Pleuritis0low10
Pneumonia0low120
Pneumonia, Eosinophilic0low50
Pneumonia, Lobar0low120
Pneumonia, Pneumococcal0low10
Pneumonia, Viral0low10
Pneumonitis0low120
PNS (Peripheral Nervous System) Diseases0low20
PNS Diseases0low20
Poisoning, 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine0low20
Poisoning, Blood0low70
Polio0low10
Polio Encephalitis0low10
Poliomyelitis0low10
Poliomyelitis Infection0low10
Poliomyelitis, Acute0low10
Poliomyelitis, Nonpoliovirus0low10
Poliomyelitis, Preparalytic0low10
Polyarthritis0low40
Polymicrobial Infection0low10
Polyostotic Fibrous Dysplasia0low10
Polyuria0low10
Post Traumatic Stress Disorder0low10
Post-Traumatic Myelopathy0low260
Post-Traumatic Stress Disorders0low10
Posterior Circulation Brain Infarction0low10
Posterior Circulation Infarction, Brain0low10
Posterior Circulation Transient Ischemic Attack0low90
Posttraumatic Stress Disorders0low10
Postviral Fatigue Syndrome0low10
Precursor Cell Lymphoblastic Leukemia-Lymphoma0low10
Pregnancy0low250
Premature Birth0low40
Premature Labor0low20
Premature Obstetric Labor0low20
Prenatal Exposure Delayed Effects0low10
Prescription Drug Abuse0low10
Presenile Alzheimer Dementia0low130
Preterm Birth0low40
Preterm Labor0low20
Primary Brain Neoplasms0low60
Primary Malignant Brain Neoplasms0low60
Primary Malignant Brain Tumors0low60
Primary Myocardial Diseases0low20
Primary Neoplasms, Cerebellum0low10
Primary Parkinsonism0medium51
Primary Senile Degenerative Dementia0low130
Primitive Neuroectodermal Tumor, Extracranial0low10
PRL-Secreting Pituitary Adenoma0low10
Progranulocytic Leukemia0low10
Progressive Chorea, Chronic Hereditary (Huntington)0low60
Progressive Chorea, Hereditary, Chronic (Huntington)0low60
Progressive Muscular Atrophy0low10
Progressive Myelopathic Muscular Atrophy0low10
Progressive Proximal Myelopathic Muscular Atrophy0low10
Prolactin-Producing Pituitary Adenoma0low10
Prolactin-Secreting Pituitary Adenoma0low10
Prolactinoma0low10
Prolactinoma, Familial0low10
Proliferative Bronchiolitis0low10
Promyelocytic Leukemia, Acute0low10
Prostate Cancer0low20
Prostate Neoplasms0low20
Prostatic Adenoma0low10
Prostatic Cancer0low20
Prostatic Hyperplasia0low10
Prostatic Hyperplasia, Benign0low10
Prostatic Hypertrophy0low10
Prostatic Hypertrophy, Benign0low10
Prostatic Neoplasms0low20
Protein Aggregation, Pathological0low10
Protein-Calorie Malnutrition0low10
Protein-Energy Malnutrition0low10
Proteinuria0low10
Proximal Myelopathic Muscular Atrophy, Progressive0low10
Pruritis0low10
Pruritus0low10
Psoriasis0low20
Psychiatric Diagnosis0low10
Psychiatric Diseases0low10
Psychiatric Disorders0low10
Psychiatric Illness0low10
Psychoses0low30
Psychoses, Traumatic0medium11
Psychosis0low30
Psychosis, Brief Reactive0low30
Psychosis, Involutional0medium71
Psychotic Disorders0low30
PTSD0low10
Pulmonary Cancer0low50
Pulmonary Cystic Fibrosis0low20
Pulmonary Disease0low60
Pulmonary Disease, Chronic Obstructive0medium181
Pulmonary Diseases0low60
Pulmonary Edema0low50
Pulmonary Edemas0low50
Pulmonary Emphysema0low10
Pulmonary Emphysemas0low10
Pulmonary Eosinophilia0low50
Pulmonary Eosinophilias0low50
Pulmonary Fibroses0low20
Pulmonary Fibrosis0low20
Pulmonary Fibrosis, Idiopathic0low20
Pulmonary Hypertension0low50
Pulmonary Inflammation0low120
Pulmonary Injury0low20
Pulmonary Neoplasms0low50
Pustular Psoriasis of Palms and Soles0low20
Pustulosis of Palms and Soles0low20
Pustulosis Palmaris et Plantaris0low20
Pyaemia0low70
Pyelonephritis0low10
Pyelonephritis, Acute Necrotizing0low10
Pyemia0low70
Pyohemia0low70
Pyrexia0low10
Rapid Fatigue of Gait0low10
Rasmussen Encephalitis0low50
Rasmussen Syndrome0low50
Rasmussen's Syndrome0low50
Reaction, Acute-Phase0low10
Recrudescence0low20
Recurrence0low20
Regional Enteritis0low10
Relapse0low20
REM Sleep Deprivation0low20
Renal Failure, Acute0low20
Renal Insufficiency, Acute0low20
Reperfusion Damage0low90
Reperfusion Injury0low90
Reperfusion Injury, Myocardial0low30
Respiration Disorders0low10
Respiratory Depression0low10
Respiratory Distress Syndrome0low70
Respiratory Distress Syndrome, Acute0low70
Respiratory Distress Syndrome, Adult0low70
Respiratory Distress Syndrome, Pediatric0low70
Respiratory Failure0low10
Respiratory Hypersensitivity0low50
Respiratory Insufficiency0low10
Respiratory Syncytial Virus Infection0low10
Respiratory Syncytial Virus Infections0low10
Respirovirus Infections0low10
Response, Acute-Phase0low10
Rest Tremor0low20
Resting Tremor0low20
Retardation, Mental0low10
Retention Disorders, Cognitive0low170
Retinitis0low10
Rett Disorder0low10
Rett Syndrome0low10
Rett's Disorder0low10
Rett's Syndrome0low10
Rheumatic Heart Disease0low10
Rheumatoid Arthritis0low80
Right Middle Cerebral Artery Infarction0low10
Right-Sided Heart Failure0low50
Rock Fever0low10
Royal Free Disease0low10
Rubinstein Syndrome0low10
Rubinstein-Taybi Syndrome0low10
Runt Disease0low20
SAH (Subarachnoid Hemorrhage)0low30
Sarcoma, Cerebellar, Circumscribed Arachnoidal0low30
Sarcoma, Osteogenic0low10
SARS Coronavirus 2 Infection0low10
SARS-CoV-2 Infection0low10
Saturnine Tremor0low20
Scapuloperoneal Form of Spinal Muscular Atrophy0low10
Scapuloperoneal Spinal Muscular Atrophy0low10
Schilder-Addison Complex0low20
Schizoaffective Disorder0low30
Schizophrenia0low50
Schizophrenic Disorders0low50
Schizophreniform Disorders0low30
Scholastic Skills Development Disorders0low20
Schwartz Jampel Aberfeld syndrome0low10
Schwartz-Jampel Syndrome0low10
Schwartz-Jampel Syndrome, Type 10low10
Schwartz-Jampel-Aberfeld Syndrome0low10
Scleroderma, Systemic0low10
Sclerosis, Disseminated0medium131
Sclerosis, Systemic0low10
Secondary Infection0low10
Secondary Infections0low10
Secondary Myocardial Diseases0low20
SED Tarda0low10
Seizure0low30
Seizure Disorder0low20
Seizures0low30
Seizures, Auditory0low30
Seizures, Clonic0low30
Seizures, Convulsive0low30
Seizures, Epileptic0low30
Seizures, Focal0low30
Seizures, Generalized0low30
Seizures, Gustatory0low30
Seizures, Motor0low30
Seizures, Olfactory0low30
Seizures, Sensory0low30
Seizures, Somatosensory0low30
Seizures, Tonic0low30
Seizures, Tonic-Clonic0low30
Seizures, Vertiginous0low30
Seizures, Vestibular0low30
Seizures, Visual0low30
Semantic Memory Disorder0low170
Senile Dementia, Acute Confusional0low130
Senile Dementia, Alzheimer Type0low130
Senile Osteoporosis0low10
Senile Paranoid Dementia0low20
Senile Plaques0low10
Senile Tremor0low20
Sensitivity and Specificity0low80
Sensitivity, Contact0low20
Sensorimotor Gait Disorder0low10
Sensorineural Hearing Loss0low10
Sepsis0low70
Sepsis Syndrome0low10
Septic Shock0low50
Septicemia0low70
Severe Sepsis0low70
Shock Lung0low70
Shock, Endotoxic0low50
Shock, Septic0low50
Shock, Toxic0low50
Sickle Cell Anemia0low10
Sickle Cell Disease0low10
Sickle Cell Disorders0low10
Sickling Disorder Due to Hemoglobin S0low10
Siemerling-Creutzfeldt Disease0low20
Simple Pulmonary Eosinophilia0low50
Single Seizure0low30
Sinoatrial Arrhythmia0low20
Sinus Arrhythmia0low20
Sinus Tachycardia0low10
SJA Syndrome0low10
Skin and Subcutaneous Tissue Disorders0low10
Skin Cancer0low20
Skin Diseases0low10
Skin Neoplasms0low20
Sleep Debt0low20
Sleep Deprivation0low20
Sleep Fragmentation0low20
Sleep Insufficiency0low20
Small Airway Remodeling0low10
Small Airway Remodelling0low10
Small-Cell Lymphoma0medium111
Smell Disorders0low10
Smell Dysfunction0low10
Somatotroph Adenoma0low10
Somatotrophinoma, Familial0low10
Somatotropinoma, Familial Isolated0low10
Sost Sclerosing Bone Dysplasia0low10
Sost-Related Sclerosing Bone Dysplasia0low10
Spasm0low10
Spasm, Ciliary Body0low10
Spasm, Generalized0low10
Spasmophilia0low10
Spatial Memory Disorder0low170
Spermatic Cord Torsion0low10
Spinal Amyotrophy0low10
Spinal Cord Compression0low10
Spinal Cord Compression, Extramedullary0low10
Spinal Cord Contusion0low260
Spinal Cord Injuries0low260
Spinal Cord Laceration0low260
Spinal Cord Transection0low260
Spinal Cord Trauma0low260
Spinal Muscular Atrophy0low10
Spinal Muscular Atrophy, Distal0low10
Spinal Muscular Atrophy, Oculopharyngeal0low10
Spinal Muscular Atrophy, Scapuloperoneal0low10
Spinal Muscular Atrophy, Scapuloperoneal Form0low10
Spondylo-Epimetaphyseal Dysplasia With Myotonia0low10
Spondyloepiphyseal Dysplasia0low10
Spondyloepiphyseal Dysplasia Tarda, X-Linked0low10
Spondyloepiphyseal Dysplasia, Late0low10
Squamous Cell Carcinoma0low10
Staphylococcal Infections0low10
Staphylococcus aureus Infection0low10
Starvation0low20
Static Tremor0low20
Status Marmoratus0low20
Stenosis, Common Carotid Artery0low10
Stenosis, External Carotid Artery0low10
Stomach Diseases0low10
Stomach Ulcer0low20
Streptococcal Infections0low10
Streptozocin Diabetes0low60
Streptozotocin Diabetes0low60
Stress Disorder, Post Traumatic0low10
Stress Disorders, Post-Traumatic0low10
Stress Disorders, Posttraumatic0low10
Stroke0low30
Stroke, Acute0low30
Stroke, Middle Cerebral Artery0low10
Subarachnoid Hemorrhage0low30
Subarachnoid Hemorrhage, Aneurysmal0low30
Subarachnoid Hemorrhage, Intracranial0low30
Subarachnoid Hemorrhage, Spontaneous0low30
Subcortical Arteriosclerotic Encephalopathy0low20
Subcortical Encephalopathy, Chronic Progressive0low20
Subcortical Leukoencephalopathy0low20
Subcortical Vascular Dementia0low20
Subendothelial Membranoproliferative Glomerulonephritis0low10
Subependymal Giant Cell Astrocytoma0low20
Submandibular Gland Neoplasms0low10
Substance Abuse0low10
Substance Addiction0low10
Substance Dependence0low10
Substance Use0low10
Substance Use Disorders0low10
Substance Withdrawal Syndrome0low70
Substance-Related Disorders0low10
Suffering, Physical0low60
Suppurative Arthritis0low20
Surgery-Induced Tissue Adhesions0low20
Surgical Adhesions0low20
Susceptibility, Disease0low10
Swine Influenza0low10
Symmetric Diabetic Proximal Motor Neuropathy0low20
Systemic Capillary Leak Syndrome0low10
Systemic Exertion Intolerance Disease0low10
Systemic Inflammatory Response Syndrome0low10
Systemic Scleroderma0low10
Systemic Sclerosis0low10
T-Lymphotropic Virus Type III Infections, Human0low20
Tachyarrhythmia0low30
Tachycardia0low30
Tachycardia, Sinus0low10
Tachycardia, Ventricular0low10
Tactile Allodynia0low100
Tauopathies0low10
Tauopathy0low10
TBI (Traumatic Brain Injury)0low30
TBIs (Traumatic Brain Injuries)0low30
Testicular Torsion0low10
Tetanilla0low10
Tetany0low10
Tetany, Neonatal0low10
Thermal Allodynia0low100
Thesaurismosis0low10
Thrombosis0low10
Thrombosis, Carotid0low10
Thrombosis, Carotid Artery0low10
Thrombosis, Common Carotid Artery0low10
Thrombosis, External Carotid Artery0low10
Thrombosis, Internal Carotid Artery0low10
Thrombosis, Middle Cerebral Artery0low10
Thrombotic Infarction, Middle Cerebral Artery0low10
Thrombus0low10
TIA (Transient Ischemic Attack)0low90
Tissue Adhesions0low20
Todd Paralysis0low10
Todd's Paralysis0low10
Tonic Clonic Seizure0low30
Tonic Seizure0low30
Tonic Seizures0low30
Tonic-Clonic Seizure0low30
Tonic-Clonic Seizures0low30
Torsion Of Testicular Cord0low10
Toxic Hepatitis0low20
Toxic Shock0low50
Toxic Shock Syndrome0low50
Transformation, Neoplastic Cell0low20
Transient Ischemic Attack0low90
Transient Ischemic Attack, Anterior Circulation0low90
Transient Ischemic Attack, Brain Stem0low90
Transient Ischemic Attack, Brainstem0low90
Transient Ischemic Attack, Carotid Circulation0low90
Transient Ischemic Attack, Posterior Circulation0low90
Transient Ischemic Attack, Vertebrobasilar Circulation0low90
Transient Ischemic Attacks, Crescendo0low90
Trauma, Brain0low30
Traumatic Brain Injury0low30
Traumatic Encephalopathy0low30
Tremor0low20
Tremor, Limb0low20
Tremor, Muscle0low20
Tremor, Neonatal0low20
Tremor, Nerve0low20
Tremor, Perioral0low20
Tremor, Semirhythmic0low20
Triple Negative Breast Cancer0low10
Triple Negative Breast Neoplasms0low10
Triple-Negative Breast Cancer0low10
Triple-Negative Breast Neoplasm0low10
Trisomy0low10
Trisomy 210low10
Trisomy 21, Meiotic Nondisjunction0low10
Trisomy 21, Mitotic Nondisjunction0low10
Trisomy G0low10
Tropical Eosinophilia0low70
Tropical Eosinophilic Pneumonia0low50
Tropical Spastic Paraparesis0low10
Trypanosomiasis, African0low10
Tuberculin-Type Hypersensitivity0low10
Tuberculosis0low10
Tumor-Associated Pain0low10
Tumor-Related Pain0low10
Tumorigenesis0low10
Tumorigenic Transformation0low20
Tumors0low50
Tumors, Breast0low40
Type 1 Diabetes0low20
Type 1 Diabetes Mellitus0low20
Type 2 Diabetes0low10
Type 2 Diabetes Mellitus0low10
Type I Hypersensitivity0low20
Type II MPGN0low10
Type IV Hypersensitivity0low10
Ulcerating Plaque, Carotid Artery0low10
Undulant Fever0low10
Unipolar Depression0medium127
Ureteral Obstruction0low10
Urinary Bladder, Overactive0low20
Usual Interstitial Pneumonia0low20
Uterine Diseases0low10
Uveitis0low10
Uveitis, Anterior0low10
Valvular Heart Diseases0low10
Van Buchem Disease0low10
Vascular Accident, Brain0low30
Vascular Dementia0low20
Vascular Dementia, Acute Onset0low20
Vascular Diseases0low10
Vascular Injuries0low10
Vascular System Injuries0low10
Vasogenic Brain Edema0low30
Vasogenic Cerebral Edema0low30
Vasopressin-Resistant Diabetes Insipidus0low10
Venous Infarction, Brain0low10
Ventilatory Depression0low10
Ventricular Fibrillation0low10
Ventricular Tachyarrhythmias0low10
Ventricular Tachycardia0low10
Vertebrobasilar Circulation Transient Ischemic Attack0low90
Vomiting0low250
Wallerian Degeneration0low20
Weight Gain0low70
Wet Lung0low50
Withdrawal Symptoms0low70
Wounds, Nonpenetrating0low10
X-ALD0low20
X-ALD (X-Linked Adrenoleukodystrophy)0low20
X-Linked Adrenoleukodystrophy0low20
X-Linked Mental Retardation and Macroorchidism0low10
X-Linked SED0low10
X-Linked SEDT0low10
X-Linked Spondyloepiphyseal Dysplasia Tarda0low10
Zika Fever0low20
Zika Virus Disease0low20
Zika Virus Infection0low20
ZikV Infection0low20

Research Highlights

Safety/Toxicity (10)

ArticleYear
GSK356278, a potent, selective, brain-penetrant phosphodiesterase 4 inhibitor that demonstrates anxiolytic and cognition-enhancing effects without inducing side effects in preclinical species.
The Journal of pharmacology and experimental therapeutics, Volume: 350, Issue: 1		2014
Evaluation of longevity enhancing compounds against transactive response DNA-binding protein-43 neuronal toxicity.
Neurobiology of aging, Volume: 34, Issue: 9		2013
Safety and efficacy of new 3,6-diaryl-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine analogs as potential phosphodiesterase-4 inhibitors in NIH-3T3 mouse fibroblastic cells.
Chemical biology & drug design, Volume: 78, Issue: 3		2011
Genistein, a competitive PDE1-4 inhibitor, may bind on high-affinity rolipram binding sites of brain cell membranes and then induce gastrointestinal adverse effects.
European journal of pharmacology, Sep-15, Volume: 643, Issue: 1		2010
Alterations of pre- and postsynaptic noradrenergic signaling in a rat model of adriamycin-induced cardiotoxicity.
Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology, Volume: 17, Issue: 2		2010
Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety.
Nature biotechnology, Volume: 28, Issue: 1		2010
Alpha2 adrenergic modulation of NMDA receptor function as a major mechanism of RGC protection in experimental glaucoma and retinal excitotoxicity.
Investigative ophthalmology & visual science, Volume: 49, Issue: 10		2008
Beneficial effects of rolipram in a quinolinic acid model of striatal excitotoxicity.
Neurobiology of disease, Volume: 25, Issue: 2		2007
The toxicity of repeated exposures to rolipram, a type IV phosphodiesterase inhibitor, in rats.
Pharmacology & toxicology, Volume: 78, Issue: 1		1996
PGE1 and prostacyclin suppression of NK-cell mediated cytotoxicity and its relation to cyclic AMP.
Medical biology, Volume: 61, Issue: 6		1983
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Long-term Use (14)

ArticleYear
Inhibition of phosphodiesterase-4 reverses the cognitive dysfunction and oxidative stress induced by Aβ25-35 in rats.
Metabolic brain disease, Volume: 31, Issue: 4		2016
Inhibition of phosphodiesterase-4 reverses memory deficits produced by Aβ25-35 or Aβ1-40 peptide in rats.
Psychopharmacology, Volume: 212, Issue: 2		2010
Systemic administration of rolipram increases medullary and spinal cAMP and activates a latent respiratory motor pathway after high cervical spinal cord injury.
The journal of spinal cord medicine, Volume: 32, Issue: 2		2009
Antidepressant- and anxiolytic-like effects of the phosphodiesterase-4 inhibitor rolipram on behavior depend on cyclic AMP response element binding protein-mediated neurogenesis in the hippocampus.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, Volume: 34, Issue: 11		2009
Administration of phosphodiesterase inhibitors and an adenosine A1 receptor antagonist induces phrenic nerve recovery in high cervical spinal cord injured rats.
Experimental neurology, Volume: 210, Issue: 2		2008
The potential of PDE4 inhibitors in respiratory disease.
Current drug targets. Inflammation and allergy, Volume: 3, Issue: 3		2004
Effect of a novel anti-inflammatory compound, YM976, on antigen-induced eosinophil infiltration into the lungs in rats, mice, and ferrets.
The Journal of pharmacology and experimental therapeutics, Volume: 295, Issue: 3		2000
Differential effects of chronic administration of the antidepressants amitriptyline and rolipram on adenylyl cyclase activity.
Nihon shinkei seishin yakurigaku zasshi = Japanese journal of psychopharmacology, Volume: 18, Issue: 1		1998
Effects of chronic caffeine administration on respiration and schedule-controlled behavior in rhesus monkeys.
The Journal of pharmacology and experimental therapeutics, Volume: 283, Issue: 1		1997
Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus.
The Journal of neuroscience : the official journal of the Society for Neuroscience, Apr-01, Volume: 16, Issue: 7		1996
Antidepressants and endogenous opioid peptide systems.
Neuropeptides, Volume: 5, Issue: 4-6		1985
Chronic treatment with the potential antidepressant drug rolipram: the effect on the behavioural responses to adrenergic and dopaminergic receptor agonists with some biochemical correlates.
Journal of neural transmission, Volume: 64, Issue: 3-4		1985
Effect of long-term rolipram administration on the sensitivity of alpha 2-adrenoceptors in rat brain.
European journal of pharmacology, Mar-29, Volume: 148, Issue: 2		1988
The pharmacodynamic action of the cyclic AMP phosphodiesterase inhibitor rolipram on prolactin producing rat pituitary adenoma (GH4C1) cells.
Bioscience reports, Volume: 10, Issue: 4		1990
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Pharmacokinetics (8)

ArticleYear
Synthesis, biological activities and pharmacokinetic properties of new fluorinated derivatives of selective PDE4D inhibitors.
Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue: 13		2015
Regulation of alveolar fluid clearance and ENaC expression in lung by exogenous angiotensin II.
Respiratory physiology & neurobiology, Apr-15, Volume: 181, Issue: 1		2012
Phosphodiesterase 4 inhibition attenuates plasma volume loss and transvascular exchange in volume-expanded mice.
The Journal of physiology, Jan-15, Volume: 590, Issue: 2		2012
Phosphodiesterase 4 inhibition attenuates atrial natriuretic peptide-induced vascular hyperpermeability and loss of plasma volume.
The Journal of physiology, Jan-15, Volume: 589, Issue: Pt 2		2011
Dissociation of the PAF-receptor from NADPH oxidase and adenylate cyclase in human neutrophils results in accelerated influx and delayed clearance of cytosolic calcium.
British journal of pharmacology, Volume: 136, Issue: 1		2002
Pharmacokinetics of rolipram in the rhesus and cynomolgus monkeys, the rat and the rabbit. Studies on species differences.
Xenobiotica; the fate of foreign compounds in biological systems, Volume: 18, Issue: 5		1988
Pharmacokinetics of the antidepressant rolipram in healthy volunteers.
Xenobiotica; the fate of foreign compounds in biological systems, Volume: 19, Issue: 6		1989
Pharmacokinetics of (+)-rolipram and (-)-rolipram in healthy volunteers.
European journal of clinical pharmacology, Volume: 38, Issue: 1		1990
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioavailability (10)

ArticleYear
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Molecular pharmacology, Volume: 96, Issue: 5		2019
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
The Journal of biological chemistry, 11-15, Volume: 294, Issue: 46		2019
Discovery of arylbenzylamines as PDE4 inhibitors with potential neuroprotective effect.
European journal of medicinal chemistry, Apr-15, Volume: 168		2019
SAR of a series of 5,6-dihydro-(9H)-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-alpha]pyridines as potent inhibitors of human eosinophil phosphodiesterase.
Journal of medicinal chemistry, Jan-25, Volume: 50, Issue: 2		2007
4-(3-Chloro-4-methoxybenzyl)aminophthalazines: synthesis and inhibitory activity toward phosphodiesterase 5.
Journal of medicinal chemistry, Jun-29, Volume: 43, Issue: 13		2000
The regulation of lung liquid absorption by endogenous cAMP in postnatal sheep lungs perfused in situ.
The Journal of physiology, Sep-01, Volume: 511 ( Pt 2)		1998
Pharmacokinetics of rolipram in the rhesus and cynomolgus monkeys, the rat and the rabbit. Studies on species differences.
Xenobiotica; the fate of foreign compounds in biological systems, Volume: 18, Issue: 5		1988
Pharmacokinetics of the antidepressant rolipram in healthy volunteers.
Xenobiotica; the fate of foreign compounds in biological systems, Volume: 19, Issue: 6		1989
Pharmacokinetics of (+)-rolipram and (-)-rolipram in healthy volunteers.
European journal of clinical pharmacology, Volume: 38, Issue: 1		1990
In-vitro and in-vivo characterisation of two sustained release formulations for the antidepressant rolipram.
Arzneimittel-Forschung, Volume: 40, Issue: 11		1990
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Dosage (38)

ArticleYear
Genetic Understanding of Stroke Treatment: Potential Role for Phosphodiesterase Inhibitors.
Advances in neurobiology, Volume: 17		2017
Reduction of alcohol drinking of alcohol-preferring (P) and high-alcohol drinking (HAD1) rats by targeting phosphodiesterase-4 (PDE4).
Psychopharmacology, Volume: 232, Issue: 13		2015
Rolipram improves renal perfusion and function during sepsis in the mouse.
The Journal of pharmacology and experimental therapeutics, Volume: 347, Issue: 2		2013
Catechol pyrazolinones as trypanocidals: fragment-based design, synthesis, and pharmacological evaluation of nanomolar inhibitors of trypanosomal phosphodiesterase B1.
Journal of medicinal chemistry, Oct-25, Volume: 55, Issue: 20		2012
Drug-eluting microfibrous patches for the local delivery of rolipram in spinal cord repair.
Journal of controlled release : official journal of the Controlled Release Society, Aug-10, Volume: 161, Issue: 3		2012
Effects of protein kinase A and G inhibitors on hippocampal cholinergic markers expressions in rolipram- and sildenafil-induced spatial memory improvement.
Pharmacology, biochemistry, and behavior, Volume: 101, Issue: 3		2012
Action of a Novel PDE4 inhibitor ZL-n-91 on lipopolysaccharide-induced acute lung injury.
International immunopharmacology, Volume: 10, Issue: 4		2010
Evidence that corticotropin-releasing hormone modulates myometrial contractility during human pregnancy.
Endocrinology, Volume: 150, Issue: 12		2009
Quinolines as a novel structural class of potent and selective PDE4 inhibitors. Optimisation for inhaled administration.
Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue: 17		2009
Pyrazolopyridines as a novel structural class of potent and selective PDE4 inhibitors.
Bioorganic & medicinal chemistry letters, Jul-15, Volume: 18, Issue: 14		2008
Preclinical assessment of curcumin as a potential therapy for B-CLL.
American journal of hematology, Volume: 82, Issue: 1		2007
Synergistic effects of cAMP-dependent signalling pathways and IL-1 on IL-6 production by H19-7/IGF-IR neuronal cells.
Cellular signalling, Volume: 18, Issue: 10		2006
A novel mechanism for the modulation of luteinizing hormone receptor mRNA expression in the rat ovary.
Molecular and cellular endocrinology, Apr-15, Volume: 233, Issue: 1-2		2005
Comparison of PDE 4 inhibitors, rolipram and SB 207499 (ariflo), in a rat model of pulmonary neutrophilia.
Pulmonary pharmacology & therapeutics, Volume: 14, Issue: 2		2001
Effects of several glucocorticosteroids and PDE4 inhibitors on increases in total lung eosinophil peroxidase (EPO) levels following either systemic or intratracheal administration in sephadex- or ovalbumin-induced inflammatory models.
Inflammation, Volume: 24, Issue: 4		2000
Cereport (RMP-7) increases the permeability of human brain microvascular endothelial cell monolayers.
Pharmaceutical research, Volume: 16, Issue: 9		1999
Emesis induced by inhibitors of type IV cyclic nucleotide phosphodiesterase (PDE IV) in the ferret.
Neuropharmacology, Volume: 38, Issue: 2		1999
Age-related effects of rolipram on [3H]quinuclidinyl benzilate and [3H]phorbol 12,13-dibutyrate binding in the rat brain.
The Tohoku journal of experimental medicine, Volume: 185, Issue: 2		1998
Rolipram and its optical isomers, phosphodiesterase 4 inhibitors, attenuated the scopolamine-induced impairments of learning and memory in rats.
Japanese journal of pharmacology, Volume: 75, Issue: 3		1997
Selective inhibitors of cyclic AMP-specific phosphodiesterase: heterocycle-condensed purines.
Journal of medicinal chemistry, Sep-26, Volume: 40, Issue: 20		1997
Pure glucagon antagonists: biological activities and cAMP accumulation using phosphodiesterase inhibitors.
Peptides, Volume: 18, Issue: 5		1997
Effects of inhibitors of phosphodiesterase, on antigen-induced bronchial hyperreactivity in conscious sensitized guinea-pigs and airway leukocyte infiltration.
British journal of pharmacology, Volume: 120, Issue: 2		1997
Phosphodiesterase specific inhibitors control cell growth of a human neuroepithelioma cell line.
Journal of neuro-oncology, Volume: 31, Issue: 1-2		1997
The human cyclic AMP-specific phosphodiesterase PDE-46 (HSPDE4A4B) expressed in transfected COS7 cells occurs as both particulate and cytosolic species that exhibit distinct kinetics of inhibition by the antidepressant rolipram.
The Journal of biological chemistry, Dec-06, Volume: 271, Issue: 49		1996
Inhibition of bronchospasm and ozone-induced airway hyperresponsiveness in the guinea-pig by CDP840, a novel phosphodiesterase type 4 inhibitor.
British journal of pharmacology, Volume: 118, Issue: 5		1996
Effects of theophylline and rolipram on antigen-induced airway responses in neonatally immunized rabbits.
British journal of pharmacology, Volume: 117, Issue: 7		1996
Effects of adenosine agonists on ventilation during hypercapnia, hypoxia and hyperoxia in rhesus monkeys.
The Journal of pharmacology and experimental therapeutics, Volume: 265, Issue: 2		1993
Pulmonary antiallergic and bronchodilator effects of isozyme-selective phosphodiesterase inhibitors in guinea pigs.
The Journal of pharmacology and experimental therapeutics, Volume: 264, Issue: 2		1993
cAMP-specific phosphodiesterase inhibitor, rolipram, reduces eosinophil infiltration evoked by leukotrienes or by histamine in guinea pig conjunctiva.
Inflammation, Volume: 17, Issue: 1		1993
Reversal of pulmonary capillary ischemia-reperfusion injury by rolipram, a cAMP phosphodiesterase inhibitor.
Journal of applied physiology (Bethesda, Md. : 1985), Volume: 77, Issue: 2		1994
Phosphodiesterase inhibitors reduce bronchial hyperreactivity and airway inflammation in unrestrained guinea pigs.
European journal of pharmacology, Feb-24, Volume: 275, Issue: 1		1995
Species differences in behavioural effects of rolipram and other adenosine cyclic 3H, 5H-monophosphate phosphodiesterase inhibitors.
Journal of neural transmission, Volume: 56, Issue: 2-3		1983
Characteristic behavioural alterations in rats induced by rolipram and other selective adenosine cyclic 3', 5'-monophosphate phosphodiesterase inhibitors.
Psychopharmacology, Volume: 77, Issue: 4		1982
A study to assess the anticholinergic activity of rolipram in healthy elderly volunteers.
Pharmacopsychiatry, Volume: 21, Issue: 5		1988
The effect of a selective phosphodiesterase inhibitor, rolipram, on muricide in olfactory bulbectomized rats.
Japanese journal of pharmacology, Volume: 48, Issue: 3		1988
Effect of long-term rolipram administration on the sensitivity of alpha 2-adrenoceptors in rat brain.
European journal of pharmacology, Mar-29, Volume: 148, Issue: 2		1988
In-vitro and in-vivo characterisation of two sustained release formulations for the antidepressant rolipram.
Arzneimittel-Forschung, Volume: 40, Issue: 11		1990
A multicenter double-blind study of three different doses of the new cAMP-phosphodiesterase inhibitor rolipram in patients with major depressive disorder.
Neuropsychobiology, Volume: 26, Issue: 1-2		1992
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Interactions (4)

ArticleYear
Ibudilast, a phosphodiesterase inhibitor, in combination with low-dose aspirin potently inhibits guinea pig carotid artery thrombosis without extending bleeding time and causing gastric mucosal injury.
Arzneimittel-Forschung, Volume: 62, Issue: 12		2012
Uterus-relaxing effect of β2-agonists in combination with phosphodiesterase inhibitors: studies on pregnant rat in vivo and on pregnant human myometrium in vitro.
The journal of obstetrics and gynaecology research, Volume: 39, Issue: 1		2013
The specific type IV phosphodiesterase inhibitor rolipram combined with adenosine reduces tumor necrosis factor-alpha-primed neutrophil oxidative activity.
International journal of immunopharmacology, Volume: 17, Issue: 10		1995
The inotropic mechanism of the phosphodiesterase inhibitor OPC 3911 alone and in combination with rolipram, studied in papillary muscles of ferret and guinea-pig and isolated myocytes of guinea-pig ventricular muscle.
Acta physiologica Scandinavica, Volume: 150, Issue: 3		1994
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]